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ABSTRACT 
 
CMV CD8+T-cell memory-inflation can occupy up to 50% of the total CD8+ T cell pool. 
Studies using an MHC class I immunevasion-deleted strain revealed novel peptide-epitopes 
across the virus genome both in-frame and translated in a non-canonical manner. This study 
functionally and phenotypically characterised CD8+T-cells responding to these CMV-derived 
epitopes with age. They were found to be frequent component of the in vivo repertoire 
dedicated towards HCMV during latency. A HLA-Cw*0702-restricted immunodominant 
CD8+T-cell response that accumulated within elderly donors was identified to reach 32% of 
the total CD8+T-cell pool producing IFN-γ/TNF-α. Subsequently, HLA-Cw*0702-restricted 
memory-inflation was observed to a further two peptides dominating the CD8+T-cell memory 
compartment. HLA-Cw*0702 CD8+T-cells demonstrated a TEMRA phenotype - 
CD45RA+/CD27-/CD28-/CCR7-/perforinhigh/granzymeBhigh - and represented promising 
candidates for inclusion in HSCT adoptive immunotherapies. Consequently, the global 
HCMV-specific CD8+T-cell response is being vastly underestimated by restricting studies to; 
in-frame translation products, HLA-A/-B-restricted peptide-epitopes and utilising WT-strains 
to characterise novel CD8+T-cell targets. Lastly, understanding why particular HCMV 
antigens induce inflationary CD8+T-cells will facilitate harnessing HCMV as a cancer 
therapy. In an attempt to direct HCMV-mediated inflationary responses towards 
malignancies, a HCMV-based vaccine vector expressing the NYESO1 CTAg was generated. 
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CHAPTER 1 – INTRODUCTION 
1.1 - Human Cytomegalovirus (HCMV) 
Herpesviridae are a family of large DNA viruses that establish lifelong persistence and 
consists of three major subfamilies - the α, β, and γ- Herpesviridae. Human Cytomegalovirus 
(HCMV) is a member of the β-Herpesvirus subfamily that infects up to 90% of the world’s 
population depending upon socioeconomic status with seropositivity tending to increase with 
age [1]. HCMV is well controlled within healthy individuals typically causing an asymptomatic 
infection. However, HCMV disease represents one of the major causes of morbidity and 
mortality within immunocompromised patients e.g. new-borns and high risk groups such as 
AIDS or both solid organ transplant (SOT) and haematopoietic stem cell transplant (HSCT) 
patients. Despite an asymptomatic primary infection within healthy individuals, HCMV is now 
being linked to the development of several disease states. Within healthy individuals, the 
pro-inflammatory response to HCMV replication over the course of the host’s lifetime is 
believed to contribute to the development of atherosclerosis [2, 3]. In chronic kidney disease 
patients, HCMV has been identified as a risk factor for arterial stiffening (arteriosclerosis) 
however the mechanisms behind this are unclear [4]. HCMV is also implicated in poor 
responses to vaccines such as Influenza and contributing to both aging and immune 
senescence within the elderly [5-7]. CMV is a highly species-specific virus i.e. HCMV will 
infect only humans and murine CMV (MCMV) infects only mice. Despite this species barrier, 
animal models of CMV have proven invaluable. For example, MCMV has provided insight 
into the virus life cycle, latency and pathogenesis of CMV and allowed for the investigation of 
potential immunotherapies for CMV-mediated disease [8, 9]. The guinea pig model of CMV 
disease has facilitated studies into congenital infection and immune protection as guinea 
CMV (gCMV) is readily able to cross the placental barrier [10]. Recently, the Rhesus 
macaque CMV (RhCMV) model has been successfully used to study the ability of CMV as a 




After an initial acute infection, HCMV establishes a life-long chronic infection whose major 
site of latency is postulated to be the CD34+ myeloid progenitor lineage such as monocyte or 
dendritic cells [14]. In this lineage, the reactivation of HCMV is hypothesised to be closely 
linked to the differentiation status of the CD34+ myeloid cells [15].  HCMV has an extensive 
cell tropism including, but most likely not restricted to; endothelial, epithelial, dendritic cells 
and fibroblasts [14]. During acute infection, HCMV is able to disseminate throughout the host 
and infect almost all organs within the human body [16] including the liver, lungs and 
kidneys. In addition, viral antigens have been detected in several different cell types within 
these organs, such as hepatocytes, monocytes, endothelial, epithelial and smooth muscle 
cells [16].  
 
HCMV has a genome of ~235Kb separated into unique long (UL) and unique short (US) 
gene regions encoding for approximately 192 open reading frames (ORFs). The virion of 
HCMV consists of a double stranded (DS) DNA genome enclosed by the icosahedral 
nucleocapsid (Fig-1). The nucleocapsid is surrounded by the proteinaceous tegument layer 
formed of phosphoproteins (Fig-1). This layer contains over half of the HCMV-encoded virion 
proteins [17]. Lastly, the tegument is enveloped by a lipid bilayer that contains the 




























Fig 1 – Schematic of a HCMV infectious virion. Adapted from Rogers et al. [18] Rights and permission 





The infectious life cycle begins when the glycoprotein envelope protein gB attaches to viral 
cellular receptors e.g. heparin sulphate proteoglycans, followed by fusion of the virus 
envelope to the cellular membrane mediated by the gH/gL complex (Fig-2) (For a review of 
the lifecycle [19]). The uncoating of the virus and exposure of the nucleocapsid triggers its 
transport to the host cell nucleus, thought to be mediated by the viral tegument proteins, 
utilising host microtubules. Within the nucleus viral proteins utilise the host-cell transcription 
machinery to replicate the genome. The transcription of the HCMV genome occurs in 
temporally controlled phases: immediate early (IE), early (E) and late (L). The transcripts 
from the IE genes are the first to be produced and represent the viral transactivators IE-1 
and IE-2 which drive the transcription of the E transcripts of the genome.  The proteins 
encoded by the E genes function to modulate the host environment and immune response 
so that replication of the viral genome may continue unimpeded. The last transcripts to be 
produced are from the L genes representing the structural proteins that will form the new 
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virions. Once the newly formed DNA genomes are exported out of the nucleus, tegument 
acquisition occurs within the ER-Golgi intermediate compartment. Final envelopment with 
the glycoprotein complexes occurs in the cytoplasm with mature and fully enveloped virions 
egressing from infected cells via a budding and exocytosis event. The entire infectious life 

















Fig 2 – Schematic representation of the HCMV lifecycle. Adapted from Crough and Khanna et al [20]. The 
infectious life cycle of HCMV within a human cell. 1. HCMV attaches to a host cell via interaction of the viral 
glycoproteins (gB and gH) with specific surface cell receptors such as ‘platelet-derived growth factor α’. 2. Entry 
of the virus is then facilitated via a fusion event of the viral glycoprotein envelope with the host cellular 
membrane. This leads to the uncoating of the virus and release of the viral nucleocapsid into the host cell 
cytoplasm. 3. Nucleocapsids are transported to and enter the host cell nucleus. 4. The expression of the viral IE-
1/IE-2 transactivators leads to the initiation of viral DNA replication. 5. Newly replicated viral DNA is encapsulated 
within newly formed capsids, known as primary envelopment, and these then egress to the host cell cytoplasm. 
6. At the ER-Golgi body interface, newly formed viral capsids acquire the proteinaceous tegument layer, known 
as secondary envelopment. 7. Mature infectious virions are produced after acquiring the viral glycoproteins, final 
envelopment, after a budding event. 8. Infectious virions are released by exocytosis. The entire life cycle is 






1.2 – CD8+T-cell immunology 
T-cell mediated immunity consists of two main components -– one for extracellularly-derived 
pathogens (CD4+T-cells) and one for intracellularly-derived pathogens (CD8+T-cells). T-
cells recognise peptides derived from pathogens that are presented on the cell surface 
within the complex of either an MHC class I (MHC-I) or class II (MHC-II) molecule via 
engagement of their ‘T cell receptor’ (TCR).  
 
CD4+T-cells are a critical component in the fight against extracellular pathogens such as 
bacteria and eukaryotic pathogens and are pivotal in providing co-stimulation and cytokines 
to the CD8+T-cell response (review on CD4+T-cell function [21]). CD4+T-cells have recently 
been demonstrated to directly kill virally infected cells via their ‘T-cell receptor’ (TCR) 
recognising peptide:MHC-II complexes on ‘Antigen presenting cells’ (APCs). The focus of 
this study will however be upon the CD8+T-cell arm of the adaptive immune response. 
 
CD8+T-cells are responsible for clearing intracellular viruses and aberrant host cells. Their 
TCR recognises peptides 8-10 amino acids (aa) long derived from intracellular pathogens 
that are presented on the cell surface within an MHC-I molecule. The peptides are generated 
via cytoplasmic proteolytic degradation of infected cells by the proteasome and their 
subsequent transport into the Endoplasmic Reticulum (ER) lumen via the membrane 
associated 'Transporter associated with Antigen Processing' (TAP). Within the ER lumen, 
the peptides are trimmed and loaded onto newly synthesised MHC-I molecules and the 
MHC:peptide complex is released to the cell surface [22]. 
 
The TCR is a complex of membrane bound proteins that facilitate the binding to foreign or 
self-derived peptides presented in the MHC molecules.  Within humans around 95% of 
CD8+T-cells contain a TCR formed of a CD8 heterodimer of αβ chains bound in a non-
covalent complex with the invariant chains of CD3 molecules. These are known as αβ 
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CD8+T-cells. The  remaining 5% are formed of γδ chains [23]. This investigation will focus 
on the αβ CD8+T-cell population.  
 
When the TCR complex engages a peptide:MHC-I complex an immunological synapse 
forms– defined as the contact point between the TCR, co-receptors on the APC (e.g. CD28 
and CTLA-4), peptide:MHC complex and host signalling pathway molecules (LCK, ZAP70, 
ITK, PLC) (reviews [24, 25]). This results in signalling cascades terminating in the 
proliferation, antigen driven differentiation and cytokine/effector molecule production of the 
CD8+T-cell. This in turn leads to the activation-induced cell death and elimination of infected 
target cells via two major cytotoxic pathways: the perforin/granzyme or the Fas ligand/Fas 
receptor apoptosis pathway [26]. In the former pathway, TCR engagement causes secretory 
granules to translocate to the immunological synapse allowing perforin molecules to be 
released and form pores within the target cells [25]. This facilitates the entry of granzyme 
molecules which induce the apoptosis caspase pathways. In the FAS mediated pathway, 
FAS ligands present on the CD8+T-cell engage FAS molecules (a member of the TNF 
receptor superfamily) on the surface of the target cell to be killed. This then also activates 
the apoptosis caspase pathways within the target cell. 
 
The CD8+T-cell repertoire within the human body has to be capable of responding to all 
potential pathogens encountered during a life time. The immune system must generate 
enough diversity of CD8+T-cell populations with distinct TCRs and therefore differing antigen 
specificity. To do this genetic recombination occurs within the thymus between the encoded 
segments – constant (C), variable (V), diversity (D) and joining (J) – of the α and β chains. 
This determines the structure of the antigen binding site of the TCR and the large overall 
diversity (Fig-3) [27]. The hypervariable sections of the TCR known as the ‘complementarity 
determining regions’ (CDRs) 1 and 2 regions are germline encoded within the V gene (Fig-3) 
and they play a role in binding to the MHC-I molecule. The third hypervariable region, CDR3, 
is situated between the V, D and J sections on both the α and β chains and is responsible for 
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recognising the peptide:MHC complex and therefore provides the antigenic specificity. 
Further diversity in the TCR chains is provided by the insertion of non-template encoded 
nucleotides within the CDR3 region (referred to as ‘N’, Fig-3). The CDR3 regions vary 
between different TCRs whilst the CDR1/2 sequences do not as they are germline encoded, 
however, the usage of common chains between TCRs varies. In total, within the human TCR 
loci, there are 43 V and 58 J α gene segments and 42 V, 2 D and 12 J β gene segments 
[28]. It has been postulated that the overall antigenic diversity of the human CD8+T-cell 





Fig 3 – Somatic recombination of the TCR α and β chains. [27]. Permission to reuse content in this thesis 
obtained from Nature Reviews Immunology. Licence number 3885290794359. A) TCRs are formed of a 
heterodimer of an α and β chain generated by somatic gene recombination between the V-J (α chain) and V-D-J 
(β chain) segments. B) Hypervariable CDR regions. CDR1 and CDR2 are germline encoded within the V gene 
segment. CDR3 is situated between the V and J gene segments. N refers to the sites of additional non-template 









1.3 – CD8+T-cell memory subsets 
During an immune response to pathogens, CD8+T-cells transit through three distinct 
phases; antigen-stimulation and expansion, death of effector cells and the formation of a 
pathogen-specific memory CD8+T-cell pool (Reviewed [29]). Once the primary infection has 
been cleared and the pathogen eliminated, ~95% of effector T-cells (defined by high 
proliferative capacity and cytotoxicity) die via apoptosis [30]. This leaves a small pool of 
about 5-10% of long lived pathogen-specific memory CD8+T-cells. These reside in organs 
until antigenic rechallenge.  This memory CD8+T-cell pool is maintained for life and can be 
broadly categorised into 4 memory subsets; ‘Central memory T-cells’ (TCM), Effector memory 
T-cells (TEM), ‘T-cell Effector Memory Revertant’ (TEMRA) and the recently defined ‘Tissue 
resident memory T-cells’ (TRM) (review [31]). 
 
Naïve CD8+T-cells (TN) that have not yet encountered cognate antigen, express selectins 
and chemokine receptors allowing migration to the secondary lymphoid organs e.g. lymph 
nodes. The cell surface expression of the CD45RA isoform and chemokine receptor 7 
(CCR7) are used to differentiate naïve T-cells from antigen experienced T-cells. Within the 
secondary lymphoid organs they encounter their cognate antigen and mature into effector T-
cells.  Effector T-cells – activated T-cells – lack CCR7/CD62L expression so that they are 
able to migrate to non-lymphoid sites of inflammation, kill infected cells and resolve the 
infection. Once the acute infection has been resolved and antigen stimulation removed, 
~90% of these effector cells die off and the remaining differentiate into resting memory 
CD8+T-cells subsets demonstrating differing surface phenotypes and effector functions.  
 
TCM patrol are memory CD8+T-cells that patrol between the blood and secondary lymphoid 
organs e.g. lymph nodes and tonsils, produce IL-2 and are able to proliferate efficiently. 
Their surface phenotype is CCR7+, CD45RO+, CD27+/CD28+ (co-stimulatory markers)  
CD127+ (IL-7 receptor) and CD62L+ (lymph node homing ligand). These TCM cells provide 
long term protective responses from within secondary organs such as the lymph nodes 
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initiate secondary immune responses to generate a second wave of effector CD8+T-cells 
which are able to enter the periphery [31, 32]. However, as this subset does not have 
immediate effector function they cannot initially contain secondary viral infections [31, 33] . 
 
TEM are memory CD8+T-cells that circulate the blood and peripheral tissues e.g. gut 
mucosa, have immediate effector function and secrete potent amounts of IFN-γ. Their 
surface phenotype is CCR7-, CD45RO+, CD62L-, and CD27-/CD28- (Reviewed [32, 34]). 
These TEM cells provide protection from secondary infections at peripheral sites where the 
primary infection occurred or subsequent infections are likely to occur [32]. Typically once 
the acute infection has been controlled, TEM in the periphery decline to low stable numbers 
until antigenic rechallenge.  
  
In addition to the TCM and TEM memory subsets, a CD8+T-cell memory subset representing 
highly differentiated memory T-cells has been described that patrols the periphery. The 
subset is termed 'T-cell Effector Memory Revertant' (TEMRA) based upon their re-acquisition 
of the CD45RA isoform. These are a subset of highly cytotoxic memory CD8+T-cells that 
lose CCR7 expression and are perforin and granzymeB positive (Reviewed [34]).  The 
development of this subset has been linked to the chronic stimulation of the T-cells by viral 
antigen [29, 35]. The re-expression of the CD45RA isoform is thought either due to 
prolonged periods of antigen absence or is re-acquired to provide long term survival signals 
to the CD8+T-cell [36] [37]. 
 
Recently, a subset of memory CD8+T-cells termed ‘Tissue resident memory T-cells) (TRM) 
have been described that are CD69+CD103+ (review [38, 39]). TRM maintain large peripheral 
tissue numbers after resolution of an acute infection but do not circulate throughout the 
periphery. TRM therefore represent an anatomically distinct population to the peripherally 
located TEM and TEMRA. At this tissue location they provide a first line of immunosurveillance 
and defence against secondary infections due to their high proliferative capacity.  
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1.4 – Immune Response to CMV 
HCMV is arguably one of the most immunogenic human pathogens studied to date. The 
virus induces both the innate and adaptive arms of the immune response including 
inflammatory cytokines, neutralising antibodies, Natural Killer (NK) cells and CD4+ and 
CD8+T-cells [40].  
  
The first line of host defence upon HCMV entering cells is provided by the innate signalling 
pathway - initiated via the interaction of the glycoprotein B (gB) and glycoprotein H (gH) with 
Toll-like receptor 2 (TLR2) on target cells. This ultimately leads to the production of 
inflammatory cytokines such as ‘Interferon gamma’ (IFN-γ) and ‘Tumour necrosis factor 
alpha’ (TNF-α) via the NF-κB dependent signal transduction pathway [41]. This inflammatory 
environment recruits NK-cells to the point of viral replication. NK-cells are now well 
recognised as being an important primary defence against viral pathogens [42] as viral 
infection leads to the up-regulation of activating ligands for NK-cells such as MICA/B and 
ULBP6 [43]. Conversely, this cytokine induced pro-inflammatory environment may be 
beneficial to HCMV replication. IFN-γ and TNF-α recruit myeloid immune cells such as 
dendritic cells and macrophages to the site of viral infection which are permissible to HCMV 
infection [14]. This inflammatory environment therefore represents a potential method of 
HCMV dissemination to establish foci throughout the peripheral system [44, 45].   
  
Little is still currently known on the role of NK-cells in controlling HCMV infection. The 
adoptive transfer of MCMV-specific NK-cells recognising the m157 protein from MCMV-
infected mice to non-infected mice provided protection from CMV challenge [46]. This 
implicates NK-cells as important in the initial control of the virus. Foley et al. have recently 
associated a population of MCMV-specific NK-cells expanding over a period of time 
expressing the NKG2C activating receptor [47]. Recently, Redeker et al. demonstrated a 
positive correlation between NK-cells and a reduced MCMV viral load by day 4 after primary 
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MCMV infection of WT mice – thus further implicating the role of NK-cells in early MCMV 
control [3].  
 
Antibodies also play a recognised role in control of CMV. The majority of antibodies directed 
towards HCMV are directed towards the pentameric envelope complex  gH/gL(ul128-131) 
but have also been detected for pp65, pp150 (Reviewed [48]). Antibodies specific for the 
multimeric gH/gL (UL128-131) complex demonstrate viral neutralisation properties 
preventing dissemination [33]. However, a recent study indicated that these HCMV-specific 
antibodies are not sufficient to prevent the cell to cell spread of HCMV [49]. Importantly, 
HCMV-specific IgG titre has been demonstrated to increase with age. This correlated with an 
increased HCMV viral load within older donors and a decrease in the IE-1-specific cellular T-
cell response. Indicating that the adaptive response is more critical than humoral for viral 
control in older age [50].  
  
The CD4+ and CD8+T-cell responses represent the critical component of the immune 
response for HCMV control.  Their development and maintenance is essential to maintaining 
the control of viral reactivation events and therefore preventing the production of new 
infectious virions. This is supported by the fact that immunosuppressed individuals develop 
uncontrolled viral replication in the absence of adaptive control [51].  The frequencies and 
magnitudes of peripheral T-cells specific for HCMV are the largest recorded for a viral 
pathogen to date, vary greatly between seropositive individuals, dominate the T-cell memory 
compartments and reduce the naïve T-cell compartment (discussed in section 1.5/1.7). 
Within young donors the HCMV-specific T-cells also represent a significant percentage of 
the memory T-cell population (discussed in section 1.5-7).  
 
Evidence supporting the role of CD4+T-cells in controlling CMV infection is provided by 
studies in renal transplant patients who acquire primary HCMV infection. Within otherwise 
healthy asymptomatic patients the emergence of HCMV-specific CD4+T-cells was at an 
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earlier time-point than CD8+T-cells. However in renal transplant patients who presented with 
a delayed CD4+T-cell response, HCMV disease developed [52]. Furthermore, the 
maintenance of adoptively transferred HCMV-specific CD8+T-cells required CD4+T-cell help 
to control HCMV within bone marrow transplant patients [53-55]. Lastly, within HSCT 
patients an inverse correlation between CMV-specific CD4+T-cell levels and viral 
reactivation episodes was observed indicating their critical role in controlling CMV viral load 
[56].  
 
The CD4+T-cell response to HCMV is broadly directed across the genome [57, 58] including 
towards but not limited to the gB, pp65, UL86, IE and gH proteins. HCMV-specific CD4+T-
cell responses within young donors have been reported to reach 10% of the total peripheral 
CD4+T-cell pool. These CD4+T-cells display a phenotype of decreased CD27/CD28 
expression, a concomitant decrease in IL-2 production and are CD57+ with age [59]. They 
can have cytotoxic phenotypes expressing high levels of GranzymeB and Th1 cytokines [60, 
61]. MCMV and HCMV-specific cytotoxic CD4+T-cells have been shown recently to directly 
kill peptide-loaded targets in vitro [61, 62] and express high levels of CX3CR1 postulated to 
direct them towards infected endothelium in vivo [61].  
 
Evidence supporting the crucial role of CD8+T-cells in MCMV control includes the adoptive 
transfer of IE-1-specific CD8+T-cells into mice depleted for CD8+T-cells. These mice were 
protected from a lethal challenge with MCMV [63]. Within humans, the same principle has 
been applied by Riddell at al. where HCMV-specific CD8+T-cells that were expanded ex 
vivo, protected patients from primary and reoccurring HCMV manifestations [64].  
 
1.5 – The CD8+T-cell response to CMV 
The ex vivo CMV-specific CD8+T-cell response has been extensively investigated due to the 
use of validated methods such as; enzyme-linked immunosorbent spot (ELISpot) assays, in 
vitro peptide stimulation followed by intracellular cytokine staining (ICS) by flow cytometry 
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and the development of MHC-I tetramer technology. These methods have increased the 
knowledge of the breadth and magnitude of the HCMV-specific CD8+T-cell response and 
allowed comparison to other antiviral CD8+T-cell populations [65, 66].   
 
HCMV primary infection is difficult to investigate due to its asymptomatic nature; therefore 
the natural progression of the HCMV-specific CD8+T-cell response with age is poorly 
understood. However, using HCMV seronegative renal transplant patients who acquire 
HCMV post-transplant, it has been shown that during primary infection HCMV-specific 
CD4+T-cells precede the emergence of CD8+T-cells. Additionally that most peripheral CMV-
specific CD8+T-cells during primary infection are of an earlier differentiated phenotype - 
CCR7-CD27+CD28+/-CD45RA-CD45R0+ [67, 68]. As these renal transplant patients enter 
latency, the peripheral CD8+T-cells progress to a later differentiated TEMRA phenotype - 
CCR7-CD27-CD28-CD45RA+CD45R0- [67, 68].  
 
The main defining features of latent CMV-specific CD8+T-cells are; CD45RA+ reexpression, 
high cytotoxic potential (defined by intracellular perforin and granyzmeB granules) [69] and 
loss of CD27/CD28 expression [70]. Altogether, CMV-specific CD8+T-cells display features 
that typically indicate a T-cell further down the maturation pathway yet are still functional 
[71]. A unique feature of the CMV-specific CD8+T-cell populations is the high expression of 
the fractalkine receptor CX3CR1. This has also been shown at the transcriptional level to be 
present on CMV-specific CD8+T-cells during acute infection and maintained through to 
latency [72]. CX3CR1 may be responsible for homing CMV-specific memory CD8+T-cells to 
the endothelium. This provides a plausible hypothesis for why these highly cytotoxic CMV-
CD8+T-cells have been implicated in causing cardiovascular disease/damage [2, 4] 
 
HCMV encodes for >160 antigenic proteins [73]. The first HCMV-specific CD8+T-cell 
responses detected were against the 72KDa IE-1 transactivator  protein [74] followed by the 
pp65 phosphoprotein [75]. The IE-1 and pp65 proteins in particular were focused upon as 
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they are the first viral protein to be expressed and most abundant tegument protein 
respectively. This has led to the assumption that they are the immunodominant proteins of 
HCMV and facilitated numerous studies into pp65/IE-1-specific CD8+T-cell responses [76-
79].  
   
Recent focus has been on evaluating the global CD8+T-cell repertoire dedicated towards 
CMV. One study investigated synthetic peptides from 14 HCMV proteins: gH, gB, IE-1, US2, 
US3, US6, US11, UL16, UL18, pp28, pp50, pp65, pp71 and pp150 to analyse the HCMV-
specific CD8+T-cell responses ex vivo. The results identified CD8+T-cell responses to all 
peptides, albeit at differing magnitudes, and new CD8+T-cell epitopes were subsequently 
characterised [58].  
 
The most detailed study to date analysed the CD4+ and CD8+T-cell response to all 213 
HCMV open reading frames (ORFs) [57]. Synthetic peptides were generated and T-cell 
responses against them investigated in 33 seropositive donors by detection of IFN-γ 
producing CD4+ and CD8+T-cells using flow cytometry [57]. A median of 8 and a total of 151 
ORFs elicited HCMV-specific CD8+T-cell responses within these donors. This study 
provided the first global picture of the breadth of the T-cell response to HCMV. However, this 
study by Sylwester et al. did not identify specific CMV-derived T-cell epitopes. 
 
However, HCMV encodes for several proteins that interfere with viral MHC-I presentation to 
the immune response [80, 81]. The above are two examples of studies that were carried out 
with donors infected with WT strains containing the MHC-I immunomodulatory proteins. 
Therefore there was the possibility that the magnitude or breadth of the HCMV-specific 
CD8+T-cell response detected was masked by the down-regulation of MHC-I within the 
seropositive donors. In order to characterise the HCMV-specific CD8+T-cell response in the 
absence of the US genes, Khan et al. utilised a US2-US11 immunevasin deleted strain of 
HCMV termed 'RV798' developed by Jones et al. [82, 83]. This was to allow all potential 
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HCMV antigenic epitopes to be displayed upon the surface of infected cells without the 
interference of MHC-I down-regulation [84]. Increased surface levels of MHC-I were 
observed on RV798 infected fibroblasts, compared to the WT- infected fibroblasts, which 
subsequently led to an increased CD8+T-cell recognition by both IE-1 and pp65-specific 
CD8+T-cell clones – up to 10-fold. After this finding, the authors then also defined novel 
target antigens of HCMV-specific CD8+T-cells and found them to be directed across the 
HCMV genome functioning in both the early and late phases of the viral life cycle. HCMV-
specific CD8+T-cells were then screened for killing ability with ‘Modified Vaccinia Ankara’ 
(MVA) modified to express individual HCMV proteins. CD8+T-cells co-cultured with RV798 
cells were efficiently able to target a broader range of HCMV targets including, pp150, pp50, 
IE-2 and gB. 
 
Manley et al. also utilised the RV798 strain to analyse both the specificity and frequency of 
HCMV-specific CD8+T-cells [82]. Fibroblasts, derived from healthy seropositive donors, 
were infected with RV798 and the overall CD8+T-cell response analysed. The authors found 
the CD8+T-cell recognition of the RV798 infected fibroblasts to be increased 40-fold 
compared to those infected with the WT strain. The results observed that the majority of the 
CD8+T-cells were directed towards the pp65 and IE-1 proteins as previously published, but 
interestingly, CD8+T-cell responses were detected towards IE and E proteins not yet 
characterised. Utilising single knockout strains of CMV to identify which proteins the CD8+T-
cell clones were specific for by observing the loss of killing, Riddell and colleagues then 
characterised the CD8+T-cell epitopes. The sequences of a selection of 16 epitopes were 
kindly provided to our research group (Table-7, [85]). The epitopes were found to be derived 
from HCMV antigens broadly spread across all phases of the viral life cycle including UL16, 
UL17, UL23, UL24, UL28, UL33, UL36, UL52, UL56, UL84, UL105, UL122 and US23. The 
same work by Riddell et al. identified novel peptides derived from the US22 and US34 
proteins that are translated in a non-canonical method – via translation of an alternative ORF 
16 
 
that begins +2aa from the canonical methionine start codon. These were termed ‘cryptic’ 
CD8+T-cell epitopes (Riddell et al. unpublished data Table-10). 
 
Clearly, the CD8+T-cell response to HCMV is one of the broadest and largest documented 
to a viral pathogen to date.  
 
 
1.6 - HCMV memory-inflation 
Memory-inflation defines the phenomenon whereby virus specific CD8+T-cells increase 
substantially within the periphery with age. The term ‘memory-inflation’ was first devised 
after investigating virus-specific T-cell responses in MCMV infected mice longitudinally using 
utilising MHC-I tetramer technology. Large peripheral increases in CMV-specific CD8+T-
cells was observed with age [86]. Memory-inflation has since been observed during infection 
with other human viral pathogens [29, 87, 88]. For example, after systemic ‘Herpes Simplex 
Virus 1’ (HSV-1) infection, gB-specific CD8+T-cells accumulate in the periphery [89]. A third 
Herpesvirus ‘Epstein Barr Virus’ (EBV) induces CD8+T-cells specific for an immunodominant 
epitope that increase with age [90]. However, the total number of EBV-specific CD8+T-cells 
within the periphery did not alter with age. Memory-inflation is therefore most pronounced for 
HCMV [87, 91-93] and has also been demonstrated within several animal models of CMV 
infection e.g. mice and monkeys [76, 94, 95].  
 
There is currently no model for EBV infection, therefore the availability of the MCMV and 
‘Rhesus CMV’ (RhCMV) model provides a good platform to study the phenomenon of 
memory inflation.  An advantage to using animal models, in particular MCMV, is the ability to 
longitudinally study the generation and maintenance of memory inflation during the animal’s 
lifetime. However there are some drawbacks to the use of such animal models and the 
translation of data obtained from these models to HCMV memory inflation. For example, the 
immunology of MCMV and RhCMV may lack important aspects of human immunology [96, 
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97]. Additionally, as CMV’s are highly species specific, the replication and pathogenesis of 
MCMV and RhCMV may differ to HCMV in vivo. For example, unlike HCMV, MCMV 
genomes and reactivation can be observed within the lungs of infected mice [98]. Therefore 
it is also important to study the phenomenon of memory inflation within the context of HCMV, 
cross-sectionally, and where possible longitudinally, within seropositive individuals.  
 
CMV specific CD4+T-cells have been documented to undergo memory-inflation however not 
to the extent of CD8+T-cells [59]. CD4+T-cell memory-inflation within the murine model has 
been documented against a single epitope m09133-147 [99]. With regards to HCMV, the total 
CMV-specific CD4+T-cell population has recently been demonstrated to increase with age 
from 2.2% (donors <50 years) to 4.7% of the total CD4+T-cells (donors >65 years) [59] [60]. 
However unlike CD8+T-cell memory inflation, this does not lead to an imbalance of the ratio 
of the memory compartments and has been poorly investigated.  The exaggerated CD8+T-
cell memory-inflation will be the focus of this investigation.   
 
To date, HCMV represents the largest immunodominant pathogen to the human immune 
response. Within elderly seropositive individuals, the HCMV-specific CD8+T-cell response is 
reported to be on average 10% of the total peripheral CD8+T-cell pool compared to 2% 
within the young [77]. Investigations by Moss et al. and Lang et al. demonstrated HCMV-
specific CD8+T-cell responses could reach 21% and 50% of the total peripheral CD8+T-cell 
pool towards a single pp65 epitope respectively [87, 100]. CD8+T-cell responses to the pp65 
and IE-1 proteins have additionally been documented to account for 50% of the total 
peripheral CD8+T-cell response within elderly individuals [77] and represent 
immunodominant antigens [71, 75, 101, 102]. The scale of HCMV epitopes that display 
memory-inflation or have the potential to inflate has not yet been identified or investigated. 
This is largely a result of the difficulty in distinguishing when individuals first become CMV-
positive making it almost impossible to longitudinally follow specific CD8+T-cell populations 
and pin-point when they begin to inflate. It is for this reason that memory-inflation has been 
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best studied within the murine model where CMV primary infection can be followed to 
latency. These studies have led to the identification of two distinct types of MCMV CD8+T-
cell epitopes– ‘stable’ vs ‘inflationary’ – whereby only ‘inflationary’ epitopes elicit CD8+T-cell 
populations that undergo memory-inflation [[103, 104].  
 
Stable CD8+T-cell epitopes e.g. M45985-993 MCMV epitope, elicit CD8+T-cell responses that 
follow the classical pattern of T-cell expansion, contraction and maintenance at low level 
after a typical pathogen infection. These CD8+T-cell populations demonstrate a TCM 
phenotype. The opposite is seen with inflationary CD8+T-cell epitopes e.g. M38316-323 MCMV 
epitope. Here the specific CD8+T-cells accumulate over time and represent a TEMRA 
phenotype. It should be noted that these distinct CD8+T-cell responses are not restricted to 
the M45 and M38 proteins and both stable and inflationary CD8+T-cell populations have 
also been identified towards the M57816-824 or m139419-426  and IE3416-423 peptides respectively 
[105].  
 
Within humans, this distinction between CD8+T-cell populations has not yet been made. 
However, through cross-sectional studies of chronically infected donors, it has been 
identified that peripherally inflated HCMV-specific CD8+T-cell responses have a unique 
phenotype associated with ‘dysfunctional’ or ‘end stage’ CD8+T-cells during latency [70, 87, 
106-108]. They have been identified as; CCR7-/CD27-/CD28-/CD45RA+/CD57+ therefore 
representing a TEMRA phenotype [71, 106]. This is in comparison to earlier-differentiated 
HCMV-specific CD8+T-cells detected during primary infection being; 
Ki67+/CD45RO+/CD45RA-/CD27+ [109]. It has since been established that inflationary CMV 
CD8+T-cells are still functional and capable of exerting anti-viral effects [87, 91]. They are 
extremely Th1 cytokine producing, with the exception of IL-2, and high for perforin and 
granzymeB [70, 72, 87, 91]. Importantly, they show no signs of functional exhaustion with 




The mechanisms driving memory-inflation and its maintenance are at present undefined. 
However, the unique TEMRA phenotype of CMV CD8+T-cell accumulations likely point to low 
level antigen presentation to these peripheral CD8+T-cells throughout the lifetime of the 
infected host. The presence of CD45RA on HCMV-specific CD8+T-cell expansions may 
suggest that they have not encountered their cognate antigen for a period of time [111]. 
CD45RO is now known to require persistent antigen-stimulation to remain expressed on the 
surface of CD8+T-cells [37]. On the other hand, others state that CD45RA re-expression is a 
product of chronic antigen stimulation and is providing survival signals to the CD8+T-cell 
[36].  
 
It is clear that the CD8+T-cell response is effective at limiting the production of infectious 
virions by halting replication at the IE/E stage within the lungs of infected mice [112, 113].  
These foci of viral IE/E gene expression may represent reservoirs of antigen source for the 
chronic stimulation of the IE/E-specific CD8+T-cell response.  Infection of mice with a mutant 
strain of MCMV (termed ΔgL-MCMV) unable to replicate more than once due to a deletion in 
the glycoprotein L (gL), still allows for the development of memory-inflation but at a lower 
magnitude [114]. Interestingly indicating that the continuous production of infectious particles 
over time is not required for memory-inflation. However, our research group has utilised a 
highly replication attenuated strain of MCMV, termed tsm5, to infect mice and followed the 
resulting CD8+T-cell response. The study demonstrated that memory-inflation is abolished. 
The difference between the two mutant CMV strains is that ΔgL-MCMV can complete viral 
DNA synthesis during reactivation events within the cells infected during primary infection 
but newly infectious virions cannot enter new cells. Conversely the tsm5 strain cannot 
complete viral DNA synthesis. 
Together this data therefore supports a hypothesis that sporadic viral reactivations resulting 
in CMV gene expression and MHC-I presentation of these proteins is required to re-stimulate 
the initial CD8+T-cell pools primed during primary HCMV infection. The production of fully 
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infectious progeny is not required. Over time this stimulation results in a CD8+T-cell 
population with an ‘end-stage’ TEMRA phenotype. This will be termed the ‘antigen encounter 
theory’ in this investigation. 
Further studies supporting the antigen encounter theory were conducted in mice whereby 
the adoptive transfer of HCMV-specific CD8+T-cells with a TCM phenotype differentiated into 
a TEMRA phenotype that quickly migrated to the periphery  - suggesting antigen stimulation is 
driving their differentiation [115]. The recruitment of new CD8+T-cells into the periphery from 
the thymus was found as a dispensable factor for memory-inflation maintenance within 
thymectomized mice - suggesting the inflated CD8+T-cell populations may be maintained by 
peripheral antigen encounter [116].  
A study by our research group implicates the replication of MCMV genomes as sufficient to 
maintain memory-inflation [117]. Moss et al. discovered that the treatment of MCMV-infected 
mice with valaciclovir over a period of 12 months, seemingly resolved memory-inflation and 
increased the total naïve CD8+T-cell pool. Furthermore, the degree of T-cell differentiation of 
inflated populations was decreased within the mice. This indicated that DNA synthesis 
during MCMV reactivation plays a role in both the maintenance and driving the differentiation 
of the inflated CD8+T-cell responses.  
The last study supporting the antigen encounter theory to be discussed is one by Snyder 
and colleagues who demonstrated that the memory-inflation pool of MCMV-specific CD8+T-
cells is maintained by the constant replenishing of MCMV-specific effector cells as they are 
short-lived [103, 118]. Adoptively transferred MCMV-specific CD8+T-cells into latently 
infected mice were described as infrequently dividing but instead replaced by new effector 
CD8+T-cells from lymphoid organs they hypothesise in response to antigen stimulation by 






1.7 – Stable vs. inflationary CMV CD8+T-cell populations and epitopes – what factors 
define whether a CD8+T-cell response will inflate? 
Clearly, the antigen encounter theory does not explain why only certain CD8+T-cell 
population’s specific for particular epitopes within individual CMV proteins inflate. Some 
explanations as to why some CMV-peptide-epitopes demonstrate inflationary capacities 
have been provided within the literature. 
 
1. Gene expression context 
One of the most obvious explanations as to why an epitope may have an inflationary 
advantage over others is the expression kinetics during the virus lifecycle. Those expressed 
earlier during the lifecycle will have an enhanced opportunity, over those expressed with L 
kinetics, for presentation to the CD8+T-cell response before elimination of the infected cell. 
Kurz et al. presented evidence of MCMV replication frequently within the lungs of infected 
mice that did not lead to the production of new infectious progeny i.e. L stages of reactivation 
[112, 113]. Reddehase and colleagues further demonstrated that MCMV RNA present within 
the lungs was transcribed from the IE genes with no E or L RNA present. This indicated the 
quick control or abortion of complete viral reactivation by IE/E-specific MCMV-specific 
CD8+T-cells before viral progeny production. In support of these findings, Simon et al. 
demonstrated the removal of MCMV-infected cells by IE-1-specific CD8+T-cells during 
stochastic reactivation events in the lung [119]. Proving that IE-derived antigens can reach 
the cell surface during a reactivation event leading to the CD8+T-cell removal of the cell 
before antigens derived from the E-L phases can also reach the cell surface. Thus 
preferentially expanding the IE-specific CD8+T-cell pool. 
Dekhtiarenko et al. showed that the fusion of a Herpes Simplex Virus 1 (HSV-1) peptide-
epitope to a MCMV promoter with IE kinetics, lead to the development of a specific CD8+T-
cell population with inflationary kinetics. Conversely, the fusion of the same HSV-1 epitope to 




Overall these studies clearly implicate the expression kinetics of the CMV protein as 
important in whether an epitope derived from said protein will be inflationary. However, these 
studies do not explain why several CMV proteins such as M102 encode for CD8+T-cell 
epitopes displaying both stable and inflationary characteristics within the same open reading 
frame. Therefore, other factors must ultimately also contribute to the overall ability of an 
epitope to be inflationary.  
2. Peptide-epitope processing and competition for peptide-epitope at the APC level 
It would be reasonable to assume that memory-inflated CD8+T-cell pools may have arisen in 
part due to the availability of mature epitope:MHC complexes on APCs. An important factor 
that determines the surface concentration of a peptide-epitope in a stable complex with 
MHC-I is the efficient generation of the mature epitope [120].  
The immunoproteasome is a derivative of the classical proteasome whose synthesis in non-
haematopoietic cells requires stimulation by IFN-γ inflammatory environments but is 
expressed constitutively in haematopoietic cells [121]. It has been proposed that stable 
(M45985-993) vs inflationary (M38316-323) epitopes are generated by the immunoproteasome vs 
classical proteasome respectively [122]. The authors hypothesise that once latency has 
been established, and the inflammatory signals have been removed, only the non-
haematopoietic cells expressing the classical proteasome can process epitopes during a 
viral reactivation event. These can then drive the accumulation of the resulting CD8+T-cell 
pool. This is important as non-haematopoietic cells are implicated as the cell type 
responsible for driving memory-inflation during latency [104, 123]. 
Studies in the murine model have led to the identification that competition between differing 
CD8+T-cell population’s for peptide:MHC-I complexes on the same MCMV-infected cells, 
influences the overall immunodominance of the CD8+T-cell repertoire. Farrington et al. 
infected mice with a recombinant MCMV expressing the SIINFEKL peptide (MCMV-GFP-
SL8) under the control of the IE2 promoter [124]. Within these mice SIINFEKL-CD8+T-cell 
responses inflated and WT MCMV-inflation was abolished.  However, a co-infection of mice 
with both WT-MCMV and the MCMV-GFP-SL8 strain allowed the development of inflationary 
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CD8+T-cell responses specific for both MCMV epitopes and SIINFEKL [124]. The authors 
hypothesised that the higher avidity of the SIINFEKL peptide within MCMV-GFP-SL8 
infected mice led to an increased surface concentration of SIINFEKL:H-2Kb complexes over 
the MCMV:H-2Kb complexes. However during co-infection, the WT MCMV vs MCMV-GFP-
SL8 strains established distinct loci of infected cells allowing the presentation of MCMV 
peptides vs SIINFEKL on different APCs. This suggests that sufficient antigen:MHC 
complexes must be available on infected cells to be presented to the CD8+T-cell response 
for them to inflate.  
3. CD8+T-cell avidity 
It has also been proposed that MCMV-specific CD8+T-cell populations with a higher avidity 
for cognate peptide are preferentially maintained during latency by the host immune 
response to more effectively control viral reactivation events [125]. In support of this, are 
numerous studies that document the oligoclonality and increase in avidity of HCMV-specific 
CD8+T-cell populations with age [126] [87] [127]. Notably, that this high avidity TCR usage is 
also conserved between several different HCMV positive individuals [128]. Inflated HCMV-
specific CD8+T-cell populations have been documented as derived from single CD8+T-cell 
clones undergoing stimulation and expansions within hosts in vivo [76] [129]. Importantly, 
conflicting evidence has been provided where an accumulation of a low affinity CD45RA+ 
pp65-specific CD8+T-cell population was observed within older adults [130]. Therefore, 
more research is needed in this area to clarify whether the accumulations of highly avid 
HCMV-specific CD8+T-cell populations are maintained at the detriment to their lower avid 
counterparts during latency and whether memory-inflated responses correspond to higher 
avidity populations.  
4. CD8+T-cell co-stimulation 
Additional information on the requirements by a CD8+T-cell that will inflate was provided by 
Arens and colleagues whose data indicated that stable vs. inflationary MCMV-specific 
memory CD8+T-cell populations require different co-stimulatory signalling with inflated 
CD8+T-cells not requiring CD28 co-interaction [131]. This implies that the stimulation of 
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memory-inflated CD8+T-cells vs initial priming of CD8+T-cell responses occur via differing 
mechanisms. It also fits with the CD28- phenotype described for inflated CMV CD8+T-cells.  
5. Antigen presenting cell type in vivo 
Evidence is now mounting that despite myeloid cells being the major latency site for HCMV, 
non-haematopoietic cells are responsible for directly presenting the CMV antigen to CD8+T-
cells that ultimately inflate [132]. Torti et al. utilised the Batf3-/- murine model to investigate 
the role of cross-presenting DCs in the generation of memory-inflation [133]. These mice are 
unable to develop CD8α+, CD11b- and CD103+ DCs. Mice were infected with MCMV and 
the M38, M139, IE3 inflationary and M45 stable responses followed over time via flow 
cytometry. The results demonstrated that within the inflationary responses there are two 
distinct kinetic patterns; early inflation developing towards the M38 and m139 proteins and a 
second later inflation developing towards the IE-3 protein. However, the IE-3 inflation after 
the initial accumulation contracted and was later abolished compared to IE-3 inflationary 
CD8+T-cells within WT infected mice. This implicates the role of DCs in priming the IE-3 
inflation but the M38 and m139 inflationary CD8+T-cell responses initiated via conventional 
priming.  
Corroborating these findings was a second murine study by Torti and others [104]. The 
authors utilised a mouse model whereby non-haematopoietic cells lacked the expression of 
H-2Kb which inflationary M38-specific CD8+T-cells are restricted through. Within the H-2KB 
deficient mice M38-inflation within the blood and peripheral tissues was lost. During latency, 
only WT mice demonstrated extensive M38 CD8+T-cell proliferation and this was within the 
lymph nodes where they presented with a TCM phenotype and M38-specific CD8+T-cells 
within the blood demonstrated low proliferation rates. They subsequently demonstrated that 
the dependence of memory-inflation on non-haematopoietic antigen presentation was a 
general phenomenon of MCMV inflationary CD8+T-cell populations towards IE-3 and m139. 
By utilising mice lacking β2-microglobulin (β2M) expression, except on DCs in the thymus, 
they demonstrated that IE-3 and m39 inflation was abrogated. This DC-restricted CD8+T-cell 
priming had little effect on typical M45 stable CD8+T-cell kinetics i.e. same percentage of 
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M45-CD8+T-cells within the periphery over time.  This implicates DC cross priming as 
sufficient in initial CD8+Tcell generation and maintenance of stable CD8+T-cells but 
insufficient for the generation of memory-inflation. The same study also quantified MCMV 
genomes within splenic and lung non-haematopoietic vs haematopoietic cells during the time 
course of an MCMV infection. Larger quantities of the MCMV genome were present within 
the non-haematopoietic population until 28 days post infection. MCMV DNA decreased 
within the haematopoietic population from day 7 p.i to non-detectable levels 28 days p.i. This 
study speculates that during lytic replication MCMV is present within both cell types to prime 
initial CMV-specific CD8+T-cell responses but as latency is established only non-
haematopoietic cells contain MCMV genomes to present during reactivation events.  
Torti et al subsequently proposed a model for memory-inflation generation. LN-residing TCM 
M38-specific populations, when restimulated by non-haematopoietic cells during reactivation 
events, proliferate extensively and serve to replenish the peripheral TEMRA pool during MCMV 
reactivation.   
Corroborating these findings, Redeker and colleagues quantified the levels of the MCMV 
genome in non vs. haematopoietic splenic cells and found that early during infection the 
genome is present in equal abundance in both cells types. As infection progresses the 
genome is predominantly situated within the non-haematopoietic population [3]. These 
studies therefore provide compelling evidence for the role of non-haematopoietic cells in 
driving memory-inflation via the presentation of CMV antigens during a CMV reactivation 
event.  
Lastly, a second model for memory-inflation has been suggested that is dependent on CMV-
specific CD8+T-cell exposure to antigen presented by non-haematopoietic cells such as 
endothelial cells with access to the blood supply [123]. Smith et al. demonstrated the 
stimulation of inflationary CD8+T-cells within LNs was dispensable for the maintenance of 
inflation after blocking CD8+T-cell regress from the LN. After treatment of mice with FTY720, 
the numbers of inflationary CD8+T-cells within the blood reduced little and retained the same 
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chronic stimulated phenotype. The M38-specific inflationary CD8+T-cells within mice that 
had migrated to peripheral tissues e.g. lungs and liver were present within areas that were 
accessible to the systemic circulation. Additionally, that the M38-specific inflationary CD8+T-
cells residing within the spleen of FTY720 treated MCMV infected mice were associated with 
the red pulp and therefore in direct association with the blood supply.  
6. Initial viral dose  
Within healthy human donors, the magnitude of HCMV-specific responses documented 
varies between 0.1-5% for young donors and >10-40% within elderly donors [57, 58, 76, 77, 
87]. Recently, Redeker et al. addressed the underlying mechanisms that may explain the 
variation in magnitude of the HCMV-specific CD8+T-cell responses [3]. Their initial 
hypothesis was based upon the assumption that the tissue initially infected by HCMV in any 
one person will have varying quantities of HCMV particle. It stated that the primary viral load 
a naïve individual receives impacts upon the magnitude of memory-inflation. Additionally the 
authors demonstrate that murine inflationary epitopes after a low dose inoculum elicit 
CD8+T-cell responses displaying stable TCM epitope kinetics and memory-inflation is absent. 
This was in comparison to high doses that elicited inflationary CD8+T-cells with TEM 
phenotypes.  Thus, this study implicates an association between an increase in the initial 
viral loads and the development of TEMRA memory-inflated CD8+T-cell populations. This 
suggests that the size of the latently infected non-haematopoietic cell pool that is established 
during a primary HCMV lytic infection is a critical factor in generating CD8+T-cell memory-
inflation. This may be by increasing the frequency of reactivation events and ultimately 
CD8+T-cell priming. 
Taken together, there are two proposed scenarios for the maintenance of memory-inflation 
within the murine model (Fig-4). The first states that latently infected non-haematopoietic 
cells within secondary lymphoid organs, chronically present viral antigens directly to LN-
residing CMV-specific TCM cells. These TCM are then able to differentiate into TEM cells and 
enter the periphery whereby they deal with the viral reactivation. The TEM cells do not 
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proliferate, accumulate systemically after viral reactivation clearance and eventually 
differentiate into TEMRA after lifelong chronic antigen encounter. The second scenario 
depicted by Smith et al. proposes that sources of antigen stimulation for inflationary CD8+T-
cells are provided by the presentation of viral antigen by latently infected non-haematopoietic 
cells within both peripheral tissues and secondary lymphoid organs that have direct access 
to the blood supply e.g. red pulp of the spleen. These CD8+T-cells then patrol the periphery 
and peripheral tissues to control viral reactivation events. However, the common consensus 
within the literature is that it is non-haematopoietic cells that restimulate the inflationary 
CMV-specific CD8+T-cell population. Finally, haematopoietic cross-presentation is 
hypothesised as responsible for the initial priming and expansion of CMV-specific CD8+T-








































Fig 4  - Models for the maintenance  of HCMV memory-inflation by chronic antigen stimulation within the 
periphery or  LN [93].  Permission to reuse within this thesis obtained from Nature Immunology. Licence 
number 3881380517852. During a reactivation event, CMV antigen, likely IE and E antigen derived, is presented 
by non-haematopoietic, cells either A) with access to the blood supply as hypothesised by Smith et al [123], or B) 
within the LN as hypothesised by Torti et al. [104]. This drives the differentiation of CMV-specific TCM to 
inflationary TEM and TEMRA with high cytotoxic effector functions. These inflationary TEM and TEMRA cells then 
migrate to and ‘patrol’ the periphery and peripheral tissues e.g. the lungs to exert their cytotoxic anti-viral effects 











1.8 HCMV immune evasion 
Despite the large CD8+ T response directed towards HCMV, the virus is able to avoid 
elimination and establish a lifelong latent infection characterised by sporadic reactivations 
[9]. This successful evasion is mainly attributed to the subversion of CD8+T-cell recognition 
of HCMV-infected cells. HCMV encodes an impressive array of immunomodulatory genes 
whose temporal expression i.e. infection phase dependent expression, interferes with the 
MHC-I antigen presentation pathway in multistep cascade [80] [48, 95]. The region of the 
viral genome best studied for MHC-I immune evasion is US2 through US11 (Table-1) (Fig-
5). Louis Picker et al. demonstrated, within the context of the Rhesus model, that the US 
immunomodulatory genes are critical for superinfection of CMV to occur within a seropositive 
host by enabling evasion of the cytotoxic CD8+T-cell response [134]. 
 
The most extensively studied of the US gene encoded proteins are the US2 and US11 gene 
products that are expressed with E kinetics and function to redirect newly synthesised MHC-I 
molecules from the ER lumen to the cytoplasm. The US2/11 genes then trigger the 
proteasomal degradation of the MHC-I molecules [81]. The US2 protein binds to the MHC-I 
and utilises the Sec61 membrane complex to direct them to the cytosol [135]. The US11 
protein is a type 1 membrane protein that transports the MHC-I to the cytosol where they are 
de-glycosylated by N-glycosylase before proteasomal degradation [136]. These proteins 
therefore hijack the host machinery that relocates misfolded host proteins or those requiring 
turnover, for degradation [135].  This MHC-I targeting has been shown to be of both a locus 
[137, 138] and allele specific manner [139] [140]. For example, both the US2 and US11 
protein targets HLA-A/B alleles but HLA-C/G-alleles are resistant [137, 141] and that in 
particular, HLA-Cw*0702 alleles are less targeted by the US2 and US11 proteins [139, 140]. 
Importantly, US2 and US11 were shown by Hesse et al. to exert the largest effects on the 

































Fig 5 – Modes of action of the human cytomegalovirus US2-11 immunevasin proteins [9]. Permission to 
reuse content in this thesis obtained from Nature Immunology – Licence number 3882640385345. A) The US3 
protein is expressed with IE kinetics. Its luminal domain functions to retain MHC-I molecules within the ER. B) 
The US2 and US11 proteins are expressed with E kinetics and facilitate the retrograde translocation of newly 
formed MHC-I molecules from the ER lumen to the cytosol via a ‘translocon’ pore complex consisting of Sec61 
and TRAM [135]. Once in the cytosol they trigger the rapid degradation of the MHC-I molecules by the 
proteasome. The US11 protein remains in the ER whilst the US2 protein translocates with the bound MHC-I 
molecule to the cytosol.  C) The US6 protein is expressed with E/L kinetics and prevents the formation of mature 
peptide:MHC-I complexes via preventing peptide translocation from the cytosol to the ER lumen by blocking the 
TAP transporter preventing ATP binding required for peptide translocation [143]. Overview of the US proteins is 











Despite being expressed with IE kinetics (1-4 hours into infection), the US3 gene product 
has been reported to exert a minor overall effect on the total MHC-I surface down-regulation 
during an infection [142]. Ameres et al have demonstrated that this immunevasin is 
preferentially unable to target two HLA alleles; HLA-A3 and HLA-Cw*0702 ([140]. Both of 
whom are ligands for NK cell inhibitory receptors. US3 also functions to retain MHC-I within 
the ER by interacting with the tapasin chaperone to hold the MHC:US3 complex within the 
ER lumen. Additionally, the US3 protein interferes with MHC-II antigen presentation by 
blocking the invariant chain from associating with immature MHC-II [144]. 
  
US6 plays an important role in subverting MHC-I antigen presentation during the E/L phase 
of HCMV infection. US6 binds to the ER luminal domain of TAP1 preventing the 
translocation of peptide from the cytosol to the ER lumen. A TAP1 conformational change 
then results in the loss of ATP binding and mode of action [143, 145].  
 
Last of the US2-11 gene products, the US10 protein can specifically target non-classical 
HLA-G alleles from an infected cell surface by targeting them for proteasomal destruction 
within the ER [146].   
  
The pp65 and IE-1 proteins also play important roles in the evasion of CTL recognition 
(Table-1). The HCMV tegument proteins are recognised to have a dual role in the viral life 
cycle; fusion/entry into the host cell and modulation of the host immune response to 
incoming virus particles [147, 148]. The tegument phosphoprotein pp65, has been shown to 
prevent peptide-generation from the IE-1 viral transactivator [147-149] and therefore reduce 
the initial CD8+T-cell response to the virus. In addition to transactivating the viral genome, 
IE-1 has been identified as interfering with the IFN signalling pathway [150]. Huh and 
colleagues demonstrate the binding of IE-1 to the STAT2 protein enhances virus growth and 









However, this viral-mediated MHC-I down-regulation poses a problem by reducing the 
inhibitory interaction of MHC-I to the inhibitory receptors present on NK-cells. Thus this may 
activate NK-cells via the ‘Missing Self Hypothesis’. This hypothesis is based upon NK-cell 
activation being highly regulated via signals from both activating e.g. NKG2D and inhibitory 
receptors e.g. ‘Killer Immunoglobulin Receptors’ (KIRs) engaging their ligands on target cells 
[161]. Inhibitory receptors discriminate between infected and healthy host cells by the 
presence of inhibitory ligands such as MHC-I. Cells lacking MHC-I are therefore likely to be 
malignant or infected by viruses modulating the MHC-I antigen presentation pathway to 
avoid immune recognition. Equally, activating NK-cell receptors detect malignant or infected 
cells as their activating ligands are up-regulated by cells as a stress mechanism during 
Protein Infection 
Phase 
Immunomodulatory function Reference 
US2 E Relocates MHC-I from the ER to the cytoplasm for 
degradation via the proteasome 
[153] 
US3 IE Retains MHC-I within the ER lumen [154] 
US6 L Prevents peptide translocation into the ER lumen via 
TAP 
[145] 
US11 E Relocates MHC-I from the ER to the cytoplasm for 
degradation via the proteasome 
[136] 
US10 E Delays MHC-I egress from the ER lumen, in 
particular HLA-G alleles 
[155] 
UL16 E/L Binds NK activating receptor ligands ULBPs [156, 157] 
UL18 - MHC-I homolog/NK evasion [158] 
UL40 E Up regulates cell surface expression of HLA-E  
molecules 
[159] 
pp65  E and L Prevents the generation of IE-1 antigenic peptides 
via IE-1 phosphorylation 
[149] 
gpUL142 E MHC-I homologue [160] 
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infection e.g. MICA/B [43]. In an effort to subvert this NK activation, CMV encodes for 
several immunomodulatory mechanisms that target NK-cells. These are carried out by the 
UL16, UL18, UL40, UL83, UL141 and the UL142 gene products [160].  
UL18 is expressed in complex with β2 microglobulin (𝛽2M) and has been shown to bind to an 
NK-cell inhibitory receptor at a higher affinity then MHC-I [160, 162], thus acting as an MHC-I 
homologue [158]. UL40 acts as an HLA-E allele up-regulator so that surface bound HLA-E 
may bind to the NK inhibitory receptor NKG2A [160]. NKG2D represents the most abundant 
NK-cell activating receptor whose seven ligands are up-regulated on the surface of cells 
when they become stressed or infected [163]. The ligands MICA/B  have structural 
homology to the MHC-I molecules consisting of α1/α2 domains - they however do not bind 
peptides or associate with β2M [163]. 
  
The HCMV-encoded UL16 protein preferentially targets NKG2D ligands MICA and ULB1/2/6 
for down-regulation from the surface via ER retention within infected cells [157]. The 
gpUL142 protein has recently been discovered to down-regulate the activating ligand MICA 
[160].  
 
Lastly, the UL40 gene which has interestingly been shown to up regulate MHC-I HLA-E 
alleles [160] which increases the interaction of UL40 with the NK inhibitory receptor NKG2A. 
This mechanism of NK evasion has also been reported for HIV infection [164].  
 
Thus these few examples demonstrate the impressive array of both NK-cell and CD8+T-cell 








1.9 – Cross-presentation of CD8+T-cell HCMV antigens  
In face of these numerous evasive mechanisms, a diverse CD8+T-cell response to HCMV is 
still generated; raising questions to how the CD8+T-cells are being primed in vivo. 
 
Virus-specific CD8+T-cells become activated by host cells presenting peptide on their 
surface in the context of MHC-I. These host cells have acquired the antigen via the 
degradation of protein products from intracellular pathogens. Dendritic cells (DCs) are 
professional APCs that play an important role in the initiation of CD8+T-cell primary 
responses towards viral pathogens [165]. DCs present in the peripheral tissues, encounter 
and uptake Ag, undergo a maturation process when their ‘pattern recognition receptors’ 
(PRRs) are engaged. They then migrate to the lymph nodes (LNs) to present the processed 
antigen to naïve T-cells. [166]. It is currently debated how CD8+T-cell responses can be 
primed towards viral pathogens who evade the MHC-I antigen presentation pathway such as 
HCMV or are unable to infect DCs.  
 
HCMV IE antigen-specific CD8+T-cells could be primed before the immunevasion 
mechanisms of the US gene region products can fully exert their effects. However, this direct 
priming is unlikely to occur for L antigen-specific CD8+T-cells whose peak expression occurs 
after the US2-11 proteins have affected the MHC-I pathway. In spite of this, HCMV-specific 
CD8+T-cell responses towards L antigens are detected ex vivo and are therefore being 
primed somewhere in vivo during WT infection. A phenomenon explaining this is 'Cross-
presentation'.  
  
Typically, exogenously acquired antigens are loaded onto MHC-II molecules for CD4+T-cell 
recognition on DCs, whilst intracellularly derived antigens are loaded onto MHC-I for CD8+T-
cell recognition. It has become increasingly clear that DCs can also acquire the ability to 
uptake exogenous antigen and process these within the MHC-I pathway for presentation to 
CD8+T-cells.  Cross-presentation therefore defines the mechanism by which naïve CD8+T-
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cells are stimulated by peptide:MHC-I complexes on the surface of DCs that have acquired 
the antigen exogenously and processed it through their MHC-I pathway  [167].  The DCs can 
acquire these exogenous antigens via the phagocytosis of apoptotic bodies derived from 
infected cells. 
 
In the context of CMV, Snyder et al. studied the role of cross-presentation in the generation 
of CD8+T-cell responses in the murine model [114, 118, 168]. The authors generated a 
spread-defective MCMV strain deleted for glycoprotein L (gL). As a result the strain was able 
to undergo productive infection within the host cells it enters initially; however any progeny 
produced would subsequently lack the gL and be unable to enter any new host cells to 
initiate another round of infection. The ΔgL strain was used to infect mouse embryonic 
fibroblasts (MEFs) which were lacking expression of MHC-I and as such are unable to 
directly present MCMV antigen. These infected MEFs were then transferred into BALB/C 
mice. In the context of this model, MCMV-specific CD8+T-cell responses would only have 
been generated if the DCs were able to access exogenous MCMV-antigen from lysed 
MCMV-infected MEFs and present them in their surface MHC-I. The results demonstrated 
CD8+T-cell responses primed by the ΔgL mutant were almost identical in breadth and 
magnitude to the CD8+T-cell responses generated by the spread-efficient WT strain. This 
implicates the role of cross-presentation in the generation of MCMV-specific CD8+T-cell 
responses. 
 
Several studies now clearly implicate cross-presentation as a major mechanism behind the 
initial priming of HCMV-specific CD8+T-cell responses and this has now been demonstrated 
for both the pp65 and IE-1 protein [169-171]. It would therefore be a reasonable argument 
that cross-presentation is also a key factor in the initial priming to HCMV antigens expressed 
after the US2-11 immunevasion proteins function in the viral lifecycle. However and 
importantly, DCs are permissible to CMV infection and direct presentation of CMV antigens 
acquired intracellularly during an infection by DCs may also play a role in CD8+T-cell 
36 
 
priming. However it has been demonstrated in vitro that the concerted action of the MCMV 
immunevasins can efficiently prevent the CD8+T-cell recognition of infected DCs [172]. If the 
same efficiency occurs in vivo, then it can be assumed that the majority of presentation to 
CMV-specific CD8+T-cells by DCs is likely by cross presentation.  
 
1.10 – Contribution of HCMV to immune senescence within immunocompetent hosts  
With regards to clinical importance, HCMV is now well established in causing severe 
mortality within immunocompromised patients due to uncontrolled viral replication resulting 
in organ damage.  
 
Conversely, the implications of HCMV in immunocompetent individuals are now being 
investigated. The large accumulations of HCMV inflationary CD8+T-cells with age have led 
to the suggestion that HCMV is involved in the development of immunesenescence, vascular 
disease and even a reduced life span [173]. 
 
It is widely accepted that with age parameters of the host immune response decline and that 
this deterioration is most distinct within the CD8+T-cell compartment of the adaptive immune 
response.  The main characterising feature of T-cell immune senescence is an increase in 
CD8+T-cells lacking the surface expression of CD27+/CD28+ molecules, increased CD57+ 
expression and enhanced pro-inflammatory production [174].  
  
Wikby et al. identified using longitudinal studies over a period of 20 years involving the 
Swedish HEXA131 (66 year old donors), OCTO (86-92 years of age) and the extended 
NONA (>90 years) cohorts a link between HCMV infection and early mortality. From these 
studies they developed a characteristic phenotype that was predictive of an increased risk of 
mortality known as the ‘Immune Risk Phenotype’ (IRP). They found this phenotype was 
already present in a HCMV-infected hexagenarians cohort [175-177]. It is not yet known how 
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representative or relevant the IRP may be to other HCMV-positive populations or ethnicity 
groups.  
 
Memory-inflation has been linked to the inversion of the CD4+ to CD8+T-cell ratio due to the 
increase in CMV-specific CD8+T-cells within the total memory T-cell repertoire. Additionally, 
these inflated responses have been demonstrated as deriving from a few CD8+T-cell clones 
specific for dominant HCMV epitopes [76]. The oligoclonal expansions within elderly HCMV-
positive individuals are hypothesised to dominate the CD8+T-cell repertoire and restrict the 
immunological space required for the development of primary immune responses. 
 
 Currently, a distinction remains to be made between the total effects of the large HCMV-
specific T-cell responses and the effects of natural aging itself on the immune system. For 
example, it is as yet undetermined whether a decrease in the total naïve CD8+ T- cell pool in 
the elderly is directly associated with the expansion of the large HCMV-specific CD8+T-cell 
responses [6]. 
 
Despite initially being thought exhausted, inflated CMV-specific CD8+T-cell responses, in 
both the human and mouse model, have been established as polyfunctional (IFN-γ+TNF-
α+IL-2+CD107a+) in response to antigen [110, 178, 179]. Furthermore these CD8+T-cell 
responses remain cytotoxic producing both granzymeB and perforin [2]. Most importantly, 
that the CMV-specific CD8+T-cells retain this functionality with age [110, 180]. Overall the 
CMV-specific CD8+T-cell populations within the periphery have as such been speculated to 
influence the total inflammatory environment within the vasculature due to their high pro-
inflammatory cytokine production (IFN-γ+TNF-α+) [2]. Due to the unique expression of 
CX3CR1 on HCMV-specific CD8+T-cells, these polyfunctional CD8+T-cells have been 
demonstrated to migrate towards infected endothelium releasing their potent inflammatory 
cytokines causing endothelial damage in vitro [2]. CMV-specific CD8+T-cells could therefore 
induce cytolysis of infected endothelium during reactivation events causing direct 
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vasculature damage in vivo [2, 181]. As such, HCMV infection has been linked to reducing 
the life span of elderly individuals by up to 4 years due to cardiovascular disease, although 
the mechanisms are currently unclear [173]. 
 
1.11 - HCMV CD8+T-cell adoptive immunotherapy for the treatment of overt CMV 
disease 
In both the HSCT and SOT setting, HCMV reactivation is a major cause of morbidity and 
mortality. Currently drugs are available for the treatment of CMV disease such as Acyclovir, 
Valacyclovir, Foscarnet, Ganciclovir and Valgancyclovir (review [182]). However the toxic 
side effects limits their use [182, 183] and it is currently debated whether to utilise these 
drugs in a prophylactic or therapeutic setting. Importantly, studies have linked the use of 
these drugs prophylactically as delaying the onset of CMV mediated disease to late time-
points post-transplant and also enhancing the emergence of drug resistant CMV strains 
[184, 185]. Clinical studies are now focused on harnessing the CMV-specific CD8+T-cell 
response to control CMV reactivation in the post-transplant setting. The isolation of HCMV-
specific CD8+T-cells from patients, expansion ex vivo and retransfer into the patients is 
known as ‘adoptive immunotherapy’.  
 
Several preclinical murine models provided promising results in treating MCMV disease by 
the adoptive transfer of CD8+T-cells [186, 187] review [188]. An interesting finding from 
these studies was although all specificities transferred resulted in protection, those directed 
towards the murine IE-1/m123 were highly protective over others in preventing MCMV 
disease [187]. CMV-specific adoptive immunotherapy in HSCT transplant patients was first 
pioneered by Riddell at al. and Walter et al. who demonstrated the successful reconstitution 
of the CMV-specific CD8+T-cell immunity and safety of the approach [64, 189]. Several 
human clinical trials have since further demonstrated the safety of the methodology and 




Unfortunately, adoptive immunotherapy for CMV disease also has its limitations and is not 
common practice within the clinic. Problems arise if a donor is CMV seronegative or has low 
frequencies of circulating CMV-specific CD8+T-cells. Clearly in this situation pre-existing 
immunity is absent or CMV-specific CD8+T-cells difficult to isolate for expansion in vitro. The 
recent developments in the methodology for the TCR profiling from a single CD8+T-cell 
clone, has allowed for the transfer of previously established HCMV-specific CD8+ TCRs 
onto endogenous CD8+T-cells isolated from seronegative HSCT patients. This therefore 
allows for the generation of a HCMV-specific CD8+T-cell repertoire in a negative donor 
potentially undergoing primary infection. The efficacy of this method been demonstrated in 
vitro [195, 196] and within the murine model [8]. Currently, Phase I and II clinical trials are 
underway.  
 
1.12 – Viral vaccine vectors 
The fact that HCMV induces large TEMRA responses that persist for life, maintain their anti-
viral functions and locate to peripheral tissues has facilitated research in using CMV as a 
vaccine vector. Both MCMV and HCMV are now being investigated for use as vectors to 
stimulate large CD8+T-cell population’s specific for antigens derived from either infectious 
agents or malignancies.  
 
Viral vectors represent gene delivery systems expressing genes of interest in situ. The 
advances in the field of molecular virology have established mechanisms for the genetic 
manipulation of viral genomes for vaccine development. Many infectious diseases have now 
been brought under successful control via the use of viral-based vaccines for example, polio, 
measles, smallpox and yellow fever. However many human viral pathogens remain a huge 
challenge for vaccination for instance, HIV and hepatitis C virus (HCV) due to their large 




The use of viruses as a therapy delivery system raises several difficulties and ethical issues 
[198]. Firstly, one of the main concerns is the potential for the vaccine strain to revert to their 
pathogenic or virulent form followed by the spread to the unvaccinated population. Or 
additionally the vaccine strain may recombine with endogenous viruses already present in 
the vaccinated host. Secondly, the virus may render itself no longer antigenic therapeutically 
to the host immune system by deleting the inserted vaccine gene. In addition to safety 
issues, the extremely stringent safety procedures, long periods of scientific research and 
prior safety testing in animal models this makes the licensure for clinical trials within humans 
difficult.  
 
Despite these difficulties, the natural biology of viruses provide them with advantages over 
the more common vector delivery systems such as bacteria and DNA. For example, their 
broad cell tropism, opportunity for genetic manipulation, host persistence and the induction 
of both humoral and cellular immunity make them ideal candidates as vectors [198]. Finally, 
viruses have evolved to utilise the host cell transcription machinery to express their own 
genes and therefore therapeutic or vaccine transgenes inserted into the viral genome.  
As well as being used to vaccinate infectious diseases, viruses can be manipulated to 
express tumour antigen (TA) transgenes and therefore be used as a cancer therapy. Overall, 
investigations into viral-based cancer vaccines have shown that TA’s are more immunogenic 
when expressed as a whole transgene within a viral vector rather than within sub-peptide or 
protein based vaccines [199, 200]. Hence viruses can be genetically manipulated to tackle 







1.13 – CMV based vaccine vectors developed by the ‘Bacterial Artificial Chromosome’ 
reverse genetic system 
Research into the full pathogenic potential of CMV has been hampered due to a lack of 
methodology allowing the analysis of individual CMV protein function. With HCMV encoding 
for >160 antigenic proteins, the functions of many of these are still currently unknown.  The 
development of the 'Bacterial Artificial Chromosome (BAC) reverse genetic system' 
represents a quick and reliable protocol introducing mutations within the CMV genome, 
introduced within Escherichia coli (E. coli), to define the functions of the mutated HCMV 
genes. The effects of these introduced mutations on the viral lifecycle are then first observed 
after infection of eukaryotic cells by analysing the phenotype of the resulting virus e.g. 
growth kinetics. The role of the protein can therefore be defined in the context of natural 
infection in vivo [201, 202].  
 
Viral BACs consist of a BAC DNA vector contained within the viral genome. A BAC vector 
contains; ~10Kb of bacterial DNA located on the E. coli circular fertility factor F (F-factor), 
two loxp sites, an origin of replication (for replication within bacterial cells), an antibiotic 
resistance marker, homologous regions of the viral gene to which the BAC is to be inserted 
and finally a Cre recombinase gene [201-203]. Once the BAC vector is inserted within the 
viral genome (via homologous recombination), the viral BAC is transformed into E. coli and 
plaques (or colonies) that have taken up the viral BAC identified via antibiotic resistance. 
Mutations can then be incorporated into the viral genomes, for example by site-directed 
mutagenesis facilitating pathogenesis studies. The genetically engineered viral-BAC DNA is 
then purified from the E.coli for transfection into eukaryotic cells and the production of 
infectious virus. The expression of the Cre recombinase and presence of the loxp sites allow 





Viral BACs have now been widely used for the study of Herpesvirus pathogenesis 
(Reviewed [202, 204]). The first use of a Herpesvirus as an infectious BAC was developed 
by Messerle et al. utilising MCMV to determine the functions of individual CMV genes after 
their removal from the CMV genome. Currently, BACs have been developed for each human 
Herpesvirus excluding HHV-7 [202].  This has since facilitated a new era for their use as viral 
vaccine vectors via the insertion of foreign sequences by BAC technology  [205]. For 
vaccination purposes, a recombinant CMV containing BAC DNA can then be modified by 
prokaryotic genetic e.g. homologous recombination, to insert the therapeutic gene of choice 
using the antibiotic marker to select for bacterial colonies containing the therapeutic gene 
insert. 
The key characteristics of Herpesvirus infections include; lifelong persistence, sporadic 
reactivations and the induction of a large virus-specific TEM CD8+T-cell response [20] – 
making this an attractive virus to develop as a vaccine for the treatment of infectious 
diseases or cancer.  
 
To examine the ability of MCMV to induce CD8+T-cell responses to non-CMV recombinant 
epitopes, Karer et al. developed recombinant MCMV-based viral vectors expressing either 
influenza peptide-epitopes or the LCMV glycoprotein using BAC technology [206]. The 
results demonstrated that CD8+T-cell responses in mice after WT influenza virus infection 
quickly reached 5% of the CD8+T-cell peripheral pool but contracted to a stable 0.5%.  After 
mice were infected with recombinant MCMV expressing the NP influenza protein, NP-
specific CD8+T-cell memory-inflation was observed up to 1.5% of the total CD8+T-cells. 
Similar results were observed with infection with Vaccinia Virus expressing the LMCV 
glycoprotein with a stable 0.4% of the total CD8+T-cell pool compared to an inflation 
reaching 1.3% after infection with recombinant MCMV expressing the glycoprotein.  
  
A replication-competent MCMV-vector encoding an Ebola virus Zaire strain glycoprotein 
protected vaccinated mice from a lethal dose of the Ebola virus and induced long term 
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polyfunctional (IFN+/TNF+) Ebola-specific CD8+T-cell responses [207]. This recombinant-
MCMV consisted of the Ebola glycoprotein gene inserted within the MCMV m157 protein 
and was designated MCMV/ZEBOV-NP. MCMV/ZEBOV-NP induced Ebola-specific CD8+T-
cell responses at a mean of 2.88% of the total CD8+T-cell response within the blood of 
vaccinated mice. Additionally, longitudinal monitoring of the peripheral CD8+T-cell 
responses within vaccinated mice showed the inflation of the CD8+T-cell responses towards 
the Ebola glycoprotein from 0.79-3.08%. Thus these two studies indicate that inflationary 
CD8+T-cell responses can also be generated towards therapeutic genes inserted into a 
CMV-vector backbone using BAC technology. 
  
Arguably the most successful use of a CMV-BAC was developed by Louis Picker and 
colleagues involving vectors of RhCMV expressing the Simian immunodeficiency virus (SIV) 
proteins Gag,  Rev, Tat and Nef individually and deleted for the HCMV US2-11 gene 
homologues [13]. Vaccinated Rhesus monkeys demonstrated firstly, protection from both 
mucosal and intra-vaginal challenge of a highly pathogenic strain of SIV. Secondly 
suppression of the virus load to undetectable levels was observed after re-challenge [11] 
and lastly the elimination of the SIV virus over time within 50% vaccinated Rhesus monkeys 
[11]. Importantly, the vaccination of RhCMV seropositive monkeys with the RhCMV vectors, 
still provided protection from lethal SIV challenge demonstrating that the established RhCMV 
immune response was not detrimental to the vaccine-specific immune responses. 
Additionally, the authors found that the vaccine-specific CD8+T-cells are primarily directed 
towards peptides presented in the context of MHC-II rather than MHC-I and that the peptides 
are not derived from the typical immunodominant proteins of HIV previously described [12]. 
This implicates that the use of a CMV vector may advantageously allow for the development 
of CD8+T-cell responses to uniquely encoded peptide-epitopes within the vaccine antigen. 
Therefore compelling evidence is being presented for the use of cmv-based vectors to 




The potent ability of HCMV to induce large and persistent TEM which are important for 
epithelial mucosal immunity, the primary site for the majority of malignancies, also makes 
CMV an attractive platform for the vaccination of malignancies affecting the mucosa. 
Memory-inflated CD8+T-cell responses induced by the CMV vector towards vaccine TA 
inserts will theoretically be maintained for life and the acquisition of a TEMRA phenotype will 
equip the vaccine-specific CD8+T-cells with high cytotoxic potential.  Importantly, the ability 
of CMV to superinfect hosts, the phenomenon whereby CMV is able to infect an established 
CMV seropositive host, will allow for the vaccination of CMV seropositive patients. As such 
these CMV vectors could be used for differing malignancies without losing efficacy. This may 
be achieved by the vaccination of patients with multiple vectors expressing differing TA’s. 
HCMV a promising choice for the development of a vaccine-vector for cancer therapy.  
 
Several laboratories have developed CMV as a vector for a cancer vaccine to target breast 
cancer, melanoma and prostate cancer [208, 209]. Klyushnenkova et al. developed two 
recombinant MCMV-based vaccines. The first expressing a MHC-II DR52b restricted peptide 
derived from the full length human prostate specific antigen (PSA) and the second 
expressing the full length protein. The authors then assessed the immunogenicity of these 
vaccines within a transgenic murine model expressing PSA as self-antigen restricted through 
MHC-II DR52b [209]. The results of these studies identified that both vaccines were able to 
induce specific CD8+T-cell responses that inflated over time. However, only the epitope-
expressing vaccine was efficiently able to induce inflationary PSA specific CD8+T-cells after 
the mice were challenged with prostate tumour and these mice presented with delayed 
tumour growth. These results indicate that epitope structure within a CMV-based vaccine 
vector may determine the success of the tumour therapy.  
  
Recently, Xu et al. developed both a replication competent and a replication-deficient 
recombinant MCMV-based vaccine vector expressing the TRP2 melanoma tumour antigen 
[208]. Those mice vaccinated with the replication competent MCMV-TRP2 and then 
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challenged 7 days later with B16-F10 melanoma cells did not develop malignancies and 
remained tumour free for >4 months post challenge. Interestingly, the replication deficient 
vector also induced comparable long term protective responses against tumour challenge– 
indicating that a live replicating CMV vaccine may not be required for efficacy.   
 
A study by Snyder et al. inferred spread-deficient CMV strains, capable of a single cycle of 
replication after vaccination, as comparably immunogenic to the WT strain with CD8+T-cell 
memory-inflation still established [118]. Vaccination against infectious diseases within 
developing countries is restricted from widespread administration due to cost for booster 
vaccinations and medical equipment and training. CMV is a promising vaccine vector for 
these regions as a result of large immune responses generated towards CMV, and therefore 
the vector antigen, after a single dose. Utilising this advantage of CMV, Tierney et al. further 
manipulated by BAC technology the recombinant MCMV strain developed by Tsuda et al. 
termed MCMV/ZEBOV-NP, to instead express the nontoxic fragment C of the tetanus toxoid 
[210]. Their study demonstrated that the vector induced durable (>13 months) antibody 
responses after a single dose via the intraperitoneal route (I.P) within mice as measured by 
serum ELISAs. Additionally, vaccinated mice were protected from a lethal paralysing 
injection of tetanus toxin. The authors state that the MCMV/TetC vaccine construct therefore 
conferred an advantage over the current licenced formaldehyde inactivated vaccine which 
requires multiple doses. 
    
In sum, these studies clearly demonstrate the ability of CMV vectors to induce durable and 








1.14 –Cancer Testis Antigens (CTAgs) 
The Cancer Testis antigens (CTAgs) are a recently characterised family of tumour 
associated antigens. CTAgs have restricted expression within healthy normal tissues but 
increased expression within immune privileged sites, such as the germ cells of the testis, 
trophoblasts of the placenta and are up-regulated in several malignancies [211, 212]. In 
health, these genes are expressed within the spermatogonia during proliferation and 
expression is progressively lost as the cells differentiate [212]. Since the discovery of the first 
CTAg termed ‘Melanoma antigen-1’ (MAGE1) in total 70 families of CTAgs and 140 protein 
members have been identified [213]. 
 
CTAgs are potentially promising antigens for the targeted therapy of several cancers due to 
their restricted expression on healthy tissues [211] and their expression on malignancies 
linked to poor outcome [214]. CTAgs have as such been the focus of several human clinical 
trials. This research study will focus on one particular CTAg – the ‘New York Esophageal 1’ 
protein.  
 
1.15 New York Esophageal (NYESO1) CTAg 
NYESO1 is a cytosolic CTAg discovered within a patient with esophageal cancer [215]. 
Along with a high number of other CTAgs, NYESO1 is positioned on chromosome Xq28 and 
encodes an mRNA of 180aa. This CTAg has been described as spontaneously inducing 
NYESO1-specific CD4/CD8+T-cell and antibody immune responses within 50% of patients 
with NYESO1 expressing malignancies [216] and is therefore thought to be highly 
immunogenic. The expression of NYESO1 has been detected in several malignancies such 
as head and neck cancer, melanoma, neuroblastoma and hepatocellular carcinoma [217]. 
These characteristics have focused the attention of cancer therapeutics on utilising NYESO1 




A few laboratories have utilised NYESO1 within the context of a viral vaccine vector for 
cancer therapy. Palmowski et al. generated a lentiviral vector expressing an HLA-A2-
restricted NYESO1 epitope and tested its immunogenicity within mice [218]. The authors 
found that the injection of as few as 5 x 105 NYESO1 expressing lentiviruses into the mice 
tail vein could establish a CD8+T-cell response directed towards NYESO1. The HIV-1 
vectors used in the study were deleted for the Gag, Pol, Tat and Nef protein coding regions 
of HIV-1 and were therefore replication incompetent. However, even replication incompetent 
lentiviral vectors raise ethical issues such as risks of integration into the germ line. 
  
A second laboratory conducted a Phase 1 clinical trial involving the generation of two viral 
vaccine vectors consisting of either; a recombinant fowlpox virus NYESO1 (rFNYESO1) 
expressing construct or a smallpox NYESO1 recombinant virus construct (VV-NYESO1). 
The immunogenicity and safety of these vaccines was assessed in 33 advanced disease 
stage patients with various malignancies including melanoma, ovarian, breast and prostate 
cancer [219]. The study detected NYESO1-specific CD8+T-cell responses in 19 patients 
after using a prime boost approach – VV-NYESO1 followed by the rFNYESO1. NYESO1-
specific T CD8+T-cell clones recognised naturally processed NYESO1 antigen expressed on 
the surface of tumour cell lines indicating that the vaccines were priming NYESO1-specific 
CD8+T-cells that would be reactive towards tumours in vivo. With these successful results, 
the group of Jager et al. then performed a Phase II clinical trial with these vectors in 22 
ovarian cancer and 25 melanoma patients following the same prime-boost based approach. 
The study found that NYESO1-specific CD4+ and CD8+T-cell responses correlated with 
tumour regression. The results implicate that prime/boost regimens combined with NYESO1-
expressing viral constructs may induce robust NYESO1-specific CD8+T-cell responses 
within cancer patients.  
 
Previous studies with NYESO1 vaccines have revealed that the form of the NYESO1 antigen 
that is administered impacts upon the immune response induced. Peptide vaccination with 
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NYESO1 induced NYESO1-specific CD8+T-cells that were of low affinity [219]. NYESO1 is 
known to induce spontaneous cytotoxic immune responses within NYESO1 expressing 
cancer patients [220]. These spontaneous immune responses were shown to have higher 
tumour reactivity than responses induced by peptide or full protein NYESO1 vaccines. 
Compared to peptide vaccination, the expression of the NYESO1 gene within viral vectors 
has been shown to effectively induce tumour reactive cytotoxic (CTL) CD8+T-cells [219] 
indicating that the use of viral vectors expressing the full NYESO1 antigen may correlate 























Chapter 3 – Characterisation of the CD8+T-cell response to ‘protected’ epitopes 
identified using the RV798 strain of the virus  
This work will focus on the characterisation of CD8+T-cells directed towards HCMV epitopes 
that were identified utilising the RV798 strain by Stanley Riddell et al (Table-7, Chapter 
3)[85]. This is to gain a greater understanding of the global HCMV-specific CD8+T-cell 
response. It has not been established the role that such HCMV CD8+T-cell responses 
directed towards these peptide-epitopes would play in vivo during a WT HCMV infection. It 
was hypothesised that they may have a different phenotypic profile to previously described 
CMV-specific CD8+T-cells characterised in the presence of the US2-11 proteins. 
 
To begin to address the role of such CD8+T-cell responses in vivo, this investigation set out 
to; 
1. Assess the magnitude to these protected epitopes between young (<70 years) vs 
older (>70 years) donors – i.e. do the CD8+ T-cells accumulate with age.  
2. Phenotypically characterise the ex vivo CD8+T-cell responses to the protected 
peptide by flow cytometry.  
3. Identify whether these CD8+T-cell responses can efficiently kill peptide-loaded and 
HCMV infected targets in vitro.  
4. Investigate which cell types infected with the WT (AD169) vs RV798 (ΔUS2-11) 
strains are able to present cognate antigen to specific CD8+T-cell clones in vitro 
during infection with strains of the virus containing the WT US2-11 gene region 
(AD169 and Merlin) or deleted (RV798). 






Chapter 4 - identification and characterisation of HLA-C restricted memory-inflation 
Previous work in our lab observed large immunodominant responses to a peptide derived 
from the UL28 protein termed ‘FRC’ (Table-7/8) reaching upto 32% of a single older donors 
total CD8+T-cell repertoire producing IFN-γ and TNF-α in response to peptide stimulation. 
These CD8+T-cells increased significantly within the periphery of older donors. This 
research chapter aims to expand on the knowledge of the HLA-C CD8+T-cell repertoire 
directed towards HCMV. 
 
In particular we wished to answer the following; is HLA-C memory-inflation restricted to 
UL28? Is HLA-C memory-inflation a general phenomenon of all HLA-C alleles? And do the 
expression kinetics of the HCMV peptide play a role in determining whether the peptide will 
inflate? 
 
To answer these the following will be investigated; 
1. Identify additional immunodominant HLA-C restricted HCMV-specific CD8+T-cell 
epitopes. A range of HLA-C restricted peptide-epitopes will be obtained from the 
literature in addition to epitopes identified by Stanley Riddell and colleagues (Table-
7).  
2. Determine the magnitude and frequency of the HLA-C restricted CD8+T-cell 
populations with the age of our donor cohort.  
3. Phenotypically characterise the HLA-C restricted CD8+T-cell responses by flow 
cytometry 
4. Functionally characterise HLA-C specific CD8+T-cell clones generated in vitro. In 
particular functional avidity, proliferation and killing capacity.  
5. Investigate which cell types in vivo may be driving HLA-C mediated memory-inflation. 
To do this non vs haematopoietic cells will be infected in vitro and assessed for their 




Chapter 5 – Investigate the potential of ‘memory-inflated’ HLA-Cw*0702 for inclusion 
as an immunotherapy for HCMV mediated disease post-transplant 
After further characterising the UL28 ‘FRC’ HLA-Cw*0702-restricted populations (Chapter 4), 
these CD8+T-cells will be investigated for their potential development as an immunotherapy 
to treat overt HCMV disease in HSCT patients.  
 
This will be done by; 
1. Sequencing the TCR of a HLA-C restricted FRC-specific CD8+T-cell clone generated 
in vitro 
2. Retrovirally transducing the TCR onto PBMCs obtained from a buffy coat preparation  
3. Investigate the lytic ability of the transduced T-cells in recognising cognate peptide 



















Chapter 6 - Characterisation of the CD8+T-cell response to ‘cryptic’ epitopes 
In addition to the protected peptide-epitopes, the work by Riddell et al. also identified two 
cryptic peptide-epitopes that are translated in a non-canonical manner (Table-10). Cryptic 
CD8+T-cell peptide-epitopes have not, to our knowledge, been described for HCMV. 
Therefore the protective role of such CD8+T-cell populations is unknown. We aimed to 
determine how non-conventional peptide-epitopes generated from the HCMV virus will 
contribute towards the already large anti HCMV CD8+T-cell repertoire in healthy donors and 
if they could provide a protective role in vivo. It was hypothesised that the cryptic-specific 
CD8+T-cell responses may have a differing phenotype to those previously described for 
CMV-specific CD8+T-cells as a result of their unconventional generation. 
 
This results section of this PhD investigation therefore aimed to; 
1. Determine the frequency and magnitude of ex vivo CD8+T-cell responses directed 
towards the two cryptic peptide-epitopes ‘RPW’ and ‘APD’ within healthy individuals. 
2. Phenotypically characterise cryptic epitope specific CD8+T-cell responses by flow 
cytometry.  
3. Generate cryptic epitope-specific CD8+T-cell clones in vitro and determine whether 












Chapter 7 – Develop a HCMV vaccine vector for the treatment of NYESO1 expressing 
malignancies 
After analysing the ability of HCMV-specific CD8+T-cell populations to inflate and 
characterising their phenotype, we sought to manipulate the large CD8+T-cell responses 
induced by CMV towards malignancies. Therefore last in this PhD investigation, we aimed to 
direct CD8+T-cells towards NYESO1 expressing malignancies using a CMV-based vaccine 
vector.   
 
To do this a vaccine vector based on a HCMV backbone will be generated to express the 
CTAg NYESO1 protein utilising BAC technology which will produce the recombinant HCMV-
NYESO1 virus. 
 
This will be achieved with the following; 
1. In collaboration with Dr Richard Stanton (University of Cardiff) replacing the RL13 
gene within a HCMV BAC (pALIIII – generated before this investigation by Dr Richard 
Stanton [221]) with the NYESO1 gene using recombineering genetics 
2. Generating NYESO1-specific CD8+T-cell clones and testing their recognition of 
NYESO1 of both NYESO1 peptide-loaded target cells and during an in vitro infection 
of fibroblasts with HCMV-NYESO1 
3. Test the cytotoxic (killing) ability of the NYESO1-specific CD8+T-cell clones against 
peptide-loaded and HMCV-NYESO1 infected fibroblasts in vitro 
 








CHAPTER 2 - MATERIALS AND 
METHODS 
2.1 Materials 
Table 2 – Materials used throughout the investigation 
Cell culture reagents Company 
FCS Gibco 
1X PBS Dulba 
4% Para formaldehyde in PBS Sigma 
RPMI 1640 Sigma 
DMEM Sigma 
Optimem Sigma 
Penicillin/Streptamycin (P/S) Gibco 
Glutamine (Q) Gibco 
Saponin  Sigma 
MACS Buffer (1X PBS, 0.5% BSA, 2mM EDTA) In House 
Fetal Calf Serum (FCS) BioSera 
Human Serum (HuS) TCS 
Lymphocyte Separation Media Cedarlane 
MLA144 cells and supernatant [222] Cultures maintained in house 
CFSE Life technologies 
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Propidium Iodide Thermo Fischer Scientific 
CountBright Absolute Counting Beads Life Technologies 
CD4 Microbeads Miltenyi Biotech 
SOC media Invitogen 
Culture Media Components 
Culture media RPMI 1640, 10% FCS, 1% P/S 
T cell media RPMI 1640, 30% MLA, 10% FCS, 1% 
HuS, 1% P/S, 50U/ml IL-2 
Cloning media RPMI 1640, 10% FCS, 1% HuS, 1% P/S 
HLA class I typing PCR reagents Company 
TDMH buffer In house 
BioTAQ DNA polymerase Bioline 
Ethidium Bromide Sigma 
100bp ladder Life Technologies 
IFN- γ ELISA reagents Company 
NUNC maxisorp ELISA plates Thermo Scientific 
Anti IFN-γ Thermo Scientific 
Streptavidin Sigma 
Biotinylated anti Streptavidin Thermo Scientific 
TMB peroxidase substrate Rockland 
Blocking Buffer – 0.05% TWEEN, 1% BSA, 1X PBS In House 
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Wash Buffer – 0.05% TWEEN, 1X PBS In House 
CMV ELISA reagents Company 
Carbonate-bicarbonate tablets Sigma 
Coating buffer (x1 capsule carbonate-bicarbonate in 
25ml ddH20) 
In house 
Dilution buffer (PBS, 0.05% Tween, 1% BSA) In house 
IgG conjugate (α-human IgG-HRP) Southern Biotech 
Western blot reagents  
NuPAGE 4-12% Bis-Tris gel Invitrogen 
NuPAGE MOPS SDS running buffer 20X Invitrogen 
Tropix CDR Star Applied Biosystems 
Blocking buffer Applied Bioscience 
Lysis buffer - 0.4M sodium 2-mercaptoethanesulfonate 
(MESNA), 125 mM Tris-HCl pH 6.8, 20% glycerol, 4% SDS, 
0.004% bromophenol blue 
In House 
Developer film Thermo Scientific 
Kits Company 
Qiagen plasmid mini prep kit Qiagen 
Purelink HiPure plasmid maxiprep kit Invitrogen 
Endo free plasmid Maxi prep kit Qiagen 
SMARTer RACE 5’/3’ Kit Clontech 
Genelute mammalian DNA miniprep kit Sigma 
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RNeasy microRNA kit Qiagen 
QIAquick Gel Extraction Kit 
Qiagen 
IOTest® Beta Mark TCR V beta Repertoire Kit Beckman Coulter 
Gibson Assembly® Cloning Kit 
NEB 
Naïve CD8+T-cell isolation kit 


























Table 3  – HLA primers  used throughout the investigation [223]. Primers used to type the HLA class I 
haplotype of HCMV seropositive donors. All primer sequences were obtained from [223]. 
Antigen Forward primer sequence Reverse 
Primer sequence 
HLA-A1  286F 431R 
HLA-A2 296F 302R 
HLA-A3 291F 299R 
HLA-A11 290F 167R 
HLA-B7  367R 394R 
HLA-B7 193F 221R 
HLA-B35 193F 223R 
HLA-B35 188F 237R 
HLA-B35 195F 213R and 277R 
HLA-B44 202F and 272F 393R and 285R 
HLA-B44 272F  276R 
HLA-B51 195F 212R 
HLA-B51 188F 212R 
HLA-B51 208F 216R 
HLA-B51 193F 216R 
HLA-Cw7 130F 378R 
HLA-Cw*0701 313F 184R 
HLA-Cw*0702, 0703 367F 183R 
HLA-Cw*0703 367F 238R 
HLA-Cw*1601 368F 146R 
HLA-Cw*1602 366F 146R 
Control forward primer 210F  
Control reverse primer  211R 
HLA class I typing PCR mastermix (14 reactions) 




Nuclease free H20 70 
Control primer mix 14 
BIOTAQ DNA polymerase 0.75 ( 5 units/µl) 
DNA 140ng in 5µl 
Primers for plasmid 
 sequencing 
 
Primer Forward sequence Reverse sequence 
M13F GTAAAACGACGGCCAG  
























Table 4 – Antibodies used throughout the investigation  
HCMV peptide stimulation antibody panel; 
Antigen Fluorchrome Company Volume/100µl Clone 
CD3 Pacific Blue eBioscence 0.5μl OKT3 
CD8 PerCp-Cy5.5 eBioscience 2μl RPA-T8 
IFN-γ FITC Biolegend 2μl 4S.B3 
TNF-α Pe Cy7 eBioscience 1μl MAb11 
IL-2 PE Biolegend 10μl MQ1-17H12 
Viability Dye Fluorchrome Company Volume/100µl  





Invitrogen 1µl of 1:100 
dilution  
 
Conventional phenotyping antibody panel; 
Antigen Fluorchrome Company Volume/100µl Clone 
CD3 Amcyan BD 
Biosciences 
3μl SK7 
CD8 PerCp-Cy5.5 eBioscience 2μl RPA-T8 
TNF-α  Pe eBioscience 3μl MAb11 
CCR7 FITC R&D 10μl 150503 
CD27 APC-Cy7 eBioscience 3μl 0323 
CD28 Pe-Cy7 Biolegend 1μl 28.2 





CD45RA AF700 Biolegend 0.5μl H1100 
CD57 APC Biolegend 0.5μl HCD56 
Viability Dye Fluorchrome Company Volume/100µl  




Invitrogen 1µl of 1:100 
dilution  
 
Cytotoxic phenotyping antibody panel; 
Antigen Fluorchrome Company Volume/100µl Clone 
CD3 Amcyan BD 
Biosciences 
3μl SK7 
CD8 APC-Cy7 Biolegend 1μl RPA-T8 
TNF-α  Pe eBioscience 3μl MAb11 
CX3CR1 PerCP-Cy5.5 Biolegend 5μl 2A9-1 
NKG2D PE Texas red BD Horizon 0.5μl 1D11 
Perforin Pe Cy7 eBioscience 2μl δG9 
GranzymeB APC Biolegend 2μl GB11 
Viability Dye Fluorchrome Company Volume/100µl  




Invitrogen 1µl of 1:100 
dilution  
 
Exhausted phenotyping antibody panel; 
Antigen Fluorchrome Company Volume/100µl Clone 
CD3 Amcyan BD 
Biosciences 
3μl SK7 
CD8 APC-Cy7 Biolegend 1μl RPA-T8 
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TNF-α  PE eBioscience 3μl MAb11 
TIM3 FITC Biolegend 5μl F38-2E2 
PD-1 BV421 Biolegend 5μl EH12.2H7 
CD38 Pe Cy7 Biolegend 5μl HIT2 
Viability Dye Fluorchrome Company Volume/100µl  




Invitrogen 1µl of 1:100 
dilution  
    
 
 
Table 5 – HCMV pp65 and IE-1-derived CD8+T-cell peptide-epitopes derived from the pp65 and IE-1 
proteins. The protein antigen, aa position within the protein antigen, peptide sequence (peptide name is denoted 




Location in the 
Virion [224] 



















modulation of host 
cell immune 
response 
YSEHPTFTSQY A0101 L 
UL123
316-324
 IE-1 protein  viral transactivator  VLEEETSVML A02 IE 
UL83
265-275
 Tegument - RPHERNGFTVL B0702 L 
UL83
417-426









Table 6 – DNA (purchased from Life Technologies) and peptides used in the generation of HCMV-
NYESO1 and NYESO1-specific CD8+T-cell clones. The DNA sequence spanning the NYESO1 protein 











DNA name DNA sequence Company 
NYESO1 NYESO1-





























Peptide sequence Company 
NYESO1 HLA-A2 SLLMWITQV GenScript 
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2.1.1 Cell lines 
Healthy lab donor fibroblasts (HLA-A1+), Human fetal foreskin fibroblasts (HFFF2 purchased 
from Sigma Aldrich) (HLA-B7+HLA-C+) and MRC5 fibroblasts (HLA-A2+HLA-B7+HLA-
Cw*0702+ kindly provided by Dr Richard Stanton, School of Medicine, University of Cardiff or 
purchased from ATCC) were maintained in DMEM supplemented with 10% fetal calf serum 
(FCS), 1% penicillin/streptomycin (P/S) and 1% glutamine (Q). Epstein Barr virus (EBV) 
transformed B lymphoblastoid cell lines (LCLs) were generated in vitro by infecting 
peripheral mononuclear cells (PBMCs) with supernatant containing EBV strain B95.8 for 2 
weeks in the presence of 200 ng/mL cyclosporine A. Following this, transformed LCLs were 
propagated in RPMI supplemented with 10% FCS and 1% P/S.  
2.1.2 Virus Strains 
The AD169 (3 x 108 pfu/ml), RV798 – lacking the US2-11 viral gene region (1 x 108 pfu/ml) 
and Merlin (RCMVIIII strain, 1 x107 pfu ml - kindly provided by Prof Gavin Wilkinson) viral 
strains used in this investigation were stored at -80oC. The viral titre of stocks was 
determined by plaque assay of HFFF2 fibroblasts. Fibroblasts were infected with dilutions of 
virus from 10-5 to 10-10 for 4 hours followed by overlaying with 0.5% carboxymethylcellulose 
(CFC), 25% x2 concentrated DMEM and 25ml DMEM supplemented with 10% FCS and 1% 
P/S. After 2 weeks at 37oC the average number of plaques per well was determined and the 
viral titre calculated as the average of the last dilution where plaques could still be observed.   
2.1.3 Study cohort 
A total of 55 young and 35 older (categorised as <70 and >70 years respectively) healthy 
HCMV seropositive healthy subjects were investigated in this study (age, sex and HLA class 
I genotype - Appendix table 1 and 2). The recruitment of healthy older and younger 
participants was approved by the Solihull ethics committee study ref 14/WM/1254. Written 





2.2.1 Preparation of Peripheral blood Mononuclear Cells (PBMC's) from healthy donor 
blood 
PBMCs were isolated from whole blood by density gradient centrifugation. Seropositive 
blood was collected into 10ml ‘BD Heparin Vacutainer Tubes’ (BD Biosciences), diluted 1:1 
with RPMI and layered onto 15ml of lymphoprep. This was centrifuged at 680xg for 30 
minutes at 22oC with the brakes off. The lymphocytes were aspirated off the interface 
between the lymphoprep and plasma/RPMI. The lymphocytes were washed twice with 30ml 
of RPMI and centrifuged at 840xg for 10 minutes at 22oC to remove the excess lymphoprep. 
Following this cells were counted on a haemocytometer. For cryopreservation, the pellet was 
resuspended in freezing medium containing 70% RPMI, 20% FCS and 10% DMSO with 
between 5-10 x 106 cells transferred per cryovial. Cryovials were transferred to a -80oC 
freezer overnight (O/N) within a controlled chilling rate ‘Mr Frosty Freezing Container’ 
(Thermo Fisher Scientific) after which they were stored long term in liquid nitrogen. 
2.2.2 Determination of CMV serostatus 
Serum from donors recruited to the investigation was tested by an ELISA for the presence of 
anti-CMV IgG to determine the donors CMV serostatus. Mock and HCMV lysate generated 
from infected fibroblasts, used as the negative and positive fractions for the IgG in serum 
samples to bind to, were generated prior to the start of this investigation by Miss Jusnara 
Begum and Dr Annette Pachnio.  
 Day 1 
Both mock and CMV lysate were diluted at 1/4000 in coating buffer (Table-2) and 50μl of 
each dilution added per well in triplicate of a NUNC MAXISORP ELISA plate (Table-2). The 





 Day 2 
The ELISA plate was washed three times in 200μl wash buffer (Table-2). A standard curve 
was generated by a ½ dilution series in dilution buffer from 1:0.244 to 1:1000. The serum 
samples were diluted 1/60 in dilution buffer and 10μl added to wells on the washed ELISA 
plate containing 90μl dilution buffer (final dilution of the serum samples = 1/600). The plate 
was incubated for 1 hour at room temperature (RT). Following incubation, the plate was 
washed a further three times and 100μl per well of a 1:8000 dilution of the IgG conjugate 
(Table-2) in dilution buffer added. The plate was left to incubate for 1 hour at RT then 
washed a further three times. The addition of 100μl TMB substrate (Table-2) for 15 minutes 
at RT was followed by the addition of 100μl 1M HCL to stop the colour reaction. Lastly, the 
absorbance of the plate was read at 450nm and results calculated in Graphpad prism 6. 
Donors with CMV titres above 10 were considered CMV positive.  
2.2.3 HLA class I typing of seropositive donor PBMCs 
DNA was extracted from donor PBMCs using the ‘GenElute mammalian DNA miniprep kit’ 
according to the manufacturer’s guidelines (Table-2). The primers used for the specific HLA 
Class I alleles and the concentrations used are provided in Table-3 [223]. The reactions 
were conducted in a total of 13µL (Table-3) and all sequences of the primers used can be 
found in [223]. Reactions were run with the following PCR programme;  
 an initial denaturing step of 96oC for 1 minute,  
 5 cycles of; 96oC for 25 seconds, 70oC for 4 seconds and 72oC for 45 seconds,  
 21 cycles of; 96oC for 25 seconds, 65oC for 50 seconds and 72oC for 45 seconds  
 4 cycles of; 96oC for 25 seconds, 55oC for 60 seconds and 72oC for 120 seconds.  
 
Products of the PCR reaction were then run on a 1% agarose gel (Ethidium Bromide 
1µL/20mL of agarose, Table-2) by electrophoresis for 60 minutes. PCR bands were 
visualised by UV light. 
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2.2.4 Stimulation of PBMCs with HCMV-derived peptides 
To assess HCMV-specific CD8+T-cell responses, PBMCs were stimulated with HCMV 
peptide. PBMCs were thawed in culture medium and counted. 1 x 106 cells per stimulation 
were used in a total volume of 500μl culture medium in FACS tubes. Relevant peptide was 
added to the tubes at a final concentration of 1μg/ml. ‘Staphylococcus enterotoxin B’ (SEB) 
served as a positive control (final concentration 0.2mg/ml) and one tube was left 
unstimulated (negative control). 0.5μl of Brefeldin A (BfA) was added to all tubes to block 
cytokine secretion to allow their measurement by flow cytometry (section 2.2.5). The tubes 
were incubated at 37oC, +5% CO2 for 6 hours before staining for surface antibodies (section 
2.2.5).  
2.2.5 Intracellular cytokine staining (ICS) 
Following 6 hours peptide stimulation, activated CD8+T-cells were detected by ICS. PBMCs 
were washed once in PBS and centrifuged at 840xg at 10oC for 5 minutes – all subsequent 
wash steps were conducted with these conditions. The supernatant was removed and 
PBMCs were stained with antibodies in 100µl PBS. First, 1μl of viability dye (Table-4) was 
added to the tubes and left to incubate for 15 minutes RT in the dark before one wash in 
PBS and one wash in MACS buffer. After the addition of surface antibodies, the tubes were 
left to incubate for 15 minutes at 4oC in the dark after which they were washed once in 
MACS buffer. To fix the cells, 100μl of 4% PFA was added and cells incubated for 15 
minutes at RT in the dark. The PFA was washed off once with MACS buffer and cells were 
permebilised by the addition of 100μl of 0.5% saponin. After 5 minutes, the intracellular 
antibodies were added to the tubes and left to incubate for 30 minutes at RT in the dark. A 
final wash step after incubation was conducted in MACS buffer and the cells analysed on the 
LSR II (BD Biosciences). A minimum of 100 000 events was acquired per sample tube and 
50 000 events for control tubes. Unless indicated, all LSR II data was analysed in Kaluza 1.3 
software (Beckman Coulter). 
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2.2.6 TCR Vβ staining 
To determine the oligoclonality of the HCMV-specific CD8+T-cell responses, PBMCs of 
seropositive donors were stained to determine TCR Vβ usage with a flow cytometry 
repertoire kit from Beckman Coulter (Table-2) following 6 hours peptide stimulation (1µg/ml 
final concentration) at 37oC. Cells were surface stained at 4oC with CD8 PerCP-Cy5.5 
(eBiosciences), CD3 PB (eBiosciences) and the TCR Vβ repertoire kit according to the 
manufacturers guide and APC LIVE/DEAD Fixable dye for 15 minutes. Cells were then 
washed once in PBS (540xg rpm, 5 minutes). Cells were stained intracellularly for TNF-α, as 
described in 2.2.5, to identify activated HCMV-specific CD8+T-cells. Cells were then 
acquired on the LSR II with a minimum of 100 000 live events recorded.  
2.2.7. CD8+T-cell cloning 
To isolate CD8+T-cells specific for the HCMV peptides used in this study, PBMCs of donors 
with identified CD8+T-cell populations to the HCMV peptide were subjected to peptide 
stimulation followed by an IFN-γ secretion assay (Miltenyi Biotech) and a limiting dilution. 
2.2.7.1 IFN-γ capture assay 
PBMCs were CD4 depleted using microbeads as per the manufacturers guide (Table-2) and 
stimulated with the relevant peptide (final concentration 1µg/ml) for 3 hours to induce the 
activation and IFN-γ production of specific CD8+T-cells. These were enriched for by IFN-γ-
capture for limiting dilution cloning. 
i) IFN-γ catch reagent labelling 
After the 3 hour stimulation, cells were washed three times in RPMI culture medium (10% 
FCS, 1% P/S). The supernatant was completely removed and the pellet resupsended in 70μl 
of cold MACS buffer and 30μl of catch reagent added per 107 PBMCs. These were then 




ii) Secretion of IFN-γ 
10ml of warm RPMI culture media (10% FCS and P/S) was added to the cells which were 
incubated at 37oC on a rotator for 45 minutes to allow the binding of secreted IFN-γ to the 
catch reagent on the cell surface. 
iii) Detection of IFN-γ 
Cells were washed with 15ml cold MACS buffer and centrifuged at 840xg for 10 minutes at 
4oC. The cell pellet was resuspended in 70μl MACS buffer and 30μl per 107 PBMCs of PE 
conjugated IFN-γ detection antibody added. The cells were then incubated at 4oC for 10 
minutes in the dark. 
iv) Magnetic labelling 
Cells were washed in MACS buffer at 840xg for 10 minutes at 4oC and the pellet 
resuspended in 120μl MACS buffer and 30μl per 107 of anti-PE microbeads added followed 
by incubation for 20 minutes at 4oC in the dark. 
v) Magnetic separation 
Unbound anti-PE microbeads were washed off in MACS buffer at 840xg for 10 minutes at 
4oC. The pellet containing the magnetic labelled cells was resuspended in 500μl cold MACS 
buffer, applied to an MS column (Miltenyi Biotech Table-2) and collected in a fresh FACS 
tube. The number of specific CD8+T-cells obtained were counted on a haemocytometer.  
2.2.7.2 Limiting Dilution Cloning 
PBMCs isolated from Buffy preparations were Phytohaemagglutinin (PHA) treated (final 
concentration 10µg/ml) for 1 hour before irradiation with 4000 rads – these served as a 
cytokine feeder layer in the cloning procedure to support the survival and proliferation of the 
specific CD8+T-cells. HLA-class I matched LCLs were peptide-pulsed (1 µg/ml final 
concentration) for 1 hour at 37oC before also being irradiated with 4000 rads to prevent 
proliferation – these served as APCs. The Buffy’s/LCLS were washed three times in RPMI 
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culture medium. For the limiting dilution cloning, 10 plates (96 –well round bottom) with 0.3 
T-cells/well and 10 plates with 3 T-cells/well for each specificity were subsequently prepared. 
Per 10 cloning plates, 100ml of cloning mixture (Table-2) consisted of; 100 x 106 Buffy cells, 
10 x 106 LCLs, CD8+T-cells at a total of 0.3 or 3 T cells/well. 100µl/well of this preparation 
was plated out on day 1. The limiting dilution cultures were supplemented on day 3 with 
100µl/well T-cell media (60% MLA Table-2), and left at 37oC for 14 days.  
2.2.7.3 Assessment of peptide specificity by IFN-γ ELISA 
14 days after cloning, expanded wells were tested for HCMV peptide specificity. For this, 
50µl of the CD8+T-cells was taken from the expanded wells and co-cultured with 1 x 104 
peptide-pulsed or DMSO-pulsed autologous LCL in duplicate at 37oC O/N. 
ELISA plates were coated overnight (O/N) with anti IFN-γ (50µl per well of a 1µg/ml dilution,, 
Thermo Scientific Table-2). The following day, ELISA plates were blocked for 1 hour in 
150μl/well of blocking buffer (Table-2) at RT. Plates were washed three times in wash buffer 
(Table-2) and 50μl supernatant from the overnight co-cultures was added to the relevant 
wells. The IFN-γ standard (20000 to 0 IFN-γ pg/ml) was also added to the plates at this point 
in duplicate. The plates were left to incubate for 2 hours at RT and after incubation washed 
six times in wash buffer. A second biotinylated antibody that binds IFN-γ was then added to 
the wells with 50µl per well of a 0.25µg/ml dilution and left to incubate for 1 hour at RT. After 
incubation, plates were washed six times in wash buffer and 50μl/well of a 5µg/ml dilution of 
streptavidin added (1:1000 in wash buffer, stock 5mg/ml) for 30 minutes at RT. The excess 
streptavidin was washed off and 50µl TMB peroxidase substrate (Table-2) added and the 
colour reaction allowed to develop for up to 30 minutes. The reaction was then stopped by 
the addition of 1M hydrochloric acid and the plate absorbance was measured at 450nm. 
Specific clones were transferred to and propagated on 24 well plates for further use in in 
vitro assays and cryopreservation.  The clones were maintained in 2ml T-cell media (Table-
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2) with the addition of 1 x 106 PHA treated, irradiated Buffy cells and 1 x 105 peptide-pulsed, 
irradiated LCLs every 14 days.  
2.2.8 CFSE proliferation assays 
PBMCs were stained with 1µM ‘Carboxyfluorescein succinimidyl ester’ (CFSE) (Life 
Technologies) in 100µL PBS for 10 minutes at 37oC before quenching the excess dye for 10 
minutes at 4oC in RPMI media (10% FCS, 1% P/S). 1 x 105 CFSE labelled PBMCs were co-
cultured for 7 days at 37oC with 2.5 x 104 γ-irradiated LCLs, which had been peptide-pulsed 
for 1 hour at 37oC prior to co-culture, on a 96 well plate. Non peptide-pulsed LCLs and SEB-
stimulated PBMCs were included as a negative and positive control. After 7 days, PBMCs 
were surface stained with CD3-pacific blue (eBioscience) and CD8-PerCP-Cy5.5 
(eBioscience) for 15 minutes at 4oC and the number of CFSElow events recorded on the LSR 
II (BD Biosciences). For HCMV-specific CD8+T-cell clones, the same protocol was followed; 
however, analysis on an LSR II occurred after 24-72 hours co-culture. 
2.2.9 CD8+T-cell clone recognition of cognate peptide on HCMV infected fibroblasts  
To assess the ability of HCMV-specific CD8+T-cell clones to recognise cognate antigen 
during a productive infection of fibroblasts in vitro, clones were co-cultured O/N with HCMV-
infected fibroblasts followed by an IFN-γ ELISA. 1 x 104 healthy lab donor fibroblasts (HLA-
A1+) or MRC5 fibroblasts (HLA-A2+HLA-B7+HLA-Cw*0702+) depending on the HLA 
restriction of the CD8+T-cell clone in question were plated per well, of a 96-well plate and 
left to adhere O/N. Fibroblasts were infected with AD169, Merlin or RV798 the following day 
at an MOI of 5 and left for 6, 12, 24, 48, 72, 96 and 120 hours. At the indicated time-points, 
10000 specific CD8+T-cells were added and co-cultured O/N at 37oC. The following day, 
50µL of the supernatant was used in an IFN-γ ELISA (described in section 2.2.7.3). Specific 
CD8+T-cell clones were also added to uninfected fibroblast as a negative control, and to 
wells without fibroblasts as an effector only negative control. As a positive control, specific 
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CD8+T-cells were added to fibroblasts that had been peptide-pulsed for 1 hour at 37oC with 
the relevant peptide. All conditions were tested in triplicate. 
 
2.2.10 CD8+T-cell recognition of HCMV infected monocytes 
To assess the ability of CD8+T-cell clones to recognise cognate antigen during a productive 
infection of monocytes in vitro, clones were co-cultured overnight with HCMV infected 
monocytes followed by an IFN-γ ELISA. PBMCs of donors with the identified CD8+T-cell 
population in question were plated at a density of 2 x 106 per well of a 24 well plate for a 
minimum of 3 hours at 37oC. After 3 hours, the monocyte layer was trypsinised and plated at 
1 x 104 per well of a v-bottom 96-well plate. Monocytes were infected with the Merlin strain at 
an MOI of 5 and recognition determined 6-120 hours p.i as described in section 2.2.9 after 
an O/N co-culture with 10000 CD8+T-cell clones.  
2.2.11 CD8+T-cell killing assays  
The ability of HCMV-specific CD8+T-cell clones to kill peptide-loaded target cells was 
assessed in vitro using CFSE cell tracker dye coupled with the membrane impermeable cell 
viability dye ‘Propidium Iodide’ (PI). Target cells were labelled with CFSE as described 
previously (section 2.2.8). CD8+T-cell clones were co-cultured O/N at 37oC with peptide-
loaded, (1µg/ml final concentration, 1 hour 37oC) CFSE labelled LCL target cells at 1:1, 2:1, 
5:1 and 10:1 effector: target ratios on a 96-well v-bottom plate to allow cell: cell contact. The 
target cell numbers were maintained at 0.5 x 104 cells to allow the accurate quantification of 
viable cell loss. Following overnight co-culture, all cells were transferred to a FACs tube, 
washed in MACS buffer at 540xg for 5 minutes and resuspended in 100µl PBS. Immediately 
before acquisition of events on the LSR II, 1µL of PI (Table-2) and 12.5µL (equating to 
13500 beads total) of CountBright absolute beads (Life technologies Table-2) were added to 
the cells. 100 000 events were recorded per sample tube and a negative control of O/N co-
culture (1:1 ratio) with DMSO-pulsed LCLs was included.  
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To calculate CD8+T-cell killing, the following equation was used (as per manufacturers guide 
(CountBright absolute beads, Life technologies Table-2); 
Cells/µl = [number of CFSE POSITIVE/PI negative cell events/number of bead 
events]*[assigned bead count of the lot/volume sample in µl] 
% specific lysis = 100 - ([cells/µl of sample]/ [cells/µl of DMSO control]*100) 
For the analysis of the specific cell lysis of HCMV infected fibroblasts 0.2 x 104 fibroblasts 
target cells were maintained and the CD8+T-cell clone effector numbers were modified 
accordingly. 10 000 events were recorded per sample tube and a peptide-pulsed fibroblast 
tube was included as a positive control.  
2.2.12 – Measurement of CD25 upregulation after co-culture of HCMV CD8+T-cell 
clones with HCMV infected fibroblasts 
To analyse the activation of HCMV-specific CD8+T-cell clones after recognising cognate 
antigen during a WT (Merlin) infection of fibroblasts, clones were subjected to CD25 staining 
by flow cytometry. 1 x 104 fibroblasts were seeded onto a flat bottom 96 well plate O/N and 
the following day infected with the RCMVIIII Merlin strain at an MOI of 0.05. After 72 hours, 
CD8+T-cell clones were removed from the infected monolayer and subjected to flow 
cytometric analysis as described in section 2.2.5 using CD8 PerCP-Cy5.5 (e Biosciences), 
CD3 PB (eBiosciences), the CD25 PE (Biolegend) and APC LIVE/DEAD Fixable dye 
(Invitrogen).  
2.2.13 Measurement of surface HLA alleles on HCMV infected fibroblasts 
To evaluate the levels of surface HLA class I alleles on the surface of fibroblasts during a 
productive HCMV infection, fibroblasts were stained with the W6/32 (anti-HLA-ABC, BD 
Biosciences) or DT9 (anti-HLA-C – kindly provided by Dr Veronique Braud Institute of 
Molecular and Cellular Pharmacology, Sophia Antipolis, Valbonne). 1 x 104 HFFF2 (HLA-
A11+HLA-B35+HLA-Cw2+HLA-Cw4+HLA-Cw7+) MRC5 (HLA-A2+HLA-B7+HLA-Cw*0702+) 
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fibroblasts were plated onto 96 well plates and left to adhere O/N. Fibroblasts were then 
infected with either AD169 or RV798 at an MOI of 5. After 3, 6, 12, 24, 48, 72, 96 and 120 
hours p.i, cells were trypsinised and washed in PBS (535xg, 5 minutes) before surface 
staining with the monoclonal antibodies. DT9 stained fibroblasts were then washed in PBS 
before staining with a secondary α-mouse FITC-conjugated antibody (Sigma) Cells were 
then analysed on an LSR II and data processed using BD Facs DIVA software 8.0 (BD 
Biosciences) 
2.2.14 CD8+T-cell clone TCR sequencing 
For the investigation of a HLA-Cw*0702-restricted HCMV-specific TCR as a potential 
immunotherapy, the TCR of specific CD8+T-cell clones was sequenced using the ‘SMARTer 
RACE 5’/3’ Kit from Clontech’. This kit allowed the amplification of the complete 5’ sequence 
of the TCR α/β chains of HCMV-specific CD8+T-cell clones. 
i. Primer design 
Gene specific primers (GSPs) for the constant region of human α and β TCR chains were 
designed and contained 15bp homology (GATTACGCCAAGCTT) sequence at the 3’-end to 
allow the amplified PCR fragment to be cloned into the pRACE vector for subsequent 
sequencing.  
ii. Generation of cDNA for fusion into RACE vector 
Firstly, the TCR α and β chain genes were amplified from cDNA generated after RNA 
extraction and a PCR reaction using the GSPs. A minimum of 2 x 106 specific CD8+T-cell 
clones were centrifuged at 540xg for 5 minutes. RNA was extracted from the CD8+T-cell 
clone pellet using the RNeasy microRNA kit from Qiagen according to the manufacturers 
guide. cDNA was generated from RNA following the ‘SMARTer RACE 5’/3’ kit’ 
manufacturers guidelines. The only deviation from the full protocol was the setup of 2 






iii. Characterisation of the cDNA products 
The α and β TCR chain PCR reaction products were electrophoresed on a 1% agarose gel 
and the DNA from the bands extracted using the ‘QIAquick Gel Extraction Kit’ from Qiagen 
following the manufacturers guidelines.  
iv. Cloning of the cDNA products into the pRACE vector for sequencing 
The following pRACE reaction mixture was incubated for 15 minutes at 50oC (50% of the 
specified volumes in the manufacturers guide); 
 0.5µl Linearized pRACE vector  
 2.5µl gel-purified cDNA product (section iii) 
 1µl In-fusion HD mastermix 
 
A total of 2.5µl of the pRACE reaction mixture was used to transform 50µl of Stellar 
competent cells (Table-2) in a 15ml tube on ice for 30 minutes, followed by heat shocking 
the cells for exactly 45 seconds at 42oC. Cells were recovered on ice for 2 minutes and a 
total of 497.5µl SOC media (Table-2) added – this was then incubated in a shaking rotator 
(200rpm) for 1 hour at 37oC. The resulting culture was then spread O/N on LB + ampicillin 
plates (final concentration 100µg/ml). Colonies were picked the following day into 5ml LB 
broth + ampicillin (final concentration 100µg/ml) and the pRACE plasmid with the FRC TCR 
insert isolated using the ‘Qiagen plasmid mini prep kit’ using the manufacturer’s guidelines.  
         V. Sequencing the pRACE vector products 
50ng of pRACE plasmid and M13F sequencing primer (Table-2) in a total volume of 11µl 
was sequenced using the University of Birmingham Genomics service. Sequencing results 
were analysed using Chromas and TCR α and β sequences determined using the IMGT/V-
Quest online sequence aligner tool http://www.imgt.org/IMGT_vquest/share/textes/  
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2.2.15 Generation of a TCR construct for transduction of CD8+T-cells  
Once the TCR sequence of the CD8+T-cell clone was known, the α and β sequences were 
inserted into the myeloproliferative sarcoma virus-derived vector pMP71 plasmid vector (a 
kind gift from Dr Christopher Baum, Hannover Medical School, Germany) as an individual 
sequence. The TCR sequences of the α and β chains (obtained in section 2.2.14) were 
entered into the ensemble website (http://www.ensembl.org/index.html) and the start codon 
of the α and β variable chain sequences were identified. This allowed for the identification of 
the full length V(D)J region for both the α and β chain. A transgene was then designed which 
added the constant regions of both chains to their respective V(D)J fragments, and each 
chain was separated by a 2A linker sequence (Fig-6). The 2A linker allowed for the cleaving 
of the α and β chains once transcribed within transduced T-cells. The sequences of the 
TRAC1 and TRBC1 constant regions used which include an extra cysteine allowing for an 
enhanced αβ folding. 
 
Fig 6 – Schematic sequence of the TCR for codon optimisation and ordered from IDT GBlocks.  
 
This sequence was codon optimised and ordered from IDT GBlocks., The resulting DNA 
‘GBlocks’ were inserted into the pMP71 plasmid via the ‘Gibson assembly method’ [226] 
using the ‘Gibson assembly kit’ (Table-2 NEB) as per the manufacturers guidelines. The 
resulting plasmid was transformed into TOP10 competent bacteria (Table-2) and plated O/N 
on LB + ampicillin (final concentration 100µg/ml). Picked colonies were grown in 5 ml LB + 
ampicillin (final concentration 100µg/ml) O/N and the plasmid isolated using the Qiagen 
plasmid mini prep kit following the manufacturer’s guidelines. Plasmids were sequenced to 
ensure that the FRC TCR had folded correctly and the sequence was intact. Plasmids with 
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the correct insert were selected for generating stocks and isolated using the ‘Endofree 
plasmid maxi prep kit’ (Table-2) as per the manufacturer’s guidelines.  
2.2.16 TCR transduction of CD8+T-cells from buffy coats 
After the insertion of the TCR into the pMP71 plasmid, this construct was used to transfect 
phoenix amphotropic cells and in turn used to transduce T-cells obtained from a buffy coat to 
test the potential immunotherapy in vitro [227].  
 Day 0 
Phoenix cells were thawed from liquid nitrogen and plated into a T75cm2 tissue culture flask 
48 hours before they were to be transfected with the TCR/pMP71 construct.  
 Day 1 
Once 50% (minimum) confluent, phoenix cells were resuspended in a flask with 11ml of 
fresh DMEM (10% FCS, no P/S) and co-transfected with the TCR/pMP71 construct (final 
concentration 5.5µg) and pPCL-ampho packaging vector (5.5µg final concentration, 
NovusBio). The pCL-Ampho packaging vector was included to maximize recombinant–
retrovirus titers.  
Prior to the transfection, the FRC-TCR/pMP71 and pCL-Ampho vectors were incubated for 
10 minutes with 28µg PEI (Sigma) in 1ml of OPTIMEM for 10 minutes at RT. For 
transfection, this DNA:PEI complex was then added to the flask of phoenix cells for 12 hours 
at 37oC.  
Retroviral based vectors require cell division for efficient infection and integration of T cells. 
Therefore transduction efficiency is dependent on the activation of the T cells prior to 
transduction [228]. PBMCs isolated from buffy preparations were stimulated with 2µg (final 
concentration) α-CD28 (Milteyni Biotech), 1µg (final concentration) α-CD3 OKT3 
(eBioscience) and 600 IU IL-2 O/N at 37oC. A non-tissue culture treated plate was coated 
with 3ml per well of retronectin (30ng/ml, clontech) O/N at 4oC.  
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 Day 2 
After the 12 hour transfection, the supernatant in the phoenix cell flask was replaced with 
fresh DMEM (10% FCS, no P/S) and the cells allowed to secrete pMP71/FRC expressing 
retrovirus into the supernatant for 24 hours. 
 Day 3 
After 24 hours, the TCR/pMP71-retroviral supernatant was harvested, centrifuged at 535xg 
for 5 minutes, filtered through a 0.45µM filter and was then ready for use in a transduction. 
The rectronectin coated plate was washed once with 3ml PBS before blocking for 1 hour at 
RT with 3ml of PBS + 2% BSA. This was then washed with 3ml PBS and 3ml of the 
TCR/pMP71-retroviral supernatant added per positive transduction well. Mock transduced 
supernatant was added to mock transduced wells and served as a negative control. The 
plate was centrifuged at 32oC for 2 hours at 2288xg to ensure the viral construct was 
attached to the retronectin on bottom of the plate.  
The stimulated buffy PBMCs were washed twice in DMEM (10% FCS, no P/S) at 1600rpm 
for 5 minutes and 4 x106 cells resuspended in 4 ml DMEM (10% FCS, no P/S).  
Once the viral supernatant had been centrifuged onto the plate for 2 hours, the supernatant 
was removed and the activated PBMCs were added to the TCR/pMP71-retroviral coated 
wells. The plate was centrifuged immediately at 535xg rpm for 5 minutes to ensure the T-







2.2.17 Generation of a HCMV vaccine vector with an NYESO1 insert by 
recombineering – in collaboration with Dr Richard Stanton, University of Cardiff 
The recombineering of the pALIIII HCMV BAC was accomplished using SW102 bacteria that 
contain a viral phage expressing the lamba red genes that are expressed when the bacteria 
are placed at 42oC. These genes mediate homologous recombination and are switched off 
at 32oC. Full protocol kindly provided by Dr Richard Stanton at 
http://medicine.cf.ac.uk/media/filer_public/2013/09/13/recombineering_merlin_bac-7.pdf.  Dr 
Richard Stanton inoculated SW102 bacteria containing the pALIIII HCMV BAC into 5ml of LB 
broth that contained a final concentration of 12.5µg/ml (same final concentration throughout) 
Chloramphenicol overnight at 32oC. The following day, Dr Richard Stanton inoculated 0.5ml 
of the overnight culture into fresh 25ml LB both + chloramphenicol and allowed to reach an 
OD600. Bacteria were transferred to a 50ml falcon tube by Miss Louise Hosie (completed the 
work from now on excluding plating the bacteria, under Dr Richard Stanton’s direct 
guidance) and the lamda red proteins within the bacteria induced via incubation at 42oC for 
15 minutes before transfer to ice for 20 minutes. Bacteria were pelleted at 1087xg for 5 
minutes and resuspended in 1ml of ice cold ddH20 before the addition of a further 25ml and 
centrifugation repeated. This wash step was repeated once more and the pellet 
resuspended in the residue ddH20. The SW102’s were transferred to a cuvette cooled to 4oC 
and kept on ice for 5 minutes. 5µL of NYESO1 DNA (purchased from Life Technologies and 
includes the DNA sequence of the full NYESO1 protein flanked either side with 80bp 
homology to the RL13 HCMV protein, Table-6) was added to the bacteria which were then 
electroporated at 250V and recovered for 5 minutes in 5ml LB broth at 32oC for 4 hours. 
After the recovery period, bacteria were spread onto LB plates + sucrose + X-gal + IPTG 
and left for 36 hours at 32oC. Positively BAC transfected colonies (white opaque) were then 
picked in 5ml LB broth + chloramphenicol O/N before isolating the BAC via a mini prep of the 
colonies and sequencing for the correct NYESO1 insertion. Additionally, DNA obtained from 
the mini plasmid preparations of colonies containing the HCMV-NYESO1 BAC were 
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restriction digested for 2 hours at 37oC (10µl plasmid, 7µl H20, 1µl HinDIII) and run on a gel 
O/N (16 hours) on a 0.8% agarose gel. Confirmation that the insert had not disrupted the 
BAC structure and had recombined correctly was provided by comparison to the parental 
BAC pALIIII digestion [221] and sequencing of plasmids (University of Birmingham, 
Genomics Services) using the M13F/R primers (Table-3). Two plasmids that had correctly 
recombined NYESO1 inserts were selected for generating DNA stocks for stable transfection 
of fibroblasts by inoculating 5ml LB broth containing chloramphenicol with 100µL of the 
residual mini preparation colonies at 32oC. After 8 hours the entire culture was inoculated 
into fresh 500ml LB + chloramphenicol O/N at 32oC and maxi prepped using the ‘Purelink 
HiPure plasmid maxiprep kit’ (Table-2). For the stable transfection of fibroblasts to generate 
viral stocks, 2 x 106 HFFF2s were electroporated with 30ng of maxi prepped HCMV-
NYESO1 DNA. Electroporated cells were recovered on tissue culture-treated 10cm2 dishes 
until plaques could be observed. At this point, the entire monolayer was trypsinised and 
inoculated into 2 x 106 uninfected HFFF2s and transferred into a T150cm2 tissue culture 
flask in 20ml DMEM culture media. Once plaques could be observed, viral supernatant was 
removed and replaced with fresh DMEM culture media. The 20ml of the viral supernatant 
was used to inoculate two flasks of uninfected HFFF2s to confirm viral progeny production 
by observing more plaques and to increase the final viral stock pfu. Once plaques could be 
observed in the newly infected flasks, over the next 21 days, the viral supernatant from the 
four flasks was removed, frozen at -80oC and replaced with fresh DMEM culture media. At 
the end of the 21 day period, viral supernatant was centrifuged at 15337xg for 2 hours in 
ultracentrifugable GSA Sorvall bottles at 4oC. The viral pellet was resuspended in 2ml 
DMEM culture media and 100µL of virus stocks transferred to cryovials and stored at -80. 
The viral titre of the stocks was determined by plaque assay as described in section 2.1.2.  
2.2.18 Generation of NYESO1-specific CD8+T-cell clones from healthy donors  
NYESO1-specific CD8+T-cell clones were generated to test the immunogenicity of the 
HCMV-NYESO1 in vitro as published [229]. Immature monocytes were isolated from buffy 
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coats of healthy donors by plating 2 x 106 PBMCs per well of a 24 well plate for a minimum 
of 3 hours to allow monocytes to adhere. After adhering, monocytes were trypsinised from 
the bottom of the plate, transferred to a fresh 24 well plate and differentiated to dendritic 
cells (DCs) over 4 days via the addition of ‘Granulocyte macrophage colony-stimulating 
factor’ (GMCSF) (800IU/ml, Peprotech) and IL-4 (10ng/ml, Peprotech) in RPMI media. DCs 
were then matured O/N with IFN-γ (100IU/ml) and LPS (10ng/ml) to induce CD44 and CD88 
expression. The DCs were peptide-pulsed for 10 days with a HLA-A2-restricted NYESO1 
peptide SLLMWITQC (aa position 157-165) [336-338] and co-cultured with autologous naïve 
CD8+T-cells (isolated from the same buffy coat and cryostored on the same day as the 
monocytes) (Table-2, Stem Cell Tech). After this 10 day co-culture, 50% of the DCs and 
CD8+T-cell co-culture was restimulated twice with γ-irradiated buffys and peptide-pulsed 
HLA-A2+ LCLs. After the second restimulation, CD8+T-cells were sorted based on CD137 
expression (Miltenyi Biotech) and CD137+ CD8+T-cells subjected to limiting dilution as 
described in 2.2.7.2 The remaining 50% were restimulated a third time after a further 14 
days and subjected to an IFN-γ catch assay (Miltenyi Biotech) and limiting dilution as 
described in 2.2.7.2. Expanded wells after 14 days were tested for peptide specificity as 
described in section 2.2.7.3. The recognition of HCMV-NYESO1 infected HLA-A2+ MRC5 
fibroblasts after an O/N co-culture was determined as described in section 2.2.9. The 
specific lysis of NYESO1 peptide-pulsed HLA-A2+ LCLs and HCMV-NYESO1 infected 
MRC5 fibroblasts (MOI 5) after 24 hours was conducted as in section 2.2.11 but with 35000 
and 10000 events recorded on an LSR II respectively.  
2.2.19 Statistics 
All statistics were computed in Graphpad Prism 6 using non parametric tests. Specific 
statistical tests are indicated in figure legends. Statistical significance was defined as a p-




CHAPTER 3  
 
 
CHARACTERISATION OF THE 
CD8+T-CELL RESPONSE TO 
‘PROTECTED’ EPITOPES  
IDENTIFIED USING THE RV798 




Chapter 3 - Introduction 
During chronic infection, the HCMV-specific CD8+T-cell response can occupy on average 
10%, reaching >20%, of the total circulating CD8+T-cell repertoire with age [87, 100, 107, 
230]. These expanded accumulations have a distinctive TEMRA phenotype (CCR7-
CD45RA+CD27-CD28-) and display high cytotoxicity [87, 108, 231]. It has since been 
realised that this current view of the CMV-specific CD8+T-cell immune response, which is 
based upon a restrictive set of immunodominant epitopes from the pp65 and IE-1 protein, is 
incomplete and vastly underestimating the global CD8+T-cell response. Further complicating 
the matter is the presence of the immunomodulatory US2-11 encoded proteins that interfere 
with the MHC-I pathway. Within infected fibroblasts these have been demonstrated to 
dampen the cytotoxic CD8+T-cell response to infected cells [232].  
A study by Gold et al. identified a novel peptide-epitope derived from the murine M45 protein 
using a strain of MCMV deleted for the immunomodulatory m152 protein [233]. Specific 
CD8+T-cell responses to this peptide were found in vivo despite the peptide not being 
presented in vitro during a fibroblast infection with the WT m152 virus. However, this may 
not represent the global priming abilities of all cell types permissible to CMV in vivo and may 
be a feature of fibroblasts.  Therefore, our view of the global CD8+T-cell targets towards 
HCMV has additionally may have been hampered by the restricted use of fibroblasts as the 
staple cell line for CMV infection in vitro. As such, important and potentially immunodominant 
CD8+T-cell responses in vivo may yet remain undetected.  
To address this, studies using both, synthetic peptide libraries derived from either 14 HCMV 
proteins or the entire HCMV genome [230, 234] have shed light into the global HCMV 
CD8+T-cell response within healthy chronically infected individuals. These studies extended 
the range of known HCMV antigens able to elicit CD8+T-cell responses from pp65 and IE-1 
including; US2, US3, US6 US11, UL16, and UL18.  
Two critical studies prior to the start of this research investigation utilised a mutant strain of 
HCMV deleted for the main US immunomodulatory genes (US2-S11) termed RV798 
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(generated by Jones et al. [83]). The studies hypothesised that the absence of the 
immunevasin region allowed for the surface presentation of potentially all antigenic targets of 
the virus. A study in our research lab identified that the CD8+T-cell response directed 
towards HCMV increased up to 10 fold upon removal of the US2-11 genes (RV798 infection) 
compared to the presence of the WT US2-11 region (AD169 infection). This was indicated 
by IFN-γ production after incubation of AD169 vs RV798 infected APCs with PBMCs. The 
work identified novel CD8+T-cell responses to additional CD8+T-cell antigens e.g. IE-2 [84].  
The research group of Dr Stanley Riddell, also utilised the RV798 virus strain of CMV to 
identify novel targets of the HCMV CD8+T-cell response [82]. Via incubation of PBMCs from 
chronically infected donors with RV798 infected APCs, the research group isolated CD8+T-
cell clones and mapped the specificities to proteins of the virus using single CMV deletion 
mutant strains. Specificity was determined by loss of recognition by CD8+T-cell clones 
towards cells infected with the CMV mutant – indicating the deleted protein contained the 
cognate peptide. Through this work, novel HCMV peptides were identified and the 
sequences of 16 were kindly provided to our research group by Prof Stanley Riddell (Table-
7). These epitopes were derived from a range of HCMV antigens and from all phases of the 
virus life cycle (IE-L). Furthermore within this study, Riddell et al demonstrated that these 
antigens were not recognised by the same CD8+T-cell clones during a WT AD169 infection 
of fibroblasts in vitro. These peptides were as such termed ‘protected epitopes’ by our 
research group as it was hypothesised they were ‘shielded’ from the CD8+T-cell clones in 
vitro during a WT infection due to the actions of the US2-11 gene region products. It was 
further hypothesised that the CD8+T-cell responses to these in vivo may be initially 
generated by cross-presentation due to the US2-11 gene region interfering with their direct 
presentation to the immune response.  
It has not yet been determined whether these novel peptide-epitopes (Table-7) identified by 
Manley et al. could be directly presented to the CD8+T-cell immune response in vivo during 
a WT HCMV infection - when the immunevasive US2-11 gene products are able to interfere 
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with MHC-I processing. Or additionally, whether such CD8+T-cell responses could play a 
protective role in removing virally infected cells in vivo.  
This investigation aimed to characterise the ex vivo responses to these peptides in terms of 
kinetics of expression, phenotype and recognition of cognate antigen during a WT (US2-11) 
infection of cells in vitro. Of particular importance is our access to the Birmingham ‘1000 
Elders’ cohort of healthy donors that are aged 60 years or over allowing us to analyse how 
the ex vivo CD8+T-cell responses change with age. It was also hoped to distinguish 
between ‘stable’ vs ‘inflationary’ HCMV epitopes within this peptide cohort as has been 
previously identified for MCMV and whether memory-inflation is restricted to 
















Chapter 3 - Results 
3.1 - Ex vivo responses to ‘protected’ HCMV epitopes are frequently detected in 
chronically infected healthy individuals 
Due to the protection of these peptides from the immune response in vitro, it was theorised 
that their specific CD8+T-cell responses in vivo may differ to those generated against 
previously researched HCMV epitopes e.g. pp65-derived ‘NLV’ (Table-5). The 
characteristics of the protected peptide-epitopes are provided in Table-7. They are derived 
from a wide range of HCMV antigens including; UL16, UL17, UL23, UL24, UL28, UL33, 
UL36, UL52, UL56, UL84, UL105, UL122 and US23. They also have diverse functions, are 
expressed across all phases of the viral lifecycle IE-L and importantly restricted through 
HLA-A, -B and –C alleles.  
The first aim of this investigation was to characterise the magnitude and kinetics of the ex 
vivo CD8+T-cell responses generated in vivo towards the ‘protected epitopes’ within healthy 
seropositive donors. These CD8+T-cells populations were analysed for changes in 
magnitude with age. Donors were therefore categorised into younger (YD <70 years) or 
older (OD >70 years) groups. To achieve this, PBMCs were screened for ex vivo CD8+T-cell 
responses indicated by intracellular cytokine production (IFN-γ, IL-2 and TNF-α) in response 
to 6 hours peptide stimulation. As positive and negative controls, PBMCs from the same 
donors were stimulated with SEB or media only (gating strategy of the ICS protocol is 
provided in Fig-7). The negative control background cytokine production ranged from 0.01-
0.22% of the total CD8+T-cells. In all cases this was subtracted from the peptide stimulated 
sample tube (data not shown). Throughout this investigation, donors were only screened for 
CD8+T-cell responses if they presented with the HLA type appropriate to the HLA-restriction 
of the peptide in question. Responding CD8+T-cells to the HLA-A/-B and –C ‘protected’ 
epitopes were previously detected in an MRes study in our research group (L.Hosie MRes, 
University of Birmingham, 2013). This work seeks to first extend this work by analysing the 
kinetics to these CD8+T-cell epitopes in a larger donor cohort. As such, 54 young and 37 
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elderly HCMV infected healthy donors aged between 23-96 years of age (donor description 
provided in appendix table 1-3 and 4-6 for YD and OD donors respectively), were screened. 
Table 7 – HCMV ‘protected’ CD8+T-cell peptide-epitopes. Protected epitope sequences (*) kindly provided by 
Dr Stanley Riddell (Some peptides unpublished data, others [85] investigated their processing). The protein 
antigen, aa position within the protein antigen, peptide sequence (peptide name is denoted by the first three aa of 
the sequence), restricting HLA allele, kinetics of expression and function of the protein antigen (if known) that the 
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Fig 7 – Gating strategy to identify activated CD8+T-cell populations following HCMV peptide stimulation. 
PBMCs from HCMV seropositive donors were stimulated with HCMV peptide (final concentration 1µg/ml) for 6 
hours. Single, live, CD3+CD8+ lymphocytes were gated on sequentially within Kaluza 1.3 software (Beckman 
Coulter). Cytokine producing CD8+T-cells were then identified in the gated CD8+ population. The cytokine gate 
was placed using the SEB stimulated control to identify the downregulation of CD8+ after stimulation. Any 
cytokine positive cells below this gate were considered background CD4+ cytokine producing cells. The 
percentages represent the percentage of activated CD8+T-cells producing cytokine as a percentage of the 








Overall, 12 out of the 16 peptides (Table-7) induced specific CD8+T-cell populations (Fig-
8/9) restricted through HLA-A/-B and –C producing cytokines. The peptides that did not elicit 
CD8+T-cell responses in this cohort were the HLA-B51-restricted peptides (n = 13). In all 
cases, the HCMV-specific CD8+T-cell populations were largely Th1 like – producing large 
amounts of IFN-γ and TNF-α. As has been previously described, the CMV-specific CD8+T-
cell populations produced little IL-2 (compared to the magnitude of IFN-γ and TNF-α 
production) (Fig-9) [235]. The CD8+T-cell IFN-γ and TNF-α production elicited by the 
peptides were of similar magnitudes (Fig-8/9). All averages and the raw ICS response 
results are provided in appendix tables 1-6. Fig-9A demonstrates the positive and negative 
spread of the CD8+T-cell responses obtained in all donors against the individual peptides. 
Fig-9B demonstrates the mean of the positive CD8+T-cell responses obtained against each 
individual peptide. 
Both the HLA-A and –B-restricted peptides elicited significant CD8+T-cell responses (Fig-8 
and 9A/B). The CD8+T-cell responses against the HLA-A peptides ranged from 0.02-5.65% 
of the total peripheral CD8+T-cell pool producing cytokine and remained at a stable 
percentage with age i.e. between donors < vs >70years  (Fig-9A/B). The UL69-derived RTD 
and UL105a-derived YAD epitopes elicited the most frequent HLA-A-restricted CD8+T-cell 
responses (Table-7) - 30% (9/30) and 33% (10/30) donors respectively (Fig-9A/B) which did 
not increase significantly with age. The RTD-specific CD8+T-cell responses producing IFN-γ 
and TNF-α ranged from 0.02%-1.00% (IFN-γ) and 0.02%-1.24% (TNF-α) of the total CD8+T-
cell response (Fig-8, 9A/B). These CD8+T-cell responses remained at an average of 0.28% 
(IFN-γ) or increased from 0.28%-0.43% (TNF-α) between the <70 vs >70 donor categories 
(Fig-8, 9A/B). The YAD-specific responses producing IFN-γ and TNF-α ranged from 0.02%-
0.28% (IFN-γ) and 0.02%-0.91% (TNF-α) of the total CD8+T-cell response. These CD8+T-
cell responses increased from an average of 0.12%-0.15% (IFN-γ) and 0.24%-0.34% (TNF-
α) between the <70 vs >70 donor categories (Fig-8, 9A/B) but was not significant. The IL-2 










































































Fig 8 – Ex vivo CD8+T-cell responses to the ‘protected’ HCMV epitopes within healthy seropositive 
individuals. PBMCs from HCMV seropositive donors were stimulated with HCMV peptide (final concentration 
1µg/ml) for 6 hours followed by intracellular staining for IFN-γ, IL-2 and TNF-α to identify specific CD8+T-cell 
responses. The flow plots represent representative dot plots for each of the protected peptides to which specific 
CD8+T-cell responses were detected. The IFN-γ, IL-2 and TNF-α production are given in the left to right hand 
columns respectively. Unstimulated negative and SEB positive controls are provided in the top and second row 
respectively. In each case the HLA-restriction, peptide name, donor ID (appendix tables 1 and 4) donor age are 
provided on the left hand side of the plots. All data was analysed in Kaluza 1.3 software (Beckman Coulter). The 
percentages represent the percentage of activated CD8+T-cells producing cytokine of the total CD8+T-cell 






identical (Appendix Table-2, 5).  The UL84-derived HLA-A3-restricted RVD peptide elicited 
the single largest HLA-A-restricted response at 5.65% IFN-γ and 4.69% TNF-α in one donor 
of 52 years. The HLA-A11-restricted UL36-derived RSA peptide also elicited stable CD8+T-
cell responses with age with an average remaining at 0.27% (IFN-γ) or increasing 0.21-
0.26% (TNF-α) of the total CD8+T-cell response between the <70 vs >70 year categories. 
The CD8+T-cell responses elicited by the HLA-B-restricted peptides were either smaller 
(average 0.04% IFN-γ, 0.02% IL-2 and 0.05% TNF-α) than those elicited by the HLA-A, or 
not present (HLA-B51-restricted peptides DAR, IPH, TLM and WPK peptides, n = 13, Fig-8, 
9A/B). These also did not demonstrate a significant increase in size with age. The largest 
HLA-B-restricted response was elicited by the UL122 (IE-2 viral trans activator) derived NEG 
peptide at 2.31%, 0.13% and 3.98% of the total CD8+T-cell pool producing IFN-γ, IL-2 and 
TNF-α respectively within a donor of 48 years.  
In comparison to the HLA-A/-B-restricted peptides, a HLA-Cw*0702-restricted CD8+T-cell 
epitope termed ‘FRC’, derived from the UL28 HCMV protein, was identified to elicit an 
average of 2.63% IFN-γ, 0.24% IL-2 and 2.44% TNF-α producing CD8+T -cells of the total 
CD8+T-cell pool within younger donors (<70 years)(Fig-9A/B). This epitope-specific CD8+T-
cell pool increased to an average of 8.24% IFN-γ, 0.85% IL-2 and 10.37% TNF-α producing 
CD8+T-cells in older donors (>70 years)(Fig-9B). The FRC peptide also induced the highest 
frequency of responses in this donor cohort with 70% (28/40) of donors responding with IFN-
γ and TNF-α CD8+T-cell production after FRC stimulation ranging from 0.03-32.25% and 
0.03-31.07% of donors total CD8+T-cell pool respectively (Fig 9A/B). Interestingly, the FRC-
peptide elicited higher percentages of CD8+T-cells producing IL-2 than the HLA-A/-B-
restricted peptides (albeit a much lower magnitude than IFN-γ/TNF-α (0.03-4.23%) (Fig-9B). 
Lastly, the magnitude of both IFN-γ and TNF-α production induced by the FRC peptide 
increased significantly between donors <70 vs >70 years of age (Fig-9B)(Investigated in 








Fig 9 – Summary of the ex vivo responses detected against the ‘protected’ peptides producing IFN-γ, IL-2 
and TNF-α. PBMCs from HCMV seropositive donors were stimulated with HCMV peptide (final concentration 
1µg/ml) for 6 hours followed by intracellular staining for IFN-γ, IL-2 and TNF-α to identify specific CD8+T-cell 
responses. Younger (<70 years) vs older (>70 years) donors were screened for ex vivo CD8+T-cell responses to 
the protected CD8+T-cell peptides. The open circles represent donors <70 years of age. Black circles represent 
donors >70 years of age. A) Summary of all negative and positive CD8+T-cell responses specific for the 
protected peptides detected in young vs older donors. The TNF-α, IFN-γ and IL-2 production elicited by the 
peptides are provided in the top, middle and bottom rows respectively. The HLA-A, -B and –C restricted peptides 
are provided in the left, middle and right hand columns respectively. B) Summary of the positive CD8+T-cell 
responses detected towards the protected peptides within young vs older donors. Lines represent mean of all 
positive CD8+T-cell responses obtained for each protected peptide. The TNF-α, IFN-γ and IL-2 production 
elicited by the peptides are provided in the top, middle and bottom rows respectively. The HLA-A, -B and –C 
restricted peptides are provided in the left, middle and right hand columns respectively. Statistical significance 
was obtained using multiple Mann Whitney tests in Graphpad Prism 6 with * as a p-value < 0.05.  
 
It must be noted that statistical significance of the FRC-specific CD8+T-cell populations was 
observed after conducting multiple Mann Whitney tests between the <70 and >70 donor 
cohorts and could be a result of statistical chance. Any statistics obtained using multiple 
comparisons will be herein stated within figure legends. 
 
CD8+T-cell responses to a further two HLA-C-restricted epitopes (HLA-Cw*0702-restricted 
UL33-derived SYR and HLA-Cw*1601-restricted UL24-derived YLC – Table-7) were 
detectable in 25% (8/32) and 62% (8/13) donors respectively ranging from 0.04%-0.34% and 
0.04%-1.16%. The YLC-specific CD8+T-cell responses did increase with age, however, 
these were not significant and in large due to one large YLC response of 12.19% IFN-γ, 
1.16% IL-2 and 14.22% TNF-α within a single donor of 86 years (Fig-9B and appendix 
tables-1-6) The SYR-specific CD8+T-cell TNF-α production increased slightly with age 
(0.06%-0.17%) but again was not significant.  
 
The US2-11 gene region products therefore do not prevent the in vivo induction of a primed 
CD8+T-cell response to novel peptide-epitopes that were identified utilising the RV798 
mutant. In addition, an immunodominant CD8+T-cell response was detected in this cohort 
specific for a HLA-C-restricted HCMV-specific CD8+T-cell epitope termed ‘FRC’ derived 




3.2 – The phenotypic characterisation of the ex vivo ‘protected’ peptide specific 
CD8+T-cell populations by flow cytometry 
Previous studies have demonstrated that the ex vivo CD8+T-cell memory phenotype 
between CD8+T-cell populations specific for a range of differing HCMV antigens, including 
UL83 (pp65), UL82 (pp71), UL123 (IE-1), UL122 (IE-2), UL99, UL28, UL48, US29, US32, 
UL55 (gB), and US3 are not significantly different to each other [236] 
 
Next in the investigation we wished to phenotypically characterise the CD8+T-cell responses 
to the protected peptides identified in the absence of the US1-11 gene region. It was 
hypothesised that during a WT (US2-11 gene region intact) infection they may be 
infrequently presented to the immune system. Resulting in a CD8+T-cell population with a 
less differentiated phenotype.  
 
The RTD, YAD and FRC peptides were selected for MHC-I tetramers to be obtained from 
the NIH tetramer facility. They were the most frequent HLA-A and HLA-C responses 
respectively and would allow a comparison between a ‘stable’ vs ‘immunodominant’ peptide. 
Unfortunately, despite the efforts of both our laboratory and the NIH tetramer facility an FRC 
MHC-I tetramer could not be obtained. Therefore all the protected peptide-specific CD8+T-
cell responses were phenotyped after ICS to identify specific cells by TNF-α production 
(phenotype gating strategy provided in Fig-10).  
 
CD8+T-cell responses specific for the HLA-A1-restricted RTD and YAD, HLA-A3-restricted 
RSA, HLA-B44-restricted NEG, HLA-Cw*0702-restricted FRC and SYR and lastly HLA-
Cw*1601-restricted YLC peptides were subsequently phenotyped after 6 hours peptide 






























Fig 10 – Gating strategy of the phenotypical analysis of ex vivo HCMV-specific CD8+T-cell responses by 
ICS after peptide stimulation. The expression of single cell phenotypic markers was assessed on epitope-
specific CD8+T-cells after peptide stimulation. PBMCs from HCMV seropositive donors were stimulated with 
HCMV peptide (final concentration 1µg/ml) for 6 hours followed by intracellular staining for TNF-α to identify 
specific CD8+T-cell responses and allow phenotypic characterisation. PBMCs were stained with the antibody 
panels outlined in Table-4. Single, viable, CD3+CD8+ lymphocytes were sequentially gated on prior to the 
analysis of phenotypic marker expression. Gates for single markers were placed using the total CD8+T-cell 
population (CD3+CD8+) to identify negative vs positive populations for the marker in question. The same gate 
was then applied to the epitope specific CD8+T-cells. Included here is an example of HLA-A3-restricted RSA-
specific cells after peptide stimulation for 6 hours, and representative dot plots demonstrating CX3CR1, 
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The CD8+T-cells were investigated for the expression of several phenotypic markers. Firstly, 
the T-cell homing marker CCR7 in combination with the CD45 isoforms – CD45RA and 
CD45RO - were included within the analysis. This allowed the characterisation of the 
CD8+T-cell responses into memory CD8+T-cell subset compartments [108, 237].  
The T-cell co-stimulatory markers CD27 and CD28 were used to determine the antigen 
differentiation status of the CD8+T-cell responses The loss of these molecules is an 
indicator of a larger proliferative history of the CD8+T-cell and typically indicates a T-cell 
further down the differentiation pathway i.e. late antigen differentiated [70, 238]. 
Cytotoxicity markers perforin, granzymeB, and NKG2D were also investigated. This was to 
assess the cytotoxic potential these CD8+T-cells possess upon antigen encounter. 
Additionally, the activation state of the CD8+T-cells was analysed by the inclusion of the 
CD38 marker.  
The exhaustion T-cell markers PD-1 and TIM3 were included. This was to assess whether 
the protected-peptide specific CD8+T-cells were functionally exhausted in vivo.  
Lastly, CMV-specific CD8+T-cells have been identified as having a unique high expression 
of the CX3CR1 fractalkine receptor hypothesised to home these T-cells to the endothelium 
[2, 72]. This marker was therefore also included within the analysis.  
3.2.1 – Single cell marker expression 
First, the expression of single cell markers was analysed on the protected peptide-specific 
CD8+T-cell responses (Fig-11). Overall, there were distinct phenotypic patterns based upon 
the HLA restriction of the CD8+T-cell responses and between epitope specificities) (Fig-11). 
However, no significance difference was obtained when looking at the expression of single 






Fig 11 – Ex vivo phenotype of protected peptide specific CD8+T-cell responses determined by flow 
cytometry after peptide stimulation and ICS. The expression of single cell markers on the HCMV-specific 
CD8+T-cells was assessed. PBMCs from HCMV seropositive donors were stimulated with HCMV peptide (final 
concentration 1µg/ml) for 6 hours followed by intracellular staining for TNF-α to identify specific CD8+T-cell 
responses and allow phenotypic characterisation. PBMCs were stained with the antibody panels outlined in 
Table-4. Graphs represent the single marker ex vivo phenotype of the individual HCMV protected peptide-specific 
CD8+T-cell populations. Epitope-specific CD8+T-cell responses identified by ICS – gating strategy provided in 
Fig-7. HLA-A-restricted CD8+T-cell responses are indicated by white or white patterned bars, HLA-B-restricted 
CD8+T-cell responses indicated by the black bar and HLA-C-restricted CD8+T-cell responses by grey or grey 
patterned bars. The blue bars represent the average ex vivo phenotype of the total CD8+T-cell responses 
excluding epitope-specific CD8+T-cells n =17. Bars represent mean and those without error bars n = 1. Error 
bars represent SEM. RTD and YAD n = 3 and 4. FRC n = 9.  
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Therefore next the phenotypic results were pooled depending upon whether the CD8+T-cell 
responses were HLA-A, -B or –C-restricted. When the ex vivo CD8+T-cell responses were 
pooled statistical significance was obtained with regards to the expression of single surface 
markers. Clear patterns between the HLA-A and –C-restricted CD8+T-cells emerged (Fig-
12).  
The pooled HLA-A CD8+T-cell responses, compared to the -B and –C restricted, presented 
with the following overall phenotype (Fig-12);  
CCR7HighCD54ROLowCD45RALow/CD28HighCD27High/CX3CR1HighNKG2DlowPerforinhighGran
zymeBhighTim3HighPD-1HighCD38High. The expression of the CD27/CD28 co-stimulatory 
molecules is indicative that the HLA-A responses are of an earlier antigen driven 
differentiated phenotype with a lower proliferative history. 
The HLA-B-restricted NEG-specific CD8+T-cell response, compared to the –A and –C 
restricted, presented with the following phenotype (Fig-12); 
CCR7negCD45ROhighCD45RAhigh/CD28highCD27Neg/CX3CR1lowNKG2DHighPerforinhighGranz
ymeBhigh/TimNeg-Pd-1HighCD38high 
Indicative that the HLA-B NEG-specific response is of an intermediate antigen driven 
phenotype as defined by Appay et al [70], having downregulated CD27 and having high 
cytotoxicity indicated by NKG2D expression. The co-expression of CD45RA/RO has 
identified T-cells in an intermediary transitional state [239]. 
The pooled HLA-C-restricted CD8+T-cell responses, compared to the –A and –B restricted, 





Fig 12 – The ex vivo phenotype of the protected peptide CD8+T-cell populations when characterised 
based upon HLA-A, -B or –C-restriction. The expression of single cell markers on the pooled HCMV-specific 
CD8+T-cells was assessed categorised on HLA-restriction. PBMCs from seropositive donors were stimulated 
with HCMV peptide (final concentration 1µg/ml) for 6 hours followed by intracellular staining for TNF-α to identify 
specific CD8+T-cell responses and allow phenotypic characterisation. PBMCs were stained with the antibody 
panels outlined in Table-4. The phenotypes obtained for the individual epitope-specific CD8+T-cell responses 
obtained in Fig-11 were pooled deepening on whether the CD8+T-cells were HLA-A, -B or –C restricted. The 
bars represent the mean expression of that particular marker within the pooled CD8+T-cell responses and error 
bars SEM. The pooled HLA-A CD8+T-cell responses included the HLA-A1 RTD and YAD and HLA-A11 RSA-
specific CD8+T-cells, n = 7. The HLA--B consisted of the NEG-specific CD8+T-cell responses, n = 1. The pooled 
HLA–C CD8+T-cell responses include the FRC-, SYR- and YLC-specific CD8+T-cells, n = 11. Those without 
error bars represent n = 1. Statistical significance was obtained using multiple Mann Whitney tests in Graphpad 6 
with a p value < 0.05.  
 
The HLA-C CD8+T-cells expressed significantly lower levels of CD27 compared to the HLA-
A-restricted CD8+T-cells (p = 0.044, Fig-12). The HLA-C CD8+T-cells also expressed lower 
levels of CD28 compared to the pooled HLA-A responses (p = 0.053) (Fig-12). Interestingly, 
the HLA-C restricted responses had a significantly lower expression of the CD38 activatory 
marker despite a phenotype suggestive of frequent antigen encounter (Fig-12). 
This is indicative that the HLA-C-restricted responses are of a later antigen driven 
differentiation phenotype compared to the HLA-A-restricted populations [70]. This TEMRA 
phenotype is suggestive of memory-inflated CD8+T-cell populations described previously 
within the murine model [105, 240].  
102 
 
3.2.2 – Memory CD8+T-cell compartment  
In the murine model, stable CD8+T-cell responses have been identified as belonging to the 
TCM compartment and inflationary to the TEMRA. After observing that the HLA-C CD8+T-cell 
populations displayed a more overall TEMRA like phenotype 
(CCR7lowCD45RO+CD28lowCD45RAhighCD27low) compared to HLA-A-restricted, it was next 
identified what CD8+T-cell memory compartments they occupy. In this section TN (naïve like 
profile), TCM, TEM and TEMRA were identified as CCR7+CD45RA+, CCR7+CD45RA-, CCR7-
CD45RA- and CCR7-CD45RA+ respectively (gating strategy is provided in Fig-13A).  
 
First, the CCR7 vs CD45RA expression was analysed on the individual HCMV-specific 
CD8+T-cell responses. The HLA-Cw*1601-restricted SYR, and HLA-A1-restricted YAD- and 
RTD-specific CD8+T-cell populations contained the largest populations of TN CD8+T-cells 
(10.81%, 11.21% and 7.60% respectively) (Fig-13B).  
The HLA-A1-restricted RTD and YAD CD8+T-cell responses consisted of the largest 
percentage of TCM (identified as CCR7+CD45RA-) at 12.48% and 12.52% respectively, 
followed by the HLA-A11-restricted RSA-specific CD8+T-cell response at 6.42% of the total 
epitope-specific CD8+T-cell response (Fig-13B).  
The HLA-Cw*0702 SYR-specific CD8+T-cell population was comprised of the largest 
percentage of TEM (identified as CCR7-CD45RA-) at 37.84% (Fig-13B). 
The HLA-Cw*0702-restricted FRC-, HLA-A11-restricted RSA-, HLA-B44-restricted NEG- and 
HLA-Cw*1601-restricted YLC-specific CD8+T-cell responses comprised the largest 
percentage of TEMRA (identified as CCR7-CD45RA+) at 58.59%, 66.86%, 74.34% and 82.48% 





















Fig 13 – CCR7 vs CD45RA memory phenotype of the ex vivo CD8+ protected peptide-epitope responses 
as detected by flow cytometry after peptide stimulation and ICS. The memory compartment phenotype of 
HCMV-specific CD8+T-cells was assessed by CCR7 vs CD45RA expression. PBMCs from seropositive donors 
were stimulated with HCMV peptide (final concentration 1µg/ml) for 6 hours followed by intracellular staining for 
TNF-α to identify specific CD8+T-cell responses before phenotypic characterisation. PBMCs were stained with 
the antibodies outlined in Table-4. A) Gating strategy for identifying the distinct CD8+T-cell memory 
compartments in Kaluza 1.3 software (Beckman Coulter). CD3+CD8+T-cells and then epitope-specific cells were 
gated upon in a hierarchal manner as outlined in Fig-7. CD45RA+, CCR7+ CD8+T-cells were identified in the 
total CD8+T-cell population (left hand flow plot) and this gate applied to the epitope-specific CD8+T-cells (right 
hand flow plot). B) Summary of the CCR7 vs CD45RA memory phenotype of the individual protected epitope-
specific CD8+T-cell responses C) Summary of the CCR7 vs CD45RA memory phenotype of the pooled CD8+T-
cell responses to the protected peptides based on their HLA-A, -B, or –C-restriction. The pooled HLA-A-restricted 
CD8+T-cell responses included the HLA-A1-restricted RTD and YAD and HLA-A11-restricted RSA-specific 
CD8+T-cells, n = 7. The HLA-B-restricted consisted of the NEG-specific CD8+T-cell responses, n = 1. The 
pooled HLA–C-restricted CD8+T-cell responses include the FRC-, SYR- and YLC-specific CD8+T-cells, n = 11.  
B/C) Bars represent mean and error bars SEM. Those without error bars n = 1. RTD N =4, YAD n = 3, FRC n = 9. 
Statistical significance was conducted in Graphpad prism 6 using multiple Mann Whitney tests with * as a p value 
< 0.05.  
Total CD8+T-cells Epitope-specific CD8+T-cells 
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Next, the CCR7 vs CD45RA expression was analysed on the pooled HLA-A- vs –B vs –C-
restricted CD8+T-cell populations. The pooled HLA-C CD8+T-cell responses had a 
significantly decreased proportion of TCM (CCR7+CD45RA-) at 5.17% than the pooled HLA-
A-restricted responses at 8.96% (Fig-13C). In addition they had a significantly increased 
percentage of TEMRA CD8+T-cells (CCR7-CD45RA+) compared to the pooled HLA-A-
restricted CD8+T-cell population - 64.18% vs 44.84% (p = 0.014). The pooled HLA-C 
CD8+T-cell populations also had a decrease in the fraction of TCM compared to the HLA-A 
(CCR7+CD45RA-) (p = 0.081) (Fig-13C). Thus corroborating the earlier observation that the 
HLA-C-restricted CD8+T-cells are of a general TEMRA phenotype whilst the HLA-A-restricted 





















3.2.3 – Antigen differentiation status 
Next we utilised the categorisation method of CD8+T-cells in differing differentiation statuses 
defined by Appay et al. whereby the acquisition of a CD27-CD28- phenotype represents a 
late antigen differentiated memory CD8+T-cell, CD27+CD28-/CD27-CD28+ an intermediate 
and CD27+CD28+ a CD8+T-cell early in the differentiation pathway [70].The association of a 
progressively more antigen differentiation status, indicated by the loss of CD27/CD28, has 
also been identified as an indicator of increased history of proliferative capacity [238].  
The CD27 vs CD28 expression was first analysed on the individual HCMV-specific CD8+T-
cell populations (gating strategy is provided in Fig-14A). The HLA-Cw*-0702-restricted FRC-
specific CD8+T-cell populations had a significant decrease in the percentage of early 
differentiated CD8+T-cells (CD27+CD28+) compared to the HLA-A1-restricted RTD-specific 
CD8+T-cell populations (13.06% vs 31.83% respectively, p = 0.016, Fig-14B). The RTD-
specific and YAD-specific CD8+T-cell populations comprised the largest proportion of early 
differentiated CD8+T-cells at 31.83% and 28.32% respectively (Fig-14B).  
The HLA-B44-restricted NEG- and HLA-Cw*0702-restricted SYR-specific CD8+T-cell 
populations had the largest populations of CD27-CD28+ intermediate differentiated T-cells at 
66.80% and 62.16%. The HLA-A11-restricted RSA, HLA-Cw*0702-restricted FRC and HLA-
Cw*1601-restricted YLC populations had the largest percentage of late differentiated 
CD8+T-cells at 84.38%, 60.74% and 93.23% respectively (Fig-14B).   
The CD27 vs CD28 expression was then subsequently interpreted when the CD8+T-cell 
responses were pooled into HLA-A, -B or –C-restriction categories. When the CD8+T-cell 
populations were pooled, the HLA-C restricted CD8+T-cells had a significantly decreased 
percentage of early differentiated CD8+T-cells at 9.28% compared to the HLA-A-restricted 
responses at 27.93% (Fig-14C). The HLA-B-restricted response was largely formed of 
CD27-CD28+ CD8+T-cells (66.8%) indicative of an intermediate phenotype [70].  
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Fig 14 – Antigen differentiation status of the ex vivo CD8+T-cell responses specific for the protected 
peptides.  The CD27 vs CD28 antigen differentiation status of HCMV-specific CD8+T-cells was assessed. 
PBMCs from seropositive donors were stimulated with HCMV peptide (final concentration 1µg/ml) for 6 hours 
followed by intracellular staining for TNF-α to identify specific CD8+T-cell responses before phenotypic 
characterisation. PBMCs were stained with the antibodies outlined in Table-4.  A) Gating strategy used in Kaluza 
1.3 software to identify early (CD27+CD28+), intermediate (CD27+, CD28-, CD27-CD28+) or late (CD27-CD28-) 
antigen differentiated epitope-specific CD8+T-cells. The CD8+ population was gated on as described in Fig-7. 
The CD27 and CD28 gate was placed using the total CD8+T-cell population (left hand flow plot) and then placed 
upon the epitope-specific CD8+T-cells (right hand flow plot) B) Summary of the stages of the antigen 
differentiated CD8+T-cell populations detected for all individual HCMV epitope-specific CD8+T-cell responses 
determined by CD27 vs CD28 expression. RTD N =4, YAD n = 3, FRC n = 9. Those without error bars n = 1  C) 
Summary of the antigen differentiation status detected within the pooled protected epitope-specific CD8+T-cell 
responses based upon HLA-A, -B or –C-restriction. The pooled HLA-A-restricted CD8+T-cell responses included 
the HLA-A1-restricted RTD and YAD and HLA-A11-restricted RSA-specific CD8+T-cells, n = 7. The HLA-B-
restricted consisted of the NEG-specific CD8+T-cell responses, n = 1. The pooled HLA–C-restricted CD8+T-cell 
responses include the FRC-, SYR- and YLC-specific CD8+T-cells, n = 11. B/C) Bars represent mean and error 
bars SEM. Those without error bras n = 1.  Statistical significance was obtained Graphpad Prism 6 with ** as a p 
value < 0.005 using multiple Mann-Whitney tests.  
Total CD8+T-cells Epitope-specific CD8+T-cells 
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Lastly, in comparison to the HLA-A-restricted, the HLA-C-specific CD8+T-cells comprised a 
slightly larger percentage of late differentiated CD8+T-cells (Fig-14C) (50.24% compared to 
58.94%).  
Altogether, the memory phenotype and differentiation status data suggests the HLA-A-
restricted CD8+T-cells are a lesser antigen differentiated TCM phenotype and the HLA-B-
restricted of an intermediate differentiated phenotype. The HLA-C-specific CD8+T-cell 
populations were of a later differentiated TEMRA phenotype. This was largely due to the 
majority of responses phenotyped being specific to the HLA-Cw*0702-restricted FRC 
peptide. To ensure this late differentiated phenotype is a general feature of HLA-C-restricted 
















3.3 - Direct and cross presentation of the HCMV ‘protected’ peptides  
Antigens expressed during the L phase of the lifecycle are less likely to be directly presented 
when the US2-11 gene region products have also been expressed. However, CD8+T-cell 
responses against antigens expressed during the E-L stages of the viral lifecycle have been 
identified [58].  Thus, this indicates a role of cross-presentation in priming CD8+T-cells to the 
full antigenic repertoire of HCMV in vivo or implicates direct presentation by a cell type in 
which the US2-11 proteins cannot exert their immunomodulatory effects.  
During the identification of these protected peptides during an RV798 (ΔUS2-11) infection, 
specific CD8+T-cell clones were unable to recognise these peptides during a WT infection in 
vitro of fibroblasts when the US2-11 gene region was present [82]. Manley et al. looked for 
recognition of these peptides at 24 and 48 hours post infection during AD169 and RV798 
infection of APCs respectively. This raises the question to how these responses are 
generated in vivo. The first explanation could be that the peptides are presented directly to 
the immune response prior to the US2-11 gene products being able to impair MHC-I 
presentation. This may be before the 24 hours p.i. time-point during an AD169 infection that 
Manley et al. investigated. A second explanation is that cell types other than fibroblasts in 
vivo may be more efficient at presenting these protected peptides. A third explanation could 
be cross-priming of the CD8+T-cells by DCs.  
This section aimed to identify if these peptides can be presented directly to specific CD8+T-
cell clones by two different cell types during a productive infection in vitro – i.e. IE to L time-
points. Furthermore it also sought to demonstrate the ability of DCs to cross present these 
peptide-epitopes to specific CD8+T-cell clones in vitro.  
HLA-A1-restricted RTD and YAD-specific CD8+T-cell clones were first generated from the 
PBMCs of HCMV infected donors (YD4 and YD5 for RTD and YAD respectively)(Appendix 
tables 1 to 3) by isolating CD8+ T cells producing IFN-γ after 3 hours peptide-stimulation 
using an IFN-γ secretion assay (Miltenyii Biotech, Table-2). These CD8+T-cells were then 
plated out on 96 well plates via a limiting dilution assay and maintained in culture for 14 days 
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with peptide-loaded LCL target cells. CD8+T-cell clone specificity was determined by IFN-γ 
ELISA of expanded wells. Examples of some of the specific CD8+T-cell clones obtained are 









Fig 15 – Generation of HLA-A1-restricted HCMV protected epitope specific CD8+T-cell clones in vitro. 
Specific CD8+T-cell clones for the UL69-derived RTD and UL105a derived YAD peptide were generated in vitro 
by isolating CD8+T-cells after 3 hours peptide stimulation of PBMCs with ether the RTD or YAD peptides by an 
IFN-γ catch assay (Miltenyi Biotech). This was followed by a limiting dilution. The PBMCs selected had previously 
identified ex vivo CD8+T-cell responses to the peptides in question. The graph demonstrates the representative 
IFN-γ production of RTD and YAD-specific CD8+ example clones determined by ELISA after O/N co-culture of 
the CD8+T-cell clones with DMSO control loaded (white bars) or peptide-loaded LCLs (black bars). 
 
The functional avidity of the specific clones was subsequently determined via a peptide 
dilution assay (Fig-16). Clones were co-cultured O/N with HLA-matched peptide-loaded 
LCLs followed by an IFN-γ ELISA. The LCLs were loaded with a range of peptide 
concentrations from 50pg-50μg (10-11-10-5 log10M). Clones specific for the pp65-derived 
HLA-A2-restricted NLV peptide were generated by Dr Miriam Ciaurriz and Dr Annette 
Pachnio. These were kindly provided for the in vitro assays in this investigation. 
The RTD-specific clones had an avidity range of 0.25μg-0.5μg (average 10-7 log10M) and the 
YAD-specific CD8+T-cell clones 0.025μg-0.25μg (average 10-8 log10M) (Fig-16). This was 

















Fig 16 – Functional avidity of Specific CD8+T-cell clones for the UL69-derived RTD and UL105a derived 
YAD peptides vs pp65-specific CD8+T-cell clones. Graphs demonstrate the functional peptide avidity (EC50) 
of the RTD (top) and YAD (bottom) and NLV-specific (right) CD8+T-cell clones. EC50 was determined as the 
concentration of peptide that induced the 50% maximal IFN-γ production. Specific CD8+T-cell clones were 
generated in vitro by an IFN-γ catch assay (Miltenyi Biotech) after 3 hours peptide stimulation assay of PBMCs 
with previously identified CD8+T-cell responses to the peptides in question followed by a limiting dilution.. 
CD8+T-cell clones were co-cultured O/N with LCLs loaded with peptide concentrations ranging from 50μg to 
50pg followed by an IFN-γ ELISA. NLV-specific CD8+T-cell clones generated by Dr Miriam Ciaurriz, University of 




The RTD and YAD-specific CD8+T-cell clones were then used to test for the ability to 
recognise cognate peptide that is naturally processed during infection with CMV strains 
containing the WT US1-11 gene region (AD169 and Merlin) in vitro (Fig-17). This was 
compared to CD8+T-cell recognition during an RV798 infection lacking this region as a 
positive control due to their method of identification with the RV798 strain. The recognition of 
haematopoietic (monocytes) vs non-haematopoietic (fibroblasts) was also compared as non-
haematopoietic cells have been implicated as either the initial priming cell type or cell type 
driving memory-inflation respectively.  
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The HLA-A1-restricted CD8+T-cell clones specific for the RTD and YAD peptides had 
differing recognition profiles depending upon the kinetics of expression of the protein from 
which they are derived (Fig-17).  
During an AD169 infection of HLA-A1+ healthy donor human fibroblasts, the E-L-expressed 
UL69-derived RTD peptide, which is also present within the incoming virion particle, was 
recognised by specific clones at IE-L time-points of an infection (6-72 hours) (Fig-17). The E-
L-expressed, UL105a-derived YAD peptide that is not present within the incoming virus 
particles was recognised by specific CD8+T-cell clones at E-L to L times of an AD169 
fibroblast infection (48-72 hours p.i) (Fig -17).  
Both the RTD- and YAD-specific clones released a larger magnitude of IFN-γ at all time-
points of a RV798 infection of the same fibroblasts compared to the level released during an 
AD169 infection (Fig-17).  
As the AD169 strain is able to only infect fibroblasts in vitro as a result of mutations that are 
quickly acquired during passaging [241], the Merlin strain was used to analyse recognition of 
infected monocytes. Interestingly, recognition of the RTD peptide was lost at IE-E (6-24 
hours p.i.) time-points of a monocyte infection. A small IFN-γ production was elicited at 24 
and 72 hours p.i (Fig-17). The recognition of the YAD peptide during a Merlin infection of 
monocytes followed the same recognition profile as that in AD169 infected fibroblasts (48-72 













Fig 17 – Recognition of fibroblasts and monocytes by HLA-A1-restricted HCMV-specific CD8+ T cell 
clones during a productive infection in vitro. The recognition of naturally processed and presented HLA-A1 
RTD and YAD peptide during a HCMV infection was analysed by the incubation of 6-72 hour infected fibroblasts 
O/N with CD8+T-cell clones. Positive recognition was determined by IFN-γ release into the supernatant detected 
by IFN-γ ELISA. HLA-A1+ healthy human donor fibroblasts were infected with wither AD169 (top row) or RV798 
(middle row) for 6-72 hours at an MOI of 5. Monocytes isolated form the PBMCs of donors with previously 
identified ex vivo CD8+T-cell responses were infected with the Merlin strain (bottom row) for 6-72 hours at an 
MOI of 5. At each time-point infected cells were incubated with 10 000 RTD- (left column) or YAD-specific (right 
column) CD8+T-cell clones. Bars represent the mean IFN-γ production in pg/ml per time-point by specific 
CD8+T-cell clones and error bars SEM. n = 1-5 per time-point for fibroblasts and n = 2 for monocytes.  
 
To determine whether the RTD and YAD peptides could be cross presented by DCs, a 
protocol developed by Mr Calum Forrest (University of Birmingham) was conducted in a 
collaboration (Fig-18).  
DCs were isolated from PBMCs from donors previously identified to have ex vivo CD8+T-cell 
responses to these peptides. The DCs were differentiated over a period of 4 days with IL-4 
and GM-CSF and fed with antigen for 2 hours with either HCMV AD169 infected fibroblast 
lysate or mock infected fibroblast lysate (Dr Annette Pachnio and Miss Jusnara Begum, 
University of Birmingham UK). This was followed by the addition of R848 and Poly(I:C) for 
24 hours. Following maturation, DCs were co-cultured with RTD- or YAD-specific HCMV-
113 
 
specific CD8+T-cell clones O/N (16 hours) at an effector: target ratio of 10:1. An IFN-γ 
ELISA of the supernatant was conducted to determine CD8+T-cell activation (Fig-18). 
Positive and negative controls included the co-culture of CD8+T-cells with peptide or mock 
lysate. An additional negative control was provided by the culture of CD8+T-cells only O/N. 
NLV-specific clones were included in the assay as the pp65 peptide has been demonstrated 









Fig 18 – Cross presentation of the HCMV protected epitopes. The cross presentation of UL69-derived RTD 
and UL105a-derived YAD peptides to specific CD8+T-cell clones in vitro was investigated. DCs from donors with 
previously identified CD8+T-cell responses to the peptide in question were isolated, differentiated and fed with 
HCMV AD169 fibroblast lysate for 2 hours at 1:1 ratios and then 24 hours with 4ug/ml R848 and 20ug/ml 
Poly(I:C). This was followed by co-culture with HCMV-specific CD8+ T cell clones for 16 hours. For positive and 
negative controls, CD8+T-cell clones were co-cultured with peptide or mock lysate. An additional negative control 
was provided by the culture of CD8+T-cell clones alone O/N. Positive cross-priming of the specific CD8+T-cells 
by the DCs was identified by IFN-γ production and therefore CD8+T-cell activation. n = 1. Bars represent the IFN-
γ production elicited by the CD8+T-cell clones into the supernatant. 
 
Both peptide derived from HCMV proteins that are present within the infectious virion – UL69 
and pp65 – were cross presented by DCs to CD8+T-cell clones (Fig-18). Both of these 
protein antigens would be present within the HCMV lysate as they are present within 
infectious virions. The UL105a protein is not present within the infectious virion as it forms 
part of the HCMV DNA helicase complex [242, 243] and was not cross presented to the 

























Chapter 3 summary 
This work undertook the first functional and phenotypical characterisation of the ex vivo 
CD8+T-cell responses to 16 CD8+T-cell peptide-epitope targets, identified and kindly 
provided by Dr Stanley Riddell. 
The identification of these peptide targets was achieved via infection of APCs with the 
RV798 strain of the virus, which is deleted for the WT US2-11 immunomodulatory gene 
region. CD8+T-cell clones were generated in vitro that recognised targets presented during 
the RV798 infection and their specificity subsequently mapped to individual proteins using 
single knock out strains of the virus. The abrogation of CD8+ recognition identified the 
HCMV antigen specificity. These peptide-epitopes were derived from the UL16, UL17, UL23, 
UL24, UL28, UL33, UL36, UL52, UL56, UL84, UL105, UL122 and US23 HCMV proteins.  
As the peptide targets were initially discovered in the absence of the US2-11 region, it was 
unknown whether the peptide-epitopes in vivo are naturally presented on the surface of cells 
infected with a WT strain e.g. AD169 with an intact US2-11 region or are cross-presented to 
the CD8+T-cell response. They were subsequently termed ‘protected’ peptides. 
Frequent ex vivo CD8+T-cell responses were identifiable to the HLA-A, -B and –C-restricted 
targets within healthy, latently infected donors. A total of 54 younger (<70 years) and 37 
older (>70 years) donors were screened for ex vivo CD8+T-cell responses to these 
‘protected’ peptides. The specific CD8+T-cell responses were identified after peptide 
stimulation of seropositive donor PBMCs with the protected peptides followed by ICS for 
IFN-γ, IL-2 and TNF-α production.  
What became clear was that the magnitude of the elicited CD8+T-cell responses differed 
depending upon the HLA-restriction.  
The HLA-C-restricted targets elicited the largest ex vivo CD8+T-cell responses, (Table-7). 
These CD8+T-cell responses were dominated by those elicited by the HLA-Cw*0702-
restricted UL28-derived FRC peptide-epitope which also induced the most frequent CD8+T-
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cell responses of the protected epitope cohort (28/39 donors). These CD8+T-cell responses 
demonstrated marked inflationary kinetics with age between donors <70 and >70 years of 
age. These could reach 32% of an 86 year old donor’s total peripheral CD8+T-cell pool 
producing IFN-γ. Interestingly, a second protective epitope ‘SYR’ also restricted through 
HLA-Cw*0702 derived from the UL33 protein did not demonstrate the same memory-inflation 
kinetics with age. However the SYR peptide did induce a large CD8+T-cell response within a 
donor of 86 years that totalled 12.19% and 14.22% of the total CD8+T-cell response 
producing IFN-γ and TNF-α respectively. 
The HLA-A-restricted protected peptide-epitopes elicited responses of a significant size 
detectable in a large percentage of donors. In particular, the HLA-A1-restricted UL69-derived 
RTD, and UL105a-derived YAD epitopes elicited CD8+T-cell IFN-γ and TNF-α production 
that remained remarkably stable with age.  
The HLA-B-restricted protected peptide-epitopes elicited infrequent or undetectable CD8+T-
cell responses. The largest was elicited by a HLA-B44-restricted, IE UL122 (IE-2) derived 
epitope NEG at 3.94% of the total CD8+T-cell population producing TNF-α. However this 
was within a single donor.  
When the phenotype of the ex vivo CD8+T-cell populations directed towards the protected 
epitopes were characterised, they were found to be cytotoxic (indicated by intracellular 
perforin/granzymeB expression) and display varying levels of activation (CD38) and 
inhibitory/exhaustion (TIM3/PD-1) markers.  
Additionally, when the phenotypic results obtained for the CD8+T-cell responses were 
categorised based upon the HLA-restriction of the eliciting peptide, these displayed differing 
memory phenotypes and antigen differentiation status. The total HLA-C-restricted CD8+T-
cell populations were more antigen differentiated, indicated by a significant decrease in the 
number of CD27+CD28+ and an increase in CD27-CD28-  CD8+T-cells. Additionally, the 
HLA-Cw*0702 FRC-specific CD8+T-cell populations consisted of TEMRA CD8+T-cells 
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(identified as CCR7-CD45RA+) - indicative of the phenotype associated with memory-inflated 
populations [105, 240]. HLA-A-restricted responses contained larger percentages of TCM 
(CCR7+CD45RA-) CD8+T-cells and consisted of a larger proportion of early and intermediate 
differentiated CD8+T-cell populations (CD27+CD28+, CD27-CD28+/CD27+CD28-). This is 
indicative of the phenotype associated with stable CD8+T-cell memory populations [70]. 
Specific CD8+T-cell clones to two of the protected peptides RTD and YAD were generated 
in vitro and their ability to recognise naturally processed antigen on the surface of infected 
cells was assessed. The clones were demonstrated to recognise peptide that is directly 
presented on the surface of either fibroblasts or monocytes that are infected with the AD169 
and Merlin CMV strains respectively in vitro. An important finding from this section was the 
demonstration that a UL69-derived protected peptide-epitope can be cross presented to 
specific CD8+T-cell clones by DCs incubated with AD169 HCMV infected cell lysate after 16 
hours (O/N) co-culture.  
The CD8+T-cell responses to these newly characterised peptides can demonstrate ex vivo 
phenotypes similar to those previously reported for inflationary HCMV-specific CD8+T-cell 
populations that are highly differentiated [71]. However, the CD8+T-cell responses directed 
to HCMV HLA-A-restricted peptides can also present with an earlier T-cell phenotype that 
have been previously identified in individual’s undergoing primary HCMV infection and stable 
CD8+T-cell populations in the mouse model [68, 105, 106]. This work additionally 
demonstrated that there may still be undiscovered immunodominant epitopes of HCMV and 
that the peripheral HLA-C restricted CD8+T-cell repertoire directed towards HCMV is both 






CHAPTER 3 DISCUSSION 
Identification of frequent CD8+T-cells to epitopes identified during an RV798 infection 
Human Cytomegalovirus has a broad tropism in vivo infecting both haematopoietic and non-
haematopoietic tissues [241, 244]. This coupled with the different priming routes (direct vs 
cross presentation) [169-171] and the phenomenon of memory-inflation creates a complex 
picture of the global CD8+T-cell immunity to this virus. For this reason it is important that the 
focus of CMV CD8+T-cell research is moved away from utilising the pp65 and IE-1 proteins 
as representative antigens. Previous work has determined CD8+T-cell epitopes from a 
range of CMV antigens [58, 82, 84, 230]. This range includes the pp28, pp50, gH, gB, US2, 
US3, US6, UL18 and IE-2 proteins. Additionally, a total global analysis of the HCMV CD8+T-
cell repertoire found 151 of 213 (70%) examined HCMV ORFs elicited CD4+ or CD8+T-cell 
responses [230]. However the kinetics and phenotype of such responses have not yet been 
determined extensively.  
Work  by the research group of Stanley Riddell identified previously uncharacterised CD8+T-
cell epitopes of HCMV which are derived from antigens across the lifecycle (IE-L) and 
restricted through HLA-A, -B and -C alleles ([82] Table-7). These were identified using the 
RV798 virus and were termed ‘protected’ epitopes by our research group. The data 
presented here has characterised the ex vivo CD8+T-cell responses to these peptides. The 
US2-11 gene products, whom function to dampen the cytotoxic CD8+T-cell response to 
CMV infected cells, do therefore not prevent the initial generation of a diverse CD8+T-cell 
repertoire to these peptides. This repertoire is directed against several antigens across all 
phases of the viral lifecycle including UL16, UL17, UL24, UL28, UL33, UL36, UL52, UL84, 




HLA-restriction of a HCMV CD8+T-cell epitope may play a role in the resulting 
phenotype of the CD8+T-cell response 
This research identified differing magnitudes of CD8+T-cells directed towards the 16 
peptide-epitopes characterised in this work when the age of our donor cohort was 
considered. Understanding the functionality and phenotype of such CD8+T-cells and how 
this alters with age will address whether they are different to previously identified CD8+T-cell 
responses for example those directed towards the pp65 protein. Additionally, it may provide 
a distinction between whether epitopes derived from HCMV can elicit inflationary vs stable 
CD8+T-cell responses that have been characterised in the murine model [88, 105].  
The HLA-B-restricted CD8+T-cell peptides elicited CD8+T-cells that were infrequent or 
absent (HLA-B51-restricted peptides derived from the US23, UL56 and UL23 proteins) within 
seropositive donors. The HLA-A-restricted peptides, in particular the UL69-derived RTD and 
UL105a-derived YAD peptides, elicited frequent CD8+T-cell responses that remained at 
similar magnitudes within the periphery with age. Lastly, the HLA-C-restricted peptide-
epitopes elicited the largest magnitudes of CD8+T-cell responses producing IFN-γ and TNF-
α. In particular, a HLA-Cw*0702-restricted UL28-derived peptide-epitope termed FRC 
induced CD8+T-cell responses that ranged from 0.03-32.25% and 0.03-31.07% producing 
IFN-γ and TNF-α respectively. This increased significantly with the age of our donor cohort. 
Therefore a distinction was made between HCMV epitopes in this peptide cohort that elicit 
stable and inflationary CD8+T-cell responses between the younger and older donors in our 
study. The following of the CD8+T-cell responses longitudinally within donors was not 
conducted within this study and should be a focus of future research to identify the point 
when FRC-specific CD8+T-cells begin to inflate. To determine that the HLA-Cw*0702-
restricted FRC responses increased with age whereas the HLA-A1 restricted did not, 
multiple Mann Whitney tests were conducted between the <70 and >70 year cohorts. A 
limitation of this work therefore arises in that significance may have arisen by statistical 
chance. In order to correct for this, a larger donor cohort should be screened for these CMV-
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specific CD8+T-cell responses to increase the statistical power to allow a multiple 
comparison corrections, such as Bonferroni, to be applied to the analysis to ensure the 
significance still holds.   
A second limitation of this work was the availability of tetramers for the HLA-Cw*0702 
restricted FRC peptide. MHC-I tetramers for the UL69- and UL-105a-derived RTD and YAD 
peptides were obtained from the NIH Tetramer facility. However both our research group 
and the NIH could not correctly refold HLA-Cw*0702 FRC monomers. It was therefore 
decided to phenotype all epitope-specific CD8+T-cell responses after peptide stimulation to 
ensure consistency between the epitope-specific CD8+T-cell responses. However, by 
utilising peptide stimulation followed by ICS, this likely underestimated the size of the 
epitope-specific CD8+T-cell population as MHC-I tetramer detection is highly sensitive. 
Using peptide stimulation may also have missed epitope-specific CD8+T-cells that do not 
produce cytokines that were investigated i.e. IL-4 or IL-10. These would be detectable using 
MHC-I tetramers which bind to specific CD8+T-cells regardless of effector function. 
Furthermore, MHC-I tetramer staining would detect very low affinity CD8+T-cells that peptide 
stimulation may leave undetected [245]. 
This work identified CCR7+CD45RA+ epitope-specific CD8+T-cells after 6 hours peptide 
stimulation. It is debated within the literature whether true naïve CD8+T-cells will respond to 
TCR engagement after 6 hours. Naïve CD8+T-cells have been documented to rapidly 
produce IFN-α and TNF-α in response to a primary viral infection but lack anti-viral function 
[246, 247]. MHC-I tetramer staining would address whether the CCR7+CD45RA+ T-cells 
represent early differentiated memory CD8+T-cells that have been newly recruited to the 
peripheral epitope-specific CD8+T-cell population or indeed true naïve populations.  
Despite these limitations, the ICS method used provided a functional readout that MHC-I 
tetramer detection would be unable to provide – only functional cells will respond to the 
peptide with cytokine production. In summary, it would be ideal to compare the MHC-I 
tetramer phenotype vs the activated CD8+T-cell phenotype after peptide stimulation of the 
120 
 
same epitope-specific populations. This would provide a true determination of the size and 
diversity of the population with regards to T-cell subsets and affinity. It will additionally 
provide a functional read out/indication of anti-viral capacity.   
Subsequently after ICS, this work delineated that the HCMV-specific CD8+T-cell responses 
directed towards the ‘protected’ epitopes differ in their ex vivo CD8+T-cell phenotype 
depending on their HLA-restriction. HLA-A-restricted protected peptides elicited CD8+T-cell 
responses with an overall earlier antigen differentiated phenotype. This was denoted by a 
larger percentage of CD27+CD28+ and CCR7+CD45RA- populations compared to HLA-C-
restricted populations and a HLA-B-restricted CD8+T-cell population [238]. However, of the 
11 responses phenotyped, 9 were specific for the HLA-Cw*0702-restricted FRC peptide. 
These phenotypic results may therefore represent a phenomenon of this particular CD8+T-
cell population. A third limitation of this work therefore presents itself in the low n numbers 
phenotyped for particular epitope-specific CD8+T-cell populations. This was a result of low 
numbers of donors available after the initial screening for CD8+T-cell responses to these 
newly characterised CMV peptides. A larger range of HLA-C peptides and larger donor 
cohort should as such be phenotyped to extend this phenotypic observation to a more 
general CMV-specific HLA-C-restricted CD8+T-cell population.  
However, the phenotype of individual HLA-A-restricted RTD/YAD-specific ‘stable’ vs HLA-C 
FRC-specific ‘inflationary’ CD8+T-cell populations corroborated the phenotypic data 
identified in murine studies [88, 105]. Stable CD8+T-cell responses are known to present 
with a TCM phenotype – and inflationary a TEMRA phenotype [105].  
It is now known that the HCMV U2-11 encoded immunevasins do not uniformly target all 
HLA alleles with the same efficacy i.e. HLA-A, –B and –C alleles are targeted for 
degradation to differing magnitudes [137, 139-141]. For example a study has implicated US2 
as being able to target HLA-A, HLA-G and the majority of HLA-B alleles for degradation in 
vitro [141]. Conversely, the remaining HLA-B alleles e.g. HLA-B7, and HLA-C alleles appear 
to be exempt from US2-mediated degradation [141]. In particular relevance to this 
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investigation, Ameres et al. identified US3 as having no impact on HLA-Cw*0702 surface 
expression [140]. They additionally showed that the US2 and US11 proteins had a minor 
effect on CD8+T-cell clone recognition of HLA-Cw*0702 peptides in vitro – translating to 
target cell lysis [139].  
Therefore it is a possibility that the HLA-restriction of a HCMV peptide is important in 
determining the frequency with which a HCMV peptide is presented to the CD8+T-cell 
response. Each cell type permissible to CMV infection may require a unique concerted mode 
of action by the US2-11 immunevasin proteins depending upon the HLA haplotype of the 
cell. In particular, within cell types that the US2-11 proteins are unable to exert their effects 
due to a particular HLA haplotype, allows the increased presentation of particular HLA-
restricted peptides. This may determine how often the resulting CD8+T-cell population 
encounters the cognate peptide.  
These findings from the literature may provide a plausible explanation for the phenotypic 
data obtained in this study for the HLA-C CD8+T-cell responses - specifically, the HLA-
Cw*0702 FRC-specific CD8+T-cells. HLA-Cw*0702 alleles may remain on the cell surface 
during an infection of a cell type in which the US2/3 and 11 proteins are unable to target 
these alleles efficiently for degradation. This may lead to the more frequent presentation of 
the HLA-Cw*0702-restricted FRC peptide-epitope over the HLA-A-restricted peptides. As 
this peptide is expressed with IE kinetics, it is more likely to be presented during a 
reactivation event before CD8+T-cell elimination of the reactivating virus [225, 248]. 
Ultimately, the FRC-specific CD8+T-cell population will develop a highly antigen driven 
phenotype e.g. CD27-CD28-CD45RA+ and the initial CD8+T-cell pool may accumulate.  
However within this investigation an additional HLA-Cw*0702-restricted peptide termed SYR 
derived from the UL33 protein did not also elicit CD8+T-cell responses that increased with 
age. The SYR peptide is expressed with L kinetics during the viral life cycle (Table-7). 
Infrequent non-inflating CD8+T-cell populations were detected towards a second IE-
expressed UL123 (IE-2)-derived HLA-B44-restricted peptide termed ‘NEG’ (Table-7).Clearly, 
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as individual factors, the HLA-restriction and IE kinetics of the peptide-epitope in question do 
not solely explain whether a CD8+T-cell response will inflate.  
Direct vs cross presentation of the ‘protected’ peptide-epitopes 
It is unknown how the CD8+T-cells to these ‘protected’ epitopes are generated initially in 
vivo if they were identified using the RV798 virus. During a WT infection in vivo, the US2-11 
gene region products are likely to interfere with the direct presentation of these peptides to 
the CD8+T-cell response and could support the theory of cross presentation as an initial 
mechanism of priming. Cross presentation is hypothesised to be vital in the generation of 
cytotoxic CD8+T-cell responses during a primary infection with WT (US2-11 gene region 
present) HCMV despite a vast array of MHC-I immunomodulatory proteins [169, 171, 249]. 
However, it remains unknown to what extent the US2-11 gene region products are able to 
prevent CMV antigen presentation within all cell types permissible to CMV in vivo. It is 
possible that these responses are primed in vivo by direct presentation from an infected cell 
type e.g. endothelium or epithelium in which the US2-11 proteins cannot interfere with the 
MHC-I presentation pathway as efficiently as observed within fibroblasts in vitro.   
It is also likely that these CD8+T-cell responses could be primed before the US2-11 gene 
region products can exert their full immunomodulatory effects. Supporting this is a study by 
Thom et al. [250]. The analysis of cell types permissible to MCMV infection within the 
salivary gland of infected mice led to the identification that CMV preferentially targets non-
epithelial cells early during a primary infection [250]. Furthermore, that MHC-I antigen 
presentation interference is incomplete within this cells during this phase. This resulted in a 
time during infection whereby CMV-specific CD8+T-cells could detect MCMV antigen. 
Therefore, the ‘protected’ peptides identified by Riddell at al. could also be primed in this 
manner during a primary infection with HCMV.  
To begin to address the mechanisms by which these CD8+T-cells can be primed, specific 
CD8+T-cell clone recognition of the RTD and YAD peptides (Table-7) during an AD169 (WT 
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US2-11 gene region) infection of fibroblasts in vitro indicated by IFN-γ production was 
assessed. The recognition profile was fitting with the expression kinetics of the protein from 
which the RTD and YAD peptides are derived from. The RTD peptide is derived from the 
UL69 protein that is part of the incoming infectious virion and is expressed with E kinetics 
[225, 251]. As such the RTD peptide was recognised at IE-L time-points of the assay as it 
may be immediately available for MHC-I processing. The YAD peptide is derived from the 
UL105a protein, part of the helicase complex, not associated with the mature virion and 
expressed with E-L kinetics [225, 242]. The YAD peptide was recognised only at E-L time-
points of the assay. HCMV peptide-epitopes that were identified in the absence of the US2-
11 gene region can as such be efficiently presented to CD8+T-cells directly during a primary 
in vitro infection of fibroblasts. It is well known that CMV rapidly mutates upon infection of 
fibroblasts in vitro to loose genetic regions that are required for entry into cell types other 
than fibroblasts [241]. Additionally, it has been extensively reported that the US2-11 gene 
region immunomodulatory protein products can efficiently interfere with the MHC-I 
presentation pathway within fibroblasts in vitro [252]. Therefore, these CD8+T-cell 
recognition experiments should be conducted within cell types more relevant to the virus 
tropism in vivo e.g. endothelial cells. In these cells it is not yet known how efficiently the 
US2-11 proteins can interfere with the MHC class I presentation pathway but they are known 
to harbour HCMV genomes [253]. 
This work then confirmed that the UL69-derived RTD peptide can also be cross presented in 
vitro to specific CD8+T-cell clones by DCs that have had access to UV-inactivated HCMV 
cell lysate. This was at levels consistent with pp65-derived NLV cross presentation. 
However, the UL105a-derived YAD peptide-epitope was not cross-presented to specific 
CD8+ T cell clones within this time frame (16 hours). This likely reflects the differences in the 
anatomical location of the HCMV antigens. The UL69 protein could be accessible within the 
lysate to the DCs for efficient processing and allow the presentation of the RTD peptide 
during the 16 hours incubation time-point. Hence, the protected peptides could theoretically 
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be presented to the immune system by both direct and cross presentation in vivo. However 
this was conducted once with a single specific clone and should be repeated. 
Future research 
The non-inflating e.g. UL69-derived RTD vs inflationary e.g. UL28-derived FRC CD8+T-cell 
populations require further characterisation with regards to phenotype and functionality 
(investigated in detail in chapter 4). This could shed light on the mechanism behind why one 
CD8+T-cell population inflates whilst the other remains stable. Importantly, the knowledge of 
HLA-C-restricted CMV epitopes and their specific CD8+T-cell populations should be 
extended to clarify if this inflation is a phenomenon of additional HLA-C-restricted peptides or 
specific to the UL28-derived FRC peptide. Finally, the maintenance of HLA-C alleles on 
HCMV infected cells in vitro with the WT US2-11 gene region present should be analysed 
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Chapter 4 - Introduction 
The role of HLA-C-restricted CD8+T-cell populations during viral infections has been poorly 
researched compared to HLA-A/-B-restricted populations. HLA-A and B alleles are more 
polymorphic and therefore able to present a more diverse repertoire of antigens to the 
immune response [254, 255]. Additionally, HLA-C alleles have a much lower surface 
expression of HLA-C alleles, compared to HLA-A and –B alleles. HLA-C-restricted CD8+T-
cells have therefore previously been considered infrequent and their antiviral activity poorly 
understood [256]. Further complicating matters is the fact that HLA-C alleles are commonly 
inherited together with HLA-B alleles (termed linkage disequilibrium) making the distinction 
between HLA-C- and HLA-B-restricted CD8+T-cell populations hard to achieve. Yet 
prominent HLA-C CD8+T-cell populations have been documented within viral infections such 
as CMV, HIV, HCV and EBV [256-258] and the presence of these HLA-C CD8+T-cell 
populations linked to the resolution of such viral infections [259, 260].  
 
HLA-A- and –B-restricted CD8+T-cell populations have been extensively studied in HCMV 
infection in particular towards the pp65 and IE-1 proteins, whereas HLA-C-restricted CD8+T-
cells have been poorly investigated. One reason for this, is the linkage disequilibrium of 
HLA-B and HLA-C alleles has led to the mistaken identification of HCMV HLA-C-restricted 
peptides as HLA-B. For example, the HLA-Cw*0702-restricted CRV peptide was initially 
identified and characterised as HLA-B7-restricted [261]. Furthermore, a HLA-B8-restricted 
peptide QIK initially characterised by Elkington et al. [58] has recently also been identified as 
presented in HLA-Cw6 [262]. [139, 261, 262]. It is entirely plausible that there are currently 
still HLA-C-restricted HCMV peptides that have yet to be identified and characterised 
correctly.  
 
Viruses efficiently target MHC-I molecules for degradation and surface down-regulation to 
avoid recognition by cytotoxic CD8+T-cells. However, this poses a problem for virally 
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infected cells by exposing them to NK cell attack. MHC-I molecules play a dual role in both 
activating the adaptive immune response and dampening the innate NK cell response [263]. 
HIV-1 was the first virus discovered to have evolved mechanisms (in particular the Nef 
protein) to regulate the specificity of which MHC-I alleles are down-regulated from the 
infected cell surface. The NEF protein was discovered to leave HLA-C alleles on infected cell 
surfaces, which are inhibitory receptors for NK cells, but downregulate HLA-A/-B which are 
vitally important for activating cytotoxic CD8+T-cells [264] [265].  
 
Ex vivo HCMV-specific CD8+T-cell responses in this work to a HLA-Cw*0702-restricted 
epitope FRC (Table-7) were observed to reach upto 32% of the total peripheral CD8+T-cell 
response in donors (Chapter 3) [76, 82, 84]. Previously, immunodominant responses to a 
HLA-Cw*0702-restricted peptide derived from the UL122 (IE-1) protein ‘CRV’, have been 
documented by Ameres et al. reaching magnitudes of 2.97-4.48% of the total peripheral 
CD8+T-cell pool. Ameres et al. demonstrated that the HLA-C CRV-specific CD8+T-cell 
responses exceeded those derived from a second immunodominant protein pp65 (HLA-B7 
TPR) and other IE-1 targets (HLA-A2-restricted VLE) within the same seropositive donors 
[139]. CD8+T-cell clones specific for the CRV peptide were efficiently able to lyse infected 
cells whereas the killing by clones specific for other IE-1-derived HLA-A/B-restricted targets 
was inhibited [139]. The authors explain the possibility that HLA-Cw*0702 alleles are exempt 
from HCMV-mediated MHC-I surface down-regulation as has been recently proposed [139]. 
Ameres et al. postulate that as HLA-Cw*0702 is known to be a ligand for the NK cell 
inhibitory receptors, HLA-Cw*0702 alleles may remain on the surface as an evasive NK-cell 
mechanism. This would allow large accumulations of virus-specific CD8+T-cells to be 
generated.  
 
HCMV reactivation within a cohort of HSCT transplant patients was reported to upregulate 
inhibitory NK cell receptors on CD8+T-cells [266]. This implicates HCMV infection as 
resulting in changes of HLA-C alleles on host immune cells. Furthermore, a proteomics 
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study of CMV-infected fibroblasts by Weekes et al. identified the delayed down-regulation of 
HLA-Cw2 and HLA-G alleles compared to HLA-A11, - A24 and HLA-E [225]. This window of 
opportunity where the HLA-C alleles are still present on an infected cell surface represents a 
time when HLA-C-restricted CD8+T-cell populations could efficiently control viral reactivation 
events and re-stimulate the initial CD8+T-cell pool.  
HLA-C-restricted CD8+T-cells can seemingly represent a large proportion of the HCMV 
CD8+T-cell repertoire in some seropositive individuals and may play an important part of 
viral reactivation and latency control in vivo. Altogether this evidence suggests that the HLA-
C CD8+T-cell response in viral infections, and in particular HCMV, as greatly under 
researched. Furthermore that HLA-C-restricted peptides represent a source of previously 
















Chapter 4 – Results 
Project 1: HLA-C CD8 T-cells dominate the anti-HCMV CD8+T-cell 
response 
4.1 HLA-C-restricted CD8+T-cell responses dominate the periphery of donors over the 
CD8+T-cell responses restricted through HLA-A and HLA-B 
After identifying and phenotyping frequent ex vivo CD8+T-cell responses specific for a panel 
of epitopes identified during a RV798 ΔUS2-11 infection it became increasingly clear that a 
HLA-C-restricted peptide elicited significantly differing CD8+T-cell responses. This was with 
regards to kinetics and phenotype to those specific for HLA-A-restricted peptides identified in 
the same panel (Fig-8/9, 12-14). The HLA-Cw*0702-restricted UL28-derived FRC-specific 
CD8+T-cell populations were of a significantly later antigen driven phenotype compared to 
the phenotype of the HLA-A-restricted RTD CD8+T-cell populations (Fig-13/14). Strikingly 
the immunodominant responses to the HLA-Cw*0702-restricted FRC peptide were observed 
that increased significantly with age (Fig-8/9). 
It was next investigated whether this HLA-C-restricted memory-inflation was a common 
feature of HCMV HLA-C-restricted peptides or a phenomenon of the UL28-derived HLA-
Cw*0702-restricted FRC peptide. Therefore, to further characterise the overall contribution of 
HLA-C-restricted CD8+T-cell populations to the total HCMV-specific CD8+T-cell repertoire, a 
panel of HLA-C-restricted CD8+T-cell peptides was obtained from the literature (Table-8)  
The panel of additional HLA-C-restricted peptides obtained from the literature consisted of 
peptides with a variety of restricting HLA-C alleles and were either derived from the pp65 or 
IE-1 protein (Table-8). As such, the HLA-C-restricted peptides from either the pp65 or IE-1 
protein had differing kinetics of expression. It was therefore also investigated whether HLA-C 
mediated memory-inflation, if observed against other peptides, was spread across phases of 
the lifecycle.  
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Table 8 – HLA-C-restricted peptides used in the investigation. *identified by Stanley Riddell et al.. The 
protein antigen, aa position within the protein antigen, peptide sequence (peptide name is denoted by the first 




Some of the donors who were previously screened for the protected epitope responses were 
then screened for CD8+T-cell populations specific for these HLA-C peptides.  Additionally, 
when the same donors presented with the correct HLA type, also screened for CD8+T-cell 
responses to well-known and documented immunodominant peptides derived from the pp65 
(HLA-A2 NLV, HLA-B7 RPH, HLA-B7 TPR), IE-1 (HLA-A1 YSE, HLA-A2 VLE) and pp50 
(HLA-A2 VTE) proteins as a comparison (Table-5). PBMCs were peptide stimulated for 6 
hours followed by intracellular cytokine staining for IFN-γ, IL-2 and TNF-α production to 









[84, 139, 262, 
267] 
 
pp65 7-15 RCPEMISVL Cw1 L [262] 
pp65 341-349 QYDPVAALF Cw4 L [262] 
IE-1 88-96 QIKVRVDMV Cw6 IE [262] 
IE-1 305-313 LSEFCRVL Cw0702 IE [267] 
IE-1 309-317 
 
CRVLCCYVL Cw0702 IE 
[84, 139, 267]  
 
UL28 327-335 FRCPRRFCF Cw0702 IE * 
UL33 120-128 SYRSTYMIL Cw0702 L * 
pp65 294-302 VAFTSHEHF Cw12 L 
[262] 
 
UL24 120-134 YLCCQTRLAFVGRFV Cw1601 L * 
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Strikingly, even when pooled CD8+T-cell responses to HLA-A/-B-restricted immunodominant 
peptides were included within the analysis (Table-5), the pooled HLA-C-restricted responses 














Fig 19 – Dominance of CMV HLA-C restricted CD8+T-cell populations within the CD8+T-cell repertoire of 
the study cohort. .  PBMCs from seropositive donors were stimulated with HCMV peptide (final concentration 
1µg/ml) for 6 hours followed by intracellular staining for TNF-α, IFN-γ and IL-2 to identify specific CD8+T-cell 
responses. PBMCs were stained with the antibodies outlined in Table-4. A) Summary of the ex vivo CD8+T-cell 
responses detected towards the HLA-C-restricted peptide-epitopes vs HLA-A/-B-restricted conventional 
immunodominant peptide-epitopes derived from the pp65 and IE-1 proteins – see Table-5 and -8 for full peptide-
epitope details. The IFN-γ, IL-2 and TNF-α production are provided in the left, middle and right hand graphs 
respectively. Statistical significance was obtained in Graphpad Prism 6 using Mann Whitney test and * as a p 
value < 0.05 and ** < 0.01.  
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4.2 - Identification of HLA-Cw*0702-restricted CD8+T-cell populations that display 
marked memory-inflation with age 
The kinetics of the individual HLA-C-restricted CD8+T-cell responses between young (<70 
years) vs older (>70 years) was next analysed. CD8+T-cell responses to a HLA-Cw*12-
restricted peptide ‘VAF’ derived from pp65 and therefore produced with L kinetics ranged 
from 0.27%-1.83% of the total CD8+T-cell producing cytokines (Fig-20, n = 3). This did not 
accumulate. 
 
A pp65-derived HLA-Cw*4-restricted peptide QYD peptide elicited 1 response of 0.03% IFN-
γ and 0.02% TNF-α in 3 donors, and a pp65-derived HLA-Cw*1-restricted peptide RCP 
elicited no responses in two donors (data not shown). However due to low n numbers on 
account of the HLA type of the donors conclusions cannot be drawn from these peptides.  
 
The IE-1-derived HLA-Cw6-restricted peptide QIK elicited responses in 6/6 donors ranging 
from 0.07-2.74% of the total CD8+T-cell pool (Fig-20). However, the responses did not 
display memory-inflation kinetics with age and on average induced 0.51%, 0.44% and 0.43% 
CD8+T-cells IFN-γ, IL-2 and TNF-α and of the total CD8+T-cell pool.  
 
As previously mentioned, the L-expressed HLA-Cw*1601-restricted peptide YLC elicited one 
large CD8+T-cell response in an elderly donor at 12.19% of the total CD8+T-cell response 
producing TNF-α (n = 13, Fig8-9, 20). In all other donors YLC elicited smaller responses 
ranging from 0.04% to 1.16% and did not increase significantly with age. 
 
Two of the HLA-C-restricted peptides, ‘CRV’ and ‘LSE’ also elicited CD8+T-cell populations 
that demonstrated striking memory-inflation with age as was observed with the UL28-derived 
FRC peptide (Fig-20/21). These were also HLA-Cw*0702-restricted, derived from the IE-1 















Fig 20 – Summary of the ex vivo CD8+T-cell responses elicited by HLA-C restricted HCMV peptides with 
age. HCMV seropositive donors were screened with a panel of HLA-C-restricted peptides to identify potential 
immunodominant epitopes. PBMCs from seropositive donors were stimulated with HCMV peptide (final 
concentration 1µg/ml) for 6 hours followed by intracellular staining for TNF-α (top graph), IL-2 (middle graph) and 
IFN-γ (bottom graph), to identify specific CD8+T-cell responses. White circles represent donors <70 years of age 
and black circles >70 years of age. Each circle represents an individual donor. Statistical significance was 
obtained using multiple Mann Whitney tests in Graphpad prism 6 between the <70 and >70 year category with * 




The dominant HLA-Cw*0702 CD8+T-cell responses were also frequent being detected in 
75% (16/21) and  85% (13/15) of donors tested for the CRV and LSE peptides respectively 
(Fig-20, 22-23). The ex vivo CD8+T-cell responses detected against the CRV peptide 
ranged from 0.08%-20.83% (IFN-γ), 0.03%-10.81% (IL-2) and 0.21%-21.43% (TNF-α) of the 
total CD8+T-cell pool (Fig-20, 22). These CD8+T-cell responses increased significantly from 
an average of 1.51% IFN-γ, 0.13% IL-2, 1.70% TNF-α within donors <70 years of age to 
9.60% IFN-γ, 4.38% IL-2, 10.02% TNF-α within donors >70 years of age of the total CD8+T-
cell pool responding (Fig-20, 22).  
 
The ex vivo CD8+T-cell responses directed against the LSE peptide ranged from 0.36%-
16.40% (IFN-γ), 0.06%-0.32% (IL-2) and 0.36%-14.09% (TNF-α) of the total CD8+T-cell pool 
(Fig-20, 23). These CD8+T-cell responses increased, trending to significance in part due to 
low n numbers in the >70 years cohort (n = 3), from an average of 0.56% IFN-γ and 0.86% 
TNF-α within donors <70 years of age to 7.80% IFN-γ and 5.92% TNF-α within donors >70 
years of age of the total CD8+T-cell pool responding (Fig-20, 23). The IL-2 production 
decreased from 0.07% to 0.05% on average of the total CD8+T-cell pool in donors <70 vs 
>70 years of age. 
 
Interestingly, as also mentioned previously (Fig-9)  the CD8+T-cell responses elicited by a 
third HLA-Cw*0702-restricted peptide SYR, expressed with L kinetics, were smaller ranging 
from 0.04% to 1.34%, less frequent (6/31, 19% donors) and did not change in magnitude 
with age (Fig-20).  
 
Therefore, HLA-C mediated memory-inflation was observed specifically towards peptides 
presented through HLA-Cw*0702 and was further restricted to peptides derived from 
antigens with IE expression kinetics. These three HLA-Cw*0702-restricted CD8+T-cell 





























Fig 21 – Representative dot plots of the ex vivo CD8+T-cell responses against the HLA-Cw*0702 UL28-
derived FRC peptide with age. PBMCs from seropositive donors were stimulated with the FRC peptide (final 
concentration 1µg/ml) for 6 hours followed by intracellular staining for IFN-γ (left column), IL-2 (middle column) 
and TNF-α (right column) to identify specific CD8+T-cell responses. The age of the donor is provided on the left 
hand side of the plots. Each row represents the cytokine production in that individual donor. Data was analysed in 
Kaluza 1.3 software. The size of the epitope-specific CD8+T-cell response is provided on the plots defined as the 
percentage of cytokine positive CD8+T-cells of the total CD8+T-cell response. In all cases, the percentages 





























Fig 22 – Representative dot plots of the ex vivo CD8+T-cell responses against the HLA-Cw*0702 IE-1-
derived CRV peptide with age. PBMCs from seropositive donors were stimulated with the CRV peptide (final 
concentration 1µg/ml) for 6 hours followed by intracellular staining for IFN-γ (left column), IL-2 (middle column) 
and TNF-α (right column) to identify specific CD8+T-cell responses. The age of the donor is provided on the left 
hand side of the plots. Each row represents the cytokine production in that individual donor. Data was analysed in 
Kaluza 1.3 software. The size of the epitope-specific CD8+T-cell response is provided on the plots defined as the 
percentage of cytokine positive CD8+T-cells of the total CD8+T-cell response. In all cases, the percentages 































Fig 23 – Representative dot plots of ex vivo CD8+T-cell responses against the HLA-Cw*0702 IE-1-derived 
LSE peptide with age. PBMCs from seropositive donors were stimulated with the LSE peptide (final 
concentration 1µg/ml) for 6 hours followed by intracellular staining for IFN-γ (left column), IL-2 (middle column) 
and TNF-α (right column) to identify specific CD8+T-cell responses. The age of the donor is provided on the left 
hand side of the plots. Each row represents the cytokine production in that individual donor. Data was analysed in 
Kaluza 1.3 software. The size of the epitope-specific CD8+T-cell response is provided on the plots defined as the 
percentage of cytokine positive CD8+T-cells of the total CD8+T-cell response. In all cases, the percentages 




4.3 - Kinetics of HLA-Cw*0702 HCMV mediated CD8+T-cell memory-inflation with age 
The striking immunodominance of the HLA-Cw*0702 CD8+T-cell responses that was 
already present in younger age led to the further investigation of the kinetics of this memory-
inflation with increment decades of the HCMV infected donors. 
The HLA-Cw*0702-restricted FRC, CRV and LSE peptides elicited IFN-γ and TNF-α 
production that significantly correlated with age by spearman’s rank correlation (Fig-24A). 
Additionally, the average increment in the epitope-specific populations each decade from 20 
to 100 years was calculated. On average the FRC-, CRV- and LSE-specific CD8+T-cell 
populations increased within the periphery of our donor cohort per decade at a rate of 
1.41%, 2.35% and 1.30% producing IFN-γ+ respectively and 1.93%, 2.45% and 1.04% 
producing TNF-α+ respectively.  The age where the largest increase in the HLA-Cw*0702 
CD8+T-cell populations was observed was between the ages of 80-100 years (Appendix 
Fig-1). Interestingly, when the FRC-specific CD8+T-cell responses within males vs females 
were correlated with age, the female population exhibited a significant increase in the 
number of CD8+T-cells producing IFN-γ (0.30%-32.25%) and TNF-α (0.18%-31.07%) 
respectively with age (Fig-24D). However this may represent a larger proportion of our 
elderly cohort being female (Appendix tables 1-6).   
To assess the overall contribution of the HLA-Cw*0702-restricted CD8+T-cell responses 
within individual donors to the total CD8+T-cell repertoire, where two or more of the HLA-
Cw*0702 epitope specific responses were present within an individual donor, these were 
summed (Fig-24B/C). The summed HLA-Cw*0702 populations ranged from a remarkable 
0.54%-39.41% producing IFN-γ, 0.16%-11% producing IL-2 and 0.54%-53.23% producing 
TNF-α of the total CD8+T-cell pool within donors aged 23 to 86 years of age (Fig-24B/C). 
These summed responses displayed marked inflation with increasing age of the donor (Fig-
24B).  On average the summed responses increased significantly between donors <70 vs 
>70 years of age 4.76%-28.69% producing IFN-γ, IL-2 0.58%-5% and 5.15-32.88% 


















Fig 24 – Kinetics of HLA-Cw*0702-restricted memory-inflated CD8+T-cell populations with age. The 
kinetics of the HLA-Cw*0702 HCMV CD8+T-cell populations were analysed with the age of the donor cohort. 
PBMCs from seropositive donors were stimulated with HCMV peptide (final concentration 1µg/ml) for 6 hours 
followed by intracellular staining for IFN-γ, IL-2 and TNF-α to identify specific CD8+T-cell responses. A) 
Magnitude of the cytokine production elicited by the HLA-Cw*0702 peptides correlated with age. Spearman’s 
rank correlation of the magnitude of cytokine production elicited by the FRC- (left), CRV- (middle), and LSE-
specific (right) CD8+T-cells with the age of the donors in our cohort. Each circle represents the percentage of the 
total CD8+T-cell response elicited by the peptide in question. Lines represent a polynomial curve to represent the 
data trend. B) The sum percentage of the FRC-, CRV- and LSE-specific CD8+T-cell populations within individual 
representative donors where all three HLA-Cw*0702 populations were present. C) Summary of the totalled 
percentage of all three HLA-Cw*-0702 CD8+T-cell populations within individual donors. White circles represent 
donors <70 years and black circles represent donors >70 years. Statistical significance was obtained via Mann 
Whitney in Graphpad Prism 6 with ** as a p-value of < 0.005 D) Correlation of the IFN-γ (left) and TNF-α (right) 
production elicited by the UL28-derived FRC peptide with age in males (dotted line) vs females (black lines). 
Lines represent linear regression. In A/D) Statistical significance was obtained by spearman’s rank correlation 






4.4 - HLA-Cw*-0702 mediated memory-inflation dominates individual CD8+T-cell 
memory compartments of older seropositive donors 
After observing that these populations dominated the total peripheral CD8+T-cell pool of 
both young and older individuals, it was next determined to what extent the HLA-Cw*0702 
CD8+T-cell responses comprised of the individual memory CD8+T-cell compartments.  
 
PBMCs of donors with ex vivo HLA-Cw*0702 CD8+T-cell responses were phenotyped for 
CCR7 vs CDR45RA expression by flow cytometry to identify; TN (CCR7+CD45RA+), TCM 
(CCR7+CD45RA-), TEM (CCR7-CD45RA-) and TEMRA (CCR7-CD45RA+) memory populations 
after 6 hours HLA-C peptide stimulation (gating strategy provided in Fig-25A). To identify the 
HLA-Cw*-0702 peptide responding CD8+T-cells within each compartment, these individual 
memory populations were then analysed for TNF-α producing CD8+T-cells (Fig-25C). To do 
this, the gate utilised to identify the HLA-C-specific CD8+T-cells within the total CD8+T-cell 
population (TNF-α gate Fig-25B) was placed upon the TN, TCM, TEM and TEMRA populations as 
demonstrated in Fig-25C. .  
Within a representative individual younger donor, the FRC-specific HLA-Cw*0702-restricted 
CD8+T-cell response (Fig-24B) comprised up to 0.88%, 1.89%, 1.61% and 5.15% of the 
total TN, TCM, TEM and TEMRA memory compartments respectively (Fig-25C). These FRC-
specific CD8+T-cells increased within the same memory compartments of a representative 
older individual donor of 86 years to 1.50%, 13.5%, 24.13% and 22.71% respectively (Fig-
25D).  
When summarised, the HLA-Cw*0702-restricted populations accounted for on average 
2.32%, 4.69%, 6.03% and 7.76% of the total TN, TCM, TEM and TEMRA memory compartments 
respectively within our younger donor cohort <70 years of age (Fig-25E). This increased 
dramatically within our elderly cohort >70 years of age to 4.57%, 12.23%, 21.14 & and 













Fig 25 - Percentage of the memory CD8+T-cell compartment comprised of the HLA-Cw*0702 inflated 
HCMV-specific CD8+T-cell response. PBMCs from seropositive donors were stimulated with HLA-C HCMV 
peptide (final concentration 1µg/ml) for 6 hours followed by staining with CCR7 vs CD45RA and intracellular 
staining for TNF-α to identify specific CD8+T-cell responses. TNF-α positive cells within the CCR7 vs CD45RA 
gates was then analysed A) Gating strategy to identify memory CD8+T-cell memory compartments. The CCR7 
vs CD45RA gates were first applied on the CD8+T-cell population to identify the memory compartments and the 
TNF-α was applied to these compartments. B) The FRC-specific CD8+T-cell response used in this gating 
strategy example in YD13 of 52 years. The percentage values shown have the unstimulated TNF-α production 
value subtracted C) Representative dot plot demonstrating the percentage of the memory CD8+T-cell 
compartments occupied by the FRC- (top row), CRV- (middle row) and LSE-specific (bottom row) CD8+T-cell 
populations in the TN (left column), TCM (second column), TEM (third column) and TEMRA (last column) memory 
CD8+T-cell compartments of the total CD8+T-cell population. Within each memory gate identified in A, the TNF-α 
positive gate was applied on the individual memory compartments. This indicated the percentage of HLA-C-
specific CD8+T-cells within that compartment. The percentage of HLA-C epitope-specific CD8+T-cells within 
































Fig 25  continued - percentage of the memory CD8+T-cell compartment occupied by the HLA-Cw*0702 
inflated HCMV-specific CD8+T-cell responses D) Representative dot plots demonstrating the percentage of 
the HLA-Cw*0702 inflated CD8+T-cell responses comprising the individual memory CD8+T-cell compartments 
within an older donor of 86 years. The top plot demonstrates the FRC-specific population within the older donor 
used in the example. The percentage of the FRC-, (top row) CRV- (bottom row) and LSE-specific (bottom row) 
populations in the TN (left column), TCM (second column), TEM (third column) and TEMRA (last column). The 
percentage of HLA-C epitope-specific CD8+T-cells within each compartment are indicated on the plots. The 
percentage values shown have the unstimulated TNF-α production value subtracted E) Summary of the 
percentage of the three HLA-Cw*0702 CD8+T-cell populations comprising the individual memory compartments 
within YD (top) vs OD donors (bottom). For <70 year category, n = 4, 4 and 3 for FRC- CRV- and LSE-specific 





The four compartments were occupied by similar percentages of the LSE-specific CD8+T-cell 
populations between <70 vs >70 years. However the percentage within the TCM compartment 
increased slightly from 1.76%-2.72% (Fig-25E). 
 
The memory compartment occupied by the largest percentage of CRV-specific CD8+T-cell 
populations was the TEMRA compartment in younger donors at 4.02% which switched to the TEM 
compartment at 11.68% within older donors (Fig-25E).  
 
In both the <70 vs >70 year donors, the memory compartment comprised of the largest FRC-
specific CD8+T-cell populations was the TEMRA compartment that increased from 1.65%-12.02% 
with age (Fig-25E).  
 
 
To conclude this section, the HLA-Cw*0702 can dominate the TEM and TEMRA compartments with 












Project 1 Summary 
This work has identified three remarkably immunodominant CD8+T-cell populations that are 
restricted through HLA-Cw*0702 and specific for IE-derived antigen. The largest populations 
were observed against a UL28-derived peptide termed ‘FRC’, followed by two populations 
specific for IE-1-derived peptides termed ‘CRV’ and ‘LSE’. These HLA-C populations 
remained the most immunodominant CD8+T-cell responses when donors were also 
screened for the conventional immunodominant pp65/IE-1-derived HLA-A1, -A2 and –B7 
restricted VTE, VLE, YSE, NLV, RPH and TPR peptides. 
Individual CD8+T-cell responses to the FRC, CRV and LSE peptides reached a maximum of 
31.07%, 21.43% and 12.75% producing TNF-α within individual donors of the total 
peripheral CD8+T-cell repertoire respectively. Notably, these HLA-Cw*0702-restricted 
populations when summed exceeded over 56% of an individual’s total peripheral CD8+T-cell 
pool. Impressively, the HLA-Cw*0702-restricted CD8+T-cells comprised on average almost 
8% of a younger donor cohorts TEMRA compartment which increased dramatically to almost 
21% in donors aged >70 years. The FRC-specific CD8+T-cells could reach an impressive 
22.71% of the TEMRA pool within a donor of 86 years. Remarkably, the summed HLA-
Cw*0702 CD8+T-cells also comprised significant proportions of the TN, TCM and TEM 
compartments reaching averages of 4.57%, 12.23%, 21.14 respectively  within older donors  
This HLA-C memory-inflation was found to be confined to CMV peptides that are HLA-
Cw*0702-restricted and expressed during the viral life cycle with IE kinetics. This was 
supported by non-inflating CD8+T-cell populations observed in this investigation towards; 
the IE-1-derived HLA-Cw6-restricted QIK peptide, the L-expressed UL33-derived HLA-
Cw*0702-restricted SYR peptide and lastly HLA-C-restricted peptides derived from the L-
expressed pp65 protein.  
145 
 
Project 2 – Phenotype and functionality of memory-inflated HLA-C 
CMV CD8 T-cells 
 
4.5 - The cytokine polyfunctionality of HLA-Cw*0702 CD8+T-cell populations alters 
with age, response size and differs significantly to other HCMV-specific CD8+T-cell 
populations 
HCMV CD8+T-cell memory-inflated populations have previously been identified as 
increasing their polyfunctionality with both the age of the donor and as the size of the 
specific CD8+T-cell response increases [110, 268]. Large populations of pp65-specific 
CD8+T-cell populations have been identified as accumulations of enhanced polyfunctional 
populations with age – indicated by IFN-γ, IL-2, TNF-α, CD107a and perforin expression - 
compared to younger individuals with smaller pp65-specific CD8+T-cell populations [110].  
Next, the cytokine polyfunctionality of the HLA-Cw*0702-restricted CD8+T-cell responses 
was analysed with the age of the donors (between <70 and >70 years) and the size of the 
epitope-specific responses. This cytokine polyfunctionality was also compared to that of 
other HCMV-specific CD8+T-cell populations. This was in order to determine whether 
polyfunctional CD8+T-cells preferentially accumulated within the HLA-Cw*0702 populations 
with age. 
To do this, boolean bimodial parameter analysis was applied within the Kaluza 1.3 software 
(gating strategy provided in Fig-26) and then the novel polyfunctionality index algorithm 
devised by Larsen et al. [funky cell software [269] was utilised to determine the percentage 
























Fig 26 – Gating strategy for Boolean cytokine polyfunctionality analysis in Kaluza 1.3 software. 
Determination of the percentage of HCMV-specific CD8+T-cells producing combination of the IFN-γ, IL-2 and 
TNF-α cytokines. PBMCs from HCMV seropositive donors were stimulated with HCMV peptide (final 
concentration 1µg/ml) for 6 hours. Single, live, CD3+CD8+ lymphocytes were gated on sequentially within Kaluza 
1.3 software (Beckman Coulter) as outlined in Fig-7. Cytokine producing CD8+T-cells were then identified in the 
gated CD8+ population. A positive gate for each cytokine function was placed on the total CD8+T-cells. Within 
the Kaluza software, Boolean gates for the 28 combinations of cytokine production were manually generated and 
the numbers of cells within each combination were then inputted  into ‘Funkycell’ software [269]. The resulting 
polyfunctional output - the percentage of cells within each cytokine combination and the polyfunctionality index - 










4.5.1 – Cytokine polyfunctionality between donors <70 vs >70 years of age 
 
The production of IFN-γ, IL-2 and TNF-α cytokines in any combination by individual CD8+T-
cells within the total HLA-Cw*0702 epitope-specific CD8+T-cell populations was evaluated 
after peptide stimulation between donors <70 vs >70 years of age.   
There were two general trends that were observed between the age categories. 
The first; within older donors the number of individual HLA-Cw*0702 epitope-specific 
CD8+T-cells producing the pro-inflammatory cytokines IFN-γ and TNF-α increased 
compared to younger donors (CRV; 69%-86% and LSE; 38%-51%, Fig-27A/C). The FRC-
specific CD8+T-cell population retained an equal proportion of individual CD8+T-cells 
producing both IFN-γ+TNF-α+ between the age categories (70%, Fig-27A/C).  
The second trend; within older donors the number of individual HLA-Cw*0702 CD8+T-cells 
producing IL-2 was decreased (Fig-27A/C).  
CRV-specific CD8+T-cells producing IL-2 as their single cytokine were not present in donors 
>70 years of age. LSE-specific CD8+T-cells producing IL-2 in combination with TNF-α were 
not present within donors >70 years of age. Finally, FRC-specific CD8+T-cells producing IL-
2+IFN-γ or IL-2/+TNF-α were not present in donors >70 years of age (Fig-27A/C).  
Despite these trends, no significant differences in cytokine production was obtained between 































Fig 27 – Cytokine polyfunctionality profiles of the HLA-Cw*0702-restricted inflated responses with age 
and response size. The proportion of HLA-Cw*0702-restricted CD8+T-cells producing combinations of IFN-γ, IL-
2 and TNF-α after peptide stimulation. PBMCs from seropositive donors were stimulated with HLA-C HCMV 
peptide (final concentration 1µg/ml) for 6 hours followed by intracellular staining for IFN-γ, IL-2 and TNF-α to 
identify specific CD8+T-cell responses. Cytokine polyfunctionality profiles were determined as outlined in Fig-26. 
A) Average cytokine polyfunctionality profiles of the FRC- (left), CRV- (middle) and LSE-specific (right) HLA-
Cw*0702-restricted responses between the <70 (top) and >70 year (bottom) donor category. The percentages 
provided per pie slice represent the percentage of epitope-specific CD8+T-cells producing the cytokine 
combination B) Average cytokine polyfunctionality profile of the FRC- (left), CRV- (middle) and LSE-specific 
(right) HLA-Cw*0702-restricted responses between small (top) vs large (bottom) epitope-specific response sizes. 
The HLA-Cw*0702-specific CD8+T-cell populations were categorised as small or large if they were <2% or > 
than 2% of the total CD8+T-cell response responding to peptide. The n numbers are provided below the pie 
charts. Statistical significance was analysed by a Kruskall-Wallis test in Graphpad prism 6 of the cytokine 



























Fig 27 continued – Cytokine polyfunctionality profiles of the HLA-Cw*0702-restricted inflated responses 
with age and response size. C) Summary of the cytokine polyfunctionality profiles of the FRC (top row), CRV 
(middle row) and LSE (bottom row) HLA-Cw*0702-specific CD8+T-cell responses in donors <70 vs >70 years 
(left hand column, white vs black circles respectively) and in small vs large epitope specific CD8+T-cell 
responses (right hand column, white vs black circles respectively). The small and large categories are defined as 
in B). The cytokine polyfunctionality was determined for all HCMV-specific CD8+T-cell populations as described 
in Fig 26. Each circle represents the percentage of the epitope-specific CD8+T-cell population producing that 










4.5.2 – Cytokine polyfunctionality between small vs large epitope-specific CD8+T-cell 
populations  
The cytokine polyfunctionality was then analysed when the HLA-Cw*-0702 CD8+T-cell 
populations were categorised depending on the epitope-specific CD8+T-cell response size. 
These were defined as; small <2% vs large >2% of the total CD8+T-cell response based 
upon the values selected by Chiu et al. [110].  
Similar trends to that observed with age (section 4.5.1) were also detected; reductions in the 
production of IL-2 but increased IFN-γ/TNF-α production.   
The proportion of HLA-Cw*0702-restricted CD8+T-cells producing IFN-γ+TNF-α+ but not IL-2 
increased as the ex vivo magnitude of the HLA-Cw*0702 CD8+T-cell populations also 
increased (FRC; 68%-71%, CRV; 68%-84% and LSE; 38%-63%) (Fig-27B/C).  
As the size of the HLA-Cw*0702 populations increased the number of individual CD8+T-cells 
producing IL-2 as their single cytokine decreased (FRC; 4%-1%, CRV; 5%-<1% and LSE; 
3%-1% between small vs large categories).  
The proportion of FRC-and CRV-specific CD8+T-cells producing IL-2+ in combination with 
TNF-α+ was lost within larger epitope populations (Fig-27B/C).  
The proportion of LSE-specific CD8+T-cells producing IL-2+ in combination with IFN-γ+ 
decreased from 9%-1% as the epitope-specific population increased (Fig-27B/C).  
Despite these trends, no significant difference in cytokine production was obtained between 






4.5.3 – Cytokine polyfunctionality of HLA-Cw*0702 CD8+T-cells vs HLA-A-restricted HCMV 
CD8+T-cell populations  
Next the HLA-Cw*-0702 CD8+T-cell population cytokine polyfunctionality was compared to 
that of CD8+T-cell responses specific for the immunodominant pp65-derived peptide NLV 
peptide (Table-5) or the HLA-A1-restricted peptides RTD and YAD characterised in this 
study (Chapter 3, Table-7).   
The overall trend observed was that the HLA-A1 restricted CD8+T-cell populations consisted 
of more CD8+T-cells producing IL-2 than the HLA-Cw*0702 or NLV-specific CD8+T-cell 
populations.  
The RTD-/YAD-specific CD8+T-cell responses consisted of the largest proportion of 
individual CD8+T-cells capable of producing IFN-γ+IL-2+TNF+ (19% and 22% respectively 
Fig-28A/C).  
The HLA-Cw*0702 FRC and CRV populations consisted of a significantly larger proportion of 
individual CD8+T-cells producing both IFN-γ+TNF-α+ but not IL-2 compared to the YAD HLA-
A1-restricted CD8+T-cell populations (Fig-28A/C). 
NLV-specific CD8+T-cells also had a larger percentage of individual CD8+T-cells producing 
both IFN-γ+TNF-α+ but not IL-2 compared to the YAD-specific CD8+T-cell response (Fig-
28A/C). 
 
Next the cytokine polyfunctionality was assessed taking into account the average ‘mean 
fluorescence intensity’ (MFI) of the TNF-α staining obtained for the HCMV-specific CD8+T-
cell populations. This is indicative of how many cytokine molecules on a per cell basis a 




















Fig 28 – Cytokine polyfunctionality and cytokine MFI of the inflated HLA-Cw*0702-restricted HCMV-
specific populations vs HCMV-specific CD8+T-cell populations that are HLA-A-restricted. The cytokine 
polyfunctionality profile of the HLA-Cw*0702-restricted CD8+T-cell populations was compared to the profiles of 
HLA-A-restricted HCMV-specific CD8+T-cell populations. PBMCs from seropositive donors were stimulated with 
HCMV peptide (final concentration 1µg/ml) for 6 hours followed by intracellular staining for IFN-γ, IL-2 and TNF-α 
to identify specific CD8+T-cell responses A) The cytokine polyfunctionality profile of HLA-C and HLA-A-restricted 
HCMV-specific CD8+T-cell responses. The cytokine polyfunctionality was determined for all HCMV-specific 
CD8+T-cell populations as described in Fig 26. The percentages represent the percentage of epitope specific-
CD8+T-cells producing the cytokine combination. Statistical significance was determined by Kruskall Wallis test 
in Graphpad Prism 6 with Dunn corrections applied * as a p value < 0.05 and ** < 0.01. B) Mean fluorescence 
intensity (MFI) of the total TNF-α produced by HCMV-specific CD8+T-cell populations after 6 hours HCMV 
peptide stimulation. The summed HLA-A-restricted CD8+T-cell responses include RD/YAD/NLV and the pooled 
HLA-Cw*0702 include FRC/CRV/LSE. Lines represent mean and errors bars SEM. Statistical significance was 
determined using multiple Mann Whitney tests in Graphpad Prism 6 with * as a p values < 0.05 and ** < 0.01.  
** p = 0.006 vs YAD 
** p = 0.002 vs YAD
 
vs YAD 
 ** p = 0.006 vs YAD 
 ** p = 0.006 vs YAD * p = 0. 14 vs YAD
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The CRV- and LSE-specific CD8+T-cells produced TNF-α with a significantly increased MFI 
over RTD- and NLV-specific CD8+T-cells (Fig-28B). When the CD8+T-cell responses were 
pooled based upon their HLA-restriction, the summed HLA-Cw*0702 CD8+T-cell responses 
produced TNF-α with a significantly increased MFI over the HLA-A-restricted HCMV-specific 
CD8+T-cell responses (Fig-28B). The MFI of the TNF-α produced by FRC-specific CD8+T-
cells trended to significance over the cytokine produced by NLV-specific CD8+T-cells (p = 
0.055, Fig-28B). 
Overall, this is suggestive that the HLA-Cw*-0702-restricted populations are producing more 
TNF-α cytokine molecules on a per cell basis over HLA-A-restricted HCMV-specific CD8+T-
cell populations, including immunodominant NLV-specific populations. The MFI of the IFN-γ 
production was not significantly different (data not shown).  
Statistical significance in Fig-28B was obtained by multiple comparison testing so it must be 
noted the possibility that significance was obtained by chance. More donors should be 
screened for these ex vivo CD8+T-cell responses to allow for statistical corrections to be 
applied. 
To summarise, the HLA-Cw*-0702-restricted populations consisted of larger percentages of 
CD8+T-cells capable of producing both the pro-inflammatory cytokines IFN-γ and TNF-α 
whilst decreasing the percentage producing IL-2. This was as both age and size of the 
epitope-specific CD8+T-cell populations increased. Additionally, the HLA-Cw*0702 CD8+T-
cell populations displayed a cytokine polyfunctionality profile similar to NLV-specific CD8+T-
cell populations whom have been identified as both inflationary and highly differentiated [71]. 
Finally, the total HLA-Cw*0702 CD8+T-cell populations produced less IL-2 than the HLA-A1 
RTD- and YAD-specific CD8+T-cell populations. In total, this supports the previous 
phenotype data where the FRC-specific HLA-Cw*0702 responses were later differentiated 
and expressed lower levels of CD28 compared to RTD/YAD-specific CD8+T-cells (Chapter 




4.6 - The ex vivo phenotype of HLA-Cw*0702 CD8+T-cell populations become 
increasingly antigen differentiated and increase their cytotoxic potential with age  
Memory-inflated CMV-specific CD8+T-cell populations are widely documented as being of a 
highly differentiated TEMRA phenotype associated with the acquisition of high cytotoxic and 
effector function [105, 237, 271].   Previously the ex vivo FRC-specific CD8+T-cell 
populations were phenotyped via flow cytometry for memory phenotype and cytotoxic 
markers (Chapter 3, Fig-12-14). The CRV- and LSE-specific CD8+T-cell populations were 
therefore next phenotyped utilising the same method of peptide stimulation followed by 
intracellular cytokine staining by flow cytometry. The same panel of phenotypic markers 
used to characterise the FRC-specific CD8+T-cells was investigated; CCR7, CD45RA, 
CD45RO, CD27, CD28, CX3CR1, NKG2D, perforin, granzymeB, CD38 and PD-1. The HLA-
Cw*0702 CD8+T-cell populations were then analysed for phenotypic changes with age, in 
particular; memory subset distribution, antigen differentiation status and cytotoxic potential. 
4.6.1 Single cell marker expression 
First, the expression of single cell markers on the HLA-Cw*0702 CD8+T-cells was correlated 
with age (Fig-29).  
The HLA-Cw*0702-restricted populations increased the expression of cytotoxic molecules 
with age (Fig-29). The intracellular perforin expression increased significantly for the 
summed HLA-Cw*0702 CD8+T-cell populations (range 29.17%-96.99%). The perforin 
expression by the FRC- and CRV-specific CD8+T-cell populations correlated significantly 
with the age of our donor cohort (range 20.63%-99.84%, 13.64%-99.60% respectively). The 
LSE-specific CD8+T-cells also increased intracellular perforin production with age (range 
40.84%-98.62%) (p = 0.06) (Fig-29). The granzymeB expression was higher than perforin 
expression within younger donors and only increased significantly with age for CRV-specific 










































































































































































































































































































































































































































































































































































































































































































Interestingly, the FRC-, CRV- and LSE-specific CD8+T-cell responses increased NKG2D 
expression with age (p = 0.09, 0.07 and 0.06 respectively, average summed HLA-Cw*0702 
response range 1.73%-61.54%, Fig-29). NKG2D is an activating receptor for NK cells that 
on CD8+T-cells acts a co-stimulatory molecule and is expressed when the CD8+T-cell has 
been recently activated to enhance pro-inflammatory cytokine production [272]. A second 
activatory marker CD38, was maintained at similar levels with age – summed HLA-Cw*0702 
CD8+T-cell response range 20.93%-47.79%, Fig-29). 
Concurrent to the observed increase in cytotoxicity markers, there was a trend for the 
inflated HLA-Cw*0702 CD8+T-cell populations to decrease PD-1 expression with age 
(summed HLA-Cw*0702 response range 45.21%-0.00%, Fig-29).  
The HLA-Cw*0702-restricted responses exhibited a progressive increase of the endothelial 
fractalkine receptor CX3CR1 within elderly individuals (summed HLA-Cw*0702 8.07%-
55.93%, CRV-specific CD8+T-cells 8.33%-78.83% and LSE-specific CD8+T-cells 7.69%-
66.13%, Fig-29). The FRC-specific CD8+T-cell populations demonstrated a small decrease 
with age (range 0.87%-89.22%, Fig-29).  
The FRC- and CRV-specific CD8+T-cells displayed a CD27midCD28mid phenotype that 
progressed to CD27lowCD28low with age (Fig-29) The LSE-specific CD8+T-cell populations 
differed with an increase in CD28 expression with age (Fig-29). All three HLA-Cw*0702 
epitope-specific CD8+T-cell populations decreased CCR7 when correlated with the age of 








4.6.2 - Memory phenotype compartment  
To determine what memory compartment the HLA-Cw*0702 responses were occupying and 
how this altered with age, CCR7 vs CD45RA expression was evaluated. This memory 
phenotype was analysed between <70 vs >70 year donor cohorts (Fig-30A). With age, the 
FRC-specific population significantly decreased the proportion of TN (CCR7+CD45RA+) 
CD8+T-cells (6.92%-0.61%) and increased the proportion of TEMRA (CCR7-CD45RA+) 
CD8+T-cells (p = 0.06, 49.62%-69.75%, Fig-30A). The CRV-specific CD8+T-cells comprised 
a larger percentage of TEM (CCR7-CD45RA-) CD8+T-cells within the total epitope-specific 
population with age (34.93%-52.34%). The CRV-specific CD8+T-cell population also 
decreased the proportion of TEMRA (CCR7-CD45RA+) CD8+T-cells with age (62.73%-
46.43%). The total LSE-specific CD8+T-cell population significantly decreased in the 
percentage of TN (CCR7+CD45RA+) CD8+T-cells (6.86%-0.40%) with a concomitant 
increase in the percentage of TEM (CCR7-CD45RA-) CD8+T-cells with age (31.85%-45.76%, 
Fig-30A).  
 
4.6.3 – Antigen differentiation status 
The antigen differentiation status of the HLA-Cw*0702 CD8+T-cells and how this altered with 
age was determined using CD27 vs CD28 expression. This was analysed between <70 vs 
>70 year donor cohorts (Fig-30B). The total FRC-specific population decreased the 
percentage of early differentiated (CD27+CD28+) (20.54%-3.72%), and increased the 
percentage of late differentiated (CD27-CD28-) CD8+T-cell populations (43.7%-83.04%, p = 
0.06, Fig-30B). The CRV-specific CD8+T-cell populations exhibited the same trends in early 
(16.28%-3.08%) and late differentiated CD8+T-cells (46.37%-67.14%) (Fig-30B). The LSE-
specific CD8+T-cell populations had a significant increase in CD8+T-cells within the 
intermediate CD27-CD28+ compartment with age coupled with a decrease in the 
CD27+CD28+ early differentiated compartment (15.84%-3.38%). This parallels with the 


















Fig 30 – Memory phenotype and antigen differentiation status of the ex vivo HLA-Cw*0702-restricted 
CD8+T-cell responses with age The HLA-Cw*0702-restricted CD8+T-cell populations were analysed for CCR7 
vs CD45RA expression and CD27 vs CD28 expression between donors <70 vs >70 years of age. PBMCS of 
donors with known HLA-Cw*0702 populations were stimulated with the HLA-C peptides for 6 hours followed by 
intracellular cytokine staining for TNF-α to identify the specific CD8+T-cell populations A) Memory phenotype of 
HLA-Cw*0702-restricted populations between donors <70 or >70 years of age determined as TN 
CCR7+CD45RA+, TCM CCR7+CD45RA-, TEM CCR7-CD45RA- and TEMRA CCR7-CD45RA+ by flow cytometry. 
Gates were applied as outlined in Fig-13 B) Antigen differentiation status of the HLA-Cw*0702 populations 
between donors <70 or >70 years of age determined as early (CD27+CD28+), intermediate (CD27+CD28- or 
CD27-CD28+) and late (CD27-CD28-) by flow cytometry. Gates were applied as outlined in Fig-14 In A/B 
statistical significance was determined by using multiple Mann Whitney tests in Graphpad Prism 6 with * as a p-
value <0.05. n = 4-5, 5, 5 for FRC, CRV and LSE <70 years category. n = 4, 3 and for FRC, CRV and LSE >70 
years category. 
 
To summarise this section, the inflated HLA-Cw*0702 CD8+T-cell responses increased their 
cytotoxic potential with age whilst displaying a decrease in the T-cell exhaustion marker PD-
1 and upregulating the NKG2D receptor – a marker of recent activation/co-stimulation. 
Additionally the FRC-specific CD8+T-cell population progressed to a TEMRA and later antigen 
driven phenotype with age – decreasing CCR7, CD27 and CD28 expression.  
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4.7 - Inflated HLA-Cw*0702 populations become increasingly antigen differentiated 
and cytotoxic as the size of the epitope specific CD8+T-cell response increases 
We demonstrated that the HLA-Cw*0702 populations alter their phenotype with age towards 
a more TEMRA memory phenotype i.e. increase in cytotoxic molecules and decrease in CCR7 
and CD27 expression (Section 4.6). Additionally, this study showed that the HLA-Cw*-0702 
populations alter their polyfunctionality with regards to cytokine production based upon age 
and the epitope-specific CD8+T-cell response size (Section 4.5). Subsequently in this 
investigation, the ex vivo phenotype of the HLA-Cw*0702 CD8+T-cell populations were 
interpreted as the epitope-specific population accumulated. In particular their memory subset 
distribution and antigen differentiation status. The phenotypic markers used previously – 
CCR7, CD45RA, CD45RO, CD27, CD28, CX3CR1, NKG2D, perforin, granzymeB, CD38 
and PD-1 – were investigated. The epitope size categories were defined as small (<2%) and 
large (>2%) of the total CD8+T-cells responding to peptide by cytokine production.  
4.7.1 – Single marker expression 
First the expression of single markers was correlated with the size of the HLA-Cw*0702 
epitope-specific CD8+T-cell response. As the size of the TNF-α producing HLA-Cw*0702 
CD8+T-cell populations increased, a concomitant increase in perforin and granzymeB (CRV-
specific CD8+T-cell perforin expression *p = 0.046, Fig-31). Converse to what was observed 
with age (Fig-29), there was a trend to decrease NKG2D expression as the FRC-specific 
populations increased but, however, trended to increase for the CRV- and LSE-specific 
CD8+T-cell populations (Fig-31). The CX3CR1 expression increased with the size of the 
CRV- and LSE-specific CD8+T-cells but decreased for FRC-specific (Fig-31). CD38 
expression was maintained with the size of FRC- and CRV-specific CD8+T-cell populations 
(Fig-31). As was confirmed with age, there was a trend to reduce PD-1 expression as the 
HLA-Cw*0702 populations accumulated (Fig-31). The largest FRC-specific CD8+T-cell 
response phenotyped (17.22% of total CD8+T-cells producing TNF-α – OD12) displayed an 
161 
 
exaggerated TEMRA phenotype with the highest; perforin/granzymeB but lowest 





























































































































































































































































































































































































































































































































































































































































































































































































































4.7.2 – Memory phenotype compartment 
To evaluate whether the HLA-C CD8+T-cells occupied different memory compartments as 
the epitope-specific CD8+T-cell populations accumulated, CCR7 vs CD45RA expression 
was analysed between the small (<2%) and large (>2%) epitope-specific responses.  
As was evidenced with age (Fig-30A), the FRC-specific populations reduced the number of 
TN (CCR7+CD45RA+) and increased the number of TEMRA (CCR7-CD45RA+) CD8+T-cells 
between the small vs large epitope-specific size categories (average 5.09%-0.71% and 
54.13%-74.23% respectively, Fig-32A).  
The CRV-specific CD8+T-cell responses significantly increased the number of TCM 
(CCR7+CD45RA-) CD8+T-cells between small vs large responses but these remained a 
small percentage of the total epitope-specific population (average 0.08%-0.79%, Fig-32A). 
The CRV-specific CD8+T-cell responses also maintained similar levels of TEM (CCR7-
CD45RA- average 40.73%-42.19%) and TEMRA (CCR7-CD45RA+ average 57.10%-56.14%) 
CD8+T-cells with size (Fig-32A).  
The LSE-specific CD8+T-cell response contained a larger percentage of TEM (average 
34.87%-43.67%) and decreased proportion of TN (average 5.77%-0.043%) within the large 
epitope-specific population category.   The LSE-specific CD8+T-cell population maintained a 

















































































Fig 32 - The memory phenotype and antigen differentiation status of the ex vivo HLA-Cw*0702 CD8+T-cell 
populations as the size of the epitope-specific CD8+T-cell response increases.  The HLA-Cw*0702-
restricted CD8+T-cell populations were analysed for CCR7 vs CD45RA expression and CD27 vs CD28 
expression between small (2%) vs large (>2%) epitope-specific CD8+T-cell populations. PBMCS of donors with 
known HLA-Cw*0702 populations were peptide stimulated with the HLA-C peptides for 6 hours followed by 
intracellular cytokine staining for TNF-α to identify the specific CD8+T-cell populations. PBMCs were subjected to 
antibody staining with the panels provided in table 4. A) Memory phenotype of the HLA-Cw*0702 populations 
between small <2% vs large >2% CD8+T-cell populations responding to peptide stimulation. Determined as TN 
CCR7+CD45RA+, TCM CCR7+CD45RA-, TEM CCR7-CD45RA- and TEMRA CCR7-CD45RA+ by flow cytometry. B) 
Antigen differentiation status of the HLA-Cw*0702 populations between small <2% vs large >2% CD8+T-cell 
populations responding to peptide stimulation. Determined as early (CD27+CD28+), intermediate (CD27+CD28- 
or CD27-CD28+) and late (CD27-CD28-) by flow cytometry.  Statistical significance was determined in Graphpad 
Prism 6 via using multiple Mann Whitney Tests with * as a p-value <0.05. n = 14, 10 and 6 for FRC, CRV and 








4.7.3 – Antigen differentiation status 
Lastly, the antigen differentiation status of the HLA-Cw*0702 CD8+T-cells was evaluated 
with size. This was to indicate whether the HLA-C CD8+T-cells were accumulations of late 
differentiated CD8+T-cells with a history of high proliferation rates [70, 238]. 
The total FRC-specific CD8+T-cells dramatically increased the percentage of late 
differentiated CD8+T-cells within larger populations (average 54.87%-81.28%, Fig-32B).  
The CRV-specific CD8+T-cells also largely increased the number of late differentiated 
CD8+T-cells (CD27-CD28- average 38.23%-70.09%, Fig-32B).  
The LSE-specific CD8+T-cell response increased the percentage of intermediate 
differentiated (CD27-CD28+) CD8+T-cells while decreasing early differentiated 
(CD27+CD28+) T-cells as the population accumulated (Fig-32B).  
Altogether, the ex vivo phenotype of HLA-Cw*-0702 CD8+T-cell populations became more 
antigen differentiated and increased their cytotoxic potential (perforin+granzymeB+) as the 
size of the epitope-specific CD8+T-cell response increased. The FRC-specific had the 
largest increase in both the TEMRA and late differentiated compartments within older donors 
and larger epitope-specific populations. The total LSE-specific CD8+T-cell population 
demonstrated the smallest proportions of late differentiated TEMRA CD8+T-cells in both older 











4.8 – HLA-Cw*0702-restricted CD8+T-cell populations display a later differentiated 
TEMRA phenotype compared to HLA-A-restricted HCMV-specific CD8+T-cells 
The ex vivo memory phenotype and antigen differentiation status of the HLA-Cw*0702 
CD8+T-cells was compared to that of HLA-A-restricted HCMV-specific CD8+T-cells. All 
three HLA-Cw*0702 CD8+T-cell populations were comprised of a significantly lower 
proportion of early CD27+CD28+ CD8+T-cells compared to NLV and RTD-specific CD8+T-
cells (Fig-33B). All three HLA-Cw*0702 populations had an increased percentage of TEMRA 
CD8+T-cells (Fig-33A) compared to RTD-specific populations. As such, the HLA-Cw*0702-
restricted populations represented CD8+T-cells that were more antigen differentiated 










Fig 33  – Memory phenotype and antigen differentiation status of ex vivo HCMV-specific HLA-Cw*0702-
restricted CD8+T-cells vs HLA-A-restricted CD8+T-cell The CCR7 vs CD45RA and CD27 vs CD28 
expression on HLA-Cw*0702 restricted CD8+T-cell populations was compared to HLA-A-restricted HCMV 
CD8+T-cell populations. PBMCS of HCMV seropositive donors populations were peptide stimulated for 6 hours 
followed by intracellular cytokine staining for TNF-α to identify the specific CD8+T-cell populations. A) Memory 
phenotype of the HCMV-specific CD8+T-cell populations determined as TN CCR7+CD45RA+, TCM 
CCR7+CD45RA-, TEM CCR7-CD45RA- and TEMRA CCR7-CD45RA+ by flow cytometry. B) Antigen differentiation 
status of the HCMV-specific populations determined as early (CD27+CD28+), intermediate (CD27+CD28- or 
CD27-CD28+) and late (CD27-CD28-) by flow cytometry.  Bars represent mean and error bars SEM. Statistical 
significance represents significance in the percentage of early (CD27+CD28+) CD8+T-cells within the FRC-, 
CRV- and LSE-specific HLA-Cw*0702 CD8+T-cell populations compared to the NLV- and RTD-specific CD8+T-
cell populations respectively determined by using multiple Mann Whitney tests in Graphpad prism6. * = a p value 
<0.05. n = 8, 8, 8, 4, 4 and 6 for FRC, CRV, LSE, RTD, YAD and NLV respectively.  
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4.9 - HLA-Cw*0702-restricted CD8+T-cell clones display high functional avidity 
 
The next step in this investigation was to assess the anti-viral functionality of the inflated 
HLA-Cw*0702 CD8+T-cells in vitro to indicate their efficacy in controlling viral infections in 
vivo. We first aimed to assess their avidity for their cognate antigen. 
Specific CD8+T-cell clones were generated in vitro from PBMCs of HCMV seropositive 
donors with previously identified HLA-Cw*0702 populations. This was conducted by an IFN-γ 
secretion assay (Miltenyi Biotech) after 3 hours peptide stimulation followed by limiting 
dilution assays. The specificity of the CD8+T-cell clones were determined by IFN-γ ELISAs 
(Fig-34A). FRC-specific clones were generated from donors YD6/YD13 and CRV- and LSE-
specific clones from donor YD13 (Fig-34A).  
The avidity of the HLA-Cw*0702 clones was then assessed after O/N co-culture with 
peptide-loaded LCLs with concentrations ranging from 50pg-50µg. The EC50 avidity of 
individual clones was calculated as the concentration of peptide that induced the 50% 
maximal IFN-γ production. This was compared to the HLA-A1 RTD/YAD- and HLA-A2 NLV-
specific CD8+T-cell clones generated in Chapter 3 Fig-15/16. This allowed a comparison of 
CD8+T-cell clones specific for ‘inflationary’ HLA-Cw*0702 epitopes to the NLV epitope that 
has been identified as both immunodominant and inflationary in the literature [87, 273, 274]. 
Additionally this allowed a comparison to the RTD/YAD peptide-epitopes that were identified 
to elicit stable CD8+T-cell responses with age (Chapter 3, Table-7).  
The avidity of both the FRC- and CRV-specific HLA-C-restricted clones was determined to 
range from 50pg-0.025μg (Fig 34B). This was significantly increased over RTD-, YAD- and 
NLV-specific CD8+T-cell clones (RTD-specific 0.25μg-0.5μg, YAD-specific 0.025μg-0.25μg 
and NLV-specific 0.025μg-0.25μg, Chapter 3, Fig-16 and Fig-34C). The EC50 of the LSE-









Fig 34 – Generation of HLA-Cw*0702-restricted HCMV-specific CD8+T-cell clones in vitro and 
determination of their functional avidity. Specific CD8+T-cell clones for the UL28-derived FRC and UL122/IE-
1-derived CRV and LSE peptides were generated in vitro by an IFN-γ catch assay (Miltenyi Biotech) following 3 
hours peptide stimulation assay of PBMCs with previously identified CD8+T-cell responses to the peptides in 
question and a limiting dilution assay. The EC50 avidity of individual clones was calculated as the concentration of 
peptide that induced the 50% maximal IFN-γ production. A) Representative IFN-γ production of some example 
clones determined by ELISA after O/N co-culture of CD8+T-cell clones with DMSO control loaded (white bars) 
and peptide-loaded LCLs (black bars). B) Functional peptide affinity assay of the FRC (top), CRV (middle) and 
LSE (bottom) CD8+T-cell clones. CD8+T-cell clones were co-cultured O/N with LCLs loaded with peptide 
concentrations ranging from 50μg to 50pg followed by an IFN-γ ELISA. The dashed lines represent the EC50 of 
the individual clones. C) Summary EC50 values obtained for CD8+T-cell clones specific for HCMV-specific 
epitopes. Statistical significance was obtained via Mann Whitney test in Graphpad Prism 6 with * as a p-value < 






4.10 - Killing of peptide-loaded and infected fibroblasts in vitro by HLA-Cw*0702-
restricted CD8+T-cell clones 
Throughout this investigation, the inflated HLA-Cw*0702 CD8+T-cell populations have been 
proven to be exceptional candidates for their inclusion within immunotherapy to treat CMV 
disease in the post HSCT setting. This is based on their high avidity, maintenance into older 
age and high cytotoxic potential (intracellular perforin and granzymeB production). A CD8+T-
cell response maintained into older age could provide lifelong protection from CMV 
reactivation events offering an advantage in the adoptive immunotherapy setting for post-
HSCT patients. However, for these CD8+T-cell populations to be successful after adoptive 
transfer, they need to be efficient in killing and therefore removing virally infected cells in 
vivo.  
The capability of HCMV HLA-C-specific CD8+T-cell clones to kill peptide-loaded targets in 
vitro was evaluated and compared to clones specific for the pp65-derived NLV peptide or the 
UL69/UL105a-derived RTD/YAD peptides. HCMV-specific CD8+T-cell clones were cultured 
with CFSE-labelled peptide-loaded HLA-matched LCLs O/N followed by staining with 
Propidium Iodide (PI). This allowed the analysis of the percentage of CFSE POSITIVE target 
cells that were PI negative and therefore still viable after incubation with the CD8+T-cell 
clones (gating strategy provided in Fig-35A).  
All clones tested were efficiently able to kill peptide-loaded targets after an O/N incubation at 
1:1 to 10:1 effector:target ratios. The NLV-specific followed by the YAD-specific clones had 
the highest percentage of specific cell lysis (range 95.99%-98.80%) (Fig-35B). The CRV-
specific clones demonstrated the lowest specific lysis (average range 17.99%-71.78%) (Fig-
35B). The FRC-specific CD8+T-cell clones lysed specific cells ranging from 59.00%-90.11%. 
(Fig-35B) (n = 2 CRV, FRC, NLV and n =1 RTD/YAD). It should be noted that the killing 
efficiency may be clone dependent in this assay and not completely representative of the 
entire epitope-specific CD8+T-cell population or in vivo killing capacity. Additionally, the in 
vitro culture conditions may also influence the killing capacity of the clones. Therefore this 
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should be repeated with a greater range of CD8+T-cell clones. The important finding is that 








Fig 35 – HCMV-specific CD8+T-cell clone killing of peptide-loaded target cells. The ability of HCMV CD8+T-
cell clones to specifically lyse HCMV infected cell targets was assessed. A) Gating strategy for identifying the 
number of CFSE positive, PI negative ‘viable’ peptide-loaded target cells remaining after incubation with HCMV 
CD8+T-cell clones a 1-10:1 effector: target ratios O/N. Single cells, effector and target cells were gated upon. To 
differentiate between effector and targets, peptide-loaded LCLs were stained with CFSE prior to incubation with 
the effectors. CFSE positive, PI negative targets were then gated upon within the DMSO-pulsed LCL control 
tubes. The PI negative gate was then applied to the CFSE positive targets cells within 1:1, 2:1, 5:1 and 10:1 
sample tubes. Lastly, a gate was placed around the counting beads (Life Technologies). The percentage specific 
cell lysis was calculated as indicated in the materials and methods and as per manufacturer’s guidelines when 
using the counting beads. B) Summary of the percentage specific lysis of the HLA-C FRC and CRV (left graph), 
HLA-A2 NLV (middle graph) and HLA-A1 RTD and YAD-specific (right graph) CD8+T-cell clones.  
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After observing the efficient removal of peptide-loaded targets by the HCMV-specific CD8+T-
cell clones, next their ability to lyse HCMV infected target cells during an in vitro infection 
was evaluated. This was to give an accurate idea of their ability to recognise and kill infected 
cells presenting naturally processed antigen. MRC5 fibroblasts were infected at a low MOI of 
0.05 with the Merlin strain for 24 hours followed by co-culture with either FRC-, CRV or NLV-
specific CD8+T-cell clones at 1-10:1 effector to target ratios for a further 48 hours (Fig-
36A/B). The CD8+T-cell clones were subsequently removed from the monolayer and 
characterised for the upregulation of the activatory marker CD25 by flow cytometry (Fig-
36B). As a negative control CD8+T-cell clones were incubated with an uninfected fibroblast 
monolayer. The background CD25 levels from this negative control were subtracted from the 
values obtained with CD8+T-cells incubated with the Merlin infected monolayer.  The Merlin 
strain was selected as it is a clinical isolate and therefore a more physiological 
representation of a CMV infection in vivo (review [241]).  
All CD8+T-cell clones were activated after incubation with Merlin infected MRC5 cells 
indicated by CD25 upregulation (Fig-36B). The CRV- and FRC-specific clones from the 10:1 
ratio had increased upregulation of CD25 compared to NLV-specific clones (43.97%, 
53.92% and 11.32% CD25 positive CD8+T-cell clones respectively) (Fig-36B). 
Subsequently, the levels of specific cell killing was quantified using AD169 infected 
fibroblasts which had been previously optimised in our research group. An FRC-specific 
CD8+T-cell clone was able to specifically lyse up to 80% of AD169 infected fibroblasts in 
vitro at 12 and 24 hours p.i at 1:1 to 10:1 effector to target ratios (range 66.58% to 82.10% 
12 hours and 70.69% to 81.47% 24 hours, Fig-36C). The FRC-specific clone also produced 
IFN-γ, detected by ELISA after incubation with 12 and 24 hour infected AD169 fibroblasts 
(data not shown). To conclude, FRC-specific CD8+T-cell clones upon positive recognition, 
engagement of antigen and production of effector molecules such as IFN-γ, induce 
subsequent death of infected cell targets. This provides premise for developing the FRC-



















Fig 36 – CD8+T-cell killing of AD169 infected targets and CD25 upregulation on activated CD8+T-cell 
clones. HCMV-specific clones were evaluated for their ability to disrupt a HCMV-infected monolayer in vitro and 
upregulate the CD25 activatory marker A) CD25 upregulation on FRC- (left), CRV- (middle) and NLV-specific 
(right) CD8+T-cell clones after 48 hours incubation with Merlin infected MRC5 cells compared to clones 
incubated with uninfected fibroblasts. CD8+T-cells were removed from the monolayer and subjected to CD25 
antibody staining and flow cytometric analysis B) Specific cell lysis of AD169 infected MRC5 fibroblasts after 12 
and 24 hours pi by an FRC-specific CD8+T-cell clone. Percentage of specific lysis was determined as outlined in 



















Project 2 Summary 
The ex vivo phenotype of HCMV-specific HLA-Cw*0702 CD8+T-cell populations were 
characterised and found to alter when both the age of the donor and the size of the epitope-
specific CD8+T-cell responses increased. The HLA-Cw*0702 FRC-specific populations 
presented with a large increase in the percentage of CD8+T-cells further down the 
differentiation pathway (CD27-CD28-). Importantly, increases in the proportion of TEM and 
TEMRA within the FRC-specific HLA-Cw*0702 CD8+T-cell populations was also observed 
within older donors and large epitope-specific accumulations. The cytotoxic potential of the 
HLA-Cw*0702-restricted CD8+T-cells within larger epitope-specific CD8+T-cell populations 
and older donors significantly increased – indicated by perforin and granzymeB expression. 
The same T-cells appeared more activated with age with an increased NKG2D expression 
and maintenance of CD38. The percentage of HLA-Cw*0702-restricted CD8+T-cells capable 
of producing both pro-inflammatory cytokines IFN-γ and TNF-α was increased within large 
accumulations and age, while the proportion of CD8+T-cells producing IL-2 was lost. This 
complemented the progressive loss of CD28 required for IL-2 production. Additionally, the 
FRC- and CRV-specific HLA-Cw*0702 CD8+T-cell populations were comprised of 
significantly more IFN-γ+TNF-α+ double-producing CD8+T-cells compared to the HLA-A1-
restricted YAD-specific CD8+T-cell populations. The latter were more capable of producing 
IL-2. The functionality of the HLA-Cw*0702 CD8+T-cell populations was confirmed within in 
vitro killing assays. Firstly, CD8+T-cell clones specific to the HLA-Cw*0702 targets were 
calculated as significantly more avid than clones specific for HLA-A-restricted pp65-, UL69-, 
and UL105a-derived targets. Secondly, FRC-specific HLA-C clones efficiently lysed HCMV 
infected fibroblasts in vitro. Providing evidence for their efficacy in providing anti-viral 
protection in vivo. In conclusion the HLA-Cw*0702 specificities, in particular FRC-specific, 
have potential for development as an adoptive therapy to treat CMV disease in the post-
transplant setting.  
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Project 3 – Antigen driven stimulation of HLA-C specific T-cells as a 
potential mechanism for memory-inflation 
4.11 - HLA-Cw*0702-restricted ex vivo PBMCs and specific CD8+T-cell clones are able 
to proliferate after antigen stimulation 
One hypothesis for memory-inflation states that antigen driven stimulation within the lymph 
nodes by infected non-haematopoietic cells drives the proliferation and differentiation of 
CMV-specific TCM. This results in a highly differentiated and cytotoxic TEMRA population that 
can enter the periphery to control reactivation. Studies in the murine model, in the absence 
of MCMV antigen, identified memory-inflated CD8+T-cells within the circulation as short lived 
with little proliferative capacity and continually replaced by CD8+T-cells [103].  These 
inflated populations then undergo extensive division upon antigen encounter [115, 123].  
This study next sought to evaluate whether the proliferation of the HLA-Cw*0702 cells after 
antigen stimulation could be a factor in their peripheral accumulation within age. The 
proliferation of both ex vivo PBMCs (Fig-37) and HLA-C-specific CD8+T-cell clones (Fig-38) 
after incubation with peptide-loaded cell targets in vitro was examined. This was conducted 
by following the dilution of the CFSE dye incorporated into epitope-specific CD8+T-cells after 
cell division by flow cytometry (Fig-37). PBMCs isolated from individual seropositive donors 
with all three identified HLA-Cw*0702 CD8+T-cell populations, were CFSE labelled and co-
cultured for 7 days at 37oC with HLA-matched γ-irradiated LCLs that were either DMSO or 
peptide-loaded. PBMC only and PBMCs co-cultured with SEB-stimulated (final concentration 
2mg/ml) negative and positive controls were included respectively (gating strategy provided 
in Fig-37A/B). As the three HLA-Cw*0702 populations were investigated within donors 
identified to have all three responses, only one SEB positive control was conducted up per 
donor. This positive control therefore represents the same value for all three HLA-Cw*0702-
specific CD8+T-cell populations (Fig-37). PBMCs of donors with NLV-specific CD8+T-cells, 
that did not have HLA-Cw*0702-specific CD8+T-cells were included as a positive 
















Fig 37 – Proliferation capacity of HCMV-specific ex vivo PBMCS determined by CFSE staining. The ability 
of ex vivo HLA-Cw*0702 CD8+ T cell populations to proliferate in response to antigen was investigated and 
compared to the proliferation of HLA-A2-restricted NLV-specific CD8+T-cells. PBMCs were co-cultured with HLA-
Matched LCLs that were either DMSO control or peptide-loaded for 7 days at 37oC. PBMCs were left 
unstimulated or SEB stimulated (0.2mg/ml) as negative and positive controls respectively. Single, live, 
CD3+CD8+ lymphocytes were gated on in Kaluza 1.3 software. Within the CD8+T-cell population, CFSE low i.e. 
proliferating CD8+T-cells were identified. A/B) Gating strategy to identify proliferating i.e. CFSE low CD8+T-cells 
within PBMCs obtained from donor OD12 after co-culture with; media only (T-cells only) (left), DMSO-pulsed 
LCLs (middle) and peptide-pulsed LCLs (right). B) The representative histogram plots represent the percentage 
of CSFE CD8+T-cells C) Summary of the CFSE low CD8+T-cell staining obtained for PBMCs incubated with 
FRC-, CRV-, LSE- and NLV-loaded LCLs. n = 3 for FRC, CRV and LSE, n = 2 for NLV. Bars represent mean and 




A hierarchy of proliferation capacities of the ex vivo PBMCs elicited by the HLA-Cw*0702-
restricted peptides was observed. The FRC peptide elicited the largest proliferation rates 
with an average CFSElow CD8+T-cell population after 7 days co-culture of 38.14% (Fig-37C). 
This was followed by an average of 22.31% for CRV and 14.11% for LSE. The NLV peptide 
elicited proliferation rates comparable to the FRC-peptide with an average of 36.88% 
CFSElow CD8+T-cell populations (Fig-37C).  
Subsequently, CD8+T-cell clones were then also analysed for proliferation after incubation 
with peptide-loaded targets after 24-72 hours (Fig-38A/B). CFSE-labelled CD8+T-cell clones 
were co-cultured with peptide-loaded HLA-matched LCL targets for 24-72 hours.  
The FRC-specific CD8+T-cell clone exhibited the highest rate of proliferation by 48 and 72 
hours reaching 76.42% and 96.14% of the total CD8+T-cell clone population with a CFSElow 
phenotype (Fig-38A/B). 49.74% and 53.06% of an NLV-specific clone population were 
proliferating after 48 and 72 hours incubation with peptide-loaded target cells. UL69-derived 
RTD- and UL105a-derived YAD-specific clone proliferated in the ranges of 9.91% to 34.94% 
and 19.08-34.83% respectively of the total CD8+T-cell clone population (Fig-38B). 
In summary, ex vivo PBMC CD8+T-cell responses specific for the HLA-Cw*0702 peptides 
are able to proliferate after antigen stimulation demonstrating a hierarchy of FRC>CRV>LSE 
with FRC comparable to that induced by the NLV peptide. Additionally, an FRC-specific 
CD8+T-cell clone population had higher proliferative capacity over a clone specific for the 
pp65-derived NLV, UL69-derived RTD and UL105a-derived YAD peptides in vitro after 


























Fig 38 – Proliferation capacity of HCMV-specific CD8+T-cell clones generated in vitro determined by 
CFSE staining by flow cytometry. The ability of specific HLA-Cw*0702 CD8+T-cell clones to proliferate in 
response to antigen was investigated and compared to the proliferation of HLA-A1 and HLA-A2-restricted 
CD8+T-cell clones. CD8+T-cell clones were incubated for 24-72 hours at 37oC with peptide-loaded HLA-matched 
LCLs to analyse proliferation after antigen stimulation indicated by the dilution of CFSE dye. CFSE low i.e. 
proliferating CD8+T-cell clones were identified as outlined in Fig-37A/B. A) Representative dot plots of CFSE 
dilution by HCMV-specific CD8+T-cell clones after 24 (top row), 48 (middle row) and 72 hours (bottom row) 
incubation with; media only (T-cells only) (left column), DMSO-pulsed LCLs (middle) and peptide-pulsed LCLs 
(right column). Example shown is for the FRC-specific CD8+T-cell clone. B) Summary of the CFSE dilution 
obtained for CD8+T-cell clones specific for the FRC, NLV, RTD and YAD HCMV peptides (Table-7/8). In all 





4.12 - The UL28-derived HLA-Cw*0702-restricted HCMV-specific CD8+T-cell response 
becomes oligoclonal with age 
Inflated HCMV memory CD8+T-cell populations are reported to be accumulations of CD8+T-
cells with a restricted TCR Vβ usage [76, 92, 276]. One theory for this oligoclonal 
development is the selection of highly avid CD8+T-cell clones over the lifetime of the host 
that confer efficient control of viral reactivation events in vivo. It was thereupon assessed 
whether the HLA-Cw*0702 accumulations represent oligoclonal populations, supporting the 
preferential selection of a particular clone in vivo.  
The ex vivo CD8+T-cell populations specific for the UL28-derived FRC peptide were 
characterised for their ‘TCR β-chain V’ (TCRβV) diversity by flow cytometry. PBMCs were 
peptide stimulated for 6 hours and surface stained with the TCR Vβ diversity repertoire kit 
(Becton Dickinson) containing MAbs to 24 TCRβV regions. PBMCS were then stained 
intracellularly for TNF-α production to identify FRC-specific CD8+T-cells. The positive gates 
for individual TCRβV usage were set upon the CD8+T-cells within the Kaluza 1.3 software 
and then applied to the FRC-specific CD8+T-cells (gating strategy provided in Fig-39).  
A dominant usage of Vβ3 was obtained within a single donor of 29 years of age at 67.09% of 
the total epitope-specific CD8+T-cell response. Within older donors dominant Vβ3 usage 
was also observed at a higher magnitude within one donor of 81 years of age at 80.17% of 
the total epitope-specific CD8+T-cell response (Fig-40). Dominant Vβ3 usage was again 
observed at a smaller magnitude at 12.35% within a donor of 86 years of age (Fig-41). The 
range of Vβ3 usage within the FRC-specific CD8+T-cell populations was 7.7%-67.09% 













Fig 39 – Gating strategy for phenotyping the TCRBV regions of the ex vivo HLA-Cw*-0702 specific 
CD8+T-cells by flow cytometry. PBMCs from donors with previously identified CD8+T-cell populations were 
characterised for TCR Vβ chain usage. Here the gating strategy utilised to identify the TCR Vβ usage within the 
ex vivo FRC-specific CD8+T-cell populations is provided. Single, live, CD3+CD8+ lymphocytes were gated upon 
sequentially in Kaluza 1.3 software. The FRC-specific CD8+T-cells were identified by TNF-α production after 6 
hours peptide stimulation of HCMV seropositive donor PBMCs with previously identified ex vivo FRC-specific 
CD8+T-cell responses. Gates for TCRβV expression were set upon the total CD8+T-cell population and then 
applied to the FRC-specific CD8+T-cells. Individual TCRβV MAbs were conjugated to either, PE, FITC or 
PE+FITC (Beckman Coulter). The example provided demonstrates the staining obtained for the total CD8+T-cells 
(top graph) vs FRC-specific CD8+T-cells with tube E of the repertoire kit (Beckman Coulter). The percentages of 
CD8+T-cells within the total CD8+T-cell (top plot) and FRC-specific CD8+T-cell population (bottom plot) utilising 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig 42 – Summary of the TCRβV staining obtained for the ex vivo HCMV-specific CD8+T-cell responses. 
The average TCR Vβ usage of the FRC-specific CD8+T-cell populations between donors <70 vs >70 years of 
age. PBMCs of donors with previously identified FRC-specific CD8+T-cell responses were peptide stimulated for 
6 hours followed by staining with the TCR VB repertoire kit (Beckman Coulter) and ICS for TNF-α to identify the 
FRC-specific CD8+T-cells. The graphs represent the summary of the TCR Vβ staining obtained for ex vivo FRC-
specific CD8+T-cell populations within donors <70 years (top) vs >70 years (bottom) of age.  
 
When the TCRβV staining was summarised, the average percentage of the FRC-specific 
CD8+T-cell population that uses Vβ3 remained almost identical with age (29.98% <70 years 
vs 31.05% >70 years) but the use of other Vβ chains reduced within the older donors (Fig-
42). 
To summarise, this section demonstrates the preferential usage of Vβ3 within inflationary ex 
vivo HLA-Cw*0702 FRC-specific CD8+T-cell populations within these six donors. However, 
a more diverse Vβ usage could be present within other donors not characterised or 
represented by a Vβ not included within the repertoire kit (Beckman Coulter). As such a 
larger donor cohort should be screened and donors followed longitudinally to observe 




4.13 - Maintenance of surface HLA-C alleles at IE times of AD169 infection of 
fibroblasts in vitro when the US2-11 immunevasins are present 
 
The observation of striking memory-inflated CD8+T-cell populations to three individual 
HCMV peptides restricted through a common HLA-Cw*0702 allele asked the question to 
what extent the HLA-restricting allele plays in the development of this HLA-C inflation.  
Encouragingly, HLA-Cw*0702 alleles have been demonstrated as exempt from the 
immunomodulatory mechanisms of the US2-11 gene region products [139-141].  
As such, last to be investigated in this research chapter was the surface expression of HLA-
C alleles on infected cells in vitro.  The downregulation of HLA-C alleles from the surface of 
HCMV infected fibroblasts during a productive infection was determined by flow cytometry 
and compared to the total HLA-ABC alleles (Fig-43/44).  
HLA-Cw*0702+ MRC5 fibroblasts were infected with the AD169 or RV798 CMV strains for 6-
72 hours. Fibroblasts were then trypsinised at the indicated time-points and stained for 
surface HLA-ABC (W6/32 monoclonal) vs HLA-C (DT9 monoclonal antibody – kindly 
provided by Dr Veronique Braud) alleles. The gating strategy is provided in Fig-43A. 
The MFI of the HLA staining on the CMV infected fibroblasts was determined and expressed 
as a percentage of an uninfected fibroblast control MFI at each time point (percentage 












Fig 43 – Representative surface HLA-C expression on HCMV infected MRC5 fibroblasts determined by 
flow cytometry over the course of a productive infection.  The levels of HLA-C alleles on the surface of 
HCMV infected fibroblasts in vitro during a productive infection were analysed by flow cytometry. A) Gating 
strategy for identifying HCMV infected fibroblasts at 3 vs 72 hours p.i. As infection progresses the size of the 
HCMV infected cells increases. For each time point, an individual uninfected fibroblast control was set up.  The 
MFI of HLA staining on the fibroblasts was obtained and expressed as a percentage of the uninfected fibroblast 
control MFI (percentage relative expression) B) Representative histograms demonstrating surface HLA-C 
staining on AD169 infected MRC5 fibroblasts using the DT9 monoclonal antibody (Kindly provided by Dr 
Veronique Braud) at 3-24 hours p.i. The white histograms represent the HLA-C MFI obtained for uninfected 
fibroblasts. The red histograms represent the HLA-C MFI obtained for AD169 infected fibroblasts. The top row of 
representative histograms represent timepoints from one representative experiment and the bottom row of 
representative histograms indicates timepoints from a second representative experiment. 
 
During an infection of fibroblasts with the AD169 strain, where the WT US2-11 gene region 
is present, the HLA-ABC (W6/32) MFI progressively decreased over the course of the 
infection (3-72 hours) compared to uninfected fibroblasts (Fig-44B). Conversely, the HLA-C 
MFI progressively increased from 3-12 hours p.i. with a significant increase at 6 hours p.i 




obtained for HLA-C staining (DT9) also progressively decreased (Fig-43B/44B). It should be 
noted that the DT9 monoclonal antibody has cross-reactivity with HLA-E alleles. However, a 
previous study by Weekes et al demonstrated that HLA-E alleles were downregulated at IE 
time-points of CMV infection of fibroblasts [225]. Therefore it is anticipated that cross 
reactivity at these time-points is minimal.  
During a ΔUS2-11 RV798 infection of MRC5 fibroblasts, the MFI obtained when staining for 
HLA-ABC (W6/32) increased up to 6-fold over the course of the infection relative to 
uninfected fibroblasts (Fig-44B). Interestingly, the HLA-C staining followed a similar trend to 
that observed during an AD169 infection, with a significant increase in the MFI obtained 
when staining for HLA-C (DT9) compared to HLA-ABC staining (W6/32) at 6-hours p.i 
followed by a progressive downregulation to reach an MFI comparable to uninfected 
fibroblasts (Fig-44B). 
This indicates that the HLA-C alleles, at least those expressed on MRC5 fibroblasts, are not 
targeted by the US2-11 gene region products otherwise there would be a similar 6-fold 
increase in the DT9 MFI during an infection in their absence.  
A second fibroblast cell line – HFFF2 – that is HLA-Cw*0702 negative was then 
characterised for surface HLA allele downregulation (Fig-44C). During IE-E times of an 
AD169 infection of HFFF2 fibroblasts both HLA-ABC and HLA-C MFI staining increased 
slightly compared to uninfected fibroblasts. After this time-point the HLA-ABC MFI decreased 
as the infection progressed whereas the HLA-C MFI was maintained at similar levels (Fig-
44C). 
During an RV798 infection of HFFF2 fibroblasts, the MFI obtained during staining for both 
HLA-ABC (W6/32) and HLA-C (DT9) increased progressively during infection 3-fold 
compared to uninfected fibroblasts (Fig-44C). This indicates that the HLA-C alleles on 
HFFF2 cell surfaces are targeted by the US2-11 gene region products preventing an 













Fig 44 – Summary of the surface expression of HLA-ABC alleles on infected MRC5 and HFFF2 fibroblasts 
during AD169 vs RV798 infections. The surface expression of HLA-C vs HLA-ABC alleles on the surface of 
HCMV infected fibroblasts in the presence vs absence of the US2-11 immunevasins was analysed. At each time 
point, the MFI obtained on infected cells was expressed as a % of the MFI obtained on an uninfected control 
harvested at the same time as the infected cells. A) Summary of the HLA-ABC and HLA-C alleles on AD169 
infected MRC5 fibroblasts at 6 hours p.i. Statistical significance was obtained using a Mann Whitney test within 
Graphpad Prism6 using * as a p-value < 0.05. B) Summary of the HLA-ABC and HLA-C staining on AD169 (left 
graph) vs RV798 (right graph) infected MRC5 HLA-Cw*0702 positive fibroblasts at 3-72 hours p.i. C) Summary of 
the HLA-ABC and HLA-C staining on AD169 (left graph) vs RV798 (right graph) infected HFFF2 fibroblasts at 3-
72 hours p.i. B/C Error bars represent SEM. Lines represent a smoothed differentiation curve to demonstrate the 





4.14 – HLA-C CD8+T-cell clones recognise cognate antigen that is naturally processed 
during a productive infection in vitro  
After identifying that HLA-C alleles are upregulated at IE time-points of an in vitro infection of 
a HLA-Cw*0702+ cell line, the ability of HLA-C specific CD8+T-cell clones to recognise 
naturally processed antigen on infected cells in vitro at IE time-points was assessed. In 
addition, it was evaluated which cell types may be presenting the HLA-Cw*0702 peptides in 
vivo. It has been hypothesised that CMV infected non-haematopoietic cells with access to 
the circulation such e.g. endothelial cells are the APCs driving memory-inflated CD8+T-cell 
populations [104, 123, 132]. 
The ability of haematopoietic vs non-haematopoietic cells to present HLA-C peptide to 
specific CD8+T-cell clones was thus investigated. Either monocytes isolated from donor 
PBMCs with identified HLA-Cw*0702 CD8+T-cell populations or fibroblasts were used in the 
assay. Two WT CMV strains were utilised - the AD169 strain that infects fibroblasts only due 
to mutations quickly acquired during passage in vitro, and the Merlin strain which is able to 
infect monocytes due to an intact UL128-131 region (Review [241]). Recognition was 
identified by IFN-γ release into the supernatant of an O/N co-culture of CD8+T-cell clones 
and infected target cells. This recognition was compared to recognition of RV798 infected 
cells, which are theoretically displaying all antigenic peptides of the virus. NLV-specific 
CD8+T-cell clones were included as comparison to a known inflationary CD8+T-cell 
population.  
The FRC-, CRV- and LSE-specific CD8+T-cell clones recognised naturally processed 
peptide at all time-points IE-L (6-72hours p.i.) of an AD169 infection of HLA-Cw*0702+ 
MRC5 fibroblasts (Fig-45).  Recognition of RV798 infection of MRC5 fibroblasts was more 
pronounced i.e. higher magnitude of IFN-γ, and also occurred at all time-points of the 
infection (Fig-45). Interestingly, strong recognition of naturally processed HLA-C antigen on 
Merlin infected monocytes by FRC and CRV-specific clones occurred only at IE-E time-













During an AD169 infection of MRC5 HLA-A2+ fibroblasts, NLV-specific clones recognised 
naturally processed antigen strongly at IE-E time-points of infection (6-24hours) with small 
but reproducible IFN-γ release at E-L (48-72 hours p.i)(Fig-45). The same clones recognised 
NLV peptide at all time-points of an RV798 infection of the MRC5 HLA-A2+ fibroblasts (Fig-
45). Thus, both haematopoietic and non-haematopoietic cells can present HLA-C peptide to 
specific CD8+T-cell clones during an in vitro WT HCMV infection with two strains but non-
haematopoietic cells are able to present HLA-C antigen to the end of a productive infection.  
Fig 45 – Recognition of fibroblasts and monocytes by HLA-C-restricted HCMV-specific CD8+T-cell clones during a productive in 
vitro infection. The ability of HCMV-specific CD8+T-cell clones to recognise and engage naturally processed antigen during a HCMV 
infection in vitro was determined. MRC5 HLA-A2/Cw*0702+ AD169 infected fibroblasts (left column), RV798 infected fibroblasts (middle 
column) or Merlin infected monocytes (right column) were infected for 6-72 hours at an MOI of 5. At the indicated time-points infected cells 
were incubated with 10 000 specific CD8+T-cell clones O/N indicated on the left of the figure. This was followed by an IFN-γ ELISA. Bars 
represent the mean IFN-γ production in pg/ml per time-point by specific CD8+T-cell clones and error bars SEM. n = 3-5 per time-point for 





Project 3 summary 
This section of this investigative study aimed to assess some of the factors that may 
culminate in HLA-C memory-inflation; CD8+T-cell proliferation and oligoclonality, antigen 
recognition and the role of the restricting HLA allele.  
Upon antigen stimulation of ex vivo PBMCS, a hierarchy of proliferation capability was 
attained; FRC>CRV>LSE-specific CD8+T-cells. This correlates with the hierarchy in the 
observed ex vivo magnitudes of CD8+T-cells detected towards these three HLA-Cw*0702-
restricted peptides. Where a dominant TCR Vβ usage was observed within the ex vivo FRC-
specific CD8+T-cell populations, it was for Vβ3 usage.  
A potential mechanism driving HLA-C CD8+T-cell inflation was investigated. Preliminarily 
data demonstrated the upregulation of HLA-C on a fibroblast line that is positive for HLA-
Cw*0702 at IE time-points of a HCMV infection in vitro.  This is the restricting allele for the 
inflationary peptides investigated in this research and correlates with the peak expression of 
the proteins from which they are derived from [225] 
Importantly, specific CD8+T-cell clones could recognise naturally processed cognate antigen 
during this window of HLA-C upregulation, and at all time-points of an AD169 infection of 
fibroblasts, and release IFN-γ. Furthermore, FRC- and CRV-specific CD8+T-cell clones were 
demonstrated to recognise naturally processed peptide during a Merlin strain infection of 
monocytes.  These HLA-C peptides are hence efficiently generated during infection with two 
strains of CMV and HLA-C specific CD8+T-cell clones are able to exert anti-viral functions 
upon antigen engagement.  
Altogether, these CD8+T-cell populations represent promising targets, in particular the 
UL28-derived FRC-specific CD8+T-cell populations, to include within adoptive 
immunotherapy regimens to treat CMV disease in the HSCT setting.  
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CHAPTER 4 -DISCUSSION 
Identification of HLA-Cw*0702-restricted CMV CD8+T-cell memory-inflation 
Focus on the CD8+T-cell response to HCMV has been primarily devoted to the pp65 and IE-
1 proteins and further restricted to HLA-A/-B restricted peptides derived from these 
immunodominant proteins. A recent investigation has shown that a HLA-C restricted CD8+T-
cell population can be an important component of the overall CD8+T-cell repertoire 
dedicated to CMV control during latency [139] Thus emphasising that the focus of analysing 
the CMV CD8+T-cell response should be extended to HLA-C peptides.  
This investigation identified memory CD8+T-cell inflation restricted through HLA-Cw*0702 
specific for three antigens expressed at IE time-points of the CMV life cycle – the ‘FRC’, 
‘CRV’ and ‘LSE’ peptides (Table-8, [77, 85, 139, 267]. These CMV CD8+T-cell populations 
dominated the total peripheral CD8+T-cell pool within older donors to individually reach 32% 
and 31% within a single donor producing IFN-γ and TNF-α respectively. Extraordinarily, the 
summation of these three populations within individual donors could exceed 56% of the 
circulating CD8+T-cells. Also, outstandingly, the HLA-Cw*0702 CD8+T-cells accounted for 
on average >7% of the peripheral TEMRA within donors <70 years of age and expanding to 
account for >20% within donors >70 years. As such, these CD8+T-cell populations represent 
one of the largest CD8+T-cell responses documented towards a viral pathogen to date. A 
hierarchy of CD8+T-cell responses directed towards the HLA-Cw*0702 peptides was 
observed where; FRC>CRV>LSE. This was in terms of the magnitude of the ex vivo CD8+T-
cell responses. 
An increased TEMRA phenotype of inflated HLA-Cw*0702 T-cells with age – does this 
point to chronic antigen stimulation? 
The ex vivo CD8+T-cell responses to the three inflationary HLA-Cw*0702 peptides were 
phenotypically characterised in this work by flow cytometry and the results interpreted with 
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the age of our donor cohort. Additionally they were interpreted as the size of the specific 
HLA-Cw*0702 CD8+T-cell population accumulated. Throughout this investigation, the 
phenotypic results obtained support the antigen encounter theory of memory-inflation [115-
117]. This hypothesis proposes that the frequent exposure of CD8+T-cells to antigen drives 
their accumulation and their phenotype down the differentiation pathway towards a CD27-
CD28-CCR7-CD45RA+ phenotype. Some of the data obtained in this investigation supporting 
this theory will now be discussed. 
LSE-specific CD8+T-cell populations demonstrated the smallest ex vivo magnitudes and 
proliferation.  The total-epitope specific CD8+T-cells were split between TEM/TEMRA (CCR7-
CD45RA-) and intermediate/late (CD27-CD28+/CD27+CD28-/CD27-CD28-) antigen 
differentiated populations. This is suggestive that these populations are the least antigen 
stimulated of the HLA-Cw*0702 populations. 
The inflationary FRC-specific CD8+T-cell populations demonstrated the largest ex vivo 
magnitudes, proliferation and exaggerated TEMRA phenotype (CCR7-CD27-CD28-CD45RA+) 
with age and population size. This implicates that they have been the most chronically 
stimulated of the HLA-Cw*0702 populations.  Additionally, the loss of both CD27/CD28 has 
been reported as indicative of a history of high proliferative capacity [238]. Importantly, a 
FRC-specific CD8+T-cell clone demonstrated the highest in vitro proliferation in comparison 
to HLA-A-restricted CD8+T-cell clones, however this is very preliminary work and was 
conducted once. Additionally, as the age of the donor and size of the epitope-specific HLA-
Cw*0702 CD8+T-cell populations increased, the HLA-Cw*0702 populations displayed an 
increased cytotoxic IFN-γ+TNF-α polyfunctional profile.  CD8+T-cells capable of producing 
IL-2 were lost. This was similar to the NLV-specific CD8+T-cell profile. NLV-specific CD8+T-
cells have previously been documented as antigen driven [71].  
Taken together, this implies that the accumulated HLA-Cw*0702-restricted CD8+T-cell 
populations are further down the T-cell differentiation pathway in older age representing 
accumulations of later differentiated specific CD8+T-cells.  
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Further supporting the chronic stimulation hypothesis is the ex vivo phenotype of the stable 
CD8+T-cell populations in our donor cohort by the HLA-A1-restricted RTD and YAD peptides 
These displayed a greater percentage of earlier differentiated TCM and TEM CD8+T-cells 
capable of producing IL-2 compared to the HLA-Cw*0702 CD8+T-cells.  
In further corroboration of antigen stimulation over the hosts lifetime, the HLA-Cw*-0702 
CD8+T-cell populations increased NKG2D expression with age. NKG2D when expressed on 
CD8+T-cells is a marker of recent CD8+T-cell activation and has been documented to act as 
a co-stimulatory molecule in replacement of CD28 [277]. The same CD8+T-cells also 
maintained CX3CR1 expression with age. This CX3CR1 expression parallels previous data 
documenting this fractalkine receptor on CMV-specific CD8+T-cells which has been linked to 
their homing to endothelium where they cause endothelial damage [2, 72, 91]. It is plausible 
that CX3CR1 expression homes these CD8+T-cells to the endothelium to be continuously 
stimulated by antigen from latently infected CD8+T-cells over the host’s lifetime. This drives 
the differentiation of the HLA-Cw*0702 CD8+T-cells to a late TEMRA phenotype whereby 
CD28 is downregulated. The progressive upregulation of NKG2D with age may therefore 
complement the loss of CD28 to provide activatory signals. However, the largest FRC-
specific CD8+T-cell population that was phenotypically characterised displayed the most 
exaggerated TEMRA phenotype and downregulated CX3CR1 and NKG2D expression.  It is 
therefore also plausible that larger accumulations of FRC-specific CD8+T-cells are at the 
end-stage of antigen driven differentiation and have also down-regulated the NKG2D co-
stimulatory mechanism in preparation for cell turnover.  
Lastly, the maintenance of Vβ3 usage, and loss of other Vβ usage, by the FRC-specific 
CD8+T-cells within older donors could possibly point to the repetitive antigen stimulation of a 
single clone over the lifetime of the infected host.  However, this Vβ usage analysis has 
been conducted within a small donor cohort (n = 3 young <70 years and n = 3 older >70 
years) and as such represents a preliminary analysis. To increase the accuracy of this TCR 
Vβ analysis, more donors should be investigated. It would also be interesting to determine 
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whether the FRC-specific Vβ3 populations within these donors represent CD8+T-cells of a 
high avidity. Thus providing a plausible selective advantage to the host for maintaining the 
Vβ3 populations within the periphery. Longitudinal TCR analysis of the FRC-specific CD8+T-
cell populations would address whether the Vβ3 using clones are truly maintained into older 
age. 
The ex vivo magnitudes and phenotypic results of these HLA-Cw*0702 CD8+T-cell 
responses were obtained after stimulating the PBMCs with peptide. It would be important, if 
such a reagent became available, to compare this ‘activated’ phenotype with the phenotype 
obtained with MHC-I tetramers. This would provide an indication of how many CD8+T-cells 
are non-functional but specific to these peptide epitopes. Additionally it will be important to 
investigate whether there are HLA-Cw*0702 epitope-specific T-cells producing regulatory 
cytokines such as IL-10.  
Factors involved in the generation of HLA-C CMV memory-inflation 
HLA-C memory-inflation observed within this study was confined to HLA-Cw*0702-restricted 
peptides. However, as evidenced by non-inflating CD8+T-cell population’s specific for a 
fourth HLA-Cw*0702-restricted peptide ‘SYR’, that HLA-Cw*0702-restriction alone does not 
result in inflation. This peptide is derived from the UL33 protein expressed with L kinetics. 
This is in comparison to the IE-expressed antigens from which the three inflationary HLA-
Cw*0702 peptides, characterised in this work, are derived from. Although, non-inflating 
CD8+T-cell responses were observed against another IE-expressed peptide restricted 
through HLA-Cw6 termed ‘QIK’. Therefore it is not also simply a matter of IE kinetics for a 
peptide to elicit inflationary CD8+T-cell populations. This suggests it may be a combination 
of factors that culminate in IE-specific HLA-Cw*0702 memory-inflation with age. Some 
factors likely involved in the HLA-C inflation in this work will now be discussed. 
 Abundance of mature MHC-I:peptide complexes on the cell surface 
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Several studies have concluded that the abundance of cognate peptide-epitope on the cell 
surface presented to CD8+T-cells determines the immunodominance of the resulting anti-
viral CD8+T-cell response [278, 279]. A critical factor that determines cell surface density of 
MHC-I:peptide complexes is the binding affinity of peptides to MHC-I molecules on the ER 
[120, 280]. The lower surface expression of HLA-C alleles on host cell surfaces has been 
linked to a higher threshold of peptide binding to the HLA-C molecules within the ER causing 
less peptide:HLA-C complexes to reach the surface [255]. Efficient post-translational 
processing ensures that a mature peptide-epitope is generated able to bind to the MHC-I 
molecule in the ER lumen with sufficient affinity [120]. Although this manuscript has not 
directly assessed the differing processing of the peptides investigated in this manuscript, a 
previous study proved that the generation of the mature HLA-Cw*0702-restricted FRC vs. 
HLA-A1-restricted YAD peptide-epitopes from precursors is critically dependent upon 
separate processing pathways – being ERAp1 dependent and independent respectively 
[85]. ERAp1 is an important enzyme involved in the generation of mature MHC-I epitopes via 
the trimming of longer precursors within the endoplasmic reticulum [281, 282]. Importantly, 
ERAp1 is implicated in the development of in vivo CD8+T-cell immunodominance within 
mice [283].  However, Kim et al. also demonstrated that the HLA-Cw*1601 YLC and HLA-B7 
WPK peptides (Table-7) - also investigated in this study and found to elicit non-inflationary 
and infrequent CD8+T-cell responses  - were also ERAp1 dependent. Therefore, post-
translational modification of the inflationary FRC peptide may contribute, but is not solely 
responsible for the resulting immunodominance of the FRC-specific over that of YAD-
specific CD8+T-cell populations.  
It is interesting to note, that the three HLA-Cw*0702 peptides displayed a hierarchy when 
MHC-I anchor residues and auxiliary residues were considered; FRC 5’ FRCPRRFCF 3’, 
CRV 5’ CRVLCCYVL 3’ and LSE 5’ LSEFCRVLV 3’ (anchor residues provided in bold and 
underlined, auxiliary residues underlined as identified by Rasmussen et al. [284]). We could 
therefore speculate that a higher number of both anchor residues and auxiliary residues 
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within the FRC peptide sequence, translates to a higher binding affinity to MHC-I, over CRV 
and LSE. This may result in a more stable MHC:peptide complex and increased cell surface 
expression of the FRC peptide to the CD8+T-cell response. This could explain the later 
differentiation phenotype and larger ex vivo CD8+T-cell responses against the FRC-peptide 
over CRV and LSE. In support of this, infection of mice with a recombinant-MCMV 
expressing the SIINFEKEL peptide abolished MCMV-specific memory-inflation in favour of 
SIINFEKLL-specific inflation. The authors hypothesised the higher affinity of the SINKFEKL 
peptide for its H-2Kb alleles over endogenous MCMV peptides led to increased surface 
presentation [124].  
 CD8+T-cell avidity 
An important result in this study was the identification of the high functional avidity of HLA-C-
specific CD8+T-cell clones generated in vitro in this investigation. CD8+T-cells that are 
specific for HLA-C targets are likely to be more avid to engage the low concentration of 
peptide:HLA-C complexes that presented on infected cell surfaces [254, 255]. In support of 
this, highly avid HCMV-specific CD8+T-cell populations have been demonstrated to be 
selected for and preferentially maintained by the host [126]. Day et al. analysed the focusing 
of the HCMV-specific CD8+T-cell response during a primary infection of renal transplant 
patients. They observed the maintenance of highly avid CD8+T-cell clones for pp65 and IE-1 
compared to lower avidity clones. This affinity based survival and selection of HCMV 
CD8+T-cell clones has been demonstrated by a second research group who showed the 
selection of public TCRs specific for the pp65 NLV peptide between individuals that were 
highly avid [128]. The results of this study demonstrated the preferential maintenance of ex 
vivo CD8+T-cells using Vβ3 chains with age within the HLA-Cw*0702 FRC-specific CD8+T-
cell population. It should be analysed whether this is the preferential systemic maintenance 
of a highly avid CD8+T-cell clone.  
 Antigen presenting cell type 
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The consensus within the literature is that non-haematopoietic cells within either peripherally 
located tissues e.g. lungs or secondary lymphoid organs e.g. the lymph nodes, present 
HCMV antigen to CMV-specific CD8+T-cells that are of a TCM phenotype. Antigen 
stimulation of the TCM population results in rapid proliferation and differentiation to a CD8+T-
cell population with a TEMRA phenotype that enters the periphery where they protect against 
CMV reactivation events and can accumulate [104, 123, 132].  
The presentation of the HLA-Cw*0702 inflationary peptides to specific CD8+T-cell clones 
was investigated in both haematopoietic (monocytes) vs non-haematopoietic (fibroblasts) in 
vitro. The IE-1 and UL28 proteins, from which the three HLA-Cw*0702-restricted peptides 
are derived, are present within the incoming virion during primary infection and among the 
first to be expressed during infection. The IE-1 protein functions to initiate the viral lifecycle 
and the UL28 protein functions to export the resulting viral mRNAs from the nucleus to the 
cytoplasm for translation using the host machinery [248, 285]. These proteins may therefore 
theoretically be immediately available for degradation and enter the MHC-I pathway for 
direct presentation during a primary infection of cells. During AD169 infection, HLA-C-
specific CD8+T-cells were activated by peptide at IE time-points in both cell types. However, 
it was the non-haematopoietic cells that presented the HLA-Cw*0702 antigens to the end of 
a productive infection (6-72 hours). Peptide recognition was only observed up to 12 and 24 
hours p.i. for FRC- and CRV-specific CD8+T-cell clones respectively on infected monocytes.  
These recognition profiles parallel the general consensus of non-haematopoietic cells driving 
memory-inflation by presenting HLA-C peptide at all time-points of an infection. [104, 123, 
132]. Direct presentation by haematopoietic and non-haematopoietic cells could both be 
capable of the initial generation of HLA-Cw*-0702-specific CD8+T-cell responses 
 Expression kinetics of the HCMV antigen 
Several research groups have now identified that the expression kinetics of a CMV peptide 
is a key factor in its inflationary capacities. Dekhtiarenko  et al. identified that only peptide-
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epitopes fused to promoters expressed with IE-kinetics induced inflationary CD8+T-cell 
populations within MCMV infected mice [286]. Importantly, work by our research group 
characterised the accumulation of IE-1-specific CD8+T-cells within a healthy CMV infected 
donor cohort but not pp65-specifc. The authors hypothesised that the IE expression kinetics 
of the IE-1 protein gave the CD8+T-cells an advantage over the pp65-specific with regards 
to CD8+T-cell priming during a reactivation event. The inflationary peptides characterised in 
this work are derived from proteins expressed with IE- kinetics – the IE-1 and UL28 proteins. 
The IE kinetics of the HLA-Cw*-0702 peptides may as such play a role in whether the 
resulting CD8+T-cells will inflate or not.  
 HLA restriction 
Importantly, this work identified that in the presence of the US2-11 proteins, HLA-C alleles 
were significantly upregulated on the cell surface of infected fibroblasts that are HLA-
Cw*0702+HLA-Cw0501+ at IE times of infection compared to the total HLA-ABC alleles. 
These were then progressively down-regulated over the course of the infection. During an 
RV798 infection of the same fibroblasts, the HLA-C alleles followed an almost identical 
pattern of significant upregulation at 6 hours p.i. followed by returning to levels similar to 
uninfected fibroblasts. Conversely, during RV798 infection the total HLA-ABC alleles 
increased 6-fold over the levels present on uninfected MFIs. If the US2-11 proteins were 
targeting these specific HLA-C alleles during infection it is likely that they would similarly 
increase 6-fold in the absence of the US2-11 proteins.  
Within a second cell line that is HLA-Cw*0702 negative, HLA-C alleles appeared to be 
maintained at levels parallel to uninfected fibroblasts during an AD169 (WT US2-11) 
infection. During an RV798 infection, the HLA-C alleles increased 3-fold over the course of 
the infection. This implicates the US2-11 proteins as efficiently preventing these particular 
HLA-C alleles from 3-fold increased cell surface expression during HCMV infection.  
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Together this data alludes to the precise HLA allele targeting specificity of the US2-11 
immunomodulatory proteins in differing cell lines. It indicates the US2-11 proteins as not 
targeting particular HLA-C alleles for downregulation within a HLA-Cw*0702+ cell line. 
Additionally that WT HCMV infection may in fact induce HLA-C allele upregulation in the IE 
phase of HLA-Cw*0702+ cell lines. However, the US2-11 proteins can prevent other HLA-C 
alleles increasing 3-fold during infection of a HLA-Cw*0702 negative cell line. Future 
research is focused on tracking HLA-Cw*0702 alleles during the course of a HCMV infection 
via transfection of a HLA-Cw*0702 construct into a HLA-C negative cell line.  
The differential targeting of HLA alleles by the HCMV US2-11 gene products has been 
demonstrated elegantly by the research group of Ameres et al [139, 140]. Specifically, HLA-
Cw*0702 alleles that are inhibitory ligands for the NK cell receptor KIR2DL3 were shown as 
less susceptible to downregulation by US3 [140] and US2/11 [139]. This translated to HLA-
Cw*-0702 CRV-specific clones being efficiently able to kill infected cells whilst this HLA-
Cw*0702 allele maintenance mediated the inhibition of NK-cell killing infected cells. An 
important finding with relevance to this study was that the US3 protein also did not target 
HLA-A3 alleles – a second NK cell inhibitory ligand [287].  
 
The US3 protein is expressed during the viral lifecycle with IE kinetics [288, 289]. If the US3 
protein is unable to target HLA-Cw*0702 alleles in an attempt to subvert NK-cell activation, 
this would provide a window whereby IE-expressed HLA-Cw*0702 peptides can be 
presented to CD8+T-cells. Indeed this was shown by Ameres et al during a fibroblast 
infection with a mutant strain deleted for all US immunevasins except US3 [140]. This 
translated functionally to an exacerbated recognition of infected cells by HLA-Cw*0702 
clones at IE time-points. Secondly upon infection with strains expressing only US2 or US11, 
increased HLA-Cw*0702 CD8+T-cell recognition was observed at 24 hours p.i. This strongly 
suggests a time frame during the early stages of an infection where HLA-C CD8+T-cells 




When it is taken into account the US3 protein did also not affect a HLA-A3 allele that is an 
inhibitory receptor for NK cells, we hypothesise that the upregulation of NK-cell inhibitory 
receptors such as HLA-A3 and HLA-Cw*0702 on HCMV infected cells may allow for NK-cell 
evasion. However, this is at the expense of a HLA-Cw*0702-restricted CD8+T-cell 
population that is efficiently able to kill virally infected cells [139].  
HLA-Cw*0702-restricted CD8+T-cells as an immunotherapy for HCMV disease 
IE-specific CD8+T-cells have been linked to an enhanced protection from MCMV disease in 
vivo [187]. Once CMV latency has been established, the majority of viral genomes are 
transcriptionally silent. However, murine studies into CMV reactivation have identified the 
random but frequent transcriptional activation of IE promoters during latency, particularly 
within the lungs [98, 119, 290, 291]. These reactivation events have led to the expression of 
IE gene products on the infected cell surface. IE-specific CD8+T-cells are importantly able to 
recognise these latency expressed transcripts leading to the termination of the viral 
reactivation event i.e. abortive not resulting in virion production [119]. As such, transcripts 
expressed after IE-E stage, i.e. L derived pp65 epitopes, are not generated and presented 
on the cell surface. It is likely that IE-specific CD8+T-cells would have an evolutionary 
advantage over those specific for L-expressed antigens with regards to engaging cognate 
antigen and undergoing antigen driven proliferation. Focus on developing novel 
immunotherapies to treat HCMV disease in the HSCT setting should be on including T-cell 
specificities towards IE-expressed antigens. 
The results presented in this work indicate that the three HLA-Cw*0702 CD8+T-cell 
populations are excellent candidates for development as an adoptive immunotherapy to treat 
overt HCMV disease. The HLA-Cw*0702 FRC-specific CD8+T-cells could efficiently 
recognise and kill peptide naturally generated during an AD169 infection of fibroblasts and 
become activated after incubation with Merlin infected fibroblasts. This is indicative that the 
HLA-Cw*0702 inflationary peptides are generated efficiently during an infection with differing 
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strains of HCMV in vivo. This coupled with their cytotoxic potential, cytokine polyfunctionality, 
peptide recognition profile and avidity – FRC-specific CD8+T-cells represent extremely 
promising populations for inclusion within adoptive immunotherapy regimes. The main 
priorities are now, firstly, to develop these as such a therapy via the retroviral transduction of 
an FRC-specific TCR onto PBMCs in vitro. Secondly, testing whether the transduced 
populations are equally as efficacious as FRC-specific CD8+T-cell clones in removing virally 
infected cells. 
Proposed model for HCMV HLA-C CD8+T-cell memory-inflation 
To summarise, it is likely that a combination of the following factors (however not 
exclusively) leads to the preferential inflation of the HLA-Cw*0702-restricted CD8+T-cell 
populations; 
1. IE kinetics of the peptide – expressed and presented in HLA-C during a reactivation 
event before termination of viral reactivation by CD8+T-cells 
2. HLA-Cw*0702-restriction of the peptide – HLA-Cw*0702 upregulation on the cell 
surface during IE time-points allows interaction with NK-cell inhibitory receptors so 
that CMV latency can be established 
3. The allele targeting specificity of the HCMV immunevasins during the IE time-points 
of a HCMV primary infection and reactivation event in differing cell types 
4. High avidity of HLA-C CD8+T-cells -  preferentially maintained by the host due to 
effective anti-viral function 
5. High affinity of peptide for HLA-C binding in the ER -  a result of the increased 
number of auxiliary and anchor residues within the mature ‘FRC’ peptide 
This discussion will conclude with a proposed model for the preferential inflation of HLA-C 
restricted CD8+T-cell populations (Fig-46). During primary infection, HLA-AB and -C alleles 
on infected cells are able to prime the initial CD8+T-cell response generating a diverse 
repertoire comprising of CD8+T-cell clones with differing avidities. The HLA-Cw*0702 
alleles, unaffected by the US2-11 gene region products, maintain-NK cell protection during 
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acute infection allowing the development of HCMV latency. During chronic infection, 
sporadic reactivations induce the upregulation of HLA-Cw*0702 alleles, preventing NK-cell 
removal of reactivating virus. At the same time the HLA-Cw*0702 alleles present the IE-
expressed FRC, CRV and LSE-targets to the CD8 T-cells driving their accumulation, 
proliferation and oligoclonality. This results in CD8+T-cell elimination of the infected cell 
halting the generation of E-L transcripts for MHC-I presentation. Over the lifetime of the host 
these reactivation events drive the differentiation of the HLA-C CD8 T-cells to downregulate 
CCR7, CD27, CD28, re-express CD45RA and upregulate cytotoxic potential and pro-







Fig 46 –Proposed model for HLA-Cw*0702-restricted ‘FRC’ HCMV-mediated memory-inflation A) During primary 
HCMV infection HLA-A/-B and –C alleles prime the CD8+T-cell response with HCMV antigens derived from potentially all 
proteins of the virus. B) During chronic infection in young age, the virus selectively down regulates HLA-A and -B alleles 
leaving HLA-C on the surface as an NK-cell evasive mechanism. HLA-Cw*0702 alleles then re-stimulate the initial FRC-
specific CD8+T-cell pool during viral reactivation. CD8+T-cells specific for L derived antigens presented through HLA-C are 
not primed due to the CD8+T-cell control of the infection after IE time-points. This leads to the accumulation of peripheral 
FRC-specific CD8+T-cells. C) In older donors, the frequency of HCMV reaction and therefore the frequency of HLA-
Cw*0702 presentation of the FRC peptide determines the magnitude of FRC-specific CD8+T-cell memory-inflation within the 
periphery. Furthermore, the chronic antigen stimulation of the FRC-specific CD8+T-cells to upregulate expression of 
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CHAPTER 5 - INTRODUCTION 
Development of CMV-mediated disease is strongly associated with the loss of CD8+T-cell 
control of the virus within immunocompromised transplant patients [292]. As a result, current 
immunotherapies for treatment of CMV disease are focused on recapitulating the CD8+T-
cell immunity against CMV within these patients (Review [293]).  
Recently, the concept that HLA-C alleles, in particular HLA-Cw*0702 and their presented 
peptides, are less affected by the HCMV MHC-I immune evasion gene region products has 
been proposed [139, 140]. We demonstrated that HLA-C-restricted CMV-specific CD8+T-
cells are highly avid for cognate peptide, effective at killing CMV-infected targets and 
demonstrate high cytotoxicity and pro-inflammatory potential. This provides great promise for 
their adaption as an immunotherapy to treat HSCT patients with CMV reactivation. 
Pp65 and IE-1-specific CD8+T-cells have previously been the focus of adoptive cell therapy 
for CMV disease and shown to have high efficacy within the murine model [187, 188] and 
human patients [64, 189-191]. However, this approach loses efficacy when a previously 
HCMV negative HSCT patient acquires HCMV after transplant or has low frequencies of 
circulating HCMV-specific CD8+T-cells. In this context it is difficult to isolate and expand the 
donor’s memory CD8+T-cells. To overcome this a new approach, whereby the TCR of CMV-
specific CD8+T-cell clones are transduced onto donor CD8+T-cells, has been adopted to 
recapitulate or generate an effective HCMV-specific CD8+T-cell effector pool [8, 195].  
This investigative chapter concentrated on developing a UL28-derived FRC-specific CD8+T-
cell population as a potential therapy. The premise of this was based upon IE expression 
kinetics, an enhanced ex vivo magnitude, killing efficacy and proliferation capacities over IE-
1-derived HLA-Cw*0702 specific clones. 
The DNA genome of HCMV encodes for approximately 200 ORFs and several distinct 
families of genes [294, 295]. The US22 CMV gene family consists of 13 members; UL23, 
UL24, UL26, UL28, UL29, UL36, UL43, IRS1, TRS1, US22, US23, US24, and US26. This 
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gene family is conserved among all the β-herpesviruses. The UL28 gene of the US22 family 
encodes for a protein product that is expressed with IE kinetics [225, 248, 285] as a 
bicistronic transcript with the UL29 protein which eventually becomes spliced. Interestingly, 
this protein has also been identified as a potential transcript that is expressed during latency 
[296].   
The role of the UL28/29 bicistronic message is to stimulate the activity of the ‘major 
immediate early protein’ (MIEP) in cooperation with the UL38 protein [248]. To do this, the 
UL28/29 interacts with the ‘Nucleosome remodelling and deacetylase complex’ (NuRD) to 
allow viral replication to proceed during IE time-points of a primary HCMV infection. This 
results in the accumulation of CMV IE RNAs required for viral replication to proceed [248, 
285].  
It is therefore hopeful that any potential immunotherapies developed from a UL28-specific 
population may provide lifelong protection of the patient from reactivation events by 
encouraging removal of infected cells during the IE phase of an infection. Furthermore it is 
hypothesised that the transfer of a CD8+T-cell population transduced with the TCR obtained 
from a highly avid FRC-specific HLA-Cw*0702 CD8+T-cell clone will be selectively 
maintained by the patient’s immune system. Thereby this may also enhance the duration of 
protection. This makes the UL28-derived FRC peptide an extremely promising HCMV target 









CHAPTER 5 – RESULTS 
 
5.1 - Sequencing the TCR of HLA-Cw*0702 specific CD8+T-cell clones 
We aimed to test the efficacy of an immunotherapy for HCMV mediated disease in the HSCT 
transplant setting via the retroviral transduction of endogenous donor T-cells with a FRC-
specific TCR sequenced from a specific CD8+T-cell clone. The first step towards this goal 
was to test the efficacy of the transduced TCR on PBMCs in in vitro functional assays.  
To start, an FRC-specific clone with high avidity (EC50 250pg) and high cytotoxic potential 
was selected from our CD8+T-cell clone repertoire (Fig-48) termed FRC 1.9. Intracellular 
perforin and GranzymeB expression of this clone was 98.26% and 82.08% respectively as 
determined by flow cytometry (Fig-48). In addition we also selected one CRV- and one LSE-
specific CD8+T-cell clone to analyse any similarities in chain usage between the HLA-
Cw*0702 specific populations and to develop these as immunotherapies in future 
investigations (Table-9 both derived from donor YD13 of 52 years). 
 
 
Table 9 – VDJ gene usage of the α and β chains of HLA-Cw*0702 specific CD8+T-cell clones determined 
using the Clontech Smarter Race 5’/3’ kit. The CDR3 gene region aa sequences are not provided due to 
ongoing work with these clones and the development of FRC 1.9 as an immunotherapy. The FRC clone was 
generated using PBMCs from donor YD6 of 49 years of age. The CRV and LSE clones were generated from 
donor YD13 of 52 years of age. 
Clone 
Specificity 
α chain β chain 
V gene J gene V gene J gene D gene 
1.9 FRC TRAV30*01  TRAJ43*01 TRBV20-1*01 TRBJ2-2*01 TRBD2*01 




















Fig 47 – PCR α and β chains reactions separated by gel electrophoresis. The amplified cDNA product α and 
β reactions were run on a 1% agarose gel for 60 minutes at 120V. The FRC clone 1.9 α and β, CRV clone 3.26 α 
and β and LSE clone 3.44 α and β are provided from left to right. The two bands represent the same chain and 
sequence with the lower molecular weight representing a truncated version confirmed by sequencing, data not 





















Fig 48 – Avidity and cytotoxicity of FRC clone 1.9 from donor YD6. The characteristics of the FRC clone 1.9 
selected for TCR sequencing and development of an immunotherapy for CMV disease. A) The EC50 of the FRC 
1.9 clone as determined after O/N co-culture with peptide-loaded LCLs (50 μg to 500 pg) followed by an IFN-γ 
ELISA. The EC50 was determined as the concentration of peptide that indicated 50% maximal IFN-γ production. 
B) Intracellular perforin (left) and granzymeB (right) expression of the FRC 1.9 clone determined by flow 






Next the α and β chains of the TCR of the FRC 1.9 clone was elucidated using the Clontech 
Smarter Race 5’/3’ kit. RNA was generated from a cell pellet of the CD8+T-cell clones, 
converted to cDNA, amplified by PCR and run by gel electrophoresis to visualise the 
separate α and β strands (Fig-47)(Materials and methods 2.2.17). This was to ensure that 
the PCR reaction correctly amplified the α and β strand cDNA products of 500-600 bp 
respectively. The DNA of the bands were extracted, cloned into pRACE plasmids and 
transformed into competent bacteria (Stellar competent cells, Clontech). Ampicillin resistant 
i.e. positively transformed colonies, were picked and subjected to mini preparations before a 
further plasmid DNA extraction and sequencing (Materials and methods 2.2.17)(University of 
Birmingham, DNA sequencing services).  
When the PCR reactions were run by electrophoresis and visualised, two distinct bands 
were observed. DNA from both bands was excised and sequenced. The lower molecular 
weight band was found to be a truncated version of the α or β chain but otherwise the same 
sequence (data not shown). 
The FRC clone 1.9 was determined to be utilising the Vα30 chain and the Vβ2 chain (Table-
9). The sequencing of the β-chain was subsequently confirmed via flow cytometry staining of 








Fig 49 – Confirmation of FRC 1.9 clone TCR Vβ2 sequencing by flow cytometry. A vial of liquid nitrogen 
cryopreserved FRC clone 1.9 was thawed and subjected to surface staining for CD3, CD8 and Vβ2. This was 
to validate the sequencing of the TCR using the SMARTer RACE kit (Table-2).  Beckman Coulter, IOTest® 





5.2 – Retroviral transduction of PBMCs with the FRC 1.9 CD8+T-cell clone TCR 
sequence 
Once the sequence was ascertained, a gBlock DNA fragment was designed and purchased, 
and consisted of the codon optimised FRC clone 1.9 complete TCR sequence. This was 
then inserted into the pMP71 vector and transformed into competent TOP10 bacteria. 
Resistant colonies containing the FRC-pMP71 construct were subjected to endotoxin-free 
plasmid maxi preparations and the resulting plasmid used to transfect phoenix cells. The 
resulting retroviral supernatant was adhered to a retronectin coated plate, then α-CD137 and 
α-CD3 activated PBMC were added to the plate.  
The transduced CD8+T-cells were incubated on the rectronectin plate for a minimum of 48 
hours before being analysed by flow cytometry for expression of the transduced TCR on the 
cell surface (Fig-49). 
As there is no HLA-Cw*0702 FRC MHC class I tetramer available to determine whether the 
transduction had worked, after 72 hours the transduced T-cells  were subjected to staining 
with tube E of the IOTest® Beta Mark TCR Vβ Repertoire Kit which detected Vβ2 positive 
cells by dual PE/FITC staining.  
After three attempts the highest transduction efficiency achieved was 4.75% (Fig-50). 
Unfortunately, the first transduction was lost due to contamination and in the subsequent 
transductions it was hard to determine if the transduction had indeed worked as the two 
separate buffy coats selected for transduction had a high percentage of Vβ2 positive 
CD8+T-cells making it hard to distinguish between the mock and transduced populations 
(Fig-50).  
However, an interesting observation was the common usage of the Vα29 chain between the 
IE-1-derived CRV- and LSE-specific CD8+T-cell clones as these were generated from 






























Fig 50 – Retroviral transduction of PBMCs obtained from buffy coats with FRC-pMP71. Representative dot 
plots of the transduction efficiency of PBMCs with mock (DMEM media only, left column) or supernatant 
containing retrovirus expressing the FRC-pMP71 TCR construct (right column) indicated by Vβ2 staining (Tube 
E, IOTest® Beta Mark TCR Vβ Repertoire Kit). Vβ2 staining was determined as dual FITC and PE staining. The 
round of transduction is indicated to the left of the plots.  
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Therefore, DNA was extracted from PBMCs of the third transduction and analysed for the 
presence of the FRC-pMP71 construct expression by PCR. Primers were designed that bind 
specifically to the FRC gBlock transgene outlined in materials and methods Fig-6. As a 
positive control, the FRC gBlock fragment was spiked into the DNA isolated from the 
transduced T-cells. A band of the correct size was present in the positive DNA-spiked control 
but was clearly absent in the transduced cells (Fig-51). This suggests that the T cells were 
not successfully transduced with the transgene, or the transduction efficiency was very low. 
Due to time constraints the transduction could not be repeated and the assessment of 
whether the FRC TCR transduced T-cells would be as efficacious as the ex vivo CD8+T-cell 










Fig 51 – Analysis of the FRC-pMP71 transduced CD8+T-cells for the positive expression of the FRC 1.9 
TCR. DNA was extracted from a DNA pellet of PBMCs from a buffy coat that were transduced with the retroviral 
supernatant expressing the FRC-pMP71 TCR construct. The DNA was then analysed for the presence of the 
FRC 1.9 TCR sequence via a PCR reaction with the Q5 polymerase (New England Biolabs) and the 
thermocycling conditions provided with the enzyme (left sample lane). The FRC gBlock fragment was spiked into 
the DNA obtained from the transduced T-cells as a positive control and ran under the same conditions (right 





CHAPTER 5 – SUMMARY 
 
The sequences of three HLA-Cw*0702-restricted CD8+T-cell clones were determined. A 
highly avid and cytotoxic FRC clone (1.9) was selected for further development as an 
immunotherapy that was generated in vitro from YD6 of 49 years. 
The FRC clone 1.9 with an EC50 of 250pg and perforin and granzymeB expression of 
98.26% and 82.08% respectively was sequenced, and revealed to be utilising Vα30 and Vβ2 
chains.  
The CRV and LSE IE-1-specific CD8+T-cell TCR shared a common Vα29 chain usage.  
Unfortunately the retroviral transduction of PBMCs obtained from a buffy coat preparation 
was suboptimal and therefore research on the testing of the functionality of FRC-pMP71 


















CHAPTER 5 - DISCUSSION 
Current anti-viral treatment of HCMV disease in the post-transplant setting that while 
effective is associated with high toxicity, expense and have been described as delaying the 
onset of CMV disease [297-299]. Thus improved treatment regimens are needed, in 
particular to treat HCMV disease in the post allogenic HSCT setting. The CD8+T-cell 
response dedicated to controlling CMV is known to be the critical component in protection 
from CMV-mediated disease [64]. As such, focus is dedicated on reconstituting the CMV-
specific CD8+T-cell memory pool within immunocompromised transplant patients. The 
murine model of CMV adoptive therapy has proven invaluable for demonstrating both the 
efficacy and safety of this approach so that human clinical trials could be undertaken [8, 
186, 188]. Phase I/II human clinical trials have since demonstrated the safety and efficacy of 
adoptively transferred donor CMV-specific CD8+T-cells to regenerate cellular immunity 
within human patients [64, 189, 190, 192, 194]. However, this approach can only be effective 
in the setting where the patient undergoing CMV reactivation was previously CMV positive 
and will therefore have a pre-established CD8+T-cell immunity that can be isolated. Recent 
focus has been on the transfer of the sequence of TCR from a previously characterised CMV 
CD8+T-cell population onto patient’s endogenous CD8+T-cells. This allows for the transfer 
of CMV immunity into previously CMV negative patients.  
Advantages of a UL28-derived FRC-specific adoptive immunotherapy  
The protein of the CMV genome to target during viral reactivation or a primary CMV infection 
after a stem cell transplant is likely imperative for the efficacy of the treatment. The pp65 and 
IE-1 proteins have been the focus of antigens to direct the CD8+T-cell response towards. 
This is based upon the immunodominant CD8+T-cell responses identified to these antigens 
as a result of them being the most abundant tegument protein and first viral protein to be 
expressed during a viral life cycle respectively. However studies are contradictory on 
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whether pp65 or IE-1-specific cells are more efficacious when included within a treatment 
regimen. The immune evasion strategies encoded by HCMV theoretically make IE-
expressed targets a more promising choice of CD8+T-cell target. The US2-11 gene region 
products are expressed in a temporal fashion from IE-L time-points of an infection [80, 81]. 
This makes it less likely that L-expressed HCMV antigens will be presented on the cell 
surface during CMV reactivation in disease once the full effects of the immunevasins are in 
place. Therefore the IE-1 antigen a represents a better target for therapy over the pp65 
antigen, as by the time pp65 is expressed, there are reduced levels of HLA-A/-B alleles or 
the viral reactivation event has been controlled.  
The presence of IE-1-specific CD8+T-cells within heart or lung patients was shown to 
correlate with protection from HCMV mediated disease [300]. The authors hypothesised that 
as a result of the IE-1 being the first protein expressed during the viral lifecycle, reactivation 
events are prevented from proceeding past the IE phase of the lifecycle. Therefore pp65-
specific CD8+T-cells would be ineffective in recognising their L-expressed cognate peptide 
in this situation. Conversely, a research group has identified within allogenic stem cell 
transplant patients the greater production of the pro inflammatory cytokines IFN-γ and TNF-α 
by pp65-specific CD8+T-cell populations translating to a higher anti-viral function of these 
cells over IE-1-specific CD8+T-cell populations [301].  
This research has identified immunodominant CD8+T-cell responses to a HLA-Cw*0702-
restricted peptide ‘FRC’ derived from the UL28 protein that is generated with IE kinetics 
during the viral life cycle. To this end, this research focused on developing a TCR based 
therapy utilising the TCR sequence of a UL28-derived ‘FRC-specific CD8+T-cell clone. This 
was achieved via the amplification and sequencing of α and β chain cDNA generated from 
HLA-Cw*0702-specific CD8+ T-cell clones (SMARTer RACE 5'/3' Kit, Clontech). An 
alternative to this cDNA amplification method approach is next generation sequencing. This 
would have provided an unbiased TCR analysis of the total HLA-Cw*0702 epitope-specific 
CD8+T-cell populations. However in order to obtain a pure epitope-specific CD8+T-cell 
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population from PBMCs for such an experiment, an MHC-I tetramer would have been 
required which unfortunately we were unable to obtain. Thus we argue that the cDNA 
amplification method, in addition to the availability of highly avid  CD8+T-cell clones specific 
to the inflationary HLA-C peptides generated in vitro within this work, was sufficient for the 
TCR sequencing purpose required for this research chapter. However for future research, if 
a HLA-Cw*0702 MHC-I tetramer was to be obtained next generation sequencing would be a 
valuable tool to analyse the total oligoclonality of these inflated HLA-Cw*0702 CD8+T-cell 
populations. 
The properties of the UL28 protein from which the inflationary FRC peptide is derived from 
may provide several therapeutic benefits.  Firstly, the UL28 protein is expressed with IE 
kinetics. This research investigation has hypothesised that the FRC peptide is presented 
frequently on infected cell surfaces at IE time-points due to the MHC-I targeting specificity of 
the US2-11 proteins and upregulation of HLA-C alleles during infection.  Secondly, a 
mechanism whereby p53 expression in an infected host cell helps to enhance replication to 
generate large concentrations of mature virions during an infection life cycle has been 
proposed [302]. Importantly, the UL28 protein is implicated in stabilising p53 expression 
[303]. As UL28 has been described as a potential latency transcript this identifies a potential 
role of p53 regulation and hence enhanced viral production during latency.  By targeting the 
UL28 protein, we may remove the advantageous effects of p53 on HCMV replication during 
a reactivation event in addition to transferring a highly avid TCR specificity. 
However, a study has implicated that it is the intrinsic functional and phenotypic abilities of 
CMV-specific CD8+T-cell responses specific for a particular epitope within a HCMV protein 
important for protection from disease. For example, pp65 HLA-A2-restricted NLV peptide-
specific CD8+T-cells provided higher protection from CMV disease compared to HLA-A4 
QYD peptide-specific [304]. This provides premise for selecting epitope-specific CD8+T-cell 
responses for immunotherapy based upon superior anti-viral protection in addition to the 
HCMV target antigen. 
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Therapy consisting of CD8+T-cell clones or TCR specific to more than one HCMV antigen 
could possibly represent one method to enhance therapeutic benefits of adoptive 
immunotherapy. Impacting on the rationale behind a multi antigen specific immunotherapy, 
is a study by Holtappels et al. [305].  The authors identified that protection from CMV 
disease can be provided by subdominant CD8+T-cell specificities and that 
immunodominance of the transferred CD8+T-cell population is not a prerequisite for 
disease protection [188, 305, 306]. Holtppels et al. also observed that a combination of two 
cytotoxic cell line (CTLL) specificities did not enhance protection over a single specificity 
when transferred into CMV infected mice. Instead they determined that efficacy was 
dependent on the absolute number of functional CD8+T-cell transferred. Holtappels et al. 
did however state that the combination of two specificities did not decrease the overall 
anti-viral function.  The inclusion of the HLA-Cw*0702-restricted FRC-specific TCR therapy 
should target infected cells in the IE stage of infection and potentially the L stages of an 
infection if the UL28 protein is confirmed as a latency transcript. It is hoped that in 
combination with HLA-A-restricted pp65-specificities this HLA-Cw*0702-specificity would 
enhance the detection of virally infected cells at IE vs L stages of the life cycle and 
reactivation. Therefore we are hopeful that the combination of UL28, pp65 and IE-1-
specificities within a therapy regimen will translate to an enhanced detection of virally 
infected cells in vivo at all stages  of a chronic infection. 
 
The ultimate aim of adoptive T cell therapy is the transfer of T-cells that persist long term, 
proliferate after antigenic rechallenge and localise to sites of viral reactivation. A study by 
Scheinberg et al. has demonstrated that the successful reconstitution of HCMV-specific 
CD8+T-cells in the post HSCT setting depends upon the maintenance of CD8+T-cells with 
a less differentiated TCM phenotype rather than TEMRA populations [307]. Additionally they 
provided a correlation between TCM in the donor and protection of CMV reactivation. These 
findings were also recently corroborated by Mackay et al [308]. The majority of HCMV 
CD8+T-cells within the periphery are of the late differentiated TEMRA phenotype as were the 
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HLA-Cw*0702 FRC-specific CD8+T-cell populations. This research investigation did 
however identify a small proportion of earlier differentiated CD8+T-cells displaying a TCM 
phenotype (CCR7+CD45RA-) within the inflated RFC-specific HLA-Cw*0702 CD8+T-cell 
populations. Therefore, to utilise the HLA-Cw*0702 populations characterised in this work 
as an immunotherapy, we would wish to isolate these TCM cells for adoptive transfer. 
Alternatively TCM CD8+T-cells isolated from patients or HSCT donors would be transduced 
with the FRC-specific TCR characterised in this work for adoptive transfer. This will 
hopefully reconstitute HCMV-specific CD8+T-cells capable of long lived proliferation and 
expansion after antigenic rechallenge and homing to sites of viral reactivation.  
Future research 
To proceed with developing the HLA-Cw*0702 CD8+T-cell population as an immunotherapy 
the TCR transduction protocol should be optimised. Lastly, the resulting transduced cells 
should be tested in vitro for similar efficacy as ex vivo FRC-specific CD8+T-cell populations 
and CD8+T-cell clones in removing virally infected cells.  
To summarise, the extremely promising phenotypic and characterisation results of FRC-
specific ex vivo CD8+T-cell populations implies that FRC-specific TCR immunotherapy will 
be efficacious for inclusion within current adoptive regimens. The HLA-Cw*0702 allele is 
highly prevalent within the Caucasian population representing ~35% of individuals positive 
for this allele (http://www.allelefrequencies.net/default.asp). Thus expanding the current 
scope of patients eligible for treatment who are HLA-Cw*0702 positive. Furthermore we 
anticipate that the overall benefits of treatment of disease will be advanced via increasing 
the current HCMV targets to 3 protein antigens; pp65, IE-1 and UL28, each with differing 
roles and peak expression time-points during the viral life cycle. We hypothesise that the 
immunodominance and superior anti-viral effector functions in vitro will translate to an 
enhanced disease protection in the immunotherapy scenario. Lastly, as UL28 is postulated 
to be one of the few identified CMV latency transcripts, we hope that the benefits of this 
immunotherapy will translate through to latency and increase the long term efficacy. 
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CHAPTER 6 - INTRODUCTION 
Cryptic epitopes represent unique CD8+T-cell targets that are translated from alternative 
reading frames (ARFs) in both sense and antisense transcripts [309]. Their generation and 
immunogenicity in vivo has been identified within viral infections [310-317] autoimmune 
diseases [318] and several malignancies including melanoma [319, 320] and colorectal 
[321]. 
Cryptic epitope generation during viral infections has been most extensively studied for HIV 
[322], murine HIV [312, 315] and SIV infection [316]. Through these studies it was identified 
that CD8+T-cell populations specific for these unconventionally generated peptides are a 
frequent and dominant component of the anti-SIV response [317]. Additionally that they are 
important for protection of mice from retroviral disease [311, 323].  
Frameshift mutations resulting in translation of a +1 shifted in frame protein has been 
demonstrated for a DNA virus – Herpes simplex virus (HSV) [310]. The resulting ‘cryptic’ 
protein was found to induce resistance of the HSV virus to acyclovir treatment [314].  
Clearly, the CD8+T-cell response to viral pathogens is much more complex than previously 
understood and not restricted to in frame transcripts.  
The use of the RV798 mutant strain (ΔUS2-11) of HCMV to infect APCs in vitro allowed the 
surface presentation of potentially all antigenic epitopes of the virus and led to the 
identification of previously uncharacterised peptide-epitopes [82, 85](Stanley Riddell. And 
Colleagues). These epitopes were derived from all phases of the lifecycle and are generated 
as in frame peptides. 
The same work also led to the identification of peptide-epitopes that are not derived from in 
frame translation of the HCMV protein. Stanley Riddell and colleagues generated CD8+T-
cell clones of an unknown specificity responding to RV798 infected fibroblasts. To identify 
the cognate CMV antigen, viruses KO for individual proteins were employed and loss of 
CD8+T-cell recognition used as indication that the deleted gene contained the clone 
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specificity. It was subsequently determined via the deletion of the US22 or US34 proteins 
that a fraction of the CD8+T-cell clones were specific for peptides derived from these 
antigens. However, upon transfection of the gene fragments into COS7 cells the peptide-
epitope could not be identified. Subsequently, the entire nucleotide sequences of the US22 
or US34 proteins was shifted by +1 (+1 ORF) and then +2 (+2 ORF) aa’s from the 
conventional initial methionine translation start site. Upon transfection of gene fragments 
derived from the +2 ORF nucleotide sequences into COS7 cells, CD8+T-cell recognition was 
regained. The aa sequence of the epitopes giving rise to the CD8+T-cell recognition were 
determined and these novel epitopes were therefore termed ‘cryptic’ epitopes (Table-10).  
It is currently unknown how frequently these would be presented to the immune response in 
vivo when the US2-11 gene region immunevasins may interfere with their reaching the cell 
surface or other unidentified mechanisms are preventing their alternative method of 


















CHAPTER 6 - RESULTS 
6.1 - Ex vivo CD8+T-cell responses to HCMV cryptic peptide-epitopes are readily 
detectable in healthy HCMV seropositive donors 
This results chapter aimed to characterise the ex vivo CD8+T-cell responses to the two 
cryptic epitopes identified and kindly provided by Dr Stanley Riddell et al. with regards to 
kinetics, magnitude and phenotype (Table-10).  
Table 10 – ‘Cryptic’ HCMV epitopes used in this investigation. CD8+T-cell epitopes identified by Stanley 
Riddell et al that are translated in a +2 ORF. The protein antigen, amino acid position within the protein antigen, 
peptide sequence (peptide name is denoted by the first three amino acids of the sequence), restricting HLA 
allele, kinetics of expression and function of the protein antigen (if known) that the cryptic peptides are derived 
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A total of 12 young and 17 older donors, classed as <70 vs >70 years of age, were screened 
for ex vivo CD8+T-cell responses by ICS to the cryptic peptides as previously outlined in 
materials and methods and gating strategy provided in Chapter 3, Fig-7 (Raw ICS provided 
in appendix Table 7-8). A BMedSci student, Miss Emily Briggs undertook her research 
project completing the first half of this chapter under the direct supervision of Miss Louise 
Hosie. The recognition of work completed by Miss Emily Briggs is indicated in figure 
legends. As previously, the background cytokine production detected in the unstimulated 























































Fig 52 – Representative dot plots of the ex vivo CD8+T-cell responses specific for the HCMV cryptic 
epitopes HCMV seropositive donors were screened for ex vivo CD8+T-cell responses to cryptic HCMV CD8+T-
cell peptides restricted through HLA-B7 and HLA-B35 (Table-10). PBMCs of donors with HLA-B7- or HLA-B35-
restriction were stimulated with RPW and APD cryptic peptide-epitopes for 6 hours followed by intracellular 
cytokine staining for IFN-γ (left), IL-2 (middle) and TNF-α (right) production to identify activated CD8+T-cells. As a 
positive control CD8+Tcells were stimulated with SEB to ensure the cytokine detection was working correctly. As 
a negative control CD8+T-cells were left unstimulated. The age of the donors is provided to the left of the plot. 
The gating strategy for identifying activating CD8+T-cells is provided in Chapter 3, Fig-7. The percentages 
represent the percentage of activated CD8+T-cells producing cytokine of the total CD8+T-cell response. RPW n 
= 22 and APD n = 12. Miss Emily Briggs n = 25 Miss Louise Hosie n = 4. In all cases, the percentages shown 








In total 32% (7/22) of donors responded to the HLA-B7-restricted US22-derived RPW 
peptide (Fig-52). The CD8+T-cell responses ranged from 0.37-2.43%, 0.06-1.22% and 0.43-
2.57% producing IFN-γ, IL-2 and TNF-α (ICS results provided in Appendix Table-7-8)(Fig-
53A/B). The average CD8+T-cell response size identified within the 7 seropositive donors 
was 0.84% IFN-γ, 0.35% IL-2 and 0.91% TNF-α (Fig-53B). The average RPW-specific 
CD8+T-cell responses producing IFN-γ, IL-2 and TNF-α increased non-significantly between 
donors <70 vs >70 years of age (Fig-53C) 
A total of 33% (4/12) donors responded to the HLA-B35-restricted US34-derived APD 
peptide (Fig-52). The CD8+T-cell responses ranged from 0.15-0.60%, 0.07-0.17% and 0.23-
0.67% producing TNF-α (Fig-53A/B). The average CD8+T-cell response size in the 4 donors 
was 0.32% IFN-γ, 0.11% IL-2 and 0.50% TNF-α (Fig-53B). Statistics could not be conducted 
on the APD-specific responses with age due to n =2 in both the <70 and >70 year donor 
cohorts, however, the IFN-γ production increased between donors aged <70 vs >70 years of 
age from 0.19%-0.44% (Fig-53C). 
Overall the size of the ex vivo CD8+T-cell responses directed towards the cryptic epitopes 
were lower than those that have been observed towards conventional immunodominant 
epitopes derived from the pp65 and IE-1 immunodominant proteins (Appendix Table-1-6).  
The CD8+T-cell responses were however of a similar magnitude to those identified to the 
protected epitopes RTD and YAD (Appendix tables 1-6, Results chapter 3).  
When the ex vivo cryptic-specific CD8+T-cell responses were correlated with the age of our 
donor cohort, the RPW-specific responses demonstrated a trend towards memory-inflation 
with age but however did not reach significance (Fig-53D). The increase in IFN-γ production 























Fig 53 – Summary of the ex vivo CD8+T-cell responses elicited by the cryptic HCMV peptide-epitopes. HCMV 
seropositive donors were screened for ex vivo CD8+T-cell responses to cryptic HCMV CD8+T-cell peptides restricted 
through HLA-B7 and HLA-B35. PBMCs of donors with HLA-B7 or HLA-B35 restriction were stimulated with RPW and 
APD cryptic peptide-epitopes for 6 hours followed by intracellular cytokine staining for TNF-α production to identify 
activated CD8+T-cells A) Summary of the negative and positive CD8+T-cell responses detected against the RPW and 
APD peptides (Table-10). B) Summary of the positive CD8+T-cell responses detected against the RPW and APD cryptic 
peptides. C) Summary of the RPW- (left graph) and APD- (right graph) specific ex vivo CD8+T-cell responses between 
donors <70 years (white circle) vs >70 years (black circles). In A/B/C lines represent SEM. D) Correlation of the RPW- 
(left graph) and APD- (right graph) specific CD8+T-cell IFN-γ, IL-2 and TNF-α production with the age of the donor cohort 
(years). Lines represent linear regression and p-values determined by Spearman’s rank correlation within Graphpad 





6.2 - CD8+T-cells specific for the cryptic epitopes display a polyfunctional cytokine profile 
with RPW-specific CD8+T-cells demonstrating an enhanced cytotoxic potential with age 
It was hypothesised that the CD8+T-cell responses to these cryptic CD8+T-cell epitopes 
may be generated less frequently during the host lifetime due to their unconventional method 
of translation. It was as such further hypothesised the specific ex vivo CD8+T-cell 
populations would show a phenotypically earlier differentiation state with higher CD28 
expression and greater magnitudes of IL-2 production [326, 327].  
6.2.1 – Cytokine polyfunctionality profile 
First, the cytokine polyfunctionality i.e. the percentage of the CD8+T-cells within the cryptic 
epitope-specific populations capable of producing IFN-γ, IL-2 and TNF-α cytokines was 
determined. This was compared to the ex vivo cytokine profile of NLV-specific CD8+T-cells 
whom are described of belonging to an end stage T cell differentiation pathway (TEMRA) 
producing little IL-2 associated with the loss of the CD28 co-receptor [326, 327].   
The cryptic CD8+T-cell responses were comprised of a larger percentage of CD8+T-cells 
capable of producing all three cytokines investigated – IFN-γ+, IL-2+ and TNF-α+ - compared 
to the NLV-specific CD8+T-cell populations (RPW 13%, APD, 17% and NLV 4% p = 0.079) 
(Fig-54). Both cryptic epitopes elicited CD8+T-cell responses comprising a higher 
percentage of CD8+T-cells that were more singular TNF-α+ producing (p = 0.058) and less 
dual IFN-γ+TNF-α+ producing than the NLV-specific CD8+T-cells (RPW 17%, APD 19% and 













Fig 54 – Cytokine polyfunctionality of the ex vivo cryptic-specific CD8+T-cell responses. The cytokine 
polyfunctionality profile of the cryptic-specific CD8+T-cell responses was determined after 6 hours peptide 
stimulation and intracellular cytokine staining for IFN-γ, IL-2 and TNF-α. This was followed by Boolean analysis in 
Kaluza 1.3 software and analysis of the output in Funky cell software [269]. Gating strategy provided in Fig-26 
chapter 4. Miss Louise Hosie conducted the Boolean analysis of the raw ICS data conducted in major by Miss 
Emily Briggs. The ICS results for the NLV peptide was conducted by Miss Louise Hosie. Graphs were generated 
in Graphpad Prism 6. Statistical significance was investigated by Kruskall-Wallis test of the individual cytokine 
combinations between the HCMV-specific CD8+T-cell populations. The n numbers for each epitope-specific 
CD8+T-cell population are provided beneath the respective pie charts. The cytokine combinations are provided in 
the figure legend.  
 
 
6.2.2 – Single marker phenotype 
The single marker phenotype of the individual cryptic CD8+T-cell responses did not differ 
significantly from the phenotype of NLV-specific (Fig-55). The CD38 expression was 
decreased on the individual RPW and APD-specific CD8+T-cell responses in comparison to 
NLV-specific CD8+T-cells. When the cryptic CD8+T-cell responses were pooled, the CD38 
expression was significantly reduced when assessed against the NLV-specific CD8+T-cell 
populations (Fig-55). 
Compared to the NLV-specific CD8+T-cells there was a trend for decreased CD45RA and 
increased CD28 and CD45RO expression on the cryptic-specific CD8+T-cells (Fig-55).The 
RPW- and APD-specific CD8+T-cell responses exhibited intracellular stores of perforin and 
granzymeB at similar magnitudes to the NLV-specific (average perforin expression; 65.79%, 
80.57% and 64.00% respectively, average granzymeB expression; 76.85%, 74.16%, 90.87% 
respectively, Fig-55). 
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Fig 55 –The phenotype of ex vivo CD8+T-cell responses specific for the cryptic CD8+T-cell responses 
determined by flow cytometry. The ex vivo CD8+T-cell phenotype of CD8+T-cells specific for the HLA-B7 
‘RPW’ and HLA-B35-restricted ‘APD’ peptides was investigated. PBMCs of donors with HLA-B7- or HLA-B35-
restriction were stimulated with RPW and APD cryptic peptide-epitopes for 6 hours followed by staining with the 
antibody panels outlined in Table-4. Intracellular cytokine staining was then conducted for TNF-α production to 
identify activated CD8+T-cells. Single, live, CD3+CD8+ lymphocytes were gated upon in Kaluza 1.3 software 
followed by CD8+TNF-α+ cells to identify the epitope-specific CD8+T-cells before phenotypic analysis. White 
bars represent APD-specific, black bars RPW-specific and lined bars NLV-specific CD8+T-cells. Bars represent 
mean and error bars SEM. Statistical significance was determined using  multiple comparison Mann Whitney 





6.2.3 – Memory compartment phenotype 
The memory CD8+T-cell phenotype of the ex vivo responses was next analysed by CCR7 
vs CD45RA expression (Fig-56A). Both RPW- and APD-specific CD8+T-cell populations 
were comprised of a larger percentage of effector TEM cells (46.99% and 65.34% 
respectively) and a significantly smaller percentage of TEMRA cells (28.34% and 23.10% 
respectively) compared to the total NLV-specific CD8+T-cell population (Fig-56A).  
6.2.4 – Antigen differentiation status 
Last in this section, the antigen differentiation status of CD8+T-cells specific for the cryptic 
epitopes was analysed using CD27 vs CD28 expression to discriminate between early, 
intermediate or late differentiated populations [70] (Fig-56B). There were no significant 
differences between the RPW-, APD- and NLV-specific CD8+T-cell populations. The RPW-
specific CD8+T-cell populations presented with a similar profile to the NLV-specific 
populations dominated by late differentiated CD8+T-cells (65.11% and 63.26% respectively) 
(Fig-56B). The APD-specific CD8+T-cells presented with a distribution of the total epitope-
specific CD8+T-cells between early (CD27+CD28+), intermediate (CD27+CD28-/CD27-
CD28+) and late differentiated T-cells (34.89% 3.02%/30.00% and 32.10% respectively) Fig-
56B). 
 
To summarise the cryptic-specific CD8+T-cell populations had a less activated ex vivo 
CD8+T-cell phenotype compared to NLV-specific CD8+T-cells. This was determined by a 
lower CD38 expression. Secondly, the cryptic-specific CD8+T-cell responses were 
comprised of a larger percentage of CD8+T-cells able to produce IL-2 compared to the 
pp65-specific CD8+T-cell populations. However the RPW- and APD-specific CD8+T-cells 
displayed similar levels of cytotoxic potential to the NLV-specific CD8+T-cells indicated by 















Fig 56 – CCR7 vs CD45RA memory phenotype of the ex vivo CD8+T-cell phenotype of the specific cryptic 
epitope responses. PBMCs of donors with HLA-B7 or HLA-B35 restriction were stimulated with RPW and APD 
cryptic peptide-epitopes for 6 hours followed by intracellular cytokine staining for TNF-α production to identify 
activated CD8+T-cells. The cells were subjected to staining with the antibody panels outlined in Table-4. RPW 
and APD phenotyping - Miss Emily Briggs n = 7 and Miss Louise Hosie n = 1. The phenotyping of NLV-specific 
CD8+T-cell populations was conducted by Miss Louise Hosie. A) Memory phenotype of the ex vivo CD8+T-cell 
responses specific for the cryptic epitopes compared to pp65 derived NLV-specific CD8+T-cells. Memory 
compartments were identified as TN (CCR7+CD45RA+), TCM (CCR7+CD45RA-), TEM (CCR7-CD45RA-) and 
TEMRA (CCR7-CD45RA+). Statistical significance of the TEMRA populations was determined using multiple 
comparison Mann-Whitney tests in Graphpad prism 6 with * as a p value <0.05. B) Antigen differentiation status 
of the cryptic specific CD8+T-cell responses identified as early (CD27+CD28+), intermediate (CD27+CD28-








p = 0.02 






6.3 - The ex vivo CD8+ T cells specific for the HLA-B7- cryptic peptide become more 
cytotoxic and more differentiated with age 
When correlated with age the RPW-specific responses trended towards inflation with age 
and the IFN-γ production elicited by the APD peptide increased significantly with age (Fig-
53D). However due to low n numbers, the ex vivo CD8+T-cell phenotype of the RPW-
specific CD8+T-cells was analysed in relation to the age of the donor (Fig-57). The panel 
previously used to phenotype HCMV-specific CD8+T-cells was investigated (Table-4)  
6.3.1 – Single marker expression 
The RPW-specific CD8+T-cells remained granzymeBhigh with age (46.56%-93.33%) and 
increased perforin expression (29.33%-97.29%). Levels of NKG2D increased slightly and 
PD-1 remained low with age (1.41%-13.94% and 6.17%-17.96% respectively, Fig-57A). 
CX3CR1 expression was dramatically increased with age (16.25%-63.39%, p = 0.08). 
Progressively the RPW-specific CD8+T-cells lost the co-stimulatory CD27 and CD28 
molecules with age (27.51%-9.86% and 47.75%-14.20% respectively, Fig-57A). The T-cell 
homing marker CCR7 expression remained low (8.80%-6.11%, Fig-57A). 
6.3.2 - Memory phenotype 
Within two younger donors <70 years of age, the majority of RPW-specific CD8+T-cells were 
TEM (CCR7-CD45RA- 67.62%, Fig-57B). Within two older donors >70 years, the percentage 
of TEM decreases (46.71%) and the percentage of TEMRA (CCR7-CD45RA+, 49.25%) 
increases (Fig-57B). 
6.3.3 - Antigen differentiation status 
The percentage of late differentiated (CD27-CD28-) CD8+T-cells within the RPW-specific 
CD8+T-cell population remained similar with age (63.47% YD donors vs 66.74% OD donors, 
Fig-57C). In addition, within two donors >70 years of age, the proportion of early 
differentiated CD8+T-cells decreased within the RPW-specific CD8+T-cell population 
(19.20% vs 9.77%, Fig-57C). 
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Fig 57 – The ex vivo phenotype of cryptic RPW-specific CD8+T-cell responses with age Changes in the CD8+T-cells specific 
for the HLA-B7-restricted RPW cryptic peptide with age was analysed.  PBMCs were stimulated with the RPW cryptic peptide-
epitope for 6 hours followed by intracellular cytokine staining for TNF-α production to identify activated CD8+T-cells. The cells were 
subjected to staining with the antibody panels outlined in Table-4. Miss Emily Briggs phenotyped n = 7 and Miss Louise Hosie n = 
1. The phenotyping of NLV-specific CD8+T-cell populations was conducted by Miss Louise Hosie A) Correlation of the expression 
of perforin, granzymeB, CD27, CD28, CCR7, CX3CR1, NKG2D and PD-1 expression on the ex vivo RPW-specific CD8+T-cell 
responses with age of the donors (years) by spearman’s rank correlation. Lines represent linear regression. B) Memory phenotype 
of the ex vivo CD8+T-cell responses specific for the RPW cryptic epitope compared to NLV-specific. Memory compartments were 
identified as TN (CCR7+CD45RA+), TCM (CCR7+CD45RA-), TEM (CCR7-CD45RA-) And TEMRA (CCR7-CD45RA+). C) Antigen 
differentiation status of the RPW cryptic specific CD8+T-cell responses identified as early (CD27+CD28+), intermediate 
(CD27+CD28-/CD27-CD28+) and late (CD27-CD28-). RPW n = 4, APD n = 3 and NLV n = 6. The NLV phenotyping was conducted 






















To conclude, the ex vivo RPW-specific CD8+T-cells from four seropositive individuals 
demonstrated an increase in cytotoxic potential, whilst remaining low for PD-1 expression 
with age.  The same CD8+T-cells acquired a more differentiated phenotype (loss of T-cell 
co-receptors CD27/CD28) with a concomitant increase in the endothelium homing marker 
CX3CR1.  This indicates, that within these four individuals, the CD8+ T cells are becoming 
more stimulated by antigen with age. 




6.4 - The functional avidity and peptide recognition profile of cryptic epitope-specific 
CD8+T-cell clones  
To provide an indication of whether the cryptic peptide-epitopes could be directly presented 
to the immune system in vivo, it was next evaluated whether specific CD8+T-cell clones can 
recognise naturally processed cryptic peptide during an in vitro infection. CD8+T-cell clones 
specific for the RPW and APD peptides were generated from PBMCs obtained from donors 
YD49 (31 years) and OD25 (79 years) respectively.  
First, the functional avidity of four RPW- and an APD-specific clone was calculated (Fig-
58A). The EC50 of the RPW clones ranged from 0.25μg – 250pg. The EC50 of the APD clone 
was 0.005μg. This is in comparison to NLV-specific CD8+T-cell clones that ranged from 
0.025μg-0.25μg (Chapter 3, Fig-16). 
These CD8+T-cell clones were then utilised in a recognition assay to determine the 
recognition of cognate peptide generated during an in vitro CMV infection of haematopoietic 
non-haematopoietic cells (Fig-58B). This was conducted during infection with the WT US2-
11 gene region AD169 and Merlin HCMV strains. Additionally, the recognition of peptide 
during a ΔUS2-11 RV798 infection was included due to their identification by Riddell et al. 
with this strain.  
First, the recognition of fibroblasts i.e. non-haematopoietic cells was determined. RPW-
specific CD8+T-cell clones recognised peptide presented on the cell surface of AD169 
infected fibroblasts (MOI 5) at E-E/L time-points (12-48hrs p.i.). APD-specific clones also 
recognised peptide on the surface of AD169 infected fibroblasts at IE time-points (12hrs p.i.) 
and released a small concentration of IFN-γ at L time-points (72hrs p.i). During an RV798 
infection, the cryptic RPW and APD epitopes were recognised at all time-points, excluding 
48hrs p.i. for APD. In all cases the magnitude of IFN-γ production was larger compared to 























Fig 58 – The EC50 avidity and peptide recognition by HLA-B7 RPW- and HLA-B35 APD-specific CD8+T-cell 
clones over the course of a productive HCMV infection Cryptic epitope-specific CD8+T-cell clones were 
generated, their functional avidity determined and the recognition of peptide on the surface of HCMV infected 
cells in vitro assessed. CD8+T-cell clones were isolated from HCMV seropositive donor PBMCs after 3 hours 
peptide stimulation, IFN-γ secretion assay and a limiting dilution assay. A) The EC50 of RPW- (left graph) and 
APD- (right graph) specific CD8+T-cell clones. The EC50 was determined as the concentration of peptide that 
induced 50% maximal IFN-γ production (pg/ml) after O/N co-culture with peptide-loaded HLA-matched LCLs. 
Each line represents an individual clone. B) Cryptic CD8+T-cell recognition of cognate peptide during HCMV 
infection of fibroblasts and monocytes. Fibroblasts were infected with the AD169 or RV798 strains and 
monocytes infected with the Merlin strain for 6-72 hours at an MOI of 5. These were then co-cultured O/N with 10 
000 CD8+T-cell clones. One clones tested per specificity, bars represent mean and error bars SEM. n = 2 




The CD8+T-cell recognition of the RPW cryptic epitope during a primary CMV infection of 
haematopoietic cells was next analysed. Monocytes isolated from PBMCs of donors with 
previously identified RPW-specific CD8+T-cell responses were infected with the Merlin strain 
at an MOI of 5 for 6-72 hours prior to incubation with CD8+T-cell clones. RPW-specific 
CD8+T-cell clones recognised cognate peptide at IE (6-12 hours p.i.) only (Fig-58B).  
To summarise, cryptic CD8+T-cell peptide-epitopes are presented in vitro directly during a 
primary infection of both haematopoietic and non-haematopoietic infections with three 
strains of HCMV – AD169, RV798 and Merlin. The peptides are efficiently recognised by 

















6.5 – Cryptic RPW-specific CD8+T-cell clones effectively kill peptide-loaded and 
HCMV target cells 
The adaptive immune system is efficiently able to recognise and generate a CD8+T-cell 
response to HCMV-derived cryptic epitopes generated in a non-canonical manner. However, 
it is as yet unclear the role that these CMV-specific CD8+T-cell populations play in the 
control of viral infection in vivo. Last in this results chapter, the functional and antiviral 
abilities of RPW-specific CD8+T-cell clones was investigated. In particular the proliferative 
and killing capacities. This was compared to NLV-specific clones already demonstrated as 
efficiently able to lyse cells and proliferate (Chapter 3 Fig-35/36).  
First, the proliferative capacity of ex vivo RPW-specific CD8+T cells in response to antigen 
stimulation was elucidated (Fig-59). CFSE labelled PBMCs from donors with previously 
identified RPW-specific CD8+T-cell responses were co-cultured for 7 days with γ-irradiated 
peptide-pulsed HLA-matched LCLs. Proliferation was determined by analysing the dilution of 
CFSE on the PBMCs (gating strategy provided in Results chapter 4, Fig-37). PBMCs 
incubated with the RPW pulsed LCLs proliferated (18.3%-21.03%, n =2) but did not reach 
the proliferation levels observed with PBMCs incubated with NLV loaded targets (19.82%-
53.94%, n = 2) (Fig-59A).  
Secondly, the activation of RPW-specific CD8+T-cell clones after recognising cognate 
peptide during a primary fibroblast infection in vitro was assessed by flow cytometry. HLA-
B7+ MRC5 fibroblasts were infected with the Merlin strain at an MOI of 0.05 for 24 hours 
followed by incubation with RPW-specific CD8+T-cell clones for a further 48 hours. 
Following incubation, CD8+T-cell clones were removed from the infected cell monolayer and 
phenotyped by flow cytometry for CD25 upregulation. All RPW-specific clones demonstrated 






















Fig 59 – The in vitro functional activity of RPW-specific CD8+T-cell clones determined by CD25 
upregulation and infected cell lysis. The proliferation of ex vivo RPW-specific CD8+T-cells and killing capacity 
of the RPW-specific CD8+T-cell clones was investigated. A) Proliferation of CFSE labelled RPW-specific PBMCs 
after incubation with peptide-loaded LCLs. Proliferation was determined by analysing the dilution of CFSE 
staining.  Single, live, CD3+CD8+ lymphocytes were gated on in Kaluza 1,3 software. Within this population, 
CFSE low i.e. proliferating CD8+T-cells were identified. n = 2 for RPW and NLV B) Activation of RPW-specific 
CD8+T-cell clones after incubation with Merlin infected (MOI 0.05) MRC5 fibroblasts indicated by CD25 
upregulation.  Fibroblasts were infected with HCMV merlin strain at MOI 0.05 for 24 hours before the addition of 
specific CD8+T-cell clones for a further 48 hours and phenotyping of the CD8+T-cell clones by flow cytometry C) 
Specific lysis of RPW loaded LCLs by a RPW-specific CD8+T-cell clone. CFSE labelled, RPW peptide-loaded, 
HLA-matched LCLs were co-cultured with 10 000 CD8+T-cell clones at a 1-10:1 effector: target ratio O/N 
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Importantly, the ability of an RPW-specific CD8+T-cell clone to efficiently lyse HCMV 
infected cell targets was determined. An RPW-specific CD8+T-cell clone was incubated with 
CFSE labelled RPW-loaded HLA-B7+ LCLs O/N. The loss i.e. specific cell lysis, of viable 
CFSE positive PI negative targets was analysed the following day by flow cytometry (method 
outlined in chapter 2 materials and methods 2.2.8). The clone was found to efficiently kill 
RPW loaded targets in vitro ranging from 77.78% at a 1:1 to 98.85% at 10:1 effector:target 





















Chapter 6 - Summary 
This work identified frequent ex vivo CD8+T-cell responses to novel peptides derived from 
the US22 and US34 proteins that are generated by a +2 amino acid shift in the translation 
from the cognate HCMV proteins (Table-9). These responses could reach 2.43% of the 
CD8+T-cell response producing TNF-α towards the US22-derived HLA-B7-restricted RPW 
peptide and 0.67% towards the US34-derived HLA-B35-restricted APD peptide. The ex vivo 
responses detected to these cryptic epitopes were largely Th1 cytokine producing but 
demonstrated larger ratios of Th1:IL-2 production than CD8+T cells specific for the 
immunodominant pp65 peptide NLV. The IFN-γ, IL-2 and TNF-α production elicited by the 
RPW peptide trended to a significant increase with age.  
The phenotypic characterisation of these ex vivo CD8+T-cell responses found them to have 
high cytotoxic potential (intracellular perforin and granzymeB expression) with a significantly 
decreased CD38 expression compared to immunodominant pp65-specific CD8+T-cell 
responses. Both the RPW- and APD-specific responses were dominated by large TEM 
responses. The RPW-specific CD8+T-cell populations were comprised of a larger 
percentage of late antigen differentiated cells, with the APD-specific CD8+T-cell populations 
a distribution between early, intermediate and late differentiated cells.  
As the age of the donor increased, the ex vivo CD8+T-cell responses directed towards the 
US22-derived RPW peptide shifted from a population comprised of mainly TEM CD8+T-cells 
to increase the percentage of TEMRA. Additionally, the RPW-specific CD8+T-cell responses 
demonstrated an increase in CX3CR1 expression and progressive down-regulation of 
CD27/CD28 and CCR7.  
The natural processing and surface presentation of these cryptic peptides on both 
haematopoietic (monocytes) and non-haematopoietic cells (fibroblasts) was established 
during a WT CMV infection in vitro. Cryptic peptide-specific CD8+T-cell clones produced 
IFN-γ in response to recognising their cognate peptides on these cell in vitro. This was 
conducted with strains of the virus where the WT US2-11 MHC-I immunomodulatory region 
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was present and compared to the RV798 mutant strain. The use of the RV798 strain to infect 
APCs originally led to the identification of the cryptic HCMV epitopes.  
Most importantly, the efficient lysis of HCMV infected fibroblasts was demonstrated by an 
RPW-specific CD8+T-cell clone and RPW-specific clones became activated after incubation 
with merlin strain infected fibroblasts.  



















CHAPTER 6 - DISCUSSION 
To our knowledge, this work represents the first characterisation of ex vivo CD8+T-cell 
responses directed towards two cryptic epitopes – US22-derived RPW and US34-derived 
APD – produced by Human Cytomegalovirus, originally identified by our collaborator Dr 
Stanley Riddell and colleagues.   
The HLA-B7-restricted RPW peptide is derived from the HCMV US22 protein which forms 
part of the infectious virion tegument [324]. The US22 gene encodes for the HWLF1 reading 
frame whose translation produces the nuclear located ICP22 protein which becomes 
released from infected cells at E (24hrs) and L (72hrs) time-points [325]. The role of this 
protein is unknown however removal of the US22 gene from HCMV was found as 
dispensable for growth [224]. The US22 gene has been identified as having peak expression 
at E-EL (24-48 hours p.i.) time-points of an infection [225].  
The HLA-B35-restricted APD peptide is derived from the US34 protein. Little is known about 
the role this protein plays in vivo, however, removal of this protein from the virus has been 
demonstrated as dispensable for growth of the virus in vitro [224]. Within the literature it has 
not yet been determined what kinetics the US34 gene is expressed with. 
This work characterised the CD8+T-cell responses towards these peptides with regards to 
kinetics, magnitude and frequency within HCMV seropositive donors and found that ex vivo 
CD8+T-cells to these peptides were frequent within HCMV infected healthy donors. The 
RPW-specific CD8+T-cells ranged from 0.37-2.43%, 0.06-1.22% and 0.43-2.57% producing 
IFN-γ, IL-2 and TNF-α respectively of the total CD8+T-cell response. The APD-specific 
CD8+T-cell responses ranged from 0.15-0.60%, 0.07-0.17% and 0.23-0.67% producing IFN-




A hypothesis for the generation of HCMV cryptic CD8+T-cel peptide-epitopes 
Previously, cryptic epitope generation has been identified with RNA viruses [313, 315, 316, 
322] whose generation during these infections has been hypothesised as resulting from 
errors in ribosomal reading during translation. It has also been identified during malignancies 
and autoimmune diseases [318, 319, 321].  
Both HIV and Influenza are viruses with a small RNA genome and the generation of cryptic 
epitopes from both sense and antisense alternative reading frames is a plausible method for 
these viral pathogens to generate several protein products from a small number of 
transcripts maximising the encoding potential. Out of frame translation within a +1 ORF 
context has also been demonstrated for a DNA virus Herpes Simplex Virus ‘HSV’ [310, 314]. 
This virus was demonstrated to induce a +1 frameshift mutation at a ribosome error prone 
site within the thymidine kinase protein that in 1% of cases resulted in viral escape from 
acyclovir treatment. More recently, a cryptic presented epitope has been identified from the 
murine m54 protein but the role of this epitope in vivo has not been determined [328]. It was, 
however, determined that the CD8+T-cell responses directed towards this alternative 
epitope gained immunodominance after the deletion of typical dominant CD8+T-cell 
populations within infected mice. 
This asks the question to why CMV, a large DNA virus encoding for ~192 unique ORFS with 
the potential to encode for functional in frame proteins [73], would also generate cryptic 
epitopes from an already large antigenic repertoire. It also asks why cryptic epitopes would 
be generated from protein antigens that are not associated with viral immunevasion and are 
dispensable for viral replication [224].  
As such, two theories are proposed. The first that the generation of these cryptic epitopes 
occurs during primary infection of cell types in vivo. This would allow the generation of an 
initial CD8+T-cell peripheral pool specific for theses epitopes. During latency the virus 
‘switches’ off this mechanism of cryptic epitope generation so that the immune system has 
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generated a CTL response that is unlikely to encounter their antigen again during latency. 
Thereby representing an immunevasion mechanism.  
The second hypothesis is that the alternatively translated proteins from which these CD8+T-
cell epitopes are generated from play an important and as yet undetermined role in the viral 
life cycle in vivo. For example, cryptic translation of the secreted ICP22 protein encoded by 
the US22 gene could generate variants with differing roles outside of the virally infected cell.  
Future research is to establish CMV CD8+T-cell peptide-epitopes of the canonically 
translated US22 and US34 proteins and to compare the recognition of these during a WT 
infection in vitro vs cryptic peptides derived from the same gene region.  
There are several mechanisms whereby alternatively derived cryptic epitopes may arise 
[329]. Transcriptional mechanisms include; the ‘Pepton Hypothesis’ whereby an unidentified 
non-traditional RNA polymerase, not utilising the canonical eukaryotic methionine start 
codon, starts translation at a distinct site which is cleaved to peptides [330]. Others include 
the presence of cryptic promoters within a gene. 
Translational mechanisms for cryptic epitope generation include; ribosomal errors where a 
non-start codon is read as a translation initiation start site, ribosomal jumping/shifting 
halfway through translation of a transcript and the credited ‘DRiP theory’ [331-333].  
The DRiPs hypothesis proposed by Jonathan Yewdell [331] states that the majority of 
antigenic peptide presented on the cell surface within MHC-I molecules are derived from the 
neosynthesis and degradation of defective or abandoned ribosomal products of both self 
and viral proteins. Not from the degradation of stable long term proteins. This hypothesis 
was then extended [332] by the proposal of an ‘immunoribosome’ that may be closely linked 
to the immunoproteasome and TAP-mediated peptide transport. This ‘immunoribosome’ is 
dedicated to generating peptide-epitopes quickly from newly synthesised protein products 
under times of cell stress such as a viral infection. This would provide an advantage to the 
infected cells for the rapid presentation of IE viral peptides to mediate efficient removal by 
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CD8+T-cells of infected cells. This work by Yewdell et al. has focused primarily on viral 
proteins derived from the Influenza virus and has as yet to be demonstrated for other viral 
pathogens such as CMV.  
This DRiPs hypothesis has been elegantly demonstrated by other research groups who 
demonstrated that MHC-I molecules within the ER are exposed primarily to peptides 
originating from newly synthesised proteins  [334]. Furthermore that the presentation of an 
immunodominant viral antigen requires neosynthesis and not the degradation of stable 
proteins present within the virus particles that enter the cell. This indicates that surface 
antigens are derived from a pool of newly synthesised proteins and not the long lived protein 
form that enters the cell with the incoming virion [335].  
The peptides investigated within this PhD study are derived from when the amino acid 
sequence is ‘read’ +2 amino acids from the canonical start methionine. The shifting of both 
the US22 and US34 nucleotide sequences +2 in frame creates a downstream internal ATG 
site which the ribosome can start translation from (Fig-60). This allows the translation of 
alternative US22 or US34 protein products containing the amino acid sequence for the HLA-
B7 RPW and HLA-B35 APD peptides. A study has previously used ribosomal profiling to 
identify that the generation of several polypeptides from the same gene occurs frequently 
during CMV infection [336]. In particular relevance, the study identified several internal out of 
frame ORFs within previously identified ORFs. The translation from these internal sites led to 
the generation of out of frame proteins as is the case with the cryptic peptides characterised 
within this investigation. However the mechanism causing the ribosome to frameshift to 
these internal ORFs during viral translation, such as slippery sequences within the HCMV 
genome, were not investigated.    
The research group of Shastri and colleagues have effectively demonstrated the misreading 
of the initial methionine start residue for translation by ribosomes as a leucine [337-340]. 
When the authors attempted to define the mechanism behind this, they observed a distinct 
ribosome complex that preferentially scans for the CUG leucine residue rather than AUG 
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methionine. Furthermore that the incorporation of the leucine residue does not involve the 
host ‘eukaryotic translation factor 2’ which halts host translation in time of viral stress. The 
author’s hypothesized that this novel mechanism of CUG-initiated translation would allow for 
the cryptic translation of viral antigens during times of cellular viral stress when translation 















Fig 60 – Schematic of the cryptic translation of the US22 and US34 by identifying internal methionine 
residues as start codons. The canonical methionine start codon is indicated in bold and underlined blue. The 
protein sequence encoded by translation is provided beneath the nucleotide sequence. The start site of the +2 
ORF is provided in bold and underlined red. The ‘cryptic’ protein sequence resulting from translation from this 
ATG start site is provided beneath the nucleotide sequence. The peptide sequence of the cryptic CD8+T-cell 
epitopes investigated in this study are provided in capital letters and underlined. The sequences used here are 




The fact that CD8+T-cell responses directed to these cryptic epitopes can be found between 
several different donors, would imply that their generation and identification was not 
fortuitous and there is a common mechanism of generation between donors. Relevantly, a 
study has implicated HCMV promoter sequences as supporting an enhanced number of 
cryptic translation events compared to an SV40 promoter in the context of a DNA vaccine 
encoding the Hepatitis B polymerase in an alternative ORF [341]. Importantly this translation 
led to the generation of immunogenic peptides from the alternative frame protein within the 
DNA vaccine. 
This investigation has not yet attempted to address the mechanism behind the US22 and 
US34 cryptic translation. We could nonetheless speculate based upon the evidence within 
the literature, a hypothesised model for HCMV cryptic epitope generation. When HCMV first 
infects a cell this cell enters a state of cellular stress and attempts to switch off translation. 
HCMV then utilises distinct cellular ribosome machinery that functions in the absence of host 
translation ‘enhancers’ to produce its protein products. However, this is at the expense of +2 
ORF protein products that have not yet been determined as having role in the viral life cycle. 
In addition, the HCMV promoter sequences, demonstrated to enhance cryptic translation, 
may also increase the generation of these alternative protein products. These newly 
synthesised cryptic protein products are then substrates for the MHC-I pathway as proposed 
by the DRiPs hypothesis ultimately leading to the surface presentation of RPW/APD:MHC-I 
complexes.    
The phenotype and peptide recognition profile of cryptic-specific CD8+T-cells 
indicates antigen encounter during an infected host’s lifetime 
The demonstration of direct presentation of the cryptic epitopes to specific CD8+T-cell 
clones during infection with three strains of the virus; AD169, RV798 and Merlin, strongly 
implies that they are indeed generated and presented naturally in vivo and may be a 
common phenomenon of CMV strains. Additionally, infection with the RV798 virus led to an 
enhanced magnitude of IFN-γ by cryptic-specific CD8+T-cell clones. In this regard, the 
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cryptic epitopes are generated and presented with similar kinetics that follows their protein 
expression profile to normally translated CMV protein peptides such as NLV from the pp65 
protein whose recognition is also enhanced during an RV798 infection. This also implicates 
the viral US2-11 gene region in dampening but not completely abrogating the initial CD8+T-
cell effector functions towards cryptic peptide presenting infected host cells.  
Phenotypic characterisation of the ex vivo CD8+T-cell populations specific for the cryptic 
peptides revealed that they consist of a higher percentage of CD8+T-cells producing all 
three cytokines investigated in this study – IFN-γ, IL-2 and TNF-α. A lower CD38 expression 
on cryptic CD8+T-cell populations indicates that these are not as activated as NLV-specific 
CD8+T-cells within the periphery. Additionally, these cryptic peptides could be hypothesised 
as less frequently generated during an in vivo infection resulting in a less chronically 
stimulated phenotype of the specific CD8+T-cell population within the periphery than inflated 
immunodominant CD8+T-cell epitopes. This is supported by a significantly smaller 
percentage of TEMRA CD8+T-cells within the total cryptic-epitope specific populations 
compared to NLV-specific CD8+T-cell populations. However, the total RPW-specific CD8+T-
cell populations did exhibit an increase of TEMRA CD8+T-cells with age - suggesting they are 
in fact encountering antigen over a period of time. The increase in CX3CR1 expression on 
RPW-specific CD8+T-cells with the age of donor would also indicate that these cytotoxic 
CD8+T-cells could efficiently migrate towards and control viral reactivation events within the 
periphery.  
This raises the question to the cell type capable of presenting these cryptic peptides in vivo. 
As such the recognition was determined in this here work of naturally presented cryptic 
peptide on haematopoietic non-haematopoietic cells in vitro. The RPW peptide was 
recognised at IE (6 hours p.i. onwards) time-points of an AD169 primary CMV infection of 
haematopoietic monocytes but only from 12 hours p.i. onwards within non-haematopoietic 
fibroblasts. This would insinuate that both cell types are capable of presenting the cryptic 
peptides in vivo however they may be generated at different time-points during the viral life 
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cycle in differing cell types. The US22 protein, from which the HLA-B7 RPW peptide is 
derived, is present within the tegument of infectious virus particles [324, 325]. The RPW 
peptide should theoretically be immediately, i.e. 6 hours p.i., available for presentation In 
MHC-I in essentially all CMV permissible cell types.  Fibroblasts could therefore contain 
cellular factors or viral factors that prevent the generation of these cryptic epitopes until time-
points past 12 hours p.i. within this cell type. It may also represent a product of the RPW 
specific clone tested for CD8+T-cell recognition.  
Future research 
Research should be focused on the precise mechanism that may induce the ribosome to 
recognise a methionine codon that is +2 nucleotides out of the normal translation frame in 
preference to the initial methionine codon of the US22 or US34 genes. Furthermore, it 
should be focused on determining how frequently this occurs.  It ought to be investigated 
whether HCMV encodes for any further cryptic CD8+T-cell epitopes and to what extent 
these contribute to the overall CD8+T-cell repertoire. To this end, it would be interesting to 
treat HCMV infected cells with aminoglycosides to enhance ribosomal errors and therefore 
gain a full picture of the extent of cryptic CMV epitopes [342]. Research should lastly be 
aimed at determining whether the alternative protein products generated by cryptic 
translation of the US22 or US34 genes have an important role in the viral life cycle in vivo or 
represent products of the virus attempting to translate its gene products within stressed host 
cells.  
At present, research into the anti-CMV CD8+T-cell response could be massively 
underestimating the antigenic profile of HCMV by focusing upon in frame peptides. CD8+T-
cell population’s specific for cryptically generated peptide-epitopes are clearly important 
contributors to immune responses in vivo. They may play an important role in controlling viral 
infection in vivo as demonstrated by the efficient removal of virus-infected targets in vitro in 
this study. The clear message is that the overall understanding and known breadth of the 
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CHAPTER 7 - INTRODUCTION 
Cytomegaloviruses persist for the lifetime of the host whereby it is hypothesised these 
viruses induce low grade chronic antigen presentation resulting in a powerful cellular 
CD8+T-cell immune response that inflates with age [3, 88, 343]. The resulting long lived 
memory CD8+T-cells are highly cytotoxic and polyfunctional with age [110]. Together this 
makes CMV an attractive vector for vaccination in the hopes that such immune responses 
can be induced towards a gene insert and will be maintained indefinitely. 
Louis Picker et al. pioneered research into CMV as a vaccine therapy for the vaccination of a 
viral disease, in particular ‘Simian Immunodeficiency Virus’ (SIV) as a prerequisite for 
whether such a vaccine construct would be applicable for the treatment of HIV disease. 
These studies demonstrated the undeniable efficacy of such a vaccine construct in the 
protection of vaccinated Rhesus Macaques from lethal SIV challenge. It was indeed the 
induction of long lived TEM CD8+T-cells as a result of chronic antigen presentation induced 
by the CMV vector that the author’s attributed to the control and protection from lethal SIV 
strain disease.  
Importantly for the context of this research chapter, CMV based vaccines have also been 
successfully used in studies and clinical trials for malignancies [208, 344, 345].  
The research groups of Qiu et al. and Xu et al. have utilised CMV as a vaccine therapy to 
investigate the efficacy of this viral pathogen in directing the immune system to melanoma 
within mice [208, 344, 345]. The results of Qiu et al. were very promising and demonstrated 
the superior efficacy of a recombinant MCMV vector over a vesicular stomatitis virus (VSV) 
vector with regards to CD8+T-cell duration and protection from melanoma [344]. 
Additionally, Xu et al demonstrated that antibodies were the critical factor in protection from 
melanoma revealing the broad immunostimulatory effects of a CMV based vaccine. 
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CMV has therefore been established as a potential and promising vaccine vector for 
inducing durable cellular and humoral responses to tumour gene inserts. The question now 
arises which cancer antigen to target.  
CTAgs are a family of tumour associated antigens that are preferentially expressed in 
immuneprivilidged sites or upregulated preferentially on several malignancies making them 
ideal and attractive targets for cancer immunotherapy [211]. The first member of this family 
of tumour antigens was identified by Van der Bruggen et al. termed MAGE-A1 [346]. 
Subsequent members were identified by either T-cell cloning methods or serologically with 
cDNA libraries generated from tumours screened with anti-tumour antibodies obtained from 
patients termed ‘Serological analysis of cDNA expression libraries (SEREX) [347]. Using this 
method Chen et al. identified the CTAG1 gene encoding for the ‘New York esophageal 
squamous cell carcinoma 1’ (NYESO1) [215]. 
The NYESO1 protein has since been the focus of numerous clinical trials [217] as a result of 
its potent immunogenicity to the immune system during malignancies [217, 348] and the 
correlation of its expression on tumours with poor prognosis [214, 349, 350].  
This research chapter aimed to develop a therapy for NYESO1 expressing malignancies 










CHAPTER 7 - RESULTS 
7.1 - Generation of a HCMV-NYESO1 vaccine vector utilising the pALIIII ‘Bacterial 
Artificial Chromosome’ (BAC) construct 
In collaboration with Dr Richard Stanton (School of Medicine, University of Cardiff), a HCMV 
BAC construct containing the NYESO1 gene was generated termed ‘pALIIII-NYESO1’ which 
would produce recombinant HCMV expressing NYESO1 (HCMV-NYESO1) when 
transfected into mammalian cells.  
The pALIIII construct was constructed from a Merlin strain background and has mutations 
within the UL128-131 region [221]. This UL128-131 gene region is critical for CMV tropism in 
vivo and its removal restricts CMV infection to fibroblasts. The virus construct generated in 
this study was replication efficient to allow for the preparation of viral HCMV-NYESO1 stocks 
to test during in vitro assays. The RL13 gene was found to be a potent inhibitor of CMV 
replication in fibroblasts in vitro [221]. Therefore the replacement of the RL13 gene with the 
NYESO1 gene was hypothesised to increase yields of viral stocks of the recombinant 
HCMV-NYESO1 after transfection of pALIIII-NYESO1 into fibroblasts.  
The pALIIII-NYESO1 construct was generated via a recombineering event within competent 
bacteria between an NYESO1 construct containing 80bp of homology to the HCMV RL13 
gene (Table-6) and the endogenous RL13 gene within the pALIIII HCMV BAC construct. 
SW102 competent bacteria containing the pALIIII BAC were incubated for 15 minutes at 
42oC to induce the lambda phage recombination genes. The NYESO1 DNA construct with 
RL13 homology was then electroporated into the bacteria and the bacteria recovered and 
selected on media containing chloramphenicol. Positively pALIIII-NYESO1 transformed 
bacterial colonies, identified by a white opaque colour (materials and methods section 
2.2.17) underwent plasmid isolation preparations. The resulting plasmid DNA was digested 
with the HinDIII restriction enzyme and electrophoresed to ensure that the integrity of the 
HCMV genome had not been significantly altered after the NYESO1 insert (Fig-61). This was 
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established by comparison to the digested pALIIII construct (previously characterised [221]), 
Fig-61).  
Once established that the NYESO1 insert had not disrupted the HCMV genome, plasmids 
were sequenced for the correct NYESO1 sequence (University of Birmingham, Genomics 
service). Two selected plasmids (p3 and p11) both had the correct sequence alignment 
(data not shown).  
After the confirmation of the correct NYESO1 sequence in the BAC, the pALIIII-NYESO1 
was transfected into HFFF2 fibroblasts to produce recombinant HCMV. Plasmid 3 was 
selected for transduction into HFFF2 fibroblasts to generate a viral stock of HCMV-NYESO1 
for in vitro assays. The titre of the HCMV-NYESO1 viral stock was quantified by a plaque 













Fig 61 – Characterisation of the correct NYESO1 gene insert into the CMV pALIIII construct Plasmids 
isolated from pALIII-NYESO1 transformed bacterial colonies were restriction digested with HinDIII to ensure the 
structural integrity of the HCMV genome was not lost after the recombination between RL13 and NYESO1. A) 
Restriction digest of the pALIIII BAC generated and digested by Dr Richard Stanton (A) [221] vs B) Restriction 
digest of plasmid isolated from pALIII-NYESO1 transformed bacterial colonies. Restriction digestion preparations 
were run for 16 hours on a 0.8% agarose gel at 60V.  
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7.2 - Generation of NYESO1-specific CD8+T-cell clones to assess the immunogenicity 
of a HCMV-NYESO1 vaccine construct 
 
To determine whether NYESO1 was generated and expressed during an in vitro infection 
with recombinant HCMV-NYESO1 and an indication of whether such a CTAg expressing 
CMV strain would be immunogenic to the immune system, CD8+T-cell recognition assays 
were conducted. 
For this, NYESO1-specific CD8+T-cell clones needed to be generated in vitro.  
The levels of detectable CTAg specific CD8+T-cells within the periphery are extremely rare 
or non-detectable within healthy donors [351]. This is a result of NYESO1 expression being 
restricted to immuneprivilidged sites such as the testis.  
In a collaboration with Dr Hayden Pearce (University of Birmingham, work recognised within 
Fig-62), rare CTAg specific CD8+T-cells within healthy donors were enriched and then 
isolated using a protocol as published [229]. This was achieved by utilising DCs loaded with 
an NYESO1 peptide to stimulate naïve CD8+T-cells isolated from an autologous buffy coat 
preparation over a course of 10 days in culture. This was followed by either; a 2 week co-
culture with γ-irradiated peptide-loaded LCLs and PBMCs from buffy coat preparations 
followed by CD137 sorting, or a further weeks co-culture.  This was to expand the low 
frequency of NYESO1-specific cells so that a limiting dilution cloning could be conducted. 
Expanded wells after limiting dilution were then grown further in vitro for functional testing. 
The entire procedure is outline in Fig-62.  
The immunodominant HLA-A2-restricted SLLMWITQC peptide (aa position 157-165) was 




















Fig 62 – Schematic of the generation of NYESO1-specific CD8+T-cells generated from PBMCs obtained 
from a HLA-A2-restricted buffy coat preparation. Monocytes were isolated from buffy coat preparations by 
allowing them to adhere to a 24 well plate after 3 hours incubation at 37oC. These were then differentiated into 
monocytes over a period of 2 days via the addition of IL-4 and GMCSF and matured O/N via the addition of IFN-γ 
and LPS. Activated DCs will have upregulated CD44 and CD88 molecules important for mature DC function. 
Naïve CD8+T-cells were subsequently isolated (Miltenyi Biotech, Table-2) from the autologous HLA-A2+ buffy 
coat preparation as the monocytes and these incubated the DCs who had been peptide-pulsed with a HLA-A2-
restricted NYESO1 peptide SLM. This co-culture was left at 37oC for 10 days. After this cultures were either 
stimulated (one stimulation per 7 days) twice with peptide-loaded γ-irradiated LCLs and buffy coat PBCs and 
sorted for CD137 expression followed by a limiting dilution cloning or stimulated three times followed by a limiting 
dilution cloning. After 2 weeks at 37oC, CD8+T-cell clones that expand within the wells of a 96-well plate after the 
limiting dilution were subjected to IFN-γ ELISA after O/N co-culture with peptide-loaded HLA-matched LCLs to 
determine their specificity. Specific clones were expanded in vitro via stimulation with peptide-loaded γ-irradiated 
LCLs and buffy preparation PBMCs. Dr Hayden Pearce devised the DC stimulation protocol, isolated both the 
monocytes and naive CD8+T-cells and provided the buffy coat PBMCs to generate the NYESO1 clones from. 





Through this method, a total of 10 expanded wells were observed. These were then tested 
for specificity by an IFN-γ ELISA after co-culture with SLL peptide-loaded HLA-A2+ LCLs (5 
representative clones are provided in Fig-63A). Of these 10 clones, 2 were found to have 
specificity towards the SLL NYESO1 peptide i.e. they produced more IFN-γ in response to 
SLL peptide-loaded target cells than control DMSO loaded target cells. The 37.1 clone was 
obtained from the CD137 sorting method prior to limiting dilution and the γ2 clone obtained 







Fig 63 – NYESO1 CD8+T-cell clone peptide specificity and recognition of naturally processed NYESO1 
antigen during an in vitro HCMV-NYESO1 infection of fibroblasts. NYESO1-specific CD8+T-cell clones were 
tested for their ability to recognise peptide-loaded and HCMV-NYESO1 infected cell targets in vitro A) Peptide 
specificity check of NYESO1-specific CD8+T-cell clones obtained after 2 weeks culture in vitro with NYESO1 
peptide-loaded DCs which was re stimulated with NYESO1 peptide-loaded γ-irradiated LCLs and PBMCs from 
buffy coat preparations. Specificity was determined by and IFN-γ ELISA after an O/N co-culture of NYESO1 
CD8+T-cell clones. B) Specific lysis of HCMV-NYESO1 infected MRC5 fibroblasts by the γ2 specific CD8+T-cell 
clone. HLA-A2+ restricted MRC5 fibroblasts were infected with HCMV-NYESO1 at an MOI of 5 for 8 hours 
followed by O/N co-culture with 10 000 of either the 37.1 or γ2 NYESO1-specific clone. This was followed by an 
IFN-γ ELISA to detect a positive recognition of NYESO1 peptide by the CD8+T-cell clones. n = 1 for both A) and 
B). In all cases each condition was tested in duplicate. 
Both of the specific clones were tested for the recognition of naturally generated NYESO1 
peptide during an in vitro infection of MRC5 fibroblasts (n = 1, Fig-63B). The fibroblasts were 
infected with HCMV-NYESO1 for 8 hours at an MOI of 5 and incubated with 10 000 
NYESO1-specific CD8+T-cell clones O/N. Positive recognition was determined by 
measuring IFN-γ release into the supernatant by an ELISA. The γ2 clone was able to 
efficiently release IFN-γ in response to incubation with HCMV-NYESO1 infected cells - 50% 
of the maximal IFN-γ production elicited after incubation with peptide-pulsed LCLs (Fig-63B).  
Unfortunately the 37.1 clone did not specifically recognise peptide on infected cells, 
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however, due to time constraints the mechanism behind this was not investigated. The  γ2 
clone was subsequently tested for the specific cell lysis of SLL peptide-loaded HLA-A2+ 
LCLs. The γ2 clone was able to lyse 8.26% to 16.69% of peptide-loaded targets which 
decreased from 1:1 to 10:1 ratios (n =2 for 1:1 and n =1 for all other ratios, Fig-64).  The γ2 
CD8+T-cell clone was lastly assessed for the ability to lyse HCMV-NYESO1 infected 
fibroblasts in vitro. Fibroblasts were infected with the HCMV-NYESO1 viral construct at an 
MOI of 5 for 24 hours followed by CFSE labelling and the addition of NYESO1-specific 
CD8+T-cell clones at 1, 2, 5 and 10:1 effector target ratios O/N. Importantly, specific cell 
lysis of HCMV-NESO1 infected targets was determined by analysing the loss of CFSE 
positive, PI negative, i.e. viable target cells, by flow cytometry compared to DMSO-pulsed 
control fibroblasts. Continued specificity of the clone was confirmed by the inclusion of a 
fibroblast that had been peptide-pulsed with the SLM peptide. Specific cell lysis reached 
comparable levels to the positive control of vaccine infect fibroblasts at a 10:1 ratio (44.28% 
vs 46.23% respectively, Fig-64). Further work should focus effort on conducting this assay 







Fig 64 – Specific cell lysis of NYESO1 peptide-loaded targets or HCMV-NYESO1 vaccine infected 
fibroblasts in vitro by the γ2 specific CD8. The NYESO1-specfic γ2 CD8+T-cell clone was evaluated for 
specific cell lysis of peptide-loaded and HCMV-NYESO1 infected target cells. A) Specific lysis of 20 000 peptide-
loaded HLA-A2+ LCLs in vitro. 20 000 CFSE labelled HLA-A2+ LCLs were peptide-loaded with the SLM NYESO1 
peptide for 1 hour at 37oC followed by O/N incubation at 1, 2, 5 and 10:1 effector:target ratios with γ2 NYESO1-
specific T-cell clones. Specific cell lysis was determined as the loss of CFSE positive PI negative target cells by 
flow cytometry. B) Specific cell lysis of 20 000 HCMV-NYESO1 infected cells at an MOI of 5 incubated with 1-
10:1 effector target ratios of CD8+T-cell clones. The lysis of fibroblasts peptide-pulsed with 1 μg/ml final 
concentration of SLM NYESO1 peptide for 1 hour prior to the addition of γ2 NYESO1-specific T cell clones was 
included as a positive control. A) n = 1 per effector:target ratio. B) n = 2 for 1:1 and n = 1 2:1, 5:1 and 10:1. In 
A/B) each ratio was tested in duplicate. 
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CHAPTER 7 - SUMMARY 
 
In a collaboration with Dr Richard Stanton (University of Cardiff), this research generated a 
vaccine construct for the treatment of NYESO1 positive malignancies based on a HCMV 
BAC construct (pALIIII [221]) containing the NYESO1 CTAg gene in place of the RL13 gene 
termed ‘pALIIII-NYESO1’. This construct was used to generate a recombinant HCMV virus 
that expresses NYESO1 - HCMV-NYESO1 - when mammalian cells were stably transfected 
in vitro. The correct insertion of NYESO1 was determined by the sequencing of plasmids 
isolated from bacteria transformed with the pALIIII-NYESO1 BAC construct. 
Positive expression of the NYESO1 protein was provided from the recognition of HCMV-
NYESO1 infected cells by an NYESO1-specific CD8+T-cell clone generated in vitro in this 
investigation. This clone was specific for the immunodominant HLA-A2-restricted SLM 
NYESO1 peptide.  
Significantly, the lytic ability of the NYESO1-specific CD8+T-cell clone was demonstrated 
against NYESO1-derived SLM peptide-loaded LCL targets and critically against HCMV-
NYESO1 infected fibroblasts in vitro.  
This research, though preliminary at present (n=1 CD8+T-cell clone tested and killing assay 
conducted) provides encouraging results that such a HCMV-NYESO1 vaccine construct 
could be immunogenic in vivo stimulating the low frequency of NYESO1-specific CD8+T-cell 









CHAPTER 7 - DISCUSSION 
The previous success of CMV as a vaccine vector [208, 344, 345] coupled with both the high 
immunogenicity [348, 352, 355] and the association of the CTAg NYESO1 protein with poor 
survival outcomes [214, 349, 350], prompted our development of a HCMV vaccine construct 
expressing NYESO1.  
The ubiquitous expression of NYESO1 on several tumours that can reach a high percentage 
would make the application of such a HCMV-NYESO1 vaccine widespread. A high 
percentage of tumours including; synovial sarcoma (80%) [356], ovarian (45%) [357], 
melanoma (17-43%) [217, 350, 358] and esophageal (32%) [359] amongst others have been 
reported positive for NYESO1 expression [217].  
The NYESO1 protein was historically discovered by Chen et al., utilising the SEREX method 
– screening patient serum with CDNA molecules derived from tumour samples [215]. 
Unfortunately the role of the NYESO1 protein is still unknown, by large a fact that there are 
no known animal homologues of this protein. However, since its discovery NYESO1 has 
been the focus of in excess of 30 clinical trials (review [217]).  
Previous clinical trials with viral constructs to induce NYESO1 immune responses utilising 
either a combined Vaccinia/Fowlpox [360, 361] or Lentiviral/Vaccinia vector regimes have 
been conducted. Whilst successful, a downfall of these trials was the requirement of prime-
boost regimens. For example, a Vaccinia construct followed by a Fowlpox [360, 361] or a 
Lentiviral construct followed by a Vaccinia [218], in order to maintain the protective NYESO1 
CD8+T-cell immune response [218, 361]. The use of a CMV-based vector in this situation 
should enhance the duration of the protective immune response after a single dose as 
studies with a spread-deficient MCMV strain have demonstrated the maintained capacity for 
memory-inflation [114]. Moreover, these previous viral constructs contained an 
immunodominant NYESO1 peptide and not the full NYESO1 protein. The HCMV-NYESO1 
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construct in this investigation was generated with the complete NYESO1 gene – meaning 
that any potential CD8+T-cell epitopes of NYESO1 can be generated and induce immune 
responses after vaccination.  
The work conducted in this chapter at present represents preliminary data with regards to 
the in vitro antigenic testing of the HCMV-NYESO1 vaccine construct. Importantly the 
research presented in this investigation demonstrated the lytic capability of NYESO1-specific 
CD8+T-cells in removing HCMV-NYESO1 infected fibroblasts in vitro. This investigation has 
therefore developed a useful tool to study the efficacy of this vaccine construct in vitro. The 
results of the CD8+T-cell recognition assay imply that the NYESO1 protein expressed by the 
recombinant HCMV-NYESO1 is antigenic. It further demonstrates that the HCMV-NYESO1 
infected fibroblast can process NYESO1 peptides within the MHC-I pathway and could 
potentially stimulate robust T-cell responses to NYESO1 in vivo. This is extremely promising 
for its efficacy in vivo in directing NYESO1-specific CD8+T-cells to NYESO1 expressing 
malignancies. Future research is concentrated on obtaining NYESO1-specific CD8+T-cells 
from the blood of patients with NYESO1 expressing malignancies and testing these during in 
vitro vaccine infection assays. This will represent a more physiological indication of whether 
this vaccine construct could stimulate CTAg-specific CD8+T-cells within patients in vivo. This 
will furthermore increase the data size of the current investigation and ensure the positive 
NYESO1-recogniton results are not a product of the specific NYESO1-clone isolated in this 
work. 
Previously Valmori et al. identified NYESO1-specific CD8+T-cells utilising MHC-I tetramer 
technology, but however, only after prior peptide stimulation of PBMCs obtained from 
melanoma patients [220]. Thus confirming the low precursor frequency of NYESO1-specific 
CD8+T-cells. Additionally, the authors did not demonstrate the ability of such tetramer 
stained cells to specifically lyse tumour targets in vivo. Our construct was determined to 
activate a specific CD8+T-cell clone in vitro resulting in the specific lysis of HCMV-NYESO1 
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infected cells. This offers preliminary evidence that the HCMV-NYESO1 vaccine construct 
could stimulate low magnitudes of NYESO1-specific CD8+T-cells.   
The HCMV-NYESO1 vaccine will theoretically induce robust CD8+T-cell responses for the 
lifetime of the host. Additionally vaccination of patients with the HCMV-NYESO1 may allow 
for the isolation of several different NYESO1-specific TCRs. This opens the possibility to 
sequence NYESO1 TCRS that confer protection for their retroviral transfer onto patient’s 
endogenous T-cells for adoptive immunotherapy. This would be of advantage for patients 
whom relapse. The transfer of NYESO1 TCR transduced CD8+T-cells has earlier been 
shown as efficacious against myeloma within a phase I/II clinical trial whose persistence was 
correlated with the clinical efficacy observed in 80% of patients [362].  
The Merlin strain engineered in this research expresses the WT US2-11 gene region [221]. 
This asks the question to how NYESO1 derived peptides will be naturally processed and 
presented when these US proteins interfere with MHC-I processing. CMV has a wide tropism 
and it is currently unknown the extent of the MHC-I targeting efficacy of these proteins in all 
cell types. NYESO1-derived peptides could be directly presented on the surface of such 
cells. Additionally, cross presentation of CMV antigens has been demonstrated both in vivo 
and in vitro. It is plausible DCs may activate CD8+T-cells by acquiring NYESO1 peptides 
from apoptotic debris of vaccine infected cells.  
As discussed previously, the presence of the US immunevasin homologues within RhCMV 
are required for superinfection of macaques [134]. This demonstrates the capacity of the US 
proteins in evading the anti-CMV cytotoxic CD8+T-cell response within seropositive 
individuals. These findings have implications for the development of the HCMV-NYESO1 
vaccine in this research. In the context of HCMV as a vaccine vector, the presence of the US 
genes would allow for the vaccination of seropositive individuals with previously established 
infections. This therefore argues premise for the inclusion of the WT US gene region within 
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CMV based vaccine vectors to evade pre-existing immunity and establish an infection foci 
resulting in repeated priming and activation of CTAg  CD8+T-cells. 
Several challenges would have to be overcome before such a HCMV-NYESO1 vaccine 
would gain safety and regulatory approval. Despite an asymptomatic infection within 
immunocompetent hosts, CMV represents a major cause of pathogenesis in both pregnant 
and immunocompromised individuals. Additionally, there may be problems with the public’s 
perception of utilising a human pathogen in its own right as a vaccine vector. The vaccine 
construct generated in this investigation was replication competent to allow for the 
generation of recombinant viral stocks to test immunogenicity during in vitro assays. 
Therefore the next steps in the generation of this vaccine would be to inactivate the 
recombinant HCMV-NYESO1 to prevent spread to the unvaccinated population, and test the 
immunogenicity of such an inactivated construct in a murine model. In parallel to the 
approach adopted in this work, Hansen et al. utilised strains of the RhCMV that are deleted 
for the UL128-131 HCMV homologues [12]. This reduced virus tropism to generate a safer 
attenuated vaccine strain. The vectors demonstrated reduced replication within cell types 
responsible for viral dissemination whilst inducing and maintaining protective CD8+T-cell 
responses.  
The safety of HCMV-NYESO1 would consequently need to be robustlessly investigated 
before human clinical trials could be conducted. The expression of NYESO1 in normal cells - 
restricted to early spermatogonia and lost with further differentiation of these sperm cells - 
support the safety of a vaccine in vivo as these locations are highly immuneprivilidged  [363]. 
However, a study did describe positive results for low mRNA detection within pancreas, 
placenta, liver and breast tissue but no protein expression [364]. Even more encouraging, a 
genome wide investigation for the NYESO1 protein found no evidence of expression within 
normal healthy tissue other than immuneprivilidged sites e.g. brain/testis [365]. Any HCMV-
NYESO1 vaccine strain that would be tested in a clinical trial would inevitably be made 
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competent only for one round of replication to reduce immune mediated damage, spread to 
the unvaccinated population and prevent recombination events with endogenous HCMV 
strains. This would allow infected cells to present NYESO1-derived peptides and generate a 
peripheral memory pool. After this time-point, no healthy cells (excluding the testis) should 
express NYESO1 peptides. Thus restricting damage caused to normal healthy NYESO1 
expressing cells and ensure specificity to NYESO1 expressing tumours.  
NYESO1 is arguably one of the most immunogenic cancer associated antigens that have 
been discovered to date. This investigation has focused primarily on the CD8+T-cell immune 
response to this vaccine, namely, due to limiting time and the availability of an 
immunodominant NYESO1 epitope SLL. NYESO1 is known for inducing cellular immune 
responses including CD4+T-cell [355] and a humoral response [366]. It is anticipated that 
further therapeutic benefits would be provided from the CD4+T-cell and antibody responses 
induced by the HCMV-NYESO1 recombinant virus.  
A major hurdle preventing the use of HCMV as a vaccine vector within human trials is the 
global burden of congenital disease and reactivation within SOT and HIV patients [52, 54]. 
HCMV vaccines must therefore factor in the differing clinical situations and pathogenicity 
between immunocompetent and compromised individuals. However this study has provided 
promising results for the first steps towards the generation of a HCMV vaccine vector to 
target NYESO1 expressing malignancies. It is hoped that such a vaccine vector will maintain 
a potent cellular response exceeding that induced naturally during cancer with regards to the 








CHAPTER 8 – FINAL 
DISCUSSION 
Cytomegaloviruses (CMVs) represent a family of herpesviruses (β) that have evolved with 
their mammalian hosts to establish lifelong latent infections. Typically these infections are 
well controlled within immunocompetent hosts and the immune compartment critical for 
maintaining this control is the CD8+T-cell response. The loss of this cellular compartment 
within patients e.g. end stage AIDS patients or HSCT and SOT transplant patients, leads to 
the development of disseminated CMV replication culminating in organ disease.  
The large antigenic repertoire of HCMV and the presence of a vast array of immunevasins 
that interfere with MHC-I presentation, namely the US2-11 gene region, makes the global 
CD8+T-cell response to HCMV difficult to completely delineate. It is undetermined to what 
extent the US2-11 gene products can reduce viral peptide:MHC-I presentation to the 
immune response in all cell types permissible to CMV. However CD8+T-cell responses 
specific for HCMV antigens across all phases of the viral lifecycle (IE-L) including those 
expressed after the US2-11 proteins, have been identified [58, 230]. Therefore CD8+T-cells 
specific for L-expressed antigens are still being primed in vivo despite the concerted actions 
of the US2-11 gene region.  
It has been demonstrated that MCMV-specific CD8+T-cells can be primed early during 
infection of salivary gland non-haematopoietic cells that still display MHC-I on their surface 
despite the presence of MHC-I immunevasins [250]. It is also now known that the US2-11 
gene region products cannot uniformly target all HLA alleles with the same efficacy and 
therefore some cells with a particular haplotype may be able to present CMV antigens on 
their surface in the context of MHC-I. As such CD8+T-cells can be directly primed by HCMV 
infected cells that are not as uniformly targeted by the US2-11 gene products. Secondly, 
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cross presentation of HCMV antigens via the uptake of apoptotic bodies of HCMV infected 
cells is also likely an important priming route [169, 171].  
This investigation characterised ex vivo CD8+T-cell responses towards HCMV peptide-
epitopes discovered during an RV798 (ΔUS2-11) strain infection of fibroblasts. These were 
found to be a frequent component of the total CD8+T-cell repertoire. These peptides were 
demonstrated to be both directly presented, and in the case of a UL69-derived peptide, 
cross presented to CD8+T-cell clones in vitro. Additionally, an immunodominant CD8+T-cell 
response towards a newly characterised HLA-Cw*0702-restricted UL28-derived peptide 
termed ‘FRC’ was identified. As such, the global CD8+T-cell response to CMV is likely 
underestimated using WT US2-11 strains and fibroblasts as the staple in vitro cell line.  
Secondly, the CD8+T-cell response to CMV is made more complex by the identification of 
two epitopes of the virus derived from non-canonical translation methods of the US22 and 
US34 proteins (Riddell at al. Unpublished data). These were termed ‘cryptic’ peptides. Ex 
vivo CD8+T-cell responses towards these cryptic epitopes are frequent within HCMV-
seropositive donors and can lyse infected cell targets in vitro. They also may accumulate 
within the periphery with age. This work has therefore also shown that by restricting studies 
to in frame derived peptides, research may be missing important CD8+ T-cells for CMV 
control in vivo. The treatment of cells with drugs that enhance translational errors will provide 
insight into the global capability of HCMV to produce cryptic peptide during an infection. The 
role of such proteins in the viral life cycle should be determined. 
Within health, the CD8+T-cell repertoire dominates the total peripheral CD8+T-cell response 
– termed memory-inflation [86, 87, 100, 343, 367]. Currently, the factors governing memory-
inflation are not definitively understood and are the focus of several research groups. The 
murine model has proven invaluable for dissecting the CMV antigens to which inflation 
occurs and the factors involved [105]. Within humans, cross-sectional studies have 
delineated that memory-inflated CD8+T-cells display a unique phenotype indicative of 
chronic antigen stimulation. They are defined as highly differentiated TEMRA cells, maintain 
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their functionality ex vivo and with age demonstrating high cytotoxicity and uniquely express 
CX3CR1 [68, 72, 87, 107, 110].  
Memory-inflation is therefore undoubtedly the result of chronic low-level antigen persistence 
as a result of viral reactivation driving the accumulation of the T-cells to the late 
compartment. There are currently two scenarios proposed within the literature of how this 
chronic antigen stimulation occurs in vivo. The first depicts non-haematopoietic cells in 
secondary lymphoid organs, particularly the LN as stimulating CMV-specific TCM. This results 
in the activation, proliferation, differentiation and the migration of the T-cells to the periphery 
and peripheral tissues. The second depicts that the TCM originating from the LN are 
restimulated by latently infected endothelium with access to the systemic circulation.  
These models however do not explain why stable vs inflationary CD8+T-cell population’s 
specific for differing epitopes within the same CMV protein can arise. As such several factors 
have been linked to the development of inflationary CD8+T-cell populations including; 
expression kinetics of the antigen, affinity of peptide for MHC-I, abundance of mature 
processed peptide and surface peptide:MHC-I concentration. Importantly, this work has 
hypothesised that the HLA-restriction of a peptide may impact upon the frequency of the 
presentation of the peptide within latently infected cells.  This is due to the HLA haplotype of 
a particular infected cell type and the HLA targeting specificity of the US2-11 proteins. 
Almost certainly, properties of the CMV-specific CD8+T-cell itself will also determine whether 
the resulting population inflates or contracts such as peptide avidity and proliferation 
capacities.  
This here work has identified three memory inflated CD8+T-cell populations specific for IE 
antigen derived from the IE-1 or UL28 proteins and restricted through HLA-Cw*0702. These 
inflated HLA-Cw*0702 CD8+T-cells demonstrated several of the factors reported as 
important for memory-inflation generation that we believe is responsible for their preferential 
inflation in vivo.  
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The inflated ex vivo HLA-Cw*0702 CD8+T-cell responses, towards the UL28-derived FRC 
peptide in particular, demonstrated; a TEMRA phenotype and retained a high cytotoxic 
potential with age. Specific CD8+T-cell clones to the HLA-Cw*0702 inflationary peptides 
demonstrated very high functional avidity, recognised peptide presented on non-
haematopoietic fibroblasts and lysed these HCMV infected targets. The antigens from which 
the HLA-Cw*0702-restricted peptides are derived from are expressed with IE kinetics and 
are theoretically immediately accessible to the MHC-I pathway. Importantly, the HLA-
Cw*0702-restriction of the peptides is likely critical as these alleles have been identified as 
less targeted by the US2-11 gene region. Lastly, HLA-C alleles were demonstrated in this 
study to be present on the infected cell surface during IE infection time-points correlating 
with the peak expression of the CMV antigens from which the inflationary targets are 
derived. This would allow a window of opportunity for the restimulation of HLA-C CD8+T-
cells which may contribute to their accumulation within the periphery.  As such, this 
investigation has identified particularly promising CD8+ T-cell candidates for 
immunotherapy. It is hoped these qualities and potential HLA-C allele upregulation during 
reactivation events will translate to a higher recognition of infected cells and therefore 
efficacy.   
A more thorough understanding of how these inflated TEMRA HCMV-specific CD8+T-cell 
populations are generated and persist over time into old age will facilitate the development of 
CMV for therapeutic uses. In particular; which antigens to target for the treatment of CMV 
disease, which CMV genes to replace with therapeutic genes that will drive inflationary 
populations i.e. IE genes and manipulating this immune response towards malignancies.  
Several features of the CMV virus make it an advantageous and extremely promising vector 
to target malignancies such as; lifelong cellular immunity with a cytotoxic TEMRA phenotype, 
ability to superinfect a previously HCMV seropositive individual and the capability of 
manipulating the CMV genome by BAC technology to introduce therapeutic genes. Studies 
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have demonstrated the use of recombinant CMV expressing tumour antigens as inducing a 
protective immune response from tumour challenge in murine models [209, 344].  
This work, in collaboration with Dr Richard Stanton (University of Cardiff), generated a 
recombinant HCMV strain that expresses the NYESO1 CTAg. In vitro assays demonstrated 
this recombinant virus to be antigenic to a CD8+T-cell clone which effectively removed 
HCMV-NYESO1 infected cells. This provides the promising first steps towards developing 
this recombinant HCMV strain as a vaccine for cancer therapy.  
If HCMV is to be treated in the post-transplant setting, then it is critically important to 
understand how the human immune system can efficiently control this virus during health. By 
doing so, the correct CD8+T-cell populations conferring the most efficacious and during 
protection can be recapitulated within immunocompromised patients. Additionally, if HCMV 
is to be used as a therapeutic agent for malignancies, it must first be understood the 
capacity of this virus to induce highly functional CD8+T-cell responses that will be 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix Table 7 and 8 – CD8+T-cell cytokine production elicited by HCMV cryptic epitopes in YD (<70 
years, Table 7) and OD (>70years, Table 8) donors 
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